PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
34064117-6	2021	The HON supplement prevented HFD-induced adipogenesis by reduced the mRNA and protein expression of SOAT1 and CCAAT/enhancer-binding protein-alpha (C/EBPalpha), suggesting that SOAT1 might play an important role in regulating adipogenesis.	honokiol	4-7	sterol O-acyltransferase 1	Mus musculus	100-105
34064117-6	2021	The HON supplement prevented HFD-induced adipogenesis by reduced the mRNA and protein expression of SOAT1 and CCAAT/enhancer-binding protein-alpha (C/EBPalpha), suggesting that SOAT1 might play an important role in regulating adipogenesis.	honokiol	4-7	CCAAT/enhancer binding protein (C/EBP), alpha	Mus musculus	110-146
34064117-6	2021	The HON supplement prevented HFD-induced adipogenesis by reduced the mRNA and protein expression of SOAT1 and CCAAT/enhancer-binding protein-alpha (C/EBPalpha), suggesting that SOAT1 might play an important role in regulating adipogenesis.	honokiol	4-7	CCAAT/enhancer binding protein (C/EBP), alpha	Mus musculus	148-158
34064117-6	2021	The HON supplement prevented HFD-induced adipogenesis by reduced the mRNA and protein expression of SOAT1 and CCAAT/enhancer-binding protein-alpha (C/EBPalpha), suggesting that SOAT1 might play an important role in regulating adipogenesis.	honokiol	4-7	sterol O-acyltransferase 1	Mus musculus	177-182
34064117-7	2021	Moreover, HON treatment increased the expression of proteins related to the classical pathways of energy and lipid metabolism, such as AMP-activated kinase (AMPK) and acetyl-CoA carboxylase (ACC), and promoted the browning of epididymal WAT by upregulation of the protein expression of uncoupling protein 1 (UCP1) in the HFD mice.	honokiol	10-13	uncoupling protein 1 (mitochondrial, proton carrier)	Mus musculus	286-306
34064117-7	2021	Moreover, HON treatment increased the expression of proteins related to the classical pathways of energy and lipid metabolism, such as AMP-activated kinase (AMPK) and acetyl-CoA carboxylase (ACC), and promoted the browning of epididymal WAT by upregulation of the protein expression of uncoupling protein 1 (UCP1) in the HFD mice.	honokiol	10-13	uncoupling protein 1 (mitochondrial, proton carrier)	Mus musculus	308-312
34066055-8	2021	Furthermore, treatment with Akt inhibitors (MK-2206, honokiol and ipatasertib) reduced USUV and ZIKV titers in cell culture but, except for honokiol, not WNV.	honokiol	53-61	AKT serine/threonine kinase 1	Homo sapiens	28-31
34151796-12	2021	Moreover, honokiol increased the expression of PPARgamma and PGC1alpha, which might play positive roles in energy metabolism and microglial phagocytosis.	honokiol	10-18	peroxisome proliferator activated receptor gamma	Mus musculus	47-56
34151796-12	2021	Moreover, honokiol increased the expression of PPARgamma and PGC1alpha, which might play positive roles in energy metabolism and microglial phagocytosis.	honokiol	10-18	peroxisome proliferative activated receptor, gamma, coactivator 1 alpha	Mus musculus	61-70
34664691-10	2021	RESULTS: In honokiol and pentoxifylline groups compared with the negative control group, tumor necrosis factor-beta and interleukin-10 levels (indicating inflammation); myeloperoxidase, malondialdehyde, and hydroxyproline levels (indicating oxidative stress); and intercellular adhesion molecule levels (indicating fibrosis) were decreased.	honokiol	12-20	lymphotoxin alpha	Rattus norvegicus	89-115
34664691-10	2021	RESULTS: In honokiol and pentoxifylline groups compared with the negative control group, tumor necrosis factor-beta and interleukin-10 levels (indicating inflammation); myeloperoxidase, malondialdehyde, and hydroxyproline levels (indicating oxidative stress); and intercellular adhesion molecule levels (indicating fibrosis) were decreased.	honokiol	12-20	interleukin 10	Rattus norvegicus	120-134
34664691-10	2021	RESULTS: In honokiol and pentoxifylline groups compared with the negative control group, tumor necrosis factor-beta and interleukin-10 levels (indicating inflammation); myeloperoxidase, malondialdehyde, and hydroxyproline levels (indicating oxidative stress); and intercellular adhesion molecule levels (indicating fibrosis) were decreased.	honokiol	12-20	myeloperoxidase	Rattus norvegicus	169-184
35617790-10	2022	These findings will provide a theoretical basis for the discovery of honokiol derivatives as potential both alpha-glucosidase and SARS-CoV-2 entry inhibitors.	honokiol	69-77	sucrase-isomaltase	Homo sapiens	108-125
35091982-10	2022	We further explored whether pharmacologically activating Sirt3 is protective for neurons, and found that treatment with honokiol (a Sirt3 agonist) after OGD exposure activated Sirt3 during reperfusion and significantly alleviated OGD/R-induced neuronal injuries.	honokiol	120-128	sirtuin 3	Homo sapiens	57-62
35615401-5	2022	PCAT19-transfected cells were treated with Honokiol and anisomycin.	honokiol	43-51	prostate cancer associated transcript 19	Homo sapiens	0-6
35615401-10	2022	Furthermore, upregulation of PCAT19 reversed the effects of Honokiol and anisomycin on promoting cell proliferation and inhibiting cell apoptosis.	honokiol	60-68	prostate cancer associated transcript 19	Homo sapiens	29-35
35217431-5	2022	3-TYP (SIRT3 inhibitor) and Honokiol (SIRT3 agonist) were used to alter SIRT3 activity.	honokiol	28-36	sirtuin 3	Homo sapiens	72-77
35091982-10	2022	We further explored whether pharmacologically activating Sirt3 is protective for neurons, and found that treatment with honokiol (a Sirt3 agonist) after OGD exposure activated Sirt3 during reperfusion and significantly alleviated OGD/R-induced neuronal injuries.	honokiol	120-128	sirtuin 3	Homo sapiens	132-137
35091982-10	2022	We further explored whether pharmacologically activating Sirt3 is protective for neurons, and found that treatment with honokiol (a Sirt3 agonist) after OGD exposure activated Sirt3 during reperfusion and significantly alleviated OGD/R-induced neuronal injuries.	honokiol	120-128	sirtuin 3	Homo sapiens	176-181
35414825-0	2022	Honokiol Provides Cardioprotection from Myocardial Ischemia/Reperfusion Injury (MI/RI) by Inhibiting Mitochondrial Apoptosis via the PI3K/AKT Signaling Pathway.	honokiol	0-8	thymoma viral proto-oncogene 1	Mus musculus	138-141
35370645-0	2022	Honokiol Inhibits Atrial Metabolic Remodeling in Atrial Fibrillation Through Sirt3 Pathway.	honokiol	0-8	sirtuin 3	Homo sapiens	77-82
35370645-3	2022	However, the effect of Sirt3 agonist Honokiol (HL) on AF is unclear.	honokiol	37-45	lipase C, hepatic type	Homo sapiens	47-49
35350760-0	2022	Honokiol Inhibits HIF-1alpha-Mediated Glycolysis to Halt Breast Cancer Growth.	honokiol	0-8	hypoxia inducible factor 1 subunit alpha	Homo sapiens	18-28
35350760-2	2022	In a recent study, honokiol (HNK) was identified as one of the potential agents that inhibited the HIF-1alpha signaling pathway.	honokiol	19-27	hypoxia inducible factor 1 subunit alpha	Homo sapiens	99-109
35414825-10	2022	Results: Honokiol can reduce the MI/RI-induced cTnT and CK-MB levels, apoptosis index, and mitochondrial swelling in cardiomyocytes via activating the PI3K/AKT signaling pathway.	honokiol	9-17	troponin T2, cardiac	Mus musculus	47-51
35414825-10	2022	Results: Honokiol can reduce the MI/RI-induced cTnT and CK-MB levels, apoptosis index, and mitochondrial swelling in cardiomyocytes via activating the PI3K/AKT signaling pathway.	honokiol	9-17	thymoma viral proto-oncogene 1	Mus musculus	156-159
35414825-11	2022	Conclusion: Honokiol provides cardiac protection from MI/RI by suppressing mitochondrial apoptosis through the PI3K/AKT signaling pathway.	honokiol	12-20	thymoma viral proto-oncogene 1	Mus musculus	116-119
33743348-0	2021	Honokiol inhibits hepatoma carcinoma cell migration through downregulated Cyclophilin B expression.	honokiol	0-8	peptidylprolyl isomerase B	Homo sapiens	74-87
35264952-0	2022	Honokiol Ameliorates Post-Myocardial Infarction Heart Failure Through Ucp3-Mediated Reactive Oxygen Species Inhibition.	honokiol	0-8	uncoupling protein 3 (mitochondrial, proton carrier)	Mus musculus	70-74
35264952-2	2022	Honokiol (HK) has previously been reported to improve myocardial ischemia/reperfusion injury and reverse myocardial hypertrophy by activating Sirt1 and Sirt3.	honokiol	0-8	sirtuin 1	Mus musculus	142-147
35264952-2	2022	Honokiol (HK) has previously been reported to improve myocardial ischemia/reperfusion injury and reverse myocardial hypertrophy by activating Sirt1 and Sirt3.	honokiol	0-8	sirtuin 3	Mus musculus	152-157
35185151-0	2022	Liposomal Honokiol induces ROS-mediated apoptosis via regulation of ERK/p38-MAPK signaling and autophagic inhibition in human medulloblastoma.	honokiol	10-18	mitogen-activated protein kinase 1	Homo sapiens	68-71
35185151-0	2022	Liposomal Honokiol induces ROS-mediated apoptosis via regulation of ERK/p38-MAPK signaling and autophagic inhibition in human medulloblastoma.	honokiol	10-18	mitogen-activated protein kinase 14	Homo sapiens	72-75
34973135-3	2022	This study aimed to discern the underlying mechanisms of Honokiol in preventing the metastatic dissemination of gastric cancer cells by inhibiting HDAC3 activity/expression.	honokiol	57-65	histone deacetylase 3	Mus musculus	147-152
34973135-5	2022	The effects of Honokiol on pharmacological characterization, functional, transcriptional activities, organelle structure changes, and molecular signaling were analyzed using binding assays, differential scanning calorimetry, luciferase reporter assay, HDAC3 activity, ER stress response element activity, transmission electron microscopy, immune-blotting, and Wnt/beta-catenin activity assays.	honokiol	15-23	histone deacetylase 3	Mus musculus	252-257
34973135-5	2022	The effects of Honokiol on pharmacological characterization, functional, transcriptional activities, organelle structure changes, and molecular signaling were analyzed using binding assays, differential scanning calorimetry, luciferase reporter assay, HDAC3 activity, ER stress response element activity, transmission electron microscopy, immune-blotting, and Wnt/beta-catenin activity assays.	honokiol	15-23	catenin (cadherin associated protein), beta 1	Mus musculus	364-376
34973135-8	2022	Honokiol significantly abolished HDAC3 activity (Y298) via inhibition of NFkappaBp65/CEBPbeta signaling, which could be reversed by the over-expression of plasmids of NFkappaBp65/CEBPbeta.	honokiol	0-8	histone deacetylase 3	Mus musculus	33-38
34973135-8	2022	Honokiol significantly abolished HDAC3 activity (Y298) via inhibition of NFkappaBp65/CEBPbeta signaling, which could be reversed by the over-expression of plasmids of NFkappaBp65/CEBPbeta.	honokiol	0-8	CCAAT/enhancer binding protein (C/EBP), alpha	Mus musculus	85-93
34973135-8	2022	Honokiol significantly abolished HDAC3 activity (Y298) via inhibition of NFkappaBp65/CEBPbeta signaling, which could be reversed by the over-expression of plasmids of NFkappaBp65/CEBPbeta.	honokiol	0-8	CCAAT/enhancer binding protein (C/EBP), alpha	Mus musculus	179-187
34973135-9	2022	Treatments with 4-phenylbutyric acid (a chemical chaperone) and calpain-2 gene silencing inhibited Honokiol-inhibited NFkappaBp65/CEBPbeta activation.	honokiol	99-107	calpain 2	Mus musculus	64-73
34973135-9	2022	Treatments with 4-phenylbutyric acid (a chemical chaperone) and calpain-2 gene silencing inhibited Honokiol-inhibited NFkappaBp65/CEBPbeta activation.	honokiol	99-107	CCAAT/enhancer binding protein (C/EBP), alpha	Mus musculus	130-138
34973135-10	2022	Honokiol increased ER stress markers and inhibited EMT-associated epithelial markers, but decreased Wnt/beta-catenin activity.	honokiol	0-8	catenin (cadherin associated protein), beta 1	Mus musculus	104-116
34973135-11	2022	Suppression of HDAC3 by both Honokiol and HDAC3 gene silencing decreased cell migration and invasion in vitro and metastasis in vivo.	honokiol	29-37	histone deacetylase 3	Mus musculus	15-20
34973135-12	2022	CONCLUSIONS AND IMPLICATIONS: Honokiol acts by suppressing HDAC3-mediated EMT and metastatic signaling.	honokiol	30-38	histone deacetylase 3	Mus musculus	59-64
34973135-15	2022	Honokiol targeting HDAC3 by ER stress cascade and mitigating the peritoneal spread of gastric cancer.	honokiol	0-8	histone deacetylase 3	Mus musculus	19-24
34973135-16	2022	Honokiol-induced ER stress-activated calpain activity targeted HDAC3 and blocked Tyr298 phosphorylation, subsequently blocked cooperating with EMT transcription factors and cancer progression.	honokiol	0-8	histone deacetylase 3	Mus musculus	63-68
34973135-18	2022	The findings here imply that overexpressed HDAC3 is a potential therapeutic target for honokiol to reverse EMT and prevent gastric cancer migration, invasion, and metastatic dissemination.	honokiol	87-95	histone deacetylase 3	Mus musculus	43-48
34973135-19	2022	Honokiol significantly abolished HDAC3 activity on catalytic tyrosine 298 residue site.	honokiol	0-8	histone deacetylase 3	Mus musculus	33-38
34973135-20	2022	In addition, Honokiol-induced ER stress markedly inhibited HDAC3 expression via inhibition of NFkappaBp65/CEBPbeta signaling.	honokiol	13-21	histone deacetylase 3	Mus musculus	59-64
34973135-20	2022	In addition, Honokiol-induced ER stress markedly inhibited HDAC3 expression via inhibition of NFkappaBp65/CEBPbeta signaling.	honokiol	13-21	CCAAT/enhancer binding protein (C/EBP), alpha	Mus musculus	106-114
34973135-21	2022	HDAC3, which is a positive regulator of metastatic gastric cancer cell growth, can be significantly inhibited by Honokiol.	honokiol	113-121	histone deacetylase 3	Mus musculus	0-5
2637453-4	1989	The results suggest that honokiol interferes with the interaction between the acetylcholine receptor and its agonists and that honokiol may also affect the steps in exocytosis after intracellular calcium has been raised, possibly at the site(s) where calmodulin acts.	honokiol	127-135	calmodulin	Bos taurus	251-261
3413728-4	1988	Thromboxane B2 formation caused by collagen, arachidonic acid or thrombin was in each case inhibited by magnolol and honokiol.	honokiol	117-125	prothrombin	Oryctolagus cuniculus	65-73
35409099-3	2022	We found that the Sirt3 activator honokiol (HNK) induced adipogenesis compared to the control, in contrast to Sirt3 inhibitor, 3-TYP.	honokiol	34-42	sirtuin 3	Homo sapiens	18-23
33529726-5	2021	It was also found that honokiol treatment decreased expression of Cluster of Differentiation 36, AMP-activated kinases and nuclear transcription factors like, Peroxisome proliferator-activated receptor gamma co-activator 1alpha/beta and Peroxisome proliferator-activated receptor alpha, surrogating the evidence of decreased fatty acid-mediated complex I respiration.	honokiol	23-31	peroxisome proliferative activated receptor, gamma, coactivator 1 alpha	Mus musculus	159-232
33950239-5	2021	Honokiol, the main constituent of M. officinalis, is a GABA modulator and a CB1 agonist, which is deeply investigated for its role in modulating mood disorders.	honokiol	0-8	cannabinoid receptor 1	Homo sapiens	76-79
33544209-0	2021	Honokiol antagonizes doxorubicin resistance in human breast cancer via miR-188-5p/FBXW7/c-Myc pathway.	honokiol	0-8	microRNA 188	Homo sapiens	71-78
33544209-0	2021	Honokiol antagonizes doxorubicin resistance in human breast cancer via miR-188-5p/FBXW7/c-Myc pathway.	honokiol	0-8	F-box and WD repeat domain containing 7	Homo sapiens	82-87
33544209-0	2021	Honokiol antagonizes doxorubicin resistance in human breast cancer via miR-188-5p/FBXW7/c-Myc pathway.	honokiol	0-8	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	88-93
33544209-7	2021	Mechanically, upregulation of miR-188-5p was associated with doxorubicin resistance, and honokiol enhanced doxorubicin sensitivity by downregulating miR-188-5p.	honokiol	89-97	microRNA 188	Homo sapiens	149-156
33544209-9	2021	FBXW7/c-Myc signaling was involved in the chemosensitization effect of honokiol.	honokiol	71-79	F-box and WD repeat domain containing 7	Homo sapiens	0-5
33544209-9	2021	FBXW7/c-Myc signaling was involved in the chemosensitization effect of honokiol.	honokiol	71-79	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	6-11
33544209-11	2021	However, FBXW7 silencing or c-Myc transfection resulted in resistance to the honokiol-induced apoptotic effect.	honokiol	77-85	F-box and WD repeat domain containing 7	Homo sapiens	9-14
33544209-11	2021	However, FBXW7 silencing or c-Myc transfection resulted in resistance to the honokiol-induced apoptotic effect.	honokiol	77-85	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	28-33
33544209-12	2021	CONCLUSION: These findings suggest that downregulation of miR-188-5p by honokiol enhances doxorubicin sensitivity through FBXW7/c-Myc signaling in human breast cancer.	honokiol	72-80	microRNA 188	Homo sapiens	58-65
33544209-12	2021	CONCLUSION: These findings suggest that downregulation of miR-188-5p by honokiol enhances doxorubicin sensitivity through FBXW7/c-Myc signaling in human breast cancer.	honokiol	72-80	F-box and WD repeat domain containing 7	Homo sapiens	122-127
33544209-12	2021	CONCLUSION: These findings suggest that downregulation of miR-188-5p by honokiol enhances doxorubicin sensitivity through FBXW7/c-Myc signaling in human breast cancer.	honokiol	72-80	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	128-133
33544209-13	2021	Our study finds an important role of miR-188-5p in the development of doxorubicin resistance in breast cancer, and enriches our understanding of the mechanism of action of honokiol in cancer therapy.	honokiol	172-180	microRNA 188	Homo sapiens	37-44
33522075-0	2021	Sirtuin-3 activation by honokiol restores mitochondrial dysfunction in the hippocampus of the hepatic encephalopathy rat model of ammonia neurotoxicity.	honokiol	24-32	sirtuin 3	Rattus norvegicus	0-9
33522075-7	2021	However, all these mitochondrial aberrations were observed to regain their normal profiles/levels, concordant to the enhanced SIRT3 expression and its activity due to treatment with HKL.	honokiol	182-185	sirtuin 3	Rattus norvegicus	126-131
33952780-0	2021	Honokiol regulates endoplasmic reticulum stress by promoting the activation of the sirtuin 1-mediated protein kinase B pathway and ameliorates high glucose/high fat-induced dysfunction in human umbilical vein endothelial cells.	honokiol	0-8	sirtuin 1	Homo sapiens	83-92
33952780-0	2021	Honokiol regulates endoplasmic reticulum stress by promoting the activation of the sirtuin 1-mediated protein kinase B pathway and ameliorates high glucose/high fat-induced dysfunction in human umbilical vein endothelial cells.	honokiol	0-8	protein tyrosine kinase 2 beta	Homo sapiens	102-118
33902432-13	2021	Meanwhile, the inhibitory effect of miR-27a-3p inhibitor on osteogenic differentiation was reversed by knockdown of CRY2 or using honokiol (ERK1/2 signal activator).	honokiol	130-138	mitogen-activated protein kinase 3	Mus musculus	140-146
33955504-0	2021	[Corrigendum] Cyclophilin D modulates cell death transition from early apoptosis to programmed necrosis induced by honokiol.	honokiol	115-123	peptidylprolyl isomerase D	Homo sapiens	14-27
33529726-5	2021	It was also found that honokiol treatment decreased expression of Cluster of Differentiation 36, AMP-activated kinases and nuclear transcription factors like, Peroxisome proliferator-activated receptor gamma co-activator 1alpha/beta and Peroxisome proliferator-activated receptor alpha, surrogating the evidence of decreased fatty acid-mediated complex I respiration.	honokiol	23-31	peroxisome proliferator activated receptor alpha	Mus musculus	237-285
33550458-0	2021	Honokiol induces paraptosis-like cell death of acute promyelocytic leukemia via mTOR & MAPK signaling pathways activation.	honokiol	0-8	mechanistic target of rapamycin kinase	Homo sapiens	80-84
33952780-7	2021	Honokiol reversed the effect of HG/HF on promoting cell apoptosis, ROS and MDA contents, and the expressions of CHOP, GRP78, p-PERK, p-IRE1alpha and cleaved caspase-3, and also reversed the inhibitory effect of HG/HF on cell viability, SOD content and SIRT1 expression.	honokiol	0-8	DNA damage inducible transcript 3	Homo sapiens	112-116
33952780-7	2021	Honokiol reversed the effect of HG/HF on promoting cell apoptosis, ROS and MDA contents, and the expressions of CHOP, GRP78, p-PERK, p-IRE1alpha and cleaved caspase-3, and also reversed the inhibitory effect of HG/HF on cell viability, SOD content and SIRT1 expression.	honokiol	0-8	heat shock protein family A (Hsp70) member 5	Homo sapiens	118-123
33952780-7	2021	Honokiol reversed the effect of HG/HF on promoting cell apoptosis, ROS and MDA contents, and the expressions of CHOP, GRP78, p-PERK, p-IRE1alpha and cleaved caspase-3, and also reversed the inhibitory effect of HG/HF on cell viability, SOD content and SIRT1 expression.	honokiol	0-8	eukaryotic translation initiation factor 2 alpha kinase 3	Homo sapiens	127-131
33952780-7	2021	Honokiol reversed the effect of HG/HF on promoting cell apoptosis, ROS and MDA contents, and the expressions of CHOP, GRP78, p-PERK, p-IRE1alpha and cleaved caspase-3, and also reversed the inhibitory effect of HG/HF on cell viability, SOD content and SIRT1 expression.	honokiol	0-8	endoplasmic reticulum to nucleus signaling 1	Homo sapiens	135-144
33952780-7	2021	Honokiol reversed the effect of HG/HF on promoting cell apoptosis, ROS and MDA contents, and the expressions of CHOP, GRP78, p-PERK, p-IRE1alpha and cleaved caspase-3, and also reversed the inhibitory effect of HG/HF on cell viability, SOD content and SIRT1 expression.	honokiol	0-8	caspase 3	Homo sapiens	157-166
33952780-7	2021	Honokiol reversed the effect of HG/HF on promoting cell apoptosis, ROS and MDA contents, and the expressions of CHOP, GRP78, p-PERK, p-IRE1alpha and cleaved caspase-3, and also reversed the inhibitory effect of HG/HF on cell viability, SOD content and SIRT1 expression.	honokiol	0-8	superoxide dismutase 1	Homo sapiens	236-239
33952780-11	2021	Therefore, honokiol activates the Akt pathway by regulating SIRT1 expression to regulate endoplasmic reticulum stress, promotes cell viability and inhibits the apoptosis of HG/HF-induced HUVECs.	honokiol	11-19	AKT serine/threonine kinase 1	Homo sapiens	34-37
32776713-0	2021	Apoptotic and antihepatofibrotic effect of honokiol via activation of GSK3beta and suppression of Wnt/beta-catenin pathway in hepatic stellate cells.	honokiol	43-51	glycogen synthase kinase 3 alpha	Homo sapiens	70-78
33528601-7	2021	Forty compounds from natural product library were screened using the SPR CM5 chip, and magnolol (Mag), honokiol (Hon), and resveratrol (Res) were screened out as potential P-gp ligands, showing a significant response signal.	honokiol	103-111	phosphoglycolate phosphatase	Homo sapiens	172-176
33830903-10	2021	After intervened with honokiol for 6 days, compared with the vehicle group, the locomotor function and the pathomorphological changes of myelin sheath of the CSCD rats were improved with obviously decreased expression of active caspase-3, caspase-12 and cytochrome C. CONCLUSIONS: Honokiol may improve locomotor function and protect neural myelin sheat from demyelination via prevention oligodendrocytes (OLs) apoptosis through mediate endoplasmic reticulum (ER)-mitochondria pathway after CSCI.	honokiol	22-30	caspase 3	Rattus norvegicus	228-237
33830903-10	2021	After intervened with honokiol for 6 days, compared with the vehicle group, the locomotor function and the pathomorphological changes of myelin sheath of the CSCD rats were improved with obviously decreased expression of active caspase-3, caspase-12 and cytochrome C. CONCLUSIONS: Honokiol may improve locomotor function and protect neural myelin sheat from demyelination via prevention oligodendrocytes (OLs) apoptosis through mediate endoplasmic reticulum (ER)-mitochondria pathway after CSCI.	honokiol	22-30	caspase 12	Rattus norvegicus	239-249
32936421-13	2021	Cellular protein light chain 3 (LC3) may play an important role in paclitaxel/honokiol induced cytoplasmic vacuolation and NSCLC cell death.	honokiol	78-86	microtubule associated protein 1 light chain 3 alpha	Homo sapiens	32-35
32776713-0	2021	Apoptotic and antihepatofibrotic effect of honokiol via activation of GSK3beta and suppression of Wnt/beta-catenin pathway in hepatic stellate cells.	honokiol	43-51	Wnt family member 3A	Homo sapiens	98-101
32776713-0	2021	Apoptotic and antihepatofibrotic effect of honokiol via activation of GSK3beta and suppression of Wnt/beta-catenin pathway in hepatic stellate cells.	honokiol	43-51	catenin beta 1	Homo sapiens	102-114
32776713-4	2021	Honokiol increased sub G1 population and activated caspase 3 and cleaved poly (ADP-ribose) polymerase (PARP) in HSCs.	honokiol	0-8	caspase 3	Homo sapiens	51-60
32776713-4	2021	Honokiol increased sub G1 population and activated caspase 3 and cleaved poly (ADP-ribose) polymerase (PARP) in HSCs.	honokiol	0-8	poly(ADP-ribose) polymerase 1	Homo sapiens	73-101
32776713-4	2021	Honokiol increased sub G1 population and activated caspase 3 and cleaved poly (ADP-ribose) polymerase (PARP) in HSCs.	honokiol	0-8	poly(ADP-ribose) polymerase 1	Homo sapiens	103-107
32776713-5	2021	Moreover, honokiol attenuated the expression of alpha smooth muscle actin (alpha-SMA), transforming growth factor beta 1 (TGF-beta1), phospho-Smad3, phospho-AKT, cyclin D1, c-Myc, Wnt3a, beta-catenin, and activated phosphorylation of glycogen synthase kinase 3 beta (GSK3beta) in HSCs.	honokiol	10-18	actin alpha 1, skeletal muscle	Homo sapiens	75-84
32776713-5	2021	Moreover, honokiol attenuated the expression of alpha smooth muscle actin (alpha-SMA), transforming growth factor beta 1 (TGF-beta1), phospho-Smad3, phospho-AKT, cyclin D1, c-Myc, Wnt3a, beta-catenin, and activated phosphorylation of glycogen synthase kinase 3 beta (GSK3beta) in HSCs.	honokiol	10-18	transforming growth factor beta 1	Homo sapiens	87-120
32776713-5	2021	Moreover, honokiol attenuated the expression of alpha smooth muscle actin (alpha-SMA), transforming growth factor beta 1 (TGF-beta1), phospho-Smad3, phospho-AKT, cyclin D1, c-Myc, Wnt3a, beta-catenin, and activated phosphorylation of glycogen synthase kinase 3 beta (GSK3beta) in HSCs.	honokiol	10-18	transforming growth factor beta 1	Homo sapiens	122-131
32776713-5	2021	Moreover, honokiol attenuated the expression of alpha smooth muscle actin (alpha-SMA), transforming growth factor beta 1 (TGF-beta1), phospho-Smad3, phospho-AKT, cyclin D1, c-Myc, Wnt3a, beta-catenin, and activated phosphorylation of glycogen synthase kinase 3 beta (GSK3beta) in HSCs.	honokiol	10-18	SMAD family member 3	Homo sapiens	142-147
32776713-5	2021	Moreover, honokiol attenuated the expression of alpha smooth muscle actin (alpha-SMA), transforming growth factor beta 1 (TGF-beta1), phospho-Smad3, phospho-AKT, cyclin D1, c-Myc, Wnt3a, beta-catenin, and activated phosphorylation of glycogen synthase kinase 3 beta (GSK3beta) in HSCs.	honokiol	10-18	AKT serine/threonine kinase 1	Homo sapiens	157-160
32776713-5	2021	Moreover, honokiol attenuated the expression of alpha smooth muscle actin (alpha-SMA), transforming growth factor beta 1 (TGF-beta1), phospho-Smad3, phospho-AKT, cyclin D1, c-Myc, Wnt3a, beta-catenin, and activated phosphorylation of glycogen synthase kinase 3 beta (GSK3beta) in HSCs.	honokiol	10-18	cyclin D1	Homo sapiens	162-171
32776713-5	2021	Moreover, honokiol attenuated the expression of alpha smooth muscle actin (alpha-SMA), transforming growth factor beta 1 (TGF-beta1), phospho-Smad3, phospho-AKT, cyclin D1, c-Myc, Wnt3a, beta-catenin, and activated phosphorylation of glycogen synthase kinase 3 beta (GSK3beta) in HSCs.	honokiol	10-18	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	173-178
32776713-5	2021	Moreover, honokiol attenuated the expression of alpha smooth muscle actin (alpha-SMA), transforming growth factor beta 1 (TGF-beta1), phospho-Smad3, phospho-AKT, cyclin D1, c-Myc, Wnt3a, beta-catenin, and activated phosphorylation of glycogen synthase kinase 3 beta (GSK3beta) in HSCs.	honokiol	10-18	Wnt family member 3A	Homo sapiens	180-185
32776713-5	2021	Moreover, honokiol attenuated the expression of alpha smooth muscle actin (alpha-SMA), transforming growth factor beta 1 (TGF-beta1), phospho-Smad3, phospho-AKT, cyclin D1, c-Myc, Wnt3a, beta-catenin, and activated phosphorylation of glycogen synthase kinase 3 beta (GSK3beta) in HSCs.	honokiol	10-18	catenin beta 1	Homo sapiens	187-199
32776713-5	2021	Moreover, honokiol attenuated the expression of alpha smooth muscle actin (alpha-SMA), transforming growth factor beta 1 (TGF-beta1), phospho-Smad3, phospho-AKT, cyclin D1, c-Myc, Wnt3a, beta-catenin, and activated phosphorylation of glycogen synthase kinase 3 beta (GSK3beta) in HSCs.	honokiol	10-18	glycogen synthase kinase 3 beta	Homo sapiens	234-265
32776713-5	2021	Moreover, honokiol attenuated the expression of alpha smooth muscle actin (alpha-SMA), transforming growth factor beta 1 (TGF-beta1), phospho-Smad3, phospho-AKT, cyclin D1, c-Myc, Wnt3a, beta-catenin, and activated phosphorylation of glycogen synthase kinase 3 beta (GSK3beta) in HSCs.	honokiol	10-18	glycogen synthase kinase 3 alpha	Homo sapiens	267-275
32776713-6	2021	Conversely, GSK3beta inhibitor SB216763 reversed the effect of honokiol on PARP, alpha-SMA, phospho-GSK3beta, beta-catenin and sub G1 population in LX-2 cells.	honokiol	63-71	glycogen synthase kinase 3 alpha	Homo sapiens	12-20
32776713-6	2021	Conversely, GSK3beta inhibitor SB216763 reversed the effect of honokiol on PARP, alpha-SMA, phospho-GSK3beta, beta-catenin and sub G1 population in LX-2 cells.	honokiol	63-71	poly(ADP-ribose) polymerase 1	Homo sapiens	75-79
32776713-6	2021	Conversely, GSK3beta inhibitor SB216763 reversed the effect of honokiol on PARP, alpha-SMA, phospho-GSK3beta, beta-catenin and sub G1 population in LX-2 cells.	honokiol	63-71	actin alpha 1, skeletal muscle	Homo sapiens	81-90
32776713-6	2021	Conversely, GSK3beta inhibitor SB216763 reversed the effect of honokiol on PARP, alpha-SMA, phospho-GSK3beta, beta-catenin and sub G1 population in LX-2 cells.	honokiol	63-71	glycogen synthase kinase 3 alpha	Homo sapiens	100-108
32776713-6	2021	Conversely, GSK3beta inhibitor SB216763 reversed the effect of honokiol on PARP, alpha-SMA, phospho-GSK3beta, beta-catenin and sub G1 population in LX-2 cells.	honokiol	63-71	catenin beta 1	Homo sapiens	110-122
32776713-7	2021	Overall, honokiol exerts apoptotic and antifibrotic effects via activation of GSK3beta and inhibition of Wnt3a/beta-catenin signalling pathway.	honokiol	9-17	glycogen synthase kinase 3 alpha	Homo sapiens	78-86
33354276-0	2020	Honokiol Alleviates Methionine-Choline Deficient Diet-Induced Hepatic Steatosis and Oxidative Stress in C57BL/6 Mice by Regulating CFLAR-JNK Pathway.	honokiol	0-8	CASP8 and FADD-like apoptosis regulator	Mus musculus	131-136
33185419-0	2020	Polyphenol Honokiol and Flavone 2",3",4"-Trihydroxyflavone Differentially Interact with alpha-Synuclein at Distinct Phases of Aggregation.	honokiol	11-19	synuclein alpha	Homo sapiens	88-103
33185419-4	2020	This study comprehensively assesses the inhibitory properties of two small molecules, the lignan polyphenol honokiol and the flavonoid 2",3",4"-trihydroxyflavone, in preventing alpha-synuclein fibrilization.	honokiol	108-116	synuclein alpha	Homo sapiens	177-192
33125121-5	2020	In vitro, it was found that honokiol inhibited excessive fibroblast proliferation induced by transforming growth factor-beta1 (TGF-beta1) and the synthesis of extracellular matrix (ECM) components, including fibronectin and type I collagen, in a dose-dependent manner.	honokiol	28-36	transforming growth factor, beta 1	Rattus norvegicus	93-125
33125121-5	2020	In vitro, it was found that honokiol inhibited excessive fibroblast proliferation induced by transforming growth factor-beta1 (TGF-beta1) and the synthesis of extracellular matrix (ECM) components, including fibronectin and type I collagen, in a dose-dependent manner.	honokiol	28-36	transforming growth factor, beta 1	Rattus norvegicus	127-136
33125121-5	2020	In vitro, it was found that honokiol inhibited excessive fibroblast proliferation induced by transforming growth factor-beta1 (TGF-beta1) and the synthesis of extracellular matrix (ECM) components, including fibronectin and type I collagen, in a dose-dependent manner.	honokiol	28-36	fibronectin 1	Rattus norvegicus	208-219
33125121-6	2020	These effects were attributed to the ability of honokiol to suppress the activity of connective tissue growth factor (CTGF), which is indispensable for the progression of fibrosis.	honokiol	48-56	cellular communication network factor 2	Rattus norvegicus	85-116
33125121-6	2020	These effects were attributed to the ability of honokiol to suppress the activity of connective tissue growth factor (CTGF), which is indispensable for the progression of fibrosis.	honokiol	48-56	cellular communication network factor 2	Rattus norvegicus	118-122
33125121-7	2020	Mechanistically, honokiol attenuated the TGF-beta1-induced activation of the Smad2/3 and mitogen-activated protein kinase (MAPK) signalling pathways in fibroblasts.	honokiol	17-25	transforming growth factor, beta 1	Rattus norvegicus	41-50
33125121-7	2020	Mechanistically, honokiol attenuated the TGF-beta1-induced activation of the Smad2/3 and mitogen-activated protein kinase (MAPK) signalling pathways in fibroblasts.	honokiol	17-25	SMAD family member 2	Rattus norvegicus	77-84
33354276-0	2020	Honokiol Alleviates Methionine-Choline Deficient Diet-Induced Hepatic Steatosis and Oxidative Stress in C57BL/6 Mice by Regulating CFLAR-JNK Pathway.	honokiol	0-8	mitogen-activated protein kinase 8	Mus musculus	137-140
33354276-1	2020	Background: Honokiol (HNK) has been reported to possess various beneficial effects in the context of metabolic disorders, including fatty liver, insulin resistance, and oxidative stress which are closely related to nonalcoholic steatohepatitis (NASH), however with no particular reference to CFLAR or JNK.	honokiol	12-20	CASP8 and FADD-like apoptosis regulator	Mus musculus	292-297
33354276-1	2020	Background: Honokiol (HNK) has been reported to possess various beneficial effects in the context of metabolic disorders, including fatty liver, insulin resistance, and oxidative stress which are closely related to nonalcoholic steatohepatitis (NASH), however with no particular reference to CFLAR or JNK.	honokiol	12-20	mitogen-activated protein kinase 8	Mus musculus	301-304
33330500-0	2020	Honokiol Inhibits Melanoma Growth by Targeting Keratin 18 in vitro and in vivo.	honokiol	0-8	keratin 18	Mus musculus	47-57
33330500-7	2020	Our results showed that honokiol treatment significantly decreased KRT18 protein level and suppressed the tumor growth in melanoma cell-derived xenograft mice models.	honokiol	24-32	keratin 18	Mus musculus	67-72
33330500-8	2020	Hence, KRT18 plays an oncogenic role in melanoma and honokiol can be an inhibitor for KRT18.	honokiol	53-61	keratin 18	Mus musculus	7-12
33330500-8	2020	Hence, KRT18 plays an oncogenic role in melanoma and honokiol can be an inhibitor for KRT18.	honokiol	53-61	keratin 18	Mus musculus	86-91
33240083-4	2020	In contrast, the combination of Hono and Mag at 40 muM decreased viability, caused cell cycle arrest and enhanced the proportion of Annexin V/7AAD-positive cells.	honokiol	32-36	annexin A5	Homo sapiens	132-141
33240083-5	2020	Moreover, Mag with Hono at 40 muM induced caspase 3-dependent apoptosis and autophagy.	honokiol	19-23	caspase 3	Homo sapiens	42-51
32942603-7	2020	Honokiol significantly increased cellular GSH levels by upregulating the subunits of glutamate-cysteine ligase (Gcl)-Gclc and Gclm.	honokiol	0-8	glutamate-cysteine ligase catalytic subunit	Homo sapiens	85-110
32901874-0	2020	Anti-proliferative effect of honokiol on SW620 cells through upregulating BMP7 expression via the TGF-beta1/p53 signaling pathway.	honokiol	29-37	bone morphogenetic protein 7	Homo sapiens	74-78
32901874-0	2020	Anti-proliferative effect of honokiol on SW620 cells through upregulating BMP7 expression via the TGF-beta1/p53 signaling pathway.	honokiol	29-37	transforming growth factor beta 1	Homo sapiens	98-107
32901874-0	2020	Anti-proliferative effect of honokiol on SW620 cells through upregulating BMP7 expression via the TGF-beta1/p53 signaling pathway.	honokiol	29-37	tumor protein p53	Homo sapiens	108-111
33095758-2	2020	The present study aimed to investigate the effects of rhein and honokiol on AP.	honokiol	64-72	LIM homeobox protein 2	Mus musculus	76-78
33095758-9	2020	The AP+rhein+honokiol group had significantly reduced interstitial edema, inflammatory cell infiltration, hemorrhage, and necrosis.	honokiol	13-21	LIM homeobox protein 2	Mus musculus	4-6
33095758-10	2020	In addition, the rhein and honokiol treatment influenced some of the metabolic pathways in AP, including riboflavin metabolism, glycerophospholipid metabolism, linoleic acid metabolism, and the pentose and glucuronate interconversions pathway.	honokiol	27-35	LIM homeobox protein 2	Mus musculus	91-93
33095758-11	2020	CONCLUSIONS This study showed that the combination of rhein and honokiol ameliorated pathological changes in the pancreas of mice with AP.	honokiol	64-72	LIM homeobox protein 2	Mus musculus	135-137
32776713-7	2021	Overall, honokiol exerts apoptotic and antifibrotic effects via activation of GSK3beta and inhibition of Wnt3a/beta-catenin signalling pathway.	honokiol	9-17	Wnt family member 3A	Homo sapiens	105-110
32776713-7	2021	Overall, honokiol exerts apoptotic and antifibrotic effects via activation of GSK3beta and inhibition of Wnt3a/beta-catenin signalling pathway.	honokiol	9-17	catenin beta 1	Homo sapiens	111-123
32813287-0	2020	Accelerated, severe lupus nephritis benefits from treatment with honokiol by immunoregulation and differentially regulating NF-kappaB/NLRP3 inflammasome and sirtuin 1/autophagy axis.	honokiol	65-73	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	124-133
32813287-0	2020	Accelerated, severe lupus nephritis benefits from treatment with honokiol by immunoregulation and differentially regulating NF-kappaB/NLRP3 inflammasome and sirtuin 1/autophagy axis.	honokiol	65-73	NLR family, pyrin domain containing 3	Mus musculus	134-139
32813287-0	2020	Accelerated, severe lupus nephritis benefits from treatment with honokiol by immunoregulation and differentially regulating NF-kappaB/NLRP3 inflammasome and sirtuin 1/autophagy axis.	honokiol	65-73	sirtuin 1	Mus musculus	157-166
33081556-0	2020	Honokiol ameliorates radiation-induced brain injury via the activation of SIRT3.	honokiol	0-8	sirtuin 3	Mus musculus	74-79
33081556-5	2020	RESULTS: HKL treatment attenuated the levels of ROS, TNF-alpha, and IL-1beta in both the in vivo and in vitro models of irradiation injury.	honokiol	9-12	tumor necrosis factor	Mus musculus	53-62
33081556-5	2020	RESULTS: HKL treatment attenuated the levels of ROS, TNF-alpha, and IL-1beta in both the in vivo and in vitro models of irradiation injury.	honokiol	9-12	interleukin 1 alpha	Mus musculus	68-76
33081556-6	2020	Furthermore, HKL treatment increased the expression of SIRT3 and decreased the expression of COX-2.	honokiol	13-16	sirtuin 3	Mus musculus	55-60
33081556-6	2020	Furthermore, HKL treatment increased the expression of SIRT3 and decreased the expression of COX-2.	honokiol	13-16	prostaglandin-endoperoxide synthase 2	Mus musculus	93-98
33081556-7	2020	The radioprotective effects of HKL were achieved via SIRT3 activation.	honokiol	31-34	sirtuin 3	Mus musculus	53-58
32942603-7	2020	Honokiol significantly increased cellular GSH levels by upregulating the subunits of glutamate-cysteine ligase (Gcl)-Gclc and Gclm.	honokiol	0-8	glutamate-cysteine ligase catalytic subunit	Homo sapiens	112-115
32942603-7	2020	Honokiol significantly increased cellular GSH levels by upregulating the subunits of glutamate-cysteine ligase (Gcl)-Gclc and Gclm.	honokiol	0-8	glutamate-cysteine ligase, catalytic subunit	Mus musculus	117-121
32942603-7	2020	Honokiol significantly increased cellular GSH levels by upregulating the subunits of glutamate-cysteine ligase (Gcl)-Gclc and Gclm.	honokiol	0-8	glutamate-cysteine ligase, modifier subunit	Mus musculus	126-130
32942603-9	2020	Consistently, honokiol treatment reduced the plasma creatinine, tubular cell death, neutrophil infiltration and lipid peroxidation in IR mice and the effect was correlated with upregulation of Gclc and Gclm.	honokiol	14-22	glutamate-cysteine ligase, catalytic subunit	Mus musculus	193-197
32942603-9	2020	Consistently, honokiol treatment reduced the plasma creatinine, tubular cell death, neutrophil infiltration and lipid peroxidation in IR mice and the effect was correlated with upregulation of Gclc and Gclm.	honokiol	14-22	glutamate-cysteine ligase, modifier subunit	Mus musculus	202-206
32862190-0	2020	Honokiol Suppression of Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Cell Biological Activity and Its Mechanism.	honokiol	0-8	erb-b2 receptor tyrosine kinase 2	Homo sapiens	24-64
32879143-6	2020	Treating T2D rats in vivo with the mitochondrial deacetylase SIRT3 activator honokiol reversed the hyperacetylation of mitochondrial proteins and restored mitochondrial respiration rates to control levels.	honokiol	77-85	sirtuin 3	Rattus norvegicus	61-66
32879143-9	2020	In conclusion, hyperacetylation drives energetic dysfunction in T2D, and reversing acetylation with the SIRT3 activator honokiol rescued myocardial and mitochondrial energetics in T2D.	honokiol	120-128	sirtuin 3	Rattus norvegicus	104-109
32576717-3	2020	In a target identification study, magnolol, honokiol, and 4-O-methylhonokiol were elucidated as PPARalpha and PPARgamma dual modulators.	honokiol	44-52	peroxisome proliferator activated receptor alpha	Homo sapiens	96-105
32576717-3	2020	In a target identification study, magnolol, honokiol, and 4-O-methylhonokiol were elucidated as PPARalpha and PPARgamma dual modulators.	honokiol	44-52	peroxisome proliferator activated receptor gamma	Homo sapiens	110-119
32755037-0	2020	Honokiol ameliorates angiotensin II-induced hypertension and endothelial dysfunction by inhibiting HDAC6-mediated cystathionine gamma-lyase degradation.	honokiol	0-8	angiotensinogen	Homo sapiens	21-35
32755037-0	2020	Honokiol ameliorates angiotensin II-induced hypertension and endothelial dysfunction by inhibiting HDAC6-mediated cystathionine gamma-lyase degradation.	honokiol	0-8	histone deacetylase 6	Homo sapiens	99-104
32755037-0	2020	Honokiol ameliorates angiotensin II-induced hypertension and endothelial dysfunction by inhibiting HDAC6-mediated cystathionine gamma-lyase degradation.	honokiol	0-8	cystathionine gamma-lyase	Homo sapiens	114-139
32934777-0	2020	Correction: Non-toxic dose of liposomal honokiol suppresses metastasis of hepatocellular carcinoma through destabilizing EGFR and inhibiting the downstream pathways.	honokiol	40-48	epidermal growth factor receptor	Homo sapiens	121-125
32862190-0	2020	Honokiol Suppression of Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Cell Biological Activity and Its Mechanism.	honokiol	0-8	erb-b2 receptor tyrosine kinase 2	Homo sapiens	66-70
32862190-1	2020	BACKGROUND The purpose of our study was to determine the effects and mechanisms of honokiol on human epidermal growth factor receptor 2 (HER2)-positive gastric cancer cells by in vitro study.	honokiol	83-91	erb-b2 receptor tyrosine kinase 2	Homo sapiens	101-135
32862190-1	2020	BACKGROUND The purpose of our study was to determine the effects and mechanisms of honokiol on human epidermal growth factor receptor 2 (HER2)-positive gastric cancer cells by in vitro study.	honokiol	83-91	erb-b2 receptor tyrosine kinase 2	Homo sapiens	137-141
32862190-9	2020	By cellular immunofluorescence, HER2 protein expression was significantly depressed in honokiol-treated groups compared with control groups (P<0.05).	honokiol	87-95	erb-b2 receptor tyrosine kinase 2	Homo sapiens	32-36
32862190-10	2020	CONCLUSIONS Honokiol has suppressive effects on HER2-positive gastric cancer cell biological activities via regulation of HER2/PI3K/AKT pathways in vitro.	honokiol	12-20	erb-b2 receptor tyrosine kinase 2	Homo sapiens	48-52
32862190-10	2020	CONCLUSIONS Honokiol has suppressive effects on HER2-positive gastric cancer cell biological activities via regulation of HER2/PI3K/AKT pathways in vitro.	honokiol	12-20	erb-b2 receptor tyrosine kinase 2	Homo sapiens	122-126
32862190-10	2020	CONCLUSIONS Honokiol has suppressive effects on HER2-positive gastric cancer cell biological activities via regulation of HER2/PI3K/AKT pathways in vitro.	honokiol	12-20	AKT serine/threonine kinase 1	Homo sapiens	132-135
32784851-5	2020	Nanosome honokiol also mitigated endoplasmic reticulum stress through down regulation of Bip-ATF4-CHOP signaling pathway.	honokiol	9-17	heat shock protein family A (Hsp70) member 5	Homo sapiens	89-92
32540353-0	2020	Honokiol attenuates oxidative stress-dependent heart dysfunction in chronic Chagas disease by targeting AMPK / NFE2L2 / SIRT3 signaling pathway.	honokiol	0-8	protein kinase AMP-activated catalytic subunit alpha 2	Homo sapiens	104-108
32540353-0	2020	Honokiol attenuates oxidative stress-dependent heart dysfunction in chronic Chagas disease by targeting AMPK / NFE2L2 / SIRT3 signaling pathway.	honokiol	0-8	NFE2 like bZIP transcription factor 2	Homo sapiens	111-117
32540353-0	2020	Honokiol attenuates oxidative stress-dependent heart dysfunction in chronic Chagas disease by targeting AMPK / NFE2L2 / SIRT3 signaling pathway.	honokiol	0-8	sirtuin 3	Homo sapiens	120-125
32784851-5	2020	Nanosome honokiol also mitigated endoplasmic reticulum stress through down regulation of Bip-ATF4-CHOP signaling pathway.	honokiol	9-17	activating transcription factor 4	Homo sapiens	93-97
32784851-5	2020	Nanosome honokiol also mitigated endoplasmic reticulum stress through down regulation of Bip-ATF4-CHOP signaling pathway.	honokiol	9-17	DNA damage inducible transcript 3	Homo sapiens	98-102
32803080-0	2020	Honokiol-Chlorambucil Co-Prodrugs Selectively Enhance the Killing Effect through STAT3 Binding on Lymphocytic Leukemia Cells In Vitro and In Vivo.	honokiol	0-8	signal transducer and activator of transcription 3	Homo sapiens	81-86
32803080-3	2020	In addition, the natural product of honokiol (HN), the novel potent chemo-preventive or therapeutic entity/carrier, can target the mitochondria of cancer cells through STAT3 to prevent cancer from spreading and metastasizing.	honokiol	36-44	signal transducer and activator of transcription 3	Homo sapiens	168-173
32365054-7	2020	Furthermore, honokiol downregulated the expression of pro-inflammatory markers, like tumor necrosis factor-alpha, interleukin (IL)-6, and IL-1beta.	honokiol	13-21	tumor necrosis factor	Mus musculus	85-112
32669873-9	2020	Knockdown of miR-101 attenuated the honokiol-induced cell apoptosis and inhibition in cell invasion of pancreatic cancer cells.	honokiol	36-44	microRNA 101a	Mus musculus	13-20
32669873-11	2020	Further mechanistic study verified that Mcl-1 was negatively regulated by miR-101, and Mcl-1 overexpression counteracted the tumor-suppressive effects of honokiol on the pancreatic cancer cells.	honokiol	154-162	myeloid cell leukemia sequence 1	Mus musculus	87-92
32669873-12	2020	In vivo studies showed that honokiol dose-dependently suppressed tumor growth of pancreatic cancer in the nude mice and up-regulated miR-101 expression but down-regulated Mcl-1 expression in tumor tissues.	honokiol	28-36	microRNA 101a	Mus musculus	133-140
32669873-12	2020	In vivo studies showed that honokiol dose-dependently suppressed tumor growth of pancreatic cancer in the nude mice and up-regulated miR-101 expression but down-regulated Mcl-1 expression in tumor tissues.	honokiol	28-36	myeloid cell leukemia sequence 1	Mus musculus	171-176
32669873-13	2020	Conclusion: Our data showed that honokiol suppressed pancreatic cancer progression via miR-101-Mcl-1 axis.	honokiol	33-41	microRNA 101a	Mus musculus	87-94
32669873-13	2020	Conclusion: Our data showed that honokiol suppressed pancreatic cancer progression via miR-101-Mcl-1 axis.	honokiol	33-41	myeloid cell leukemia sequence 1	Mus musculus	95-100
32439965-4	2020	Honokiol is a natural biphenolic compound that, by activating mitochondrial SIRT3, can carry out anti-oxidant, anti-inflammatory and anti-fibrotic activities.	honokiol	0-8	sirtuin 3	Mus musculus	76-81
32439965-5	2020	Here, we sought to investigate the renoprotective effects of honokiol in BTBR ob/ob mice with type 2 diabetes.	honokiol	61-69	leptin	Mus musculus	78-80
32439965-5	2020	Here, we sought to investigate the renoprotective effects of honokiol in BTBR ob/ob mice with type 2 diabetes.	honokiol	61-69	leptin	Mus musculus	81-83
32439965-9	2020	Selective activation of SIRT3 through honokiol administration translated into the attenuation of albuminuria, amelioration of glomerular damage, and a reduction in podocyte injury.	honokiol	38-46	sirtuin 3	Mus musculus	24-29
32635337-0	2020	A Novel Combination Treatment with Honokiol and Rapamycin Effectively Restricts c-Met-Induced Growth of Renal Cancer Cells, and also Inhibits the Expression of Tumor Cell PD-L1 Involved in Immune Escape.	honokiol	35-43	met proto-oncogene	Mus musculus	80-85
32635337-0	2020	A Novel Combination Treatment with Honokiol and Rapamycin Effectively Restricts c-Met-Induced Growth of Renal Cancer Cells, and also Inhibits the Expression of Tumor Cell PD-L1 Involved in Immune Escape.	honokiol	35-43	CD274 antigen	Mus musculus	171-176
32635337-6	2020	We observed that compared with Rapamycin alone, Rapamycin + Honokiol combination can effectively down-regulate c-Met-induced Akt phosphorylation in renal cancer cells; and it markedly inhibited Ras activation and cell proliferation and promoted G1 phase cell cycle arrest.	honokiol	60-68	met proto-oncogene	Mus musculus	111-116
32635337-6	2020	We observed that compared with Rapamycin alone, Rapamycin + Honokiol combination can effectively down-regulate c-Met-induced Akt phosphorylation in renal cancer cells; and it markedly inhibited Ras activation and cell proliferation and promoted G1 phase cell cycle arrest.	honokiol	60-68	thymoma viral proto-oncogene 1	Mus musculus	125-128
32635337-8	2020	Importantly, Honokiol, but not Rapamycin, decreased c-Met-induced expression of the co-inhibitory molecule PD-L1, implied in the immune escape of renal cancer cells.	honokiol	13-21	met proto-oncogene	Mus musculus	52-57
32635337-8	2020	Importantly, Honokiol, but not Rapamycin, decreased c-Met-induced expression of the co-inhibitory molecule PD-L1, implied in the immune escape of renal cancer cells.	honokiol	13-21	CD274 antigen	Mus musculus	107-112
32635337-9	2020	In mouse renal cancer cells and Balb/c splenocytes co-culture assay, Rapamycin + Honokiol markedly potentiated immune-cell-mediated killing of cancer cells, possibly through the down-regulation of PD-L1.	honokiol	81-89	CD274 antigen	Mus musculus	197-202
32669873-0	2020	Honokiol Suppressed Pancreatic Cancer Progression via miR-101/Mcl-1 Axis.	honokiol	0-8	microRNA 101a	Mus musculus	54-61
32669873-0	2020	Honokiol Suppressed Pancreatic Cancer Progression via miR-101/Mcl-1 Axis.	honokiol	0-8	myeloid cell leukemia sequence 1	Mus musculus	62-67
32669873-7	2020	In addition, honokiol increased the caspase-3 activity and cell apoptotic rates, induced cell cycle arrest at G0/G1 phase, and inhibited cell invasion in pancreatic cancer.	honokiol	13-21	caspase 3	Mus musculus	36-45
32669873-8	2020	Interestingly, honokiol treatment induced up-regulation of miR-101 in pancreatic cancer cells.	honokiol	15-23	microRNA 101a	Mus musculus	59-66
32365054-7	2020	Furthermore, honokiol downregulated the expression of pro-inflammatory markers, like tumor necrosis factor-alpha, interleukin (IL)-6, and IL-1beta.	honokiol	13-21	interleukin 6	Mus musculus	114-132
32365054-7	2020	Furthermore, honokiol downregulated the expression of pro-inflammatory markers, like tumor necrosis factor-alpha, interleukin (IL)-6, and IL-1beta.	honokiol	13-21	interleukin 1 alpha	Mus musculus	138-146
32365054-9	2020	Nitric oxide level, inducible nitric oxide synthase (iNOS) expression, and aberrant activation of nuclear factor-kappaB pathway were also significantly inhibited by honokiol treatment.	honokiol	165-173	nitric oxide synthase 2, inducible	Mus musculus	20-51
32365054-9	2020	Nitric oxide level, inducible nitric oxide synthase (iNOS) expression, and aberrant activation of nuclear factor-kappaB pathway were also significantly inhibited by honokiol treatment.	honokiol	165-173	nitric oxide synthase 2, inducible	Mus musculus	53-57
32210117-0	2020	Major Contribution of Caspase-9 to Honokiol-Induced Apoptotic Insults to Human Drug-Resistant Glioblastoma Cells.	honokiol	35-43	caspase 9	Homo sapiens	22-31
32041837-10	2020	CRISPR and pharmacologic targeting of ZEB1 with honokiol reversed the mesenchymal gene expression and associated stem cell, invasion, and metabolic changes defining resistance.	honokiol	48-56	zinc finger E-box binding homeobox 1	Homo sapiens	38-42
32003107-0	2020	Overcoming acquired resistance of EGFR-mutant NSCLC cells to the third generation EGFR inhibitor, osimertinib, with the natural product honokiol.	honokiol	136-144	epidermal growth factor receptor	Homo sapiens	34-38
32003107-0	2020	Overcoming acquired resistance of EGFR-mutant NSCLC cells to the third generation EGFR inhibitor, osimertinib, with the natural product honokiol.	honokiol	136-144	epidermal growth factor receptor	Homo sapiens	82-86
32281286-8	2020	The activation of Sirt3 by honokiol could improve FAO and renal function and reduced fatty acid deposition in wide-type mice, but not Sirt3-defective mice.	honokiol	27-35	sirtuin 3	Mus musculus	18-23
32281286-10	2020	Also, the activation of Sirt3 by honokiol increased ATP production as well as reduced ROS and lipid peroxidation through improving mitochondrial function.	honokiol	33-41	sirtuin 3	Mus musculus	24-29
32895138-8	2020	CONCLUSIONS: Honokiol can inhibit the proliferation and migration and induce apoptosis of CAL-27 cells in vitro possibly by regulating the expressions of p-Pi3k, p-Fak, MMP-2, MMP-9, p-Akt, Bax, Bcl-2 and cleaved-caspase-3.	honokiol	13-21	protein tyrosine kinase 2	Homo sapiens	164-167
32895138-8	2020	CONCLUSIONS: Honokiol can inhibit the proliferation and migration and induce apoptosis of CAL-27 cells in vitro possibly by regulating the expressions of p-Pi3k, p-Fak, MMP-2, MMP-9, p-Akt, Bax, Bcl-2 and cleaved-caspase-3.	honokiol	13-21	matrix metallopeptidase 2	Homo sapiens	169-174
32895138-8	2020	CONCLUSIONS: Honokiol can inhibit the proliferation and migration and induce apoptosis of CAL-27 cells in vitro possibly by regulating the expressions of p-Pi3k, p-Fak, MMP-2, MMP-9, p-Akt, Bax, Bcl-2 and cleaved-caspase-3.	honokiol	13-21	matrix metallopeptidase 9	Homo sapiens	176-181
32895138-8	2020	CONCLUSIONS: Honokiol can inhibit the proliferation and migration and induce apoptosis of CAL-27 cells in vitro possibly by regulating the expressions of p-Pi3k, p-Fak, MMP-2, MMP-9, p-Akt, Bax, Bcl-2 and cleaved-caspase-3.	honokiol	13-21	AKT serine/threonine kinase 1	Homo sapiens	185-188
32895138-8	2020	CONCLUSIONS: Honokiol can inhibit the proliferation and migration and induce apoptosis of CAL-27 cells in vitro possibly by regulating the expressions of p-Pi3k, p-Fak, MMP-2, MMP-9, p-Akt, Bax, Bcl-2 and cleaved-caspase-3.	honokiol	13-21	BCL2 associated X, apoptosis regulator	Homo sapiens	190-193
32895138-8	2020	CONCLUSIONS: Honokiol can inhibit the proliferation and migration and induce apoptosis of CAL-27 cells in vitro possibly by regulating the expressions of p-Pi3k, p-Fak, MMP-2, MMP-9, p-Akt, Bax, Bcl-2 and cleaved-caspase-3.	honokiol	13-21	BCL2 apoptosis regulator	Homo sapiens	195-200
32210117-8	2020	Compared to caspase-8 activation, honokiol chiefly increased activity of caspase-9 in U87-MG-R9 cells.	honokiol	34-42	caspase 9	Homo sapiens	73-82
32210117-9	2020	Successively, levels of cleaved caspase-3 and activities of caspase-3 and caspase-6 in human TMZ-tolerant glioblastoma cells were augmented following honokiol administration.	honokiol	150-158	caspase 3	Homo sapiens	32-41
32210117-9	2020	Successively, levels of cleaved caspase-3 and activities of caspase-3 and caspase-6 in human TMZ-tolerant glioblastoma cells were augmented following honokiol administration.	honokiol	150-158	caspase 6	Homo sapiens	74-83
32210117-12	2020	Fascinatingly, suppressing caspase-9 activity using its specific inhibitors repressed honokiol-induced caspase-6 activation, DNA fragmentation, and cell apoptosis.	honokiol	86-94	caspase 9	Homo sapiens	27-36
32210117-12	2020	Fascinatingly, suppressing caspase-9 activity using its specific inhibitors repressed honokiol-induced caspase-6 activation, DNA fragmentation, and cell apoptosis.	honokiol	86-94	caspase 6	Homo sapiens	103-112
32210117-13	2020	Taken together, this study has shown the major roles of caspase-9 in transducing honokiol-induced mitochondria-dependent apoptosis in human drug-resistant glioblastoma cells.	honokiol	81-89	caspase 9	Homo sapiens	56-65
31936371-3	2020	Recently, honokiol (HKL), as apharmaceutical SIRT3 activator, has been observed to have a protective effect against pressureoverload-induced cardiac hypertrophy by increasing SIRT3 activity.	honokiol	10-18	sirtuin 3	Rattus norvegicus	45-50
32180962-0	2020	Suppressing migration and invasion of H1299 lung cancer cells by honokiol through disrupting expression of an HDAC6-mediated matrix metalloproteinase 9.	honokiol	65-73	histone deacetylase 6	Homo sapiens	110-115
32180962-0	2020	Suppressing migration and invasion of H1299 lung cancer cells by honokiol through disrupting expression of an HDAC6-mediated matrix metalloproteinase 9.	honokiol	65-73	matrix metallopeptidase 9	Homo sapiens	125-151
32180962-5	2020	However, the regulation of MMPs-mediated migration and invasion by honokiol through epigenetic regulation in lung cancer is still a mystery.	honokiol	67-75	matrix metallopeptidase 2	Homo sapiens	27-31
32180962-7	2020	The proteolytic activity of MMP-9, rather than MMP-2, was inhibited in honokiol-treated H1299 cells.	honokiol	71-79	matrix metallopeptidase 9	Homo sapiens	28-33
32180962-7	2020	The proteolytic activity of MMP-9, rather than MMP-2, was inhibited in honokiol-treated H1299 cells.	honokiol	71-79	matrix metallopeptidase 2	Homo sapiens	47-52
32180962-8	2020	Honokiol-inhibited MMP-9 expression was through promoting MMP-9 protein degradation rather than suppressing transcription mechanism.	honokiol	0-8	matrix metallopeptidase 9	Homo sapiens	19-24
32180962-8	2020	Honokiol-inhibited MMP-9 expression was through promoting MMP-9 protein degradation rather than suppressing transcription mechanism.	honokiol	0-8	matrix metallopeptidase 9	Homo sapiens	58-63
32180962-10	2020	The disassociation of MMP-9 with hyper-acetylated heat shock protein 90 (Hsp90) was observed resulting in MMP-9 degradation after honokiol treatment.	honokiol	130-138	matrix metallopeptidase 9	Homo sapiens	22-27
32180962-10	2020	The disassociation of MMP-9 with hyper-acetylated heat shock protein 90 (Hsp90) was observed resulting in MMP-9 degradation after honokiol treatment.	honokiol	130-138	heat shock protein 90 alpha family class A member 1	Homo sapiens	50-71
32180962-10	2020	The disassociation of MMP-9 with hyper-acetylated heat shock protein 90 (Hsp90) was observed resulting in MMP-9 degradation after honokiol treatment.	honokiol	130-138	heat shock protein 90 alpha family class A member 1	Homo sapiens	73-78
32180962-10	2020	The disassociation of MMP-9 with hyper-acetylated heat shock protein 90 (Hsp90) was observed resulting in MMP-9 degradation after honokiol treatment.	honokiol	130-138	matrix metallopeptidase 9	Homo sapiens	106-111
32180962-11	2020	Meanwhile, honokiol-suppressed MMP-9 expression and invasion ability of H1299 lung cancer cells was rescued by HDAC6 overexpression.	honokiol	11-19	matrix metallopeptidase 9	Homo sapiens	31-36
32180962-11	2020	Meanwhile, honokiol-suppressed MMP-9 expression and invasion ability of H1299 lung cancer cells was rescued by HDAC6 overexpression.	honokiol	11-19	histone deacetylase 6	Homo sapiens	111-116
32180962-12	2020	Accordingly, the results suggested that the suppression of migration and invasion activities by honokiol was through inhibiting HDAC6-mediated Hsp90/MMP-9 interaction and followed by MMP-9 degradation in lung cancer.	honokiol	96-104	histone deacetylase 6	Homo sapiens	128-133
32180962-12	2020	Accordingly, the results suggested that the suppression of migration and invasion activities by honokiol was through inhibiting HDAC6-mediated Hsp90/MMP-9 interaction and followed by MMP-9 degradation in lung cancer.	honokiol	96-104	heat shock protein 90 alpha family class A member 1	Homo sapiens	143-148
32180962-12	2020	Accordingly, the results suggested that the suppression of migration and invasion activities by honokiol was through inhibiting HDAC6-mediated Hsp90/MMP-9 interaction and followed by MMP-9 degradation in lung cancer.	honokiol	96-104	matrix metallopeptidase 9	Homo sapiens	149-154
32180962-12	2020	Accordingly, the results suggested that the suppression of migration and invasion activities by honokiol was through inhibiting HDAC6-mediated Hsp90/MMP-9 interaction and followed by MMP-9 degradation in lung cancer.	honokiol	96-104	matrix metallopeptidase 9	Homo sapiens	183-188
32148818-9	2020	Results from our in vitro study further indicated that honokiol, the principle component of MEMO, would protect human umbilical vein endothelial cells (HUVECs) from H2O2-induced damages and inhibit H2O2-induced vascular smooth muscles cells (VSMCs) proliferation, which was evident by the decreased expression of pFAK, and p-Erk1/2.	honokiol	55-63	mitogen-activated protein kinase 3	Homo sapiens	325-331
32032644-0	2020	Honokiol: A polyphenol neolignan ameliorates pulmonary fibrosis by inhibiting TGF-beta/Smad signaling, matrix proteins and IL-6/CD44/STAT3 axis both in vitro and in vivo.	honokiol	0-8	transforming growth factor alpha	Homo sapiens	78-86
32032644-0	2020	Honokiol: A polyphenol neolignan ameliorates pulmonary fibrosis by inhibiting TGF-beta/Smad signaling, matrix proteins and IL-6/CD44/STAT3 axis both in vitro and in vivo.	honokiol	0-8	interleukin 6	Homo sapiens	123-127
32032644-0	2020	Honokiol: A polyphenol neolignan ameliorates pulmonary fibrosis by inhibiting TGF-beta/Smad signaling, matrix proteins and IL-6/CD44/STAT3 axis both in vitro and in vivo.	honokiol	0-8	CD44 molecule (Indian blood group)	Homo sapiens	128-132
32032644-0	2020	Honokiol: A polyphenol neolignan ameliorates pulmonary fibrosis by inhibiting TGF-beta/Smad signaling, matrix proteins and IL-6/CD44/STAT3 axis both in vitro and in vivo.	honokiol	0-8	signal transducer and activator of transcription 3	Homo sapiens	133-138
31862719-0	2020	Honokiol Restores Polymyxin Susceptibility to MCR-1-Positive Pathogens both In Vitro and In Vivo.	honokiol	0-8	melanocortin 1 receptor	Mus musculus	46-51
31862719-4	2020	The MIC results indicated that honokiol can recover the sensitivity of polymyxins against MCR-1-positive Klebsiella pneumoniae and Escherichia coli (with a fractional inhibitory concentration index ranging from 0.09 +- 0.00 to 0.27 +- 0.06).	honokiol	31-39	melanocortin 1 receptor	Mus musculus	90-95
31862719-6	2020	Molecular simulation dynamics results suggested that honokiol directly binds to the MCR-1 active region, reducing the biological activity of MCR-1.	honokiol	53-61	melanocortin 1 receptor	Mus musculus	84-89
31862719-6	2020	Molecular simulation dynamics results suggested that honokiol directly binds to the MCR-1 active region, reducing the biological activity of MCR-1.	honokiol	53-61	melanocortin 1 receptor	Mus musculus	141-146
31862719-8	2020	Our study indicates that honokiol is a predominant natural compound whose combination therapy with polymyxins is very promising in future treatment options for MCR-1-positive Enterobacteriaceae infections.IMPORTANCE In the present study, honokiol could effectively inhibit the activity of MCR-1 and showed almost no cytotoxicity to MH-S cells.	honokiol	25-33	melanocortin 1 receptor	Mus musculus	160-165
31862719-8	2020	Our study indicates that honokiol is a predominant natural compound whose combination therapy with polymyxins is very promising in future treatment options for MCR-1-positive Enterobacteriaceae infections.IMPORTANCE In the present study, honokiol could effectively inhibit the activity of MCR-1 and showed almost no cytotoxicity to MH-S cells.	honokiol	25-33	melanocortin 1 receptor	Mus musculus	289-294
31862719-8	2020	Our study indicates that honokiol is a predominant natural compound whose combination therapy with polymyxins is very promising in future treatment options for MCR-1-positive Enterobacteriaceae infections.IMPORTANCE In the present study, honokiol could effectively inhibit the activity of MCR-1 and showed almost no cytotoxicity to MH-S cells.	honokiol	238-246	melanocortin 1 receptor	Mus musculus	160-165
31862719-8	2020	Our study indicates that honokiol is a predominant natural compound whose combination therapy with polymyxins is very promising in future treatment options for MCR-1-positive Enterobacteriaceae infections.IMPORTANCE In the present study, honokiol could effectively inhibit the activity of MCR-1 and showed almost no cytotoxicity to MH-S cells.	honokiol	238-246	melanocortin 1 receptor	Mus musculus	289-294
31862719-9	2020	According to our results, the combination of honokiol and polymyxin had a clear synergistic effect against MCR-1-positive Enterobacteriaceae in vitro Combination therapy also showed a powerful therapeutic effect in vivo, which can significantly improve mouse livability, reduced the load of bacteria, and reduced pathological change.	honokiol	45-53	melanocortin 1 receptor	Mus musculus	107-112
31862719-10	2020	This combined therapy of small molecule compounds and antibiotics may not continue to induce new bacterial resistance, due to the fact that MCR-1 targeted by honokiol is not indispensable for the bacterial viability; on the other hand, it can reduce the dosage of combined antibiotics, and it is also a promising alternative therapy for the treatment of drug-resistant infections in the future.	honokiol	158-166	melanocortin 1 receptor	Mus musculus	140-145
31936371-3	2020	Recently, honokiol (HKL), as apharmaceutical SIRT3 activator, has been observed to have a protective effect against pressureoverload-induced cardiac hypertrophy by increasing SIRT3 activity.	honokiol	10-18	sirtuin 3	Rattus norvegicus	175-180
31936371-3	2020	Recently, honokiol (HKL), as apharmaceutical SIRT3 activator, has been observed to have a protective effect against pressureoverload-induced cardiac hypertrophy by increasing SIRT3 activity.	honokiol	20-23	sirtuin 3	Rattus norvegicus	45-50
31936371-3	2020	Recently, honokiol (HKL), as apharmaceutical SIRT3 activator, has been observed to have a protective effect against pressureoverload-induced cardiac hypertrophy by increasing SIRT3 activity.	honokiol	20-23	sirtuin 3	Rattus norvegicus	175-180
31936371-8	2020	In conclusion, activation of SIRT3 via HKL treatment might havebeneficial effects on UUO-induced renal fibrosis through SIRT3-dependent regulation ofmitochondrial dynamics and the NF-kappaB/TGF-beta1/Smad signaling pathway.	honokiol	39-42	sirtuin 3	Rattus norvegicus	29-34
31936371-8	2020	In conclusion, activation of SIRT3 via HKL treatment might havebeneficial effects on UUO-induced renal fibrosis through SIRT3-dependent regulation ofmitochondrial dynamics and the NF-kappaB/TGF-beta1/Smad signaling pathway.	honokiol	39-42	sirtuin 3	Rattus norvegicus	120-125
31936371-8	2020	In conclusion, activation of SIRT3 via HKL treatment might havebeneficial effects on UUO-induced renal fibrosis through SIRT3-dependent regulation ofmitochondrial dynamics and the NF-kappaB/TGF-beta1/Smad signaling pathway.	honokiol	39-42	transforming growth factor, beta 1	Rattus norvegicus	190-199
31746354-0	2020	Honokiol antagonizes doxorubicin-induced cardiomyocyte senescence by inhibiting TXNIP-mediated NLRP3 inflammasome activation.	honokiol	0-8	thioredoxin interacting protein	Homo sapiens	80-85
32922930-6	2020	The pharmacological agonist of SIRT3, Honokiol (HKL), was injected in an intraperitoneal manner (10 mg/kg) immediately after the operation.	honokiol	38-46	sirtuin 3	Mus musculus	31-36
32922930-6	2020	The pharmacological agonist of SIRT3, Honokiol (HKL), was injected in an intraperitoneal manner (10 mg/kg) immediately after the operation.	honokiol	48-51	sirtuin 3	Mus musculus	31-36
32922930-11	2020	Result: SIRT3 was downregulated after SAH, and additional treatment of SIRT3 agonist HKL alleviated brain edema and neurobehavioral deficits after SAH.	honokiol	85-88	sirtuin 3	Mus musculus	8-13
32922930-11	2020	Result: SIRT3 was downregulated after SAH, and additional treatment of SIRT3 agonist HKL alleviated brain edema and neurobehavioral deficits after SAH.	honokiol	85-88	sirtuin 3	Mus musculus	71-76
31746354-0	2020	Honokiol antagonizes doxorubicin-induced cardiomyocyte senescence by inhibiting TXNIP-mediated NLRP3 inflammasome activation.	honokiol	0-8	NLR family pyrin domain containing 3	Homo sapiens	95-100
31746354-6	2020	The present study demonstrated that Hnk was able to prevent Dox-induced senescence of H9c2 cardiomyocytes, indicated by decreased senescence-associated beta-galactosidase (SA-beta-gal) staining, as well as decreased expression of p16INK4A and p21.	honokiol	36-39	galactosidase beta 1	Homo sapiens	152-170
31746354-6	2020	The present study demonstrated that Hnk was able to prevent Dox-induced senescence of H9c2 cardiomyocytes, indicated by decreased senescence-associated beta-galactosidase (SA-beta-gal) staining, as well as decreased expression of p16INK4A and p21.	honokiol	36-39	cyclin dependent kinase inhibitor 2A	Homo sapiens	230-238
31746354-6	2020	The present study demonstrated that Hnk was able to prevent Dox-induced senescence of H9c2 cardiomyocytes, indicated by decreased senescence-associated beta-galactosidase (SA-beta-gal) staining, as well as decreased expression of p16INK4A and p21.	honokiol	36-39	H3 histone pseudogene 16	Homo sapiens	243-246
31746354-7	2020	Hnk also inhibited TXNIP expression and NLRP3 inflammasome activation in Dox-stimulated H9c2 cardiomyocytes.	honokiol	0-3	thioredoxin interacting protein	Homo sapiens	19-24
31746354-7	2020	Hnk also inhibited TXNIP expression and NLRP3 inflammasome activation in Dox-stimulated H9c2 cardiomyocytes.	honokiol	0-3	NLR family pyrin domain containing 3	Homo sapiens	40-45
31746354-8	2020	When TXNIP expression was enforced by adenovirus-mediated gene overexpression, the NLRP3 inflammasome was activated, which led to inhibition of the anti-inflammation and anti-senescence effects of Hnk on H9c2 cardiomyocytes under Dox treatment.	honokiol	197-200	thioredoxin interacting protein	Homo sapiens	5-10
31746354-8	2020	When TXNIP expression was enforced by adenovirus-mediated gene overexpression, the NLRP3 inflammasome was activated, which led to inhibition of the anti-inflammation and anti-senescence effects of Hnk on H9c2 cardiomyocytes under Dox treatment.	honokiol	197-200	NLR family pyrin domain containing 3	Homo sapiens	83-88
31746354-10	2020	Consistently, TXNIP knockdown enhanced the anti-inflammation and anti-senescence effects of Hnk on H9c2 cardiomyocytes under Dox stimulation.	honokiol	92-95	thioredoxin interacting protein	Homo sapiens	14-19
31760097-11	2020	Contrariwise, honokiol co-treatment significantly restored antioxidant defence mechanisms, down-regulated inflammatory cascades and inhibited TGF-beta/SMAD/MAPK signaling pathways.	honokiol	14-22	transforming growth factor alpha	Rattus norvegicus	142-150
31760097-12	2020	CONCLUSION: The results provide an evidence for the promising antifibrotic effect of honokiol that could be partially due to suppressing oxidative stress and inflammatory processes as well as inhibition of TGF-beta/SMAD/MAPK signaling pathways.	honokiol	85-93	transforming growth factor alpha	Rattus norvegicus	206-214
30849265-3	2020	Honokiol has been reported to bind directly to GPVI but only at a concentration that is three orders of magnitude higher than that needed for inhibition of aggregation.	honokiol	0-8	glycoprotein VI platelet	Homo sapiens	47-51
31129139-10	2019	Further investigation suggested that HO induced inhibition of CYP 2E1 and CYP2A1 as well as upregulation of GSH co-contributed to the reduction of APAP-protein adducts.	honokiol	37-39	cytochrome P450, family 2, subfamily e, polypeptide 1	Mus musculus	62-69
31175627-0	2019	Inhibition of Rat CYP1A2 and CYP2C11 by Honokiol, a Component of Traditional Chinese Medicine.	honokiol	40-48	cytochrome P450, family 1, subfamily a, polypeptide 2	Rattus norvegicus	18-24
31175627-0	2019	Inhibition of Rat CYP1A2 and CYP2C11 by Honokiol, a Component of Traditional Chinese Medicine.	honokiol	40-48	cytochrome P450, subfamily 2, polypeptide 11	Rattus norvegicus	29-36
31175627-2	2019	However, the effect of honokiol on cytochrome P450 (CYP) has not been thoroughly investigated.	honokiol	23-31	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	35-50
31175627-2	2019	However, the effect of honokiol on cytochrome P450 (CYP) has not been thoroughly investigated.	honokiol	23-31	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	52-55
31175627-3	2019	The aim of this study was to investigate the effect of honokiol on CYP1A2 and CYP2C11 in vitro and in vivo.	honokiol	55-63	cytochrome P450, family 1, subfamily a, polypeptide 2	Rattus norvegicus	67-73
31175627-3	2019	The aim of this study was to investigate the effect of honokiol on CYP1A2 and CYP2C11 in vitro and in vivo.	honokiol	55-63	cytochrome P450, subfamily 2, polypeptide 11	Rattus norvegicus	78-85
31175627-8	2019	CONCLUSION: The inhibition of CYP1A2 by honokiol is greater than the inhibition of CYP2C11.	honokiol	40-48	cytochrome P450, family 1, subfamily a, polypeptide 2	Rattus norvegicus	30-36
31600935-0	2019	Nanoparticulated Honokiol Mitigates Cisplatin-Induced Chronic Kidney Injury by Maintaining Mitochondria Antioxidant Capacity and Reducing Caspase 3-Associated Cellular Apoptosis.	honokiol	17-25	caspase 3	Homo sapiens	138-147
31235819-0	2019	Honokiol inhibits breast cancer cell metastasis by blocking EMT through modulation of Snail/Slug protein translation.	honokiol	0-8	IL2 inducible T cell kinase	Mus musculus	60-63
31235819-0	2019	Honokiol inhibits breast cancer cell metastasis by blocking EMT through modulation of Snail/Slug protein translation.	honokiol	0-8	snail family zinc finger 1	Mus musculus	86-91
31235819-0	2019	Honokiol inhibits breast cancer cell metastasis by blocking EMT through modulation of Snail/Slug protein translation.	honokiol	0-8	snail family zinc finger 2	Mus musculus	92-96
30807551-3	2019	Honokiol analogs, especially 3,5"-diformylated honokiol HK-(CHO)2, have been found to moderately block the newly grown segmental vessels from the dorsal aorta in the transgenic zebrafish-based assay, show antiangiogenic property, and exert medium cytotoxicity against two lung cell lines (Lewis lung carcinoma LL/2 cells and human non-small-cell lung cancer A549 cells).	honokiol	0-8	hook	Mus musculus	56-65
30807551-5	2019	In the study, two formylated honokiol derivatives also showed potent antitumor effects in the Lewis lung carcinoma cells, K-ras-dirived lung adenocarcinoma mice, and a mouse lung tumor xenograft model, with HK-(CHO)2 being most efficacious.	honokiol	29-37	Kirsten rat sarcoma viral oncogene homolog	Mus musculus	122-127
30807551-5	2019	In the study, two formylated honokiol derivatives also showed potent antitumor effects in the Lewis lung carcinoma cells, K-ras-dirived lung adenocarcinoma mice, and a mouse lung tumor xenograft model, with HK-(CHO)2 being most efficacious.	honokiol	29-37	hook	Mus musculus	207-216
31176168-16	2019	CONCLUSION: Let-7c-5p, miR-148a-3p, miR-148a-5p, and miR-7-5p are favorable indicators of NSCLC patients treated with honokiol.	honokiol	118-126	microRNA 7-3	Homo sapiens	53-61
31877856-8	2019	Additionally, honokiol possesses the capability to supress cell migration and invasion via the downregulation of several matrix-metalloproteinases (activation of 5" AMP-activated protein kinase (AMPK) and KISS1/KISS1R signalling), inhibiting cell migration, invasion, and metastasis, as well as inducing anti-angiogenesis activity (via the down-regulation of vascular endothelial growth factor (VEGFR) and vascular endothelial growth factor (VEGF)).	honokiol	14-22	KiSS-1 metastasis suppressor	Homo sapiens	205-210
31877856-8	2019	Additionally, honokiol possesses the capability to supress cell migration and invasion via the downregulation of several matrix-metalloproteinases (activation of 5" AMP-activated protein kinase (AMPK) and KISS1/KISS1R signalling), inhibiting cell migration, invasion, and metastasis, as well as inducing anti-angiogenesis activity (via the down-regulation of vascular endothelial growth factor (VEGFR) and vascular endothelial growth factor (VEGF)).	honokiol	14-22	KISS1 receptor	Homo sapiens	211-217
31877856-8	2019	Additionally, honokiol possesses the capability to supress cell migration and invasion via the downregulation of several matrix-metalloproteinases (activation of 5" AMP-activated protein kinase (AMPK) and KISS1/KISS1R signalling), inhibiting cell migration, invasion, and metastasis, as well as inducing anti-angiogenesis activity (via the down-regulation of vascular endothelial growth factor (VEGFR) and vascular endothelial growth factor (VEGF)).	honokiol	14-22	vascular endothelial growth factor A	Homo sapiens	359-393
31877856-8	2019	Additionally, honokiol possesses the capability to supress cell migration and invasion via the downregulation of several matrix-metalloproteinases (activation of 5" AMP-activated protein kinase (AMPK) and KISS1/KISS1R signalling), inhibiting cell migration, invasion, and metastasis, as well as inducing anti-angiogenesis activity (via the down-regulation of vascular endothelial growth factor (VEGFR) and vascular endothelial growth factor (VEGF)).	honokiol	14-22	kinase insert domain receptor	Homo sapiens	395-400
31877856-8	2019	Additionally, honokiol possesses the capability to supress cell migration and invasion via the downregulation of several matrix-metalloproteinases (activation of 5" AMP-activated protein kinase (AMPK) and KISS1/KISS1R signalling), inhibiting cell migration, invasion, and metastasis, as well as inducing anti-angiogenesis activity (via the down-regulation of vascular endothelial growth factor (VEGFR) and vascular endothelial growth factor (VEGF)).	honokiol	14-22	vascular endothelial growth factor A	Homo sapiens	406-440
31877856-8	2019	Additionally, honokiol possesses the capability to supress cell migration and invasion via the downregulation of several matrix-metalloproteinases (activation of 5" AMP-activated protein kinase (AMPK) and KISS1/KISS1R signalling), inhibiting cell migration, invasion, and metastasis, as well as inducing anti-angiogenesis activity (via the down-regulation of vascular endothelial growth factor (VEGFR) and vascular endothelial growth factor (VEGF)).	honokiol	14-22	vascular endothelial growth factor A	Homo sapiens	395-399
31817770-0	2019	Honokiol Enhances TRAIL-Mediated Apoptosis through STAMBPL1-Induced Survivin and c-FLIP Degradation.	honokiol	0-8	TNF superfamily member 10	Homo sapiens	18-23
31817770-0	2019	Honokiol Enhances TRAIL-Mediated Apoptosis through STAMBPL1-Induced Survivin and c-FLIP Degradation.	honokiol	0-8	STAM binding protein like 1	Homo sapiens	51-59
31817770-0	2019	Honokiol Enhances TRAIL-Mediated Apoptosis through STAMBPL1-Induced Survivin and c-FLIP Degradation.	honokiol	0-8	CASP8 and FADD like apoptosis regulator	Homo sapiens	81-87
31817770-2	2019	Here, we found that honokiol sensitizes cancer cells to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis through downregulation of anti-apoptotic proteins survivin and c-FLIP.	honokiol	20-28	TNF superfamily member 10	Homo sapiens	56-111
31817770-2	2019	Here, we found that honokiol sensitizes cancer cells to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis through downregulation of anti-apoptotic proteins survivin and c-FLIP.	honokiol	20-28	TNF superfamily member 10	Homo sapiens	113-118
31817770-2	2019	Here, we found that honokiol sensitizes cancer cells to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis through downregulation of anti-apoptotic proteins survivin and c-FLIP.	honokiol	20-28	CASP8 and FADD like apoptosis regulator	Homo sapiens	201-207
31817770-3	2019	Ectopic expression of survivin and c-FLIP markedly abolished honokiol and TRAIL-induced apoptosis.	honokiol	61-69	CASP8 and FADD like apoptosis regulator	Homo sapiens	35-41
31817770-4	2019	Mechanistically, honokiol induced protein degradation of c-FLIP and survivin through STAMBPL1, a deubiquitinase.	honokiol	17-25	CASP8 and FADD like apoptosis regulator	Homo sapiens	57-63
31817770-4	2019	Mechanistically, honokiol induced protein degradation of c-FLIP and survivin through STAMBPL1, a deubiquitinase.	honokiol	17-25	STAM binding protein like 1	Homo sapiens	85-93
31817770-7	2019	Our findings provided that honokiol could overcome TRAIL resistance through survivin and c-FLIP degradation induced by inhibition of STAMBPL1 expression.	honokiol	27-35	TNF superfamily member 10	Homo sapiens	51-56
31817770-7	2019	Our findings provided that honokiol could overcome TRAIL resistance through survivin and c-FLIP degradation induced by inhibition of STAMBPL1 expression.	honokiol	27-35	CASP8 and FADD like apoptosis regulator	Homo sapiens	89-95
31817770-7	2019	Our findings provided that honokiol could overcome TRAIL resistance through survivin and c-FLIP degradation induced by inhibition of STAMBPL1 expression.	honokiol	27-35	STAM binding protein like 1	Homo sapiens	133-141
31175627-9	2019	The changes in the pharmacokinetics of theophylline and tolbutamide in rats treated with honokiol are due to the inhibition of CYP1A2 and CYP2C11 activity in a dose-dependent manner.	honokiol	89-97	cytochrome P450, family 1, subfamily a, polypeptide 2	Rattus norvegicus	127-133
31175627-9	2019	The changes in the pharmacokinetics of theophylline and tolbutamide in rats treated with honokiol are due to the inhibition of CYP1A2 and CYP2C11 activity in a dose-dependent manner.	honokiol	89-97	cytochrome P450, subfamily 2, polypeptide 11	Rattus norvegicus	138-145
31515676-6	2019	Additional observations indicated that the phytochemical, honokiol downregulates the expression of Neu1.	honokiol	58-66	neuraminidase 1	Homo sapiens	99-103
31515676-7	2019	As a consequence of blocking Neu1, honokiol reduced the levels of sialic acid in the two subtypes of breast cancer.	honokiol	35-43	neuraminidase 1	Homo sapiens	29-33
31115492-11	2019	Using Honokiol and FR180204, the activator and inhibitor of ERK1/2, respectively, it was then revealed that Honokiol partially eliminated the decrease in HGF expression, whereas FR180204 further promoted the reduction in HGF caused by NMDA.	honokiol	108-116	mitogen-activated protein kinase 3	Mus musculus	60-66
31115492-11	2019	Using Honokiol and FR180204, the activator and inhibitor of ERK1/2, respectively, it was then revealed that Honokiol partially eliminated the decrease in HGF expression, whereas FR180204 further promoted the reduction in HGF caused by NMDA.	honokiol	108-116	hepatocyte growth factor	Mus musculus	154-157
31022495-0	2019	Role of Nrf2 in the antioxidation and oxidative stress induced developmental toxicity of honokiol in zebrafish.	honokiol	89-97	nfe2 like bZIP transcription factor 2a	Danio rerio	8-12
30925455-0	2019	Suppression of TRPV1 and P2Y nociceptors by honokiol isolated from Magnolia officinalis in 3rd degree burn mice by inhibiting inflammatory mediators.	honokiol	44-52	transient receptor potential cation channel, subfamily V, member 1	Mus musculus	15-20
30925455-9	2019	Effect of honokiol on cytokines and mRNA expression levels of TRPV1 and P2Y were also assessed.	honokiol	10-18	transient receptor potential cation channel, subfamily V, member 1	Mus musculus	62-67
30925455-10	2019	Honokiol significantly decreases the expression of TNF-alpha, IL-1beta and IL-6 and decreases expression level of TRPV1 and P2Y.	honokiol	0-8	tumor necrosis factor	Mus musculus	51-60
30925455-10	2019	Honokiol significantly decreases the expression of TNF-alpha, IL-1beta and IL-6 and decreases expression level of TRPV1 and P2Y.	honokiol	0-8	interleukin 1 beta	Mus musculus	62-70
30925455-10	2019	Honokiol significantly decreases the expression of TNF-alpha, IL-1beta and IL-6 and decreases expression level of TRPV1 and P2Y.	honokiol	0-8	interleukin 6	Mus musculus	75-79
30925455-10	2019	Honokiol significantly decreases the expression of TNF-alpha, IL-1beta and IL-6 and decreases expression level of TRPV1 and P2Y.	honokiol	0-8	transient receptor potential cation channel, subfamily V, member 1	Mus musculus	114-119
30925455-11	2019	Additionally, TRPV1 and P2Y proteins expression levels were also assessed by Western blot in paw skin tissue, sciatic nerve and spinal cord which were remarkably down-regulated by honokiol.	honokiol	180-188	transient receptor potential cation channel, subfamily V, member 1	Mus musculus	14-19
30925455-14	2019	Honokiol treatment also potentiates the expression of reduced glutathione and glutathione S-transferase, and catalase levels and reduced significantly the nitric oxide (NO) as compared to the burn-induced group.	honokiol	0-8	hematopoietic prostaglandin D synthase	Mus musculus	78-103
30925455-14	2019	Honokiol treatment also potentiates the expression of reduced glutathione and glutathione S-transferase, and catalase levels and reduced significantly the nitric oxide (NO) as compared to the burn-induced group.	honokiol	0-8	catalase	Mus musculus	109-117
30925455-15	2019	It can be concluded on the base of the results that honokiol has a significant analgesic activity through its action on cytokines and by downregulating TRPV1 and P2Y receptors.	honokiol	52-60	transient receptor potential cation channel, subfamily V, member 1	Mus musculus	152-157
30680694-5	2019	The levels of iNOS, NO, and myeloperoxidase in NRK-52E cells were increased during sepsis, which could be reversed by honokiol.	honokiol	118-126	nitric oxide synthase 2	Rattus norvegicus	14-18
30680694-5	2019	The levels of iNOS, NO, and myeloperoxidase in NRK-52E cells were increased during sepsis, which could be reversed by honokiol.	honokiol	118-126	myeloperoxidase	Rattus norvegicus	28-43
30680694-7	2019	The administration of honokiol significantly inhibited TLR2/4/MyD88 signaling pathway in AKI-induced NRK-52E cells.	honokiol	22-30	toll-like receptor 2	Rattus norvegicus	55-61
30680694-7	2019	The administration of honokiol significantly inhibited TLR2/4/MyD88 signaling pathway in AKI-induced NRK-52E cells.	honokiol	22-30	MYD88, innate immune signal transduction adaptor	Rattus norvegicus	62-67
30680694-9	2019	Finally, Honokiol was shown to connect with the Nrf2-Keap1 dimensionally.	honokiol	9-17	NFE2 like bZIP transcription factor 2	Rattus norvegicus	48-52
30680694-9	2019	Finally, Honokiol was shown to connect with the Nrf2-Keap1 dimensionally.	honokiol	9-17	Kelch-like ECH-associated protein 1	Rattus norvegicus	53-58
31141940-7	2019	Moreover, honokiol ameliorated LPS-induced NF-kappaB activation in the hippocampus and significantly reduced the levels of the pro-inflammatory cytokines; tumor necrosis factor alpha (TNF-alpha), interleukin 1beta (IL-1beta), and interferon gamma (IFN-gamma).	honokiol	10-18	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	43-52
31141940-7	2019	Moreover, honokiol ameliorated LPS-induced NF-kappaB activation in the hippocampus and significantly reduced the levels of the pro-inflammatory cytokines; tumor necrosis factor alpha (TNF-alpha), interleukin 1beta (IL-1beta), and interferon gamma (IFN-gamma).	honokiol	10-18	tumor necrosis factor	Mus musculus	155-182
31141940-7	2019	Moreover, honokiol ameliorated LPS-induced NF-kappaB activation in the hippocampus and significantly reduced the levels of the pro-inflammatory cytokines; tumor necrosis factor alpha (TNF-alpha), interleukin 1beta (IL-1beta), and interferon gamma (IFN-gamma).	honokiol	10-18	tumor necrosis factor	Mus musculus	184-193
31141940-7	2019	Moreover, honokiol ameliorated LPS-induced NF-kappaB activation in the hippocampus and significantly reduced the levels of the pro-inflammatory cytokines; tumor necrosis factor alpha (TNF-alpha), interleukin 1beta (IL-1beta), and interferon gamma (IFN-gamma).	honokiol	10-18	interleukin 1 beta	Mus musculus	196-213
31141940-7	2019	Moreover, honokiol ameliorated LPS-induced NF-kappaB activation in the hippocampus and significantly reduced the levels of the pro-inflammatory cytokines; tumor necrosis factor alpha (TNF-alpha), interleukin 1beta (IL-1beta), and interferon gamma (IFN-gamma).	honokiol	10-18	interleukin 1 alpha	Mus musculus	215-223
31141940-7	2019	Moreover, honokiol ameliorated LPS-induced NF-kappaB activation in the hippocampus and significantly reduced the levels of the pro-inflammatory cytokines; tumor necrosis factor alpha (TNF-alpha), interleukin 1beta (IL-1beta), and interferon gamma (IFN-gamma).	honokiol	10-18	interferon gamma	Mus musculus	230-257
31141940-8	2019	In addition, honokiol inhibited LPS-induced indoleamine 2,3-dioxygenase (IDO) activation and quinolinic acid (a toxic product) increase and reduced the level of free calcium in brain tissue, thereby inhibiting calcium overload.	honokiol	13-21	indoleamine 2,3-dioxygenase 1	Mus musculus	44-71
31141940-8	2019	In addition, honokiol inhibited LPS-induced indoleamine 2,3-dioxygenase (IDO) activation and quinolinic acid (a toxic product) increase and reduced the level of free calcium in brain tissue, thereby inhibiting calcium overload.	honokiol	13-21	indoleamine 2,3-dioxygenase 1	Mus musculus	73-76
31141940-10	2019	Honokiol may inhibit the LPS-induced neuroinflammatory response through the NF-kappaB signaling pathway, reducing the levels of related pro-inflammatory cytokines, and furthermore, this may affect tryptophan metabolism and increase neuroprotective metabolites.	honokiol	0-8	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	76-85
30988795-9	2019	Finally, caspase-3/7 activation was identified in high-dose honokiol-treated bladder cancer cells.	honokiol	60-68	caspase 3	Homo sapiens	9-18
30864681-0	2019	Honokiol induces apoptosis and suppresses migration and invasion of ovarian carcinoma cells via AMPK/mTOR signaling pathway.	honokiol	0-8	protein kinase AMP-activated catalytic subunit alpha 2	Homo sapiens	96-100
30864681-0	2019	Honokiol induces apoptosis and suppresses migration and invasion of ovarian carcinoma cells via AMPK/mTOR signaling pathway.	honokiol	0-8	mechanistic target of rapamycin kinase	Homo sapiens	101-105
30864681-3	2019	The present study aimed to investigate whether the anticancer activities of honokiol in ovarian cancer cells were mediated through the activation of AMPK.	honokiol	76-84	protein kinase AMP-activated catalytic subunit alpha 2	Homo sapiens	149-153
30864681-5	2019	Honokiol induced apoptosis via activation of caspase-3, caspase-7 and caspase-9, and cleavage of poly-(adenosine 5"-diphosphate-ribose) polymerase.	honokiol	0-8	caspase 3	Homo sapiens	45-54
30864681-5	2019	Honokiol induced apoptosis via activation of caspase-3, caspase-7 and caspase-9, and cleavage of poly-(adenosine 5"-diphosphate-ribose) polymerase.	honokiol	0-8	caspase 7	Homo sapiens	56-65
30864681-5	2019	Honokiol induced apoptosis via activation of caspase-3, caspase-7 and caspase-9, and cleavage of poly-(adenosine 5"-diphosphate-ribose) polymerase.	honokiol	0-8	caspase 9	Homo sapiens	70-79
30864681-6	2019	Apoptosis induced by honokiol was weakened by compound C, an AMPK inhibitor, suggesting that honokiol-induced apoptosis was dependent on the AMPK/mechanistic target of rapamycin signaling pathway.	honokiol	21-29	protein kinase AMP-activated catalytic subunit alpha 2	Homo sapiens	61-65
30864681-6	2019	Apoptosis induced by honokiol was weakened by compound C, an AMPK inhibitor, suggesting that honokiol-induced apoptosis was dependent on the AMPK/mechanistic target of rapamycin signaling pathway.	honokiol	21-29	protein kinase AMP-activated catalytic subunit alpha 2	Homo sapiens	141-145
30864681-6	2019	Apoptosis induced by honokiol was weakened by compound C, an AMPK inhibitor, suggesting that honokiol-induced apoptosis was dependent on the AMPK/mechanistic target of rapamycin signaling pathway.	honokiol	93-101	protein kinase AMP-activated catalytic subunit alpha 2	Homo sapiens	61-65
30864681-6	2019	Apoptosis induced by honokiol was weakened by compound C, an AMPK inhibitor, suggesting that honokiol-induced apoptosis was dependent on the AMPK/mechanistic target of rapamycin signaling pathway.	honokiol	93-101	protein kinase AMP-activated catalytic subunit alpha 2	Homo sapiens	141-145
30864681-9	2019	These results indicated that honokiol may have therapeutic potential in ovarian cancer by targeting AMPK activation.	honokiol	29-37	protein kinase AMP-activated catalytic subunit alpha 2	Homo sapiens	100-104
31022495-10	2019	These results suggest that honokiol has antioxidative effects at low doses but causes embryo-developmental toxicity at high doses, and the Nrf2 gene may play a pivotal role in regulating these processes.	honokiol	27-35	nfe2 like bZIP transcription factor 2a	Danio rerio	139-143
30708101-8	2019	Furthermore, honokiol treatment decreased cell migration and enhanced cell apoptosis, which is accompanied by the upregulation of the expressions of ER stress-induced apoptotic signaling molecules such as GRP78, phosphorylated PERK, phosphorylated eIF2alpha, CHOP, Bcl-2, Bax, and cleaved Caspase 9.	honokiol	13-21	heat shock protein family A (Hsp70) member 5	Homo sapiens	205-210
30708101-8	2019	Furthermore, honokiol treatment decreased cell migration and enhanced cell apoptosis, which is accompanied by the upregulation of the expressions of ER stress-induced apoptotic signaling molecules such as GRP78, phosphorylated PERK, phosphorylated eIF2alpha, CHOP, Bcl-2, Bax, and cleaved Caspase 9.	honokiol	13-21	eukaryotic translation initiation factor 2 alpha kinase 3	Homo sapiens	227-231
30708101-8	2019	Furthermore, honokiol treatment decreased cell migration and enhanced cell apoptosis, which is accompanied by the upregulation of the expressions of ER stress-induced apoptotic signaling molecules such as GRP78, phosphorylated PERK, phosphorylated eIF2alpha, CHOP, Bcl-2, Bax, and cleaved Caspase 9.	honokiol	13-21	eukaryotic translation initiation factor 2A	Homo sapiens	248-257
30708101-8	2019	Furthermore, honokiol treatment decreased cell migration and enhanced cell apoptosis, which is accompanied by the upregulation of the expressions of ER stress-induced apoptotic signaling molecules such as GRP78, phosphorylated PERK, phosphorylated eIF2alpha, CHOP, Bcl-2, Bax, and cleaved Caspase 9.	honokiol	13-21	DNA damage inducible transcript 3	Homo sapiens	259-263
30708101-8	2019	Furthermore, honokiol treatment decreased cell migration and enhanced cell apoptosis, which is accompanied by the upregulation of the expressions of ER stress-induced apoptotic signaling molecules such as GRP78, phosphorylated PERK, phosphorylated eIF2alpha, CHOP, Bcl-2, Bax, and cleaved Caspase 9.	honokiol	13-21	BCL2 apoptosis regulator	Homo sapiens	265-270
30708101-8	2019	Furthermore, honokiol treatment decreased cell migration and enhanced cell apoptosis, which is accompanied by the upregulation of the expressions of ER stress-induced apoptotic signaling molecules such as GRP78, phosphorylated PERK, phosphorylated eIF2alpha, CHOP, Bcl-2, Bax, and cleaved Caspase 9.	honokiol	13-21	BCL2 associated X, apoptosis regulator	Homo sapiens	272-275
30708101-8	2019	Furthermore, honokiol treatment decreased cell migration and enhanced cell apoptosis, which is accompanied by the upregulation of the expressions of ER stress-induced apoptotic signaling molecules such as GRP78, phosphorylated PERK, phosphorylated eIF2alpha, CHOP, Bcl-2, Bax, and cleaved Caspase 9.	honokiol	13-21	caspase 9	Homo sapiens	289-298
30708101-9	2019	Honokiol treatment-induced increase of ER stress-related signaling molecules and apoptotic proteins in A549 and 95-D cells were reversed by CHOP siRNA.	honokiol	0-8	DNA damage inducible transcript 3	Homo sapiens	140-144
30296006-0	2019	SIRT3 activator honokiol ameliorates surgery/anesthesia-induced cognitive decline in mice through anti-oxidative stress and anti-inflammatory in hippocampus.	honokiol	16-24	sirtuin 3	Mus musculus	0-5
30770282-0	2019	The effect of honokiol on pulmonary artery endothelium cell autophagy mediated by cyclophilin A in hypoxic pulmonary arterial hypertension.	honokiol	14-22	peptidylprolyl isomerase A	Rattus norvegicus	82-95
30770282-7	2019	We found that honokiol could reduce the expression of CyPA and autophagy markers in vivo and in vitro.	honokiol	14-22	peptidylprolyl isomerase A	Rattus norvegicus	54-58
30770282-10	2019	The results revealed that honokiol can alleviate autophagy and pulmonary arterial hypertension regulated by CyPA in PAECs.	honokiol	26-34	peptidylprolyl isomerase A	Rattus norvegicus	108-112
31037127-11	2019	Finally, we proved that honokiol could prevent melanocyte apoptosis under oxidative stress by activating SIRT3-OPA1 axis.	honokiol	24-32	sirtuin 3	Homo sapiens	105-110
31037127-11	2019	Finally, we proved that honokiol could prevent melanocyte apoptosis under oxidative stress by activating SIRT3-OPA1 axis.	honokiol	24-32	OPA1 mitochondrial dynamin like GTPase	Homo sapiens	111-115
30833971-0	2019	Honokiol alleviates sepsis-induced acute kidney injury in mice by targeting the miR-218-5p/heme oxygenase-1 signaling pathway.	honokiol	0-8	heme oxygenase 1	Mus musculus	91-107
30833971-9	2019	Inflammatory cytokines, such as TNF-alpha, IL-6 and IL-1beta, were significantly inhibited in honokiol-treated septic mice compared with the CLP group.	honokiol	94-102	tumor necrosis factor	Mus musculus	32-41
30833971-9	2019	Inflammatory cytokines, such as TNF-alpha, IL-6 and IL-1beta, were significantly inhibited in honokiol-treated septic mice compared with the CLP group.	honokiol	94-102	interleukin 6	Mus musculus	43-47
30833971-9	2019	Inflammatory cytokines, such as TNF-alpha, IL-6 and IL-1beta, were significantly inhibited in honokiol-treated septic mice compared with the CLP group.	honokiol	94-102	interleukin 1 beta	Mus musculus	52-60
30833971-11	2019	Furthermore, heme oxygenase-1 (HO-1) expression levels were significantly up-regulated and miR-218-5p was markedly down-regulated in honokiol-treated septic mice as compared to CLP-operated mice.	honokiol	133-141	heme oxygenase 1	Mus musculus	13-29
30833971-13	2019	In vitro experiments showed that both honokiol and miR-218-5p inhibitors blocked lipopolysaccharide (LPS)-induced cell growth inhibition and GMC apoptosis by increasing the expression of HO-1.	honokiol	38-46	heme oxygenase 1	Mus musculus	187-191
30833971-14	2019	Conclusions: Honokiol ameliorated AKI in septic mice and LPS-induced GMC dysfunction, and the underlying mechanism was mediated, at least partially, through the regulation of miR-218-5p/HO-1 signaling.	honokiol	13-21	heme oxygenase 1	Mus musculus	186-190
30918581-0	2019	Honokiol-Mediated Mitophagy Ameliorates Postoperative Cognitive Impairment Induced by Surgery/Sevoflurane via Inhibiting the Activation of NLRP3 Inflammasome in the Hippocampus.	honokiol	0-8	NLR family, pyrin domain containing 3	Mus musculus	139-144
30918581-10	2019	Honokiol-mediated mitophagy inhibited the activation of NLRP3 inflammasome and neuroinflammation in the hippocampus.	honokiol	0-8	NLR family, pyrin domain containing 3	Mus musculus	56-61
30391358-0	2019	Exploiting Honokiol-induced ER stress CHOP activation inhibits the growth and metastasis of melanoma by suppressing the MITF and beta-catenin pathways.	honokiol	11-19	DNA-damage inducible transcript 3	Mus musculus	38-42
30391358-0	2019	Exploiting Honokiol-induced ER stress CHOP activation inhibits the growth and metastasis of melanoma by suppressing the MITF and beta-catenin pathways.	honokiol	11-19	melanogenesis associated transcription factor	Mus musculus	120-124
30391358-0	2019	Exploiting Honokiol-induced ER stress CHOP activation inhibits the growth and metastasis of melanoma by suppressing the MITF and beta-catenin pathways.	honokiol	11-19	catenin (cadherin associated protein), beta 1	Mus musculus	129-141
30391358-7	2019	Knockdown Calpain-10 or CHOP/GADD153 blocked all of the biological effects in Honokiol-induced beta-catenin/MITF cleavage, ERSE or TCF/LEF luciferase activity, and beta-catenin kinase activity.	honokiol	78-86	calpain 10	Mus musculus	10-20
30391358-7	2019	Knockdown Calpain-10 or CHOP/GADD153 blocked all of the biological effects in Honokiol-induced beta-catenin/MITF cleavage, ERSE or TCF/LEF luciferase activity, and beta-catenin kinase activity.	honokiol	78-86	DNA-damage inducible transcript 3	Mus musculus	24-28
30391358-7	2019	Knockdown Calpain-10 or CHOP/GADD153 blocked all of the biological effects in Honokiol-induced beta-catenin/MITF cleavage, ERSE or TCF/LEF luciferase activity, and beta-catenin kinase activity.	honokiol	78-86	DNA-damage inducible transcript 3	Mus musculus	29-36
30391358-7	2019	Knockdown Calpain-10 or CHOP/GADD153 blocked all of the biological effects in Honokiol-induced beta-catenin/MITF cleavage, ERSE or TCF/LEF luciferase activity, and beta-catenin kinase activity.	honokiol	78-86	catenin (cadherin associated protein), beta 1	Mus musculus	95-107
30391358-7	2019	Knockdown Calpain-10 or CHOP/GADD153 blocked all of the biological effects in Honokiol-induced beta-catenin/MITF cleavage, ERSE or TCF/LEF luciferase activity, and beta-catenin kinase activity.	honokiol	78-86	melanogenesis associated transcription factor	Mus musculus	108-112
30391358-7	2019	Knockdown Calpain-10 or CHOP/GADD153 blocked all of the biological effects in Honokiol-induced beta-catenin/MITF cleavage, ERSE or TCF/LEF luciferase activity, and beta-catenin kinase activity.	honokiol	78-86	catenin (cadherin associated protein), beta 1	Mus musculus	164-176
30391358-8	2019	These findings suggest that Honokiol can significantly thwart the progression of highly metastatic melanoma using the beta-catenin/MITF axis via prompt Calpain-10 and CHOP/GADD153 regulated cascades.	honokiol	28-36	catenin (cadherin associated protein), beta 1	Mus musculus	118-130
30391358-8	2019	These findings suggest that Honokiol can significantly thwart the progression of highly metastatic melanoma using the beta-catenin/MITF axis via prompt Calpain-10 and CHOP/GADD153 regulated cascades.	honokiol	28-36	melanogenesis associated transcription factor	Mus musculus	131-135
30391358-8	2019	These findings suggest that Honokiol can significantly thwart the progression of highly metastatic melanoma using the beta-catenin/MITF axis via prompt Calpain-10 and CHOP/GADD153 regulated cascades.	honokiol	28-36	calpain 10	Mus musculus	152-162
30391358-8	2019	These findings suggest that Honokiol can significantly thwart the progression of highly metastatic melanoma using the beta-catenin/MITF axis via prompt Calpain-10 and CHOP/GADD153 regulated cascades.	honokiol	28-36	DNA-damage inducible transcript 3	Mus musculus	167-171
30391358-8	2019	These findings suggest that Honokiol can significantly thwart the progression of highly metastatic melanoma using the beta-catenin/MITF axis via prompt Calpain-10 and CHOP/GADD153 regulated cascades.	honokiol	28-36	DNA-damage inducible transcript 3	Mus musculus	172-179
30296006-2	2019	Honokiol (HNK), as an activator of Sirtuin3 (SIRT3), has potential multiple biological functions.	honokiol	0-8	sirtuin 3	Mus musculus	35-43
30296006-2	2019	Honokiol (HNK), as an activator of Sirtuin3 (SIRT3), has potential multiple biological functions.	honokiol	0-8	sirtuin 3	Mus musculus	45-50
30296006-13	2019	CONCLUSIONS: These results suggested that activation of SIRT3 by honokiol may attenuate surgery/anesthesia-induced cognitive impairment in mice through regulation of oxidative stress and neuroinflammatory in hippocampus.	honokiol	65-73	sirtuin 3	Mus musculus	56-61
30343517-6	2019	In addition, cytochrome P450 (CYP450) isoenzymes of the major rat metabolites of magnolol and honokiol were identified using a specific inhibitor.	honokiol	94-102	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	13-28
30343517-6	2019	In addition, cytochrome P450 (CYP450) isoenzymes of the major rat metabolites of magnolol and honokiol were identified using a specific inhibitor.	honokiol	94-102	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	30-36
30343517-7	2019	RESULTS: This study suggests that the CYP2E1 subtype is responsible for the oxidation of magnolol and honokiol terminal double bonds to epoxy metabolites.	honokiol	102-110	cytochrome P450, family 2, subfamily e, polypeptide 1	Rattus norvegicus	38-44
30343517-10	2019	CONCLUSIONS: This study demonstrated that different CYP450 enzyme isoforms showed different activities in the in vitro metabolism of magnolol and honokiol in rat liver microsomes.	honokiol	146-154	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	52-58
31091975-0	2019	Honokiol Induces Autophagic Apoptosis in Neuroblastoma Cells through a P53-Dependent Pathway.	honokiol	0-8	transformation related protein 53, pseudogene	Mus musculus	71-74
31091975-5	2019	As to the mechanisms, honokiol consecutively induced cytochrome c release from mitochondria, caspase-3 activation, DNA fragmentation and cell apoptosis.	honokiol	22-30	caspase 3	Mus musculus	93-102
31091975-7	2019	Pretreatment of neuro-2a cells with 3-methyladenine, an inhibitor of autophagy, attenuated honokiol-induced cell autophagy, caspase-3 activation, DNA damage and cell apoptosis.	honokiol	91-99	caspase 3	Mus musculus	124-133
31091975-10	2019	Knocking down translation of p53 using RNA interference attenuated honokiol-induced autophagy and apoptosis in neuro-2a and NB41A3 cells.	honokiol	67-75	transformation related protein 53, pseudogene	Mus musculus	29-32
31091975-11	2019	Taken together, this study showed that at early periods, honokiol can induce autophagic apoptosis of neuroblastoma cells through activating a p53-dependent mechanism.	honokiol	57-65	transformation related protein 53, pseudogene	Mus musculus	142-145
30259402-6	2018	Anti-cancer effect of honokiol was demonstrated with the decrease in the release of cytokine IL-6 and further suppression of Ki-67 proliferative protein.	honokiol	22-30	interleukin 6	Homo sapiens	93-97
30835336-0	2019	Expression of VEGF and GFAP in a rat model of traumatic brain injury treated with Honokiol: a biochemical and immunohistochemical study.	honokiol	82-90	vascular endothelial growth factor A	Rattus norvegicus	14-18
30835336-0	2019	Expression of VEGF and GFAP in a rat model of traumatic brain injury treated with Honokiol: a biochemical and immunohistochemical study.	honokiol	82-90	glial fibrillary acidic protein	Rattus norvegicus	23-27
30835336-9	2019	In TBI + Honokiol group, vascular endothelial growth factor (VEGF) expression was positive in the endothelial and few inflammatory cells of the mildly dilated blood vessels.	honokiol	9-17	vascular endothelial growth factor A	Rattus norvegicus	25-59
30835336-9	2019	In TBI + Honokiol group, vascular endothelial growth factor (VEGF) expression was positive in the endothelial and few inflammatory cells of the mildly dilated blood vessels.	honokiol	9-17	vascular endothelial growth factor A	Rattus norvegicus	61-65
31322570-0	2019	Honokiol Attenuates the Memory Impairments, Oxidative Stress, Neuroinflammation, and GSK-3beta Activation in Vascular Dementia Rats.	honokiol	0-8	glycogen synthase kinase 3 beta	Rattus norvegicus	85-94
31322570-10	2019	We also found that HKL inhibited the activity of GSK-3beta, which may be critical for the neuroprotective activity of HKL.	honokiol	19-22	glycogen synthase kinase 3 beta	Rattus norvegicus	49-58
31322570-10	2019	We also found that HKL inhibited the activity of GSK-3beta, which may be critical for the neuroprotective activity of HKL.	honokiol	118-121	glycogen synthase kinase 3 beta	Rattus norvegicus	49-58
30587839-0	2018	Honokiol Eliminates Glioma/Glioblastoma Stem Cell-Like Cells Via JAK-STAT3 Signaling and Inhibits Tumor Progression by Targeting Epidermal Growth Factor Receptor.	honokiol	0-8	signal transducer and activator of transcription 3	Homo sapiens	69-74
30587839-0	2018	Honokiol Eliminates Glioma/Glioblastoma Stem Cell-Like Cells Via JAK-STAT3 Signaling and Inhibits Tumor Progression by Targeting Epidermal Growth Factor Receptor.	honokiol	0-8	epidermal growth factor receptor	Homo sapiens	129-161
30587839-10	2018	In addition, honokiol promoted apoptosis and reduced Bcl-2 expression, accompanied by increase in Bax expression.	honokiol	13-21	BCL2 apoptosis regulator	Homo sapiens	53-58
30587839-10	2018	In addition, honokiol promoted apoptosis and reduced Bcl-2 expression, accompanied by increase in Bax expression.	honokiol	13-21	BCL2 associated X, apoptosis regulator	Homo sapiens	98-101
30587839-11	2018	Honokiol reduced expression of EGFR, CD133 and Nestin.	honokiol	0-8	epidermal growth factor receptor	Homo sapiens	31-35
30587839-11	2018	Honokiol reduced expression of EGFR, CD133 and Nestin.	honokiol	0-8	prominin 1	Homo sapiens	37-42
30587839-12	2018	Moreover, honokiol inhibited the activation of both AKT and ERK signaling pathways, increased active caspase-3 level and reduced phosphorylation of STAT3.	honokiol	10-18	AKT serine/threonine kinase 1	Homo sapiens	52-55
30587839-12	2018	Moreover, honokiol inhibited the activation of both AKT and ERK signaling pathways, increased active caspase-3 level and reduced phosphorylation of STAT3.	honokiol	10-18	caspase 3	Homo sapiens	101-110
30587839-12	2018	Moreover, honokiol inhibited the activation of both AKT and ERK signaling pathways, increased active caspase-3 level and reduced phosphorylation of STAT3.	honokiol	10-18	signal transducer and activator of transcription 3	Homo sapiens	148-153
30223096-0	2018	Therapeutic effects of honokiol on motor impairment in hemiparkinsonian mice are associated with reversing neurodegeneration and targeting PPARgamma regulation.	honokiol	23-31	peroxisome proliferator activated receptor gamma	Mus musculus	139-148
30223096-2	2018	While the current treatment strategies present limitations on halting the progression of PD, this study aimed to investigate the therapeutic potential of honokiol, as a partial peroxisome proliferator-activated receptor-gamma (PPARgamma) mimic, on the proceeding behavioral and biochemical alterations in hemiparkinsonian mice.	honokiol	154-162	peroxisome proliferator activated receptor gamma	Mus musculus	177-225
30223096-2	2018	While the current treatment strategies present limitations on halting the progression of PD, this study aimed to investigate the therapeutic potential of honokiol, as a partial peroxisome proliferator-activated receptor-gamma (PPARgamma) mimic, on the proceeding behavioral and biochemical alterations in hemiparkinsonian mice.	honokiol	154-162	peroxisome proliferator activated receptor gamma	Mus musculus	227-236
30223096-6	2018	Furthermore, honokiol attenuated oxidative stress and reactive astrocyte induction via decreasing NADPH-oxidase and glial fibrillary acidic protein (GFAP) expressions in 6-OHDA-lesioned striatum.	honokiol	13-21	glial fibrillary acidic protein	Mus musculus	116-147
30223096-6	2018	Furthermore, honokiol attenuated oxidative stress and reactive astrocyte induction via decreasing NADPH-oxidase and glial fibrillary acidic protein (GFAP) expressions in 6-OHDA-lesioned striatum.	honokiol	13-21	glial fibrillary acidic protein	Mus musculus	149-153
30223096-7	2018	The reversal effects of honokiol on behavioral impairment and striatal PPARgamma expression were impeded by PPARgamma antagonist GW9662.	honokiol	24-32	peroxisome proliferator activated receptor gamma	Mus musculus	71-80
30223096-7	2018	The reversal effects of honokiol on behavioral impairment and striatal PPARgamma expression were impeded by PPARgamma antagonist GW9662.	honokiol	24-32	peroxisome proliferator activated receptor gamma	Mus musculus	108-117
30223096-9	2018	The present findings demonstrate the therapeutic activities of honokiol in ameliorating motor impairment and progressive dopaminergic damage that could be associated with regulating PPARgamma signaling.	honokiol	63-71	peroxisome proliferator activated receptor gamma	Mus musculus	182-191
30223096-10	2018	Therefore, honokiol may potentially exert as a novel therapeutic candidate through PPARgamma activation for management of motor symptoms and progressive neurodegeneration in PD.	honokiol	11-19	peroxisome proliferator activated receptor gamma	Mus musculus	83-92
30039429-3	2018	The aim of this study was to examine the effect of honokiol and magnolol on CXC chemokine receptor 3 (CXCR3) ligands, which are related with Th1 cell migration, production in interleukin (IL)-27-stimulated human oral epithelial cells (TR146 cells).	honokiol	51-59	interleukin 27	Homo sapiens	175-194
30039429-4	2018	Honokiol and magnolol inhibited CXC chemokine ligand (CXCL)10 and CXCL11 production in IL-27-stimulated TR146 cells in a dose-dependent manner.	honokiol	0-8	C-X-C motif chemokine ligand 10	Homo sapiens	54-61
30039429-4	2018	Honokiol and magnolol inhibited CXC chemokine ligand (CXCL)10 and CXCL11 production in IL-27-stimulated TR146 cells in a dose-dependent manner.	honokiol	0-8	C-X-C motif chemokine ligand 11	Homo sapiens	66-72
30039429-4	2018	Honokiol and magnolol inhibited CXC chemokine ligand (CXCL)10 and CXCL11 production in IL-27-stimulated TR146 cells in a dose-dependent manner.	honokiol	0-8	interleukin 27	Homo sapiens	87-92
30039429-5	2018	Moreover, we revealed that honokiol and magnolol could suppress signal transducer and activator of transcription (STAT)3 and protein kinase B (Akt) phosphorylation in IL-27-stimulated TR146 cells though STAT1 phosphorylation was not suppressed by honokiol and magnolol treatment.	honokiol	27-35	signal transducer and activator of transcription 3	Homo sapiens	64-120
30039429-5	2018	Moreover, we revealed that honokiol and magnolol could suppress signal transducer and activator of transcription (STAT)3 and protein kinase B (Akt) phosphorylation in IL-27-stimulated TR146 cells though STAT1 phosphorylation was not suppressed by honokiol and magnolol treatment.	honokiol	27-35	protein tyrosine kinase 2 beta	Homo sapiens	125-141
30039429-5	2018	Moreover, we revealed that honokiol and magnolol could suppress signal transducer and activator of transcription (STAT)3 and protein kinase B (Akt) phosphorylation in IL-27-stimulated TR146 cells though STAT1 phosphorylation was not suppressed by honokiol and magnolol treatment.	honokiol	27-35	AKT serine/threonine kinase 1	Homo sapiens	143-146
30039429-5	2018	Moreover, we revealed that honokiol and magnolol could suppress signal transducer and activator of transcription (STAT)3 and protein kinase B (Akt) phosphorylation in IL-27-stimulated TR146 cells though STAT1 phosphorylation was not suppressed by honokiol and magnolol treatment.	honokiol	27-35	interleukin 27	Homo sapiens	167-172
30039429-5	2018	Moreover, we revealed that honokiol and magnolol could suppress signal transducer and activator of transcription (STAT)3 and protein kinase B (Akt) phosphorylation in IL-27-stimulated TR146 cells though STAT1 phosphorylation was not suppressed by honokiol and magnolol treatment.	honokiol	27-35	signal transducer and activator of transcription 1	Homo sapiens	203-208
30039429-5	2018	Moreover, we revealed that honokiol and magnolol could suppress signal transducer and activator of transcription (STAT)3 and protein kinase B (Akt) phosphorylation in IL-27-stimulated TR146 cells though STAT1 phosphorylation was not suppressed by honokiol and magnolol treatment.	honokiol	247-255	interleukin 27	Homo sapiens	167-172
30039429-7	2018	In summary, honokiol and magnolol could reduce CXCR3 ligand production in oral epithelial cell by inhibiting STAT3 and Akt activation.	honokiol	12-20	C-X-C motif chemokine receptor 3	Homo sapiens	47-52
30039429-7	2018	In summary, honokiol and magnolol could reduce CXCR3 ligand production in oral epithelial cell by inhibiting STAT3 and Akt activation.	honokiol	12-20	signal transducer and activator of transcription 3	Homo sapiens	109-114
30039429-7	2018	In summary, honokiol and magnolol could reduce CXCR3 ligand production in oral epithelial cell by inhibiting STAT3 and Akt activation.	honokiol	12-20	AKT serine/threonine kinase 1	Homo sapiens	119-122
31119985-5	2019	Consequently, the biologically active forms of the inflammatory cytokines IL-1beta and IL-18 are reduced significantly in response to Honokiol in mice infected with S. aureus.	honokiol	134-142	interleukin 1 beta	Mus musculus	74-82
31119985-5	2019	Consequently, the biologically active forms of the inflammatory cytokines IL-1beta and IL-18 are reduced significantly in response to Honokiol in mice infected with S. aureus.	honokiol	134-142	interleukin 18	Mus musculus	87-92
31708532-5	2019	Our results revealed that honokiol and magnolol induced both NAD(P)H:quinone oxidoreductase 1 (NQO1) and catalase enzyme activities in a concentration-dependent manner.	honokiol	26-34	NAD(P)H quinone dehydrogenase 1	Rattus norvegicus	61-93
31708532-5	2019	Our results revealed that honokiol and magnolol induced both NAD(P)H:quinone oxidoreductase 1 (NQO1) and catalase enzyme activities in a concentration-dependent manner.	honokiol	26-34	NAD(P)H quinone dehydrogenase 1	Rattus norvegicus	95-99
29989791-0	2018	Honokiol Alleviates Oxidative Stress-Induced Neurotoxicity via Activation of Nrf2.	honokiol	0-8	NFE2 like bZIP transcription factor 2	Rattus norvegicus	77-81
29989791-3	2018	In this study, we reported that Hon attenuates the H2O2- or 6-hydroxydopamine (6-OHDA)-induced apoptosis of PC12 cells by increasing the glutathione level and upregulating a multitude of cytoprotective proteins, including heme oxygenase 1, NAD(P)H:quinone oxidoreductase 1, thioredoxin 1, and thioredoxin reductase 1.	honokiol	32-35	heme oxygenase 1	Rattus norvegicus	222-238
29989791-3	2018	In this study, we reported that Hon attenuates the H2O2- or 6-hydroxydopamine (6-OHDA)-induced apoptosis of PC12 cells by increasing the glutathione level and upregulating a multitude of cytoprotective proteins, including heme oxygenase 1, NAD(P)H:quinone oxidoreductase 1, thioredoxin 1, and thioredoxin reductase 1.	honokiol	32-35	NAD(P)H quinone dehydrogenase 1	Rattus norvegicus	240-272
29989791-3	2018	In this study, we reported that Hon attenuates the H2O2- or 6-hydroxydopamine (6-OHDA)-induced apoptosis of PC12 cells by increasing the glutathione level and upregulating a multitude of cytoprotective proteins, including heme oxygenase 1, NAD(P)H:quinone oxidoreductase 1, thioredoxin 1, and thioredoxin reductase 1.	honokiol	32-35	thioredoxin 1	Rattus norvegicus	274-287
29989791-3	2018	In this study, we reported that Hon attenuates the H2O2- or 6-hydroxydopamine (6-OHDA)-induced apoptosis of PC12 cells by increasing the glutathione level and upregulating a multitude of cytoprotective proteins, including heme oxygenase 1, NAD(P)H:quinone oxidoreductase 1, thioredoxin 1, and thioredoxin reductase 1.	honokiol	32-35	thioredoxin reductase 1	Rattus norvegicus	293-316
29989791-6	2018	Taken together, our study identified that Hon is an effective agonist of Nrf2 in the neuronal system and displays potent neuroprotection against oxidative stress-mediated PC12 cell damage.	honokiol	42-45	NFE2 like bZIP transcription factor 2	Rattus norvegicus	73-77
30515999-0	2018	Honokiol induces apoptosis of lung squamous cell carcinoma by targeting FGF2-FGFR1 autocrine loop.	honokiol	0-8	fibroblast growth factor 2	Homo sapiens	72-76
30515999-0	2018	Honokiol induces apoptosis of lung squamous cell carcinoma by targeting FGF2-FGFR1 autocrine loop.	honokiol	0-8	fibroblast growth factor receptor 1	Homo sapiens	77-82
30515999-3	2018	Honokiol is a chemical compound that has been proven to be effective against various malignancies and whose analog has been reported to target the mitogen-activated protein kinase family, members of a downstream signaling pathway of FGFR1.	honokiol	0-8	fibroblast growth factor receptor 1	Homo sapiens	233-238
30515999-4	2018	This was an explorative study to determine the mechanism of honokiol in lung SCC.	honokiol	60-68	serpin family B member 3	Homo sapiens	77-80
30515999-5	2018	We found that honokiol induced apoptosis and cell cycle arrest in lung SCC cell lines in a time- and dose-dependent manner.	honokiol	14-22	serpin family B member 3	Homo sapiens	71-74
30515999-6	2018	Honokiol also restricted cell migration in lung SCC cell lines.	honokiol	0-8	serpin family B member 3	Homo sapiens	48-51
30515999-7	2018	Moreover, the expression of FGF2 and the activation of FGFR1 were both downregulated by honokiol.	honokiol	88-96	fibroblast growth factor 2	Homo sapiens	28-32
30515999-7	2018	Moreover, the expression of FGF2 and the activation of FGFR1 were both downregulated by honokiol.	honokiol	88-96	fibroblast growth factor receptor 1	Homo sapiens	55-60
30515999-9	2018	Our in vivo study indicated that honokiol could suppress the growth of xenograft tumors, and this effect was associated with the inhibition of the FGF2-FGFR1 signaling pathway.	honokiol	33-41	fibroblast growth factor 2	Homo sapiens	147-151
30515999-9	2018	Our in vivo study indicated that honokiol could suppress the growth of xenograft tumors, and this effect was associated with the inhibition of the FGF2-FGFR1 signaling pathway.	honokiol	33-41	fibroblast growth factor receptor 1	Homo sapiens	152-157
30515999-10	2018	In conclusion, honokiol induced cell apoptosis in lung SCC by targeting the FGF2-FGFR1 autocrine loop.	honokiol	15-23	serpin family B member 3	Homo sapiens	55-58
30515999-10	2018	In conclusion, honokiol induced cell apoptosis in lung SCC by targeting the FGF2-FGFR1 autocrine loop.	honokiol	15-23	fibroblast growth factor 2	Homo sapiens	76-80
30515999-10	2018	In conclusion, honokiol induced cell apoptosis in lung SCC by targeting the FGF2-FGFR1 autocrine loop.	honokiol	15-23	fibroblast growth factor receptor 1	Homo sapiens	81-86
30039429-0	2018	Honokiol and Magnolol Inhibit CXCL10 and CXCL11 Production in IL-27-Stimulated Human Oral Epithelial Cells.	honokiol	0-8	C-X-C motif chemokine ligand 10	Homo sapiens	30-36
30039429-0	2018	Honokiol and Magnolol Inhibit CXCL10 and CXCL11 Production in IL-27-Stimulated Human Oral Epithelial Cells.	honokiol	0-8	C-X-C motif chemokine ligand 11	Homo sapiens	41-47
30039429-0	2018	Honokiol and Magnolol Inhibit CXCL10 and CXCL11 Production in IL-27-Stimulated Human Oral Epithelial Cells.	honokiol	0-8	interleukin 27	Homo sapiens	62-67
30039429-3	2018	The aim of this study was to examine the effect of honokiol and magnolol on CXC chemokine receptor 3 (CXCR3) ligands, which are related with Th1 cell migration, production in interleukin (IL)-27-stimulated human oral epithelial cells (TR146 cells).	honokiol	51-59	C-X-C motif chemokine receptor 3	Homo sapiens	76-100
30039429-3	2018	The aim of this study was to examine the effect of honokiol and magnolol on CXC chemokine receptor 3 (CXCR3) ligands, which are related with Th1 cell migration, production in interleukin (IL)-27-stimulated human oral epithelial cells (TR146 cells).	honokiol	51-59	C-X-C motif chemokine receptor 3	Homo sapiens	102-107
30114639-5	2018	KEY FINDINGS AND CONCLUSIONS: Honokiol lowers the expression of pluripotency-factors, the formation of mammosphere, P-glycoprotein expression, receptor CXCR4 level, c-FLIP, steroid receptor coactivator-3 (SRC-3), Twist1, matrix metalloproteinases, class I histone deacetylases, H3K27 methyltransferase among numerous other anticancer functions.	honokiol	30-38	C-X-C motif chemokine receptor 4	Homo sapiens	152-157
30114639-5	2018	KEY FINDINGS AND CONCLUSIONS: Honokiol lowers the expression of pluripotency-factors, the formation of mammosphere, P-glycoprotein expression, receptor CXCR4 level, c-FLIP, steroid receptor coactivator-3 (SRC-3), Twist1, matrix metalloproteinases, class I histone deacetylases, H3K27 methyltransferase among numerous other anticancer functions.	honokiol	30-38	nuclear receptor coactivator 3	Homo sapiens	205-210
30114639-5	2018	KEY FINDINGS AND CONCLUSIONS: Honokiol lowers the expression of pluripotency-factors, the formation of mammosphere, P-glycoprotein expression, receptor CXCR4 level, c-FLIP, steroid receptor coactivator-3 (SRC-3), Twist1, matrix metalloproteinases, class I histone deacetylases, H3K27 methyltransferase among numerous other anticancer functions.	honokiol	30-38	twist family bHLH transcription factor 1	Homo sapiens	213-219
30076764-0	2018	Chemosensitizing effect of honokiol in oral carcinoma stem cells via regulation of IL-6/Stat3 signaling.	honokiol	27-35	interleukin 6	Homo sapiens	83-87
30076764-0	2018	Chemosensitizing effect of honokiol in oral carcinoma stem cells via regulation of IL-6/Stat3 signaling.	honokiol	27-35	signal transducer and activator of transcription 3	Homo sapiens	88-93
30076764-5	2018	Moreover, honokiol downregulated the expression of 2 selective markers of OCSCs, ALDH1, and CD44, as well as the migration and invasion abilities, indicating its potential to suppress cancer stemness.	honokiol	10-18	aldehyde dehydrogenase 1 family member A1	Homo sapiens	81-86
30076764-5	2018	Moreover, honokiol downregulated the expression of 2 selective markers of OCSCs, ALDH1, and CD44, as well as the migration and invasion abilities, indicating its potential to suppress cancer stemness.	honokiol	10-18	CD44 molecule (Indian blood group)	Homo sapiens	92-96
30076764-6	2018	We showed that honokiol reduced the secretion of IL-6 and phosphorylation of STAT3, and the honokiol-inhibited self-renewal, invasion and colony formation were reversed by administration of IL-6.	honokiol	15-23	interleukin 6	Homo sapiens	49-53
30076764-6	2018	We showed that honokiol reduced the secretion of IL-6 and phosphorylation of STAT3, and the honokiol-inhibited self-renewal, invasion and colony formation were reversed by administration of IL-6.	honokiol	15-23	signal transducer and activator of transcription 3	Homo sapiens	77-82
30076764-6	2018	We showed that honokiol reduced the secretion of IL-6 and phosphorylation of STAT3, and the honokiol-inhibited self-renewal, invasion and colony formation were reversed by administration of IL-6.	honokiol	15-23	interleukin 6	Homo sapiens	190-194
30076764-6	2018	We showed that honokiol reduced the secretion of IL-6 and phosphorylation of STAT3, and the honokiol-inhibited self-renewal, invasion and colony formation were reversed by administration of IL-6.	honokiol	92-100	interleukin 6	Homo sapiens	190-194
30523227-0	2018	[Honokiol attenuates lipopolysaccharide-induced acute respiratory distress syndrome via activation of mitochondrion-dependent Sirt3/AMPK pathway].	honokiol	1-9	sirtuin 3	Mus musculus	126-131
30420619-4	2018	We subsequently activated SIRT3 using honokiol to evaluate its therapeutic potential for IVDD.	honokiol	38-46	sirtuin 3	Rattus norvegicus	26-31
30420619-6	2018	SIRT3 was knocked down by lentivirus and activated by honokiol to determine its role in oxidative stress-induced NPCs.	honokiol	54-62	sirtuin 3	Rattus norvegicus	0-5
30420619-7	2018	The mechanism by which honokiol affected SIRT3 regulation was investigated in vitro, and the therapeutic potential of honokiol was assessed in vitro and in vivo.	honokiol	23-31	sirtuin 3	Rattus norvegicus	41-46
30420619-9	2018	Honokiol (10 muM) improved the viability of NPCs under oxidative stress and promoted their properties of anti-oxidation, mitochondrial dynamics and mitophagy in a SIRT3-dependent manner.	honokiol	0-8	sirtuin 3	Rattus norvegicus	163-168
30420619-10	2018	Furthermore, honokiol activated SIRT3 through the AMPK-PGC-1alpha signaling pathway.	honokiol	13-21	sirtuin 3	Rattus norvegicus	32-37
30420619-10	2018	Furthermore, honokiol activated SIRT3 through the AMPK-PGC-1alpha signaling pathway.	honokiol	13-21	PPARG coactivator 1 alpha	Rattus norvegicus	55-65
30420619-12	2018	Our study indicated that SIRT3 is involved in IVDD and showed the potential of the SIRT3 agonist honokiol for the treatment of IVDD.	honokiol	97-105	sirtuin 3	Rattus norvegicus	25-30
30420619-12	2018	Our study indicated that SIRT3 is involved in IVDD and showed the potential of the SIRT3 agonist honokiol for the treatment of IVDD.	honokiol	97-105	sirtuin 3	Rattus norvegicus	83-88
30287800-0	2018	Bioinspired Honokiol Analogs and Their Evaluation for Activity on the Norepinephrine Transporter.	honokiol	12-20	solute carrier family 6 member 2	Homo sapiens	70-96
30287800-5	2018	We present here interactions of honokiol and other synthesized biphenyl-type neolignans and diphenylmethane analogs with the norepinephrine transporter (NET), which is responsible for the synaptic clearance of norepinephrine and the target of many anxiolytics.	honokiol	32-40	solute carrier family 6 member 2	Homo sapiens	125-151
30171880-0	2018	Honokiol protects pulmonary microvascular endothelial barrier against lipopolysaccharide-induced ARDS partially via the Sirt3/AMPK signaling axis.	honokiol	0-8	sirtuin 3	Homo sapiens	120-125
30217257-7	2018	A luciferase assay was used to determine the effect of honokiol on nuclear factor kappa B (NF-kappaB) RelA transcriptional activity.	honokiol	55-63	nuclear factor kappa B subunit 1	Homo sapiens	67-89
30217257-7	2018	A luciferase assay was used to determine the effect of honokiol on nuclear factor kappa B (NF-kappaB) RelA transcriptional activity.	honokiol	55-63	nuclear factor kappa B subunit 1	Homo sapiens	91-100
30217257-7	2018	A luciferase assay was used to determine the effect of honokiol on nuclear factor kappa B (NF-kappaB) RelA transcriptional activity.	honokiol	55-63	RELA proto-oncogene, NF-kB subunit	Homo sapiens	102-106
30217257-8	2018	RESULTS: Honokiol significantly decreased pro-inflammatory cytokine (IL1A, IL6) and chemokine (CXCL8, CXCL1, CCL2) mRNA expression and secretion from fetal membranes (amnion and choriodecidua) and myometrium stimulated with LPS, fsl-1 or poly(I:C).	honokiol	9-17	interleukin 1 alpha	Homo sapiens	69-73
30217257-8	2018	RESULTS: Honokiol significantly decreased pro-inflammatory cytokine (IL1A, IL6) and chemokine (CXCL8, CXCL1, CCL2) mRNA expression and secretion from fetal membranes (amnion and choriodecidua) and myometrium stimulated with LPS, fsl-1 or poly(I:C).	honokiol	9-17	interleukin 6	Homo sapiens	75-78
30217257-8	2018	RESULTS: Honokiol significantly decreased pro-inflammatory cytokine (IL1A, IL6) and chemokine (CXCL8, CXCL1, CCL2) mRNA expression and secretion from fetal membranes (amnion and choriodecidua) and myometrium stimulated with LPS, fsl-1 or poly(I:C).	honokiol	9-17	C-X-C motif chemokine ligand 8	Homo sapiens	95-100
30217257-8	2018	RESULTS: Honokiol significantly decreased pro-inflammatory cytokine (IL1A, IL6) and chemokine (CXCL8, CXCL1, CCL2) mRNA expression and secretion from fetal membranes (amnion and choriodecidua) and myometrium stimulated with LPS, fsl-1 or poly(I:C).	honokiol	9-17	C-X-C motif chemokine ligand 1	Homo sapiens	102-107
30217257-8	2018	RESULTS: Honokiol significantly decreased pro-inflammatory cytokine (IL1A, IL6) and chemokine (CXCL8, CXCL1, CCL2) mRNA expression and secretion from fetal membranes (amnion and choriodecidua) and myometrium stimulated with LPS, fsl-1 or poly(I:C).	honokiol	9-17	C-C motif chemokine ligand 2	Homo sapiens	109-113
30217257-9	2018	In amnion cells, honokiol also significantly decreased the expression and secretion of the extracellular matrix degrading enzyme MMP9.	honokiol	17-25	matrix metallopeptidase 9	Homo sapiens	129-133
30217257-10	2018	Moreover, in myometrium, honokiol significantly suppressed the expression of the contraction associated protein PTGFR, the secretion of the uterotonic prostaglandins PGE2 and PGF2alpha, and blocked TNF-induced myometrial cell contractility.	honokiol	25-33	prostaglandin F receptor	Homo sapiens	112-117
30217257-10	2018	Moreover, in myometrium, honokiol significantly suppressed the expression of the contraction associated protein PTGFR, the secretion of the uterotonic prostaglandins PGE2 and PGF2alpha, and blocked TNF-induced myometrial cell contractility.	honokiol	25-33	tumor necrosis factor	Homo sapiens	198-201
30217257-11	2018	Finally, honokiol significantly suppressed IL1B- and TNF-induced NF-kappaB RelA transcriptional activity in primary amnion and myometrial cells.	honokiol	9-17	interleukin 1 beta	Homo sapiens	43-47
30217257-11	2018	Finally, honokiol significantly suppressed IL1B- and TNF-induced NF-kappaB RelA transcriptional activity in primary amnion and myometrial cells.	honokiol	9-17	tumor necrosis factor	Homo sapiens	53-56
30217257-11	2018	Finally, honokiol significantly suppressed IL1B- and TNF-induced NF-kappaB RelA transcriptional activity in primary amnion and myometrial cells.	honokiol	9-17	nuclear factor kappa B subunit 1	Homo sapiens	65-74
30217257-11	2018	Finally, honokiol significantly suppressed IL1B- and TNF-induced NF-kappaB RelA transcriptional activity in primary amnion and myometrial cells.	honokiol	9-17	RELA proto-oncogene, NF-kB subunit	Homo sapiens	75-79
30217257-12	2018	CONCLUSIONS: Honokiol reduced the expression of pro-inflammatory and pro-labour mediators in human amnion, choriodecidua and myometrium and that this may be facilitated through the suppression of NF-kappaB activation.	honokiol	13-21	nuclear factor kappa B subunit 1	Homo sapiens	196-205
30217261-14	2018	Interestingly, honokiol enhanced intrinsic caspase-9 activity without affecting extrinsic Fas ligand levels and caspase-8 activity.	honokiol	15-23	caspase 9	Homo sapiens	43-52
30217261-15	2018	Sequentially, TMZ-induced changes in Bax translocation, the MMP, mitochondrial complex I enzyme activity, intracellular ROS levels, and cytochrome c release were enhanced by honokiol.	honokiol	174-182	BCL2 associated X, apoptosis regulator	Homo sapiens	37-40
30217261-15	2018	Sequentially, TMZ-induced changes in Bax translocation, the MMP, mitochondrial complex I enzyme activity, intracellular ROS levels, and cytochrome c release were enhanced by honokiol.	honokiol	174-182	cytochrome c, somatic	Homo sapiens	136-148
30217261-17	2018	Fascinatingly, suppressing caspase-6 activity concurrently decreased honokiol-induced DNA fragmentation and cell apoptosis.	honokiol	69-77	caspase 6	Homo sapiens	27-36
30036533-0	2018	Honokiol protects hepatocytes from oxidative injury through mitochondrial deacetylase SIRT3.	honokiol	0-8	sirtuin 3	Mus musculus	86-91
30036533-4	2018	This study aims to evaluate the hepatoprotective potential of honokiol against oxidative injury in tert-butyl hydroperoxide (t-BHP)-injured AML12 hepatocytes in vitro and carbon tetrachloride (CCl4)-stimulated liver damaged mice in vivo and to determine whether or not this effect occurs by activating SIRT3.	honokiol	62-70	chemokine (C-C motif) ligand 4	Mus musculus	193-197
30036533-4	2018	This study aims to evaluate the hepatoprotective potential of honokiol against oxidative injury in tert-butyl hydroperoxide (t-BHP)-injured AML12 hepatocytes in vitro and carbon tetrachloride (CCl4)-stimulated liver damaged mice in vivo and to determine whether or not this effect occurs by activating SIRT3.	honokiol	62-70	sirtuin 3	Mus musculus	302-307
30036533-5	2018	The results showed honokiol protects t-BHP-injured AML12 hepatocytes and CCl4-stimulated liver damage in mice by activating SIRT3.	honokiol	19-27	chemokine (C-C motif) ligand 4	Mus musculus	73-77
30036533-5	2018	The results showed honokiol protects t-BHP-injured AML12 hepatocytes and CCl4-stimulated liver damage in mice by activating SIRT3.	honokiol	19-27	sirtuin 3	Mus musculus	124-129
30036533-7	2018	Honokiol increases the deacetylated peroxisome proliferator-activated receptor gamma coactivator 1-alpha level to promote mitochondrial biogenesis.	honokiol	0-8	peroxisome proliferative activated receptor, gamma, coactivator 1 alpha	Mus musculus	36-104
30036533-9	2018	These results suggest that honokiol can ameliorate oxidative damage in hepatocytes by activating SIRT3, which might be a potential therapeutic agent for liver oxidative injury.	honokiol	27-35	sirtuin 3	Mus musculus	97-102
30196838-3	2018	In this study, we show that Honokiol reduces the inflammatory response to LPS of primary cultures of microglia and astrocytes through the inhibition of pro-inflammatory mediators (iNOS, IL-6, IL-1beta and TNF-alpha) and the simultaneous stimulation of anti-inflammatory cytokines (IL-10).	honokiol	28-36	interleukin 6	Homo sapiens	186-190
30196838-3	2018	In this study, we show that Honokiol reduces the inflammatory response to LPS of primary cultures of microglia and astrocytes through the inhibition of pro-inflammatory mediators (iNOS, IL-6, IL-1beta and TNF-alpha) and the simultaneous stimulation of anti-inflammatory cytokines (IL-10).	honokiol	28-36	interleukin 1 alpha	Homo sapiens	192-200
30196838-3	2018	In this study, we show that Honokiol reduces the inflammatory response to LPS of primary cultures of microglia and astrocytes through the inhibition of pro-inflammatory mediators (iNOS, IL-6, IL-1beta and TNF-alpha) and the simultaneous stimulation of anti-inflammatory cytokines (IL-10).	honokiol	28-36	tumor necrosis factor	Homo sapiens	205-214
30196838-3	2018	In this study, we show that Honokiol reduces the inflammatory response to LPS of primary cultures of microglia and astrocytes through the inhibition of pro-inflammatory mediators (iNOS, IL-6, IL-1beta and TNF-alpha) and the simultaneous stimulation of anti-inflammatory cytokines (IL-10).	honokiol	28-36	interleukin 10	Homo sapiens	281-286
30196838-4	2018	Expression of KLF4 was induced in microglia and astrocytes after treatment with LPS and this response was mitigated by Honokiol.	honokiol	119-127	Kruppel like factor 4	Homo sapiens	14-18
30033411-5	2018	(IL-4 and IFN- NF-kappaB were found to be involved in the honokiol induced biological process.	honokiol	58-66	interleukin 4	Mus musculus	1-24
29991481-3	2018	Honokiol significantly lowered Abeta production and senile plaque deposition by downregulating beta-site amyloid precursor protein cleavage enzyme 1 and enhancing Abeta phagocytosis by microglia.	honokiol	0-8	amyloid beta (A4) precursor protein	Mus musculus	31-36
29991481-3	2018	Honokiol significantly lowered Abeta production and senile plaque deposition by downregulating beta-site amyloid precursor protein cleavage enzyme 1 and enhancing Abeta phagocytosis by microglia.	honokiol	0-8	amyloid beta (A4) precursor protein	Mus musculus	163-168
29991481-4	2018	Honokiol reduced glial cell activation and the production of proinflammatory cytokines (TNF-alpha, IL-1beta, and IL-6).	honokiol	0-8	tumor necrosis factor	Mus musculus	88-97
29991481-4	2018	Honokiol reduced glial cell activation and the production of proinflammatory cytokines (TNF-alpha, IL-1beta, and IL-6).	honokiol	0-8	interleukin 1 alpha	Mus musculus	99-107
29991481-4	2018	Honokiol reduced glial cell activation and the production of proinflammatory cytokines (TNF-alpha, IL-1beta, and IL-6).	honokiol	0-8	interleukin 6	Mus musculus	113-117
29991481-5	2018	Honokiol increased the transcriptional activity and protein levels of peroxisome proliferator-activated receptor-gamma (PPARgamma) However, all of the beneficial effects of honokiol on pathologic changes, including biochemistry and cognitive function, could be blocked by GW9662, a specific PPARgamma inhibitor.	honokiol	0-8	peroxisome proliferator activated receptor gamma	Mus musculus	70-118
29991481-5	2018	Honokiol increased the transcriptional activity and protein levels of peroxisome proliferator-activated receptor-gamma (PPARgamma) However, all of the beneficial effects of honokiol on pathologic changes, including biochemistry and cognitive function, could be blocked by GW9662, a specific PPARgamma inhibitor.	honokiol	0-8	peroxisome proliferator activated receptor gamma	Mus musculus	120-129
29991481-5	2018	Honokiol increased the transcriptional activity and protein levels of peroxisome proliferator-activated receptor-gamma (PPARgamma) However, all of the beneficial effects of honokiol on pathologic changes, including biochemistry and cognitive function, could be blocked by GW9662, a specific PPARgamma inhibitor.	honokiol	0-8	peroxisome proliferator activated receptor gamma	Mus musculus	291-300
29991481-5	2018	Honokiol increased the transcriptional activity and protein levels of peroxisome proliferator-activated receptor-gamma (PPARgamma) However, all of the beneficial effects of honokiol on pathologic changes, including biochemistry and cognitive function, could be blocked by GW9662, a specific PPARgamma inhibitor.	honokiol	173-181	peroxisome proliferator activated receptor gamma	Mus musculus	70-118
29991481-5	2018	Honokiol increased the transcriptional activity and protein levels of peroxisome proliferator-activated receptor-gamma (PPARgamma) However, all of the beneficial effects of honokiol on pathologic changes, including biochemistry and cognitive function, could be blocked by GW9662, a specific PPARgamma inhibitor.	honokiol	173-181	peroxisome proliferator activated receptor gamma	Mus musculus	120-129
29991481-5	2018	Honokiol increased the transcriptional activity and protein levels of peroxisome proliferator-activated receptor-gamma (PPARgamma) However, all of the beneficial effects of honokiol on pathologic changes, including biochemistry and cognitive function, could be blocked by GW9662, a specific PPARgamma inhibitor.	honokiol	173-181	peroxisome proliferator activated receptor gamma	Mus musculus	291-300
29991481-6	2018	These findings suggested that honokiol may be a natural PPARgamma agonist, acting to attenuate Abeta generation and neuroinflammation.	honokiol	30-38	peroxisome proliferator activated receptor gamma	Mus musculus	56-65
29991481-6	2018	These findings suggested that honokiol may be a natural PPARgamma agonist, acting to attenuate Abeta generation and neuroinflammation.	honokiol	30-38	amyloid beta (A4) precursor protein	Mus musculus	95-100
29660403-8	2018	Exposure to 10 microM honokiol induced responses similar to those observed following NAC exposure in TP53 WT and Mut cells.	honokiol	22-30	X-linked Kx blood group	Homo sapiens	85-88
29855846-0	2018	Honokiol Exerts Antidepressant Effects in Rats Exposed to Chronic Unpredictable Mild Stress by Regulating Brain Derived Neurotrophic Factor Level and Hypothalamus-Pituitary-Adrenal Axis Activity.	honokiol	0-8	brain-derived neurotrophic factor	Rattus norvegicus	106-139
29909247-7	2018	The 6-OHDA-induced increases in nigrostriatal expression of inducible nitric oxide synthase (iNOS) and decreases in that of nNOS were also reversed by honokiol posttreatment.	honokiol	151-159	nitric oxide synthase 2, inducible	Mus musculus	60-91
29909247-7	2018	The 6-OHDA-induced increases in nigrostriatal expression of inducible nitric oxide synthase (iNOS) and decreases in that of nNOS were also reversed by honokiol posttreatment.	honokiol	151-159	nitric oxide synthase 2, inducible	Mus musculus	93-97
29909247-7	2018	The 6-OHDA-induced increases in nigrostriatal expression of inducible nitric oxide synthase (iNOS) and decreases in that of nNOS were also reversed by honokiol posttreatment.	honokiol	151-159	nitric oxide synthase 1, neuronal	Mus musculus	124-128
29023360-0	2018	Honokiol Increases CD4+ T Cell Activation and Decreases TNF but Fails to Improve Survival Following Sepsis.	honokiol	0-8	tumor necrosis factor	Mus musculus	56-59
29023360-6	2018	Honokiol treatment after sepsis increased the frequency of CD4 T cells and increased activation of CD4 T cells as measured by the activation marker CD69.	honokiol	0-8	CD69 antigen	Mus musculus	148-152
30116474-0	2018	Honokiol Protects against Anti-beta1-Adrenergic Receptor Autoantibody-Induced Myocardial Dysfunction via Activation of Autophagy.	honokiol	0-8	adrenoceptor beta 1	Homo sapiens	31-56
30116474-4	2018	The actions and underlying mechanisms of honokiol (HNK) in beta1-AAB-positive patients await to be unraveled.	honokiol	41-49	potassium calcium-activated channel subfamily M regulatory beta subunit 1	Homo sapiens	59-64
29892225-0	2018	Honokiol Inhibits Proliferation, Invasion and Induces Apoptosis Through Targeting Lyn Kinase in Human Lung Adenocarcinoma Cells.	honokiol	0-8	LYN proto-oncogene, Src family tyrosine kinase	Homo sapiens	82-85
30317758-0	2018	[Study on effect and mechanism of Honokiol enhancing tumor necrosis factor-related apoptosis inducing ligand against hepatocellular carcinoma HepG2 cells via activating JNK signaling pathway].	honokiol	34-42	TNF superfamily member 10	Homo sapiens	53-108
30317758-0	2018	[Study on effect and mechanism of Honokiol enhancing tumor necrosis factor-related apoptosis inducing ligand against hepatocellular carcinoma HepG2 cells via activating JNK signaling pathway].	honokiol	34-42	mitogen-activated protein kinase 8	Homo sapiens	169-172
30317758-1	2018	Objective: To investigate the effect and intrinsic mechanism of Honokiol (HNK) enhanced tumor necrosis factor-related apoptosis inducing ligand (TRAIL) on hepatocellular carcinoma HepG2 cells.	honokiol	64-72	TNF superfamily member 10	Homo sapiens	88-143
30317758-1	2018	Objective: To investigate the effect and intrinsic mechanism of Honokiol (HNK) enhanced tumor necrosis factor-related apoptosis inducing ligand (TRAIL) on hepatocellular carcinoma HepG2 cells.	honokiol	64-72	TNF superfamily member 10	Homo sapiens	145-150
29970985-7	2018	Honokiol (HKL, a pharmacological agonist of sirt3) was injected intraperitoneally at doses of 2.5, 5, or 10 mg/kg.	honokiol	0-8	sirtuin 3	Rattus norvegicus	44-49
29970985-16	2018	Sirt3 knockdown could exacerbate the neuronal apoptosis and reverse the positive effects of HKL.	honokiol	92-95	sirtuin 3	Rattus norvegicus	0-5
30693685-6	2018	Honokiol at the dose of 10 mg/kg and 30 mg/kg decreased SOD acetylation, MDA content, expression of LC3-II and P62, as well as neuronal death, and the cognitive function was improved (P&lt;0.05 or P&lt;0.01), especially in 30 mg/kg Honokiol group.	honokiol	0-8	nucleoporin 62	Mus musculus	111-114
29649568-0	2018	Honokiol alleviates the degeneration of intervertebral disc via suppressing the activation of TXNIP-NLRP3 inflammasome signal pathway.	honokiol	0-8	thioredoxin interacting protein	Rattus norvegicus	94-99
29649568-0	2018	Honokiol alleviates the degeneration of intervertebral disc via suppressing the activation of TXNIP-NLRP3 inflammasome signal pathway.	honokiol	0-8	NLR family, pyrin domain containing 3	Rattus norvegicus	100-105
29649568-4	2018	In the current study, we demonstrated that honokiol inhibits the H2O2-induced apoptosis (caspase-9, caspase-3, and bax), levels of oxidative stress mediators (ROS, MDA), expression of inflammatory mediators (Interleukin-6, COX-2, and iNOS), major matrix degrading proteases (MMP-3, MMP-13, ADAMTS5, and ADAMTS4) associated with nucleus pulposus degradation.	honokiol	43-51	caspase 9	Rattus norvegicus	89-98
29649568-4	2018	In the current study, we demonstrated that honokiol inhibits the H2O2-induced apoptosis (caspase-9, caspase-3, and bax), levels of oxidative stress mediators (ROS, MDA), expression of inflammatory mediators (Interleukin-6, COX-2, and iNOS), major matrix degrading proteases (MMP-3, MMP-13, ADAMTS5, and ADAMTS4) associated with nucleus pulposus degradation.	honokiol	43-51	caspase 3	Rattus norvegicus	100-109
29649568-4	2018	In the current study, we demonstrated that honokiol inhibits the H2O2-induced apoptosis (caspase-9, caspase-3, and bax), levels of oxidative stress mediators (ROS, MDA), expression of inflammatory mediators (Interleukin-6, COX-2, and iNOS), major matrix degrading proteases (MMP-3, MMP-13, ADAMTS5, and ADAMTS4) associated with nucleus pulposus degradation.	honokiol	43-51	BCL2 associated X, apoptosis regulator	Rattus norvegicus	115-118
29649568-4	2018	In the current study, we demonstrated that honokiol inhibits the H2O2-induced apoptosis (caspase-9, caspase-3, and bax), levels of oxidative stress mediators (ROS, MDA), expression of inflammatory mediators (Interleukin-6, COX-2, and iNOS), major matrix degrading proteases (MMP-3, MMP-13, ADAMTS5, and ADAMTS4) associated with nucleus pulposus degradation.	honokiol	43-51	interleukin 6	Rattus norvegicus	208-221
29649568-4	2018	In the current study, we demonstrated that honokiol inhibits the H2O2-induced apoptosis (caspase-9, caspase-3, and bax), levels of oxidative stress mediators (ROS, MDA), expression of inflammatory mediators (Interleukin-6, COX-2, and iNOS), major matrix degrading proteases (MMP-3, MMP-13, ADAMTS5, and ADAMTS4) associated with nucleus pulposus degradation.	honokiol	43-51	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	223-228
29649568-4	2018	In the current study, we demonstrated that honokiol inhibits the H2O2-induced apoptosis (caspase-9, caspase-3, and bax), levels of oxidative stress mediators (ROS, MDA), expression of inflammatory mediators (Interleukin-6, COX-2, and iNOS), major matrix degrading proteases (MMP-3, MMP-13, ADAMTS5, and ADAMTS4) associated with nucleus pulposus degradation.	honokiol	43-51	nitric oxide synthase 2	Rattus norvegicus	234-238
29649568-4	2018	In the current study, we demonstrated that honokiol inhibits the H2O2-induced apoptosis (caspase-9, caspase-3, and bax), levels of oxidative stress mediators (ROS, MDA), expression of inflammatory mediators (Interleukin-6, COX-2, and iNOS), major matrix degrading proteases (MMP-3, MMP-13, ADAMTS5, and ADAMTS4) associated with nucleus pulposus degradation.	honokiol	43-51	matrix metallopeptidase 3	Rattus norvegicus	275-280
29649568-4	2018	In the current study, we demonstrated that honokiol inhibits the H2O2-induced apoptosis (caspase-9, caspase-3, and bax), levels of oxidative stress mediators (ROS, MDA), expression of inflammatory mediators (Interleukin-6, COX-2, and iNOS), major matrix degrading proteases (MMP-3, MMP-13, ADAMTS5, and ADAMTS4) associated with nucleus pulposus degradation.	honokiol	43-51	matrix metallopeptidase 13	Rattus norvegicus	282-288
29649568-4	2018	In the current study, we demonstrated that honokiol inhibits the H2O2-induced apoptosis (caspase-9, caspase-3, and bax), levels of oxidative stress mediators (ROS, MDA), expression of inflammatory mediators (Interleukin-6, COX-2, and iNOS), major matrix degrading proteases (MMP-3, MMP-13, ADAMTS5, and ADAMTS4) associated with nucleus pulposus degradation.	honokiol	43-51	ADAM metallopeptidase with thrombospondin type 1 motif, 5	Rattus norvegicus	290-297
29649568-4	2018	In the current study, we demonstrated that honokiol inhibits the H2O2-induced apoptosis (caspase-9, caspase-3, and bax), levels of oxidative stress mediators (ROS, MDA), expression of inflammatory mediators (Interleukin-6, COX-2, and iNOS), major matrix degrading proteases (MMP-3, MMP-13, ADAMTS5, and ADAMTS4) associated with nucleus pulposus degradation.	honokiol	43-51	ADAM metallopeptidase with thrombospondin type 1 motif, 4	Rattus norvegicus	303-310
29649568-5	2018	Furthermore, we found nucleus pulposus protective ability of honokiol by up-regulating extra cellular matrix anabolic factors like type II collagen (Col II) and SOX9 in nucleus pulposus.	honokiol	61-69	SRY-box transcription factor 9	Rattus norvegicus	161-165
29649568-6	2018	We also found that honokiol suppressed the phosphorylation of NF-kB and JNK, and activation of TXNIP-NLRP3 inflammasome in H2O2-stimulated nucleus pulposus cells, thereby inhibiting the activation of downstream inflammatory mediators such as Interleukin-1beta.	honokiol	19-27	mitogen-activated protein kinase 8	Rattus norvegicus	72-75
29649568-6	2018	We also found that honokiol suppressed the phosphorylation of NF-kB and JNK, and activation of TXNIP-NLRP3 inflammasome in H2O2-stimulated nucleus pulposus cells, thereby inhibiting the activation of downstream inflammatory mediators such as Interleukin-1beta.	honokiol	19-27	thioredoxin interacting protein	Rattus norvegicus	95-100
29649568-6	2018	We also found that honokiol suppressed the phosphorylation of NF-kB and JNK, and activation of TXNIP-NLRP3 inflammasome in H2O2-stimulated nucleus pulposus cells, thereby inhibiting the activation of downstream inflammatory mediators such as Interleukin-1beta.	honokiol	19-27	NLR family, pyrin domain containing 3	Rattus norvegicus	101-106
29649568-6	2018	We also found that honokiol suppressed the phosphorylation of NF-kB and JNK, and activation of TXNIP-NLRP3 inflammasome in H2O2-stimulated nucleus pulposus cells, thereby inhibiting the activation of downstream inflammatory mediators such as Interleukin-1beta.	honokiol	19-27	interleukin 1 beta	Rattus norvegicus	242-259
29649568-8	2018	Thus, our results demonstrate that honokiol inhibited the H2O2 induced apoptosis, oxidative stress, and inflammatory responses through the depression of TXNIP/NLRP3/caspase-1/ Interleukin - 1beta signaling axis and the activation of NF-kB and JNK.	honokiol	35-43	thioredoxin interacting protein	Rattus norvegicus	153-158
29649568-8	2018	Thus, our results demonstrate that honokiol inhibited the H2O2 induced apoptosis, oxidative stress, and inflammatory responses through the depression of TXNIP/NLRP3/caspase-1/ Interleukin - 1beta signaling axis and the activation of NF-kB and JNK.	honokiol	35-43	NLR family, pyrin domain containing 3	Rattus norvegicus	159-164
29649568-8	2018	Thus, our results demonstrate that honokiol inhibited the H2O2 induced apoptosis, oxidative stress, and inflammatory responses through the depression of TXNIP/NLRP3/caspase-1/ Interleukin - 1beta signaling axis and the activation of NF-kB and JNK.	honokiol	35-43	caspase 1	Rattus norvegicus	165-174
29649568-8	2018	Thus, our results demonstrate that honokiol inhibited the H2O2 induced apoptosis, oxidative stress, and inflammatory responses through the depression of TXNIP/NLRP3/caspase-1/ Interleukin - 1beta signaling axis and the activation of NF-kB and JNK.	honokiol	35-43	interleukin 1 beta	Rattus norvegicus	176-195
29649568-8	2018	Thus, our results demonstrate that honokiol inhibited the H2O2 induced apoptosis, oxidative stress, and inflammatory responses through the depression of TXNIP/NLRP3/caspase-1/ Interleukin - 1beta signaling axis and the activation of NF-kB and JNK.	honokiol	35-43	mitogen-activated protein kinase 8	Rattus norvegicus	243-246
29892225-5	2018	As shown in this study, honokiol is an effective drug on inhibiting proliferation and inducing apoptosis depended on Lyn and EGFR signal pathway regulated by Lyn, and its efficacy is stronger in PC-9 cells than A549 cells.	honokiol	24-32	LYN proto-oncogene, Src family tyrosine kinase	Homo sapiens	117-120
29892225-5	2018	As shown in this study, honokiol is an effective drug on inhibiting proliferation and inducing apoptosis depended on Lyn and EGFR signal pathway regulated by Lyn, and its efficacy is stronger in PC-9 cells than A549 cells.	honokiol	24-32	epidermal growth factor receptor	Homo sapiens	125-129
29892225-5	2018	As shown in this study, honokiol is an effective drug on inhibiting proliferation and inducing apoptosis depended on Lyn and EGFR signal pathway regulated by Lyn, and its efficacy is stronger in PC-9 cells than A549 cells.	honokiol	24-32	LYN proto-oncogene, Src family tyrosine kinase	Homo sapiens	158-161
29614990-8	2018	As to the mechanism, combined treatment of human U87-MG cells with honokiol and TMZ induced greater caspase-3 activation, DNA fragmentation, cell apoptosis, and cell-cycle arrest at the G1 phase but did not affect cell necrosis.	honokiol	67-75	caspase 3	Homo sapiens	100-109
29393336-0	2018	Honokiol suppresses proliferation and induces apoptosis via regulation of the miR-21/PTEN/PI3K/AKT signaling pathway in human osteosarcoma cells.	honokiol	0-8	microRNA 21	Homo sapiens	78-84
29393336-0	2018	Honokiol suppresses proliferation and induces apoptosis via regulation of the miR-21/PTEN/PI3K/AKT signaling pathway in human osteosarcoma cells.	honokiol	0-8	phosphatase and tensin homolog	Homo sapiens	85-89
29393336-0	2018	Honokiol suppresses proliferation and induces apoptosis via regulation of the miR-21/PTEN/PI3K/AKT signaling pathway in human osteosarcoma cells.	honokiol	0-8	AKT serine/threonine kinase 1	Homo sapiens	95-98
29534510-0	2018	Effects of Honokiol on CYP450 Activity and Transporter mRNA Expression in Type 2 Diabetic Rats.	honokiol	11-19	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	23-29
29534510-1	2018	This study was aimed to clarify the effect of honokiol (Hon) on the activity of Cytochrome P450 (CYP450) enzymes, and the level of mRNA expression of liver and kidney transporters in type 2 diabetic rats induced by high-fat diet and strepotozotocin.	honokiol	46-54	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	80-95
29534510-1	2018	This study was aimed to clarify the effect of honokiol (Hon) on the activity of Cytochrome P450 (CYP450) enzymes, and the level of mRNA expression of liver and kidney transporters in type 2 diabetic rats induced by high-fat diet and strepotozotocin.	honokiol	46-54	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	97-103
29534510-6	2018	Compared to the DC group, Hon treatment significantly inhibited the activity of hepatic CYP2E1, CYP4A, 3A and CYP1A2 by 45.6%, 29.2%, 22.7% and 20.7% in Hon high dose group, respectively.	honokiol	26-29	cytochrome P450, family 2, subfamily e, polypeptide 1	Rattus norvegicus	88-94
29534510-6	2018	Compared to the DC group, Hon treatment significantly inhibited the activity of hepatic CYP2E1, CYP4A, 3A and CYP1A2 by 45.6%, 29.2%, 22.7% and 20.7% in Hon high dose group, respectively.	honokiol	26-29	cytochrome P450, family 1, subfamily a, polypeptide 2	Rattus norvegicus	110-116
29534510-6	2018	Compared to the DC group, Hon treatment significantly inhibited the activity of hepatic CYP2E1, CYP4A, 3A and CYP1A2 by 45.6%, 29.2%, 22.7% and 20.7% in Hon high dose group, respectively.	honokiol	153-156	cytochrome P450, family 2, subfamily e, polypeptide 1	Rattus norvegicus	88-94
29534510-6	2018	Compared to the DC group, Hon treatment significantly inhibited the activity of hepatic CYP2E1, CYP4A, 3A and CYP1A2 by 45.6%, 29.2%, 22.7% and 20.7% in Hon high dose group, respectively.	honokiol	153-156	cytochrome P450, family 1, subfamily a, polypeptide 2	Rattus norvegicus	110-116
29534510-7	2018	Moreover, Hon treatment significantly inhibited the mRNA expression levels of renal Bcrp and Mrp4 by 2.63-fold and 1.54-fold, while significantly upregulated the mRNA expression levels of hepatic Oat2 and Oatp2b1 by 1.52-fold and 1.54-fold in Hon high dose group, respectively.	honokiol	10-13	ATP binding cassette subfamily C member 4	Rattus norvegicus	93-97
29534510-7	2018	Moreover, Hon treatment significantly inhibited the mRNA expression levels of renal Bcrp and Mrp4 by 2.63-fold and 1.54-fold, while significantly upregulated the mRNA expression levels of hepatic Oat2 and Oatp2b1 by 1.52-fold and 1.54-fold in Hon high dose group, respectively.	honokiol	10-13	solute carrier family 22 (organic anion transporter), member 7, pseudogene 1	Rattus norvegicus	196-200
29534510-9	2018	The present work firstly reported that Hon treatment ameliorated the abnormal change of hepatic CYP activity (including CYP2E1, CYP4A and CYP1A2) and the transporter mRNA expression (including hepatic Oat2 and Oatp2b1, renal Bcrp and Mrp4) in type 2 diabetic rats induced by high-fat diet and strepotozotocin, which are associated with the occurrence and development of diabetes.	honokiol	39-42	cytochrome P450, family 2, subfamily e, polypeptide 1	Rattus norvegicus	120-126
29534510-9	2018	The present work firstly reported that Hon treatment ameliorated the abnormal change of hepatic CYP activity (including CYP2E1, CYP4A and CYP1A2) and the transporter mRNA expression (including hepatic Oat2 and Oatp2b1, renal Bcrp and Mrp4) in type 2 diabetic rats induced by high-fat diet and strepotozotocin, which are associated with the occurrence and development of diabetes.	honokiol	39-42	cytochrome P450, family 1, subfamily a, polypeptide 2	Rattus norvegicus	138-144
29534510-9	2018	The present work firstly reported that Hon treatment ameliorated the abnormal change of hepatic CYP activity (including CYP2E1, CYP4A and CYP1A2) and the transporter mRNA expression (including hepatic Oat2 and Oatp2b1, renal Bcrp and Mrp4) in type 2 diabetic rats induced by high-fat diet and strepotozotocin, which are associated with the occurrence and development of diabetes.	honokiol	39-42	solute carrier family 22 (organic anion transporter), member 7, pseudogene 1	Rattus norvegicus	201-205
29534510-9	2018	The present work firstly reported that Hon treatment ameliorated the abnormal change of hepatic CYP activity (including CYP2E1, CYP4A and CYP1A2) and the transporter mRNA expression (including hepatic Oat2 and Oatp2b1, renal Bcrp and Mrp4) in type 2 diabetic rats induced by high-fat diet and strepotozotocin, which are associated with the occurrence and development of diabetes.	honokiol	39-42	ATP binding cassette subfamily C member 4	Rattus norvegicus	234-238
29241737-9	2018	AMH was advantageous for the targeted cutaneous treatment due to the high skin deposition and minimal penetration across the skin (8.40nmol/cm2 compared to 93.49nmol/cm2 for honokiol).	honokiol	174-182	anti-Mullerian hormone	Homo sapiens	0-3
30023810-4	2018	Honokiol, magnolol, CAPE, xanthohumol, and anacardic acid activated the MDR1 promoter in LS174T cells, and the cellular uptake of rhodamine 123 and calcein-AM, fluorescent substrates of P-glycoprotein, decreased in polyphenol-treated LS174T cells.	honokiol	0-8	ATP binding cassette subfamily B member 1	Homo sapiens	72-76
29165856-0	2018	Saccharomyces cerevisiae Hog1 MAP kinase pathway is activated in response to honokiol exposure.	honokiol	77-85	mitogen-activated protein kinase HOG1	Saccharomyces cerevisiae S288C	25-29
29165856-6	2018	We found that the sod1  mutant was hypersensitive to honokiol and produced more ROS compared with wild-type and sod2  cells.	honokiol	53-61	superoxide dismutase SOD1	Saccharomyces cerevisiae S288C	18-22
29165856-7	2018	Hog1 was phosphorylated in response to honokiol exposure and deletion of HOG1 increased the sensitivity to honokiol.	honokiol	39-47	mitogen-activated protein kinase HOG1	Saccharomyces cerevisiae S288C	0-4
29165856-7	2018	Hog1 was phosphorylated in response to honokiol exposure and deletion of HOG1 increased the sensitivity to honokiol.	honokiol	107-115	mitogen-activated protein kinase HOG1	Saccharomyces cerevisiae S288C	0-4
29165856-7	2018	Hog1 was phosphorylated in response to honokiol exposure and deletion of HOG1 increased the sensitivity to honokiol.	honokiol	107-115	mitogen-activated protein kinase HOG1	Saccharomyces cerevisiae S288C	73-77
29165856-8	2018	The expressions of genes involved in the Ras-cAMP pathway were down-regulated after honokiol exposure; exogenous cAMP significantly reduced the phosphorylation of Hog1, although the level was higher than the control level.	honokiol	84-92	mitogen-activated protein kinase HOG1	Saccharomyces cerevisiae S288C	163-167
29165856-9	2018	CONCLUSIONS: In addition to SOD1, the Ras-cAMP cascade and Hog1 MAP kinase pathway is essential for protecting against honokiol-induced oxidative stress.	honokiol	119-127	superoxide dismutase SOD1	Saccharomyces cerevisiae S288C	28-32
29165856-9	2018	CONCLUSIONS: In addition to SOD1, the Ras-cAMP cascade and Hog1 MAP kinase pathway is essential for protecting against honokiol-induced oxidative stress.	honokiol	119-127	mitogen-activated protein kinase HOG1	Saccharomyces cerevisiae S288C	59-63
30023810-4	2018	Honokiol, magnolol, CAPE, xanthohumol, and anacardic acid activated the MDR1 promoter in LS174T cells, and the cellular uptake of rhodamine 123 and calcein-AM, fluorescent substrates of P-glycoprotein, decreased in polyphenol-treated LS174T cells.	honokiol	0-8	ATP binding cassette subfamily B member 1	Homo sapiens	186-200
29675132-0	2018	Honokiol Ameliorates Myocardial Ischemia/Reperfusion Injury in Type 1 Diabetic Rats by Reducing Oxidative Stress and Apoptosis through Activating the SIRT1-Nrf2 Signaling Pathway.	honokiol	0-8	sirtuin 1	Rattus norvegicus	150-155
29363886-3	2018	Treatment of two OSCC cell lines with honokiol resulted in reducing the cell proliferation and arresting the cell cycle at G1 stage which was correlated with the down-regulation of Cdk2 and Cdk4 and the up-regulation of cell cycle suppressors, p21 and p27.	honokiol	38-46	cyclin dependent kinase 2	Homo sapiens	181-185
29363886-3	2018	Treatment of two OSCC cell lines with honokiol resulted in reducing the cell proliferation and arresting the cell cycle at G1 stage which was correlated with the down-regulation of Cdk2 and Cdk4 and the up-regulation of cell cycle suppressors, p21 and p27.	honokiol	38-46	cyclin dependent kinase 4	Homo sapiens	190-194
29363886-3	2018	Treatment of two OSCC cell lines with honokiol resulted in reducing the cell proliferation and arresting the cell cycle at G1 stage which was correlated with the down-regulation of Cdk2 and Cdk4 and the up-regulation of cell cycle suppressors, p21 and p27.	honokiol	38-46	H3 histone pseudogene 16	Homo sapiens	244-247
29363886-3	2018	Treatment of two OSCC cell lines with honokiol resulted in reducing the cell proliferation and arresting the cell cycle at G1 stage which was correlated with the down-regulation of Cdk2 and Cdk4 and the up-regulation of cell cycle suppressors, p21 and p27.	honokiol	38-46	interferon alpha inducible protein 27	Homo sapiens	252-255
29363886-5	2018	Modulation of autophagy by autophagic inducer, rapamycin or inhibitors, 3-MA or bafilomycin, potentiated the honokiol-mediated anti-OSCC effects where honokiol exerted multiple actions in suppression of MAPK pathway and regulation of Akt/mTOR or AMPK pathways.	honokiol	109-117	AKT serine/threonine kinase 1	Homo sapiens	234-237
29363886-5	2018	Modulation of autophagy by autophagic inducer, rapamycin or inhibitors, 3-MA or bafilomycin, potentiated the honokiol-mediated anti-OSCC effects where honokiol exerted multiple actions in suppression of MAPK pathway and regulation of Akt/mTOR or AMPK pathways.	honokiol	109-117	mechanistic target of rapamycin kinase	Homo sapiens	238-242
29363886-5	2018	Modulation of autophagy by autophagic inducer, rapamycin or inhibitors, 3-MA or bafilomycin, potentiated the honokiol-mediated anti-OSCC effects where honokiol exerted multiple actions in suppression of MAPK pathway and regulation of Akt/mTOR or AMPK pathways.	honokiol	109-117	protein kinase AMP-activated catalytic subunit alpha 2	Homo sapiens	246-250
29363886-5	2018	Modulation of autophagy by autophagic inducer, rapamycin or inhibitors, 3-MA or bafilomycin, potentiated the honokiol-mediated anti-OSCC effects where honokiol exerted multiple actions in suppression of MAPK pathway and regulation of Akt/mTOR or AMPK pathways.	honokiol	151-159	AKT serine/threonine kinase 1	Homo sapiens	234-237
29363886-5	2018	Modulation of autophagy by autophagic inducer, rapamycin or inhibitors, 3-MA or bafilomycin, potentiated the honokiol-mediated anti-OSCC effects where honokiol exerted multiple actions in suppression of MAPK pathway and regulation of Akt/mTOR or AMPK pathways.	honokiol	151-159	mechanistic target of rapamycin kinase	Homo sapiens	238-242
29363886-5	2018	Modulation of autophagy by autophagic inducer, rapamycin or inhibitors, 3-MA or bafilomycin, potentiated the honokiol-mediated anti-OSCC effects where honokiol exerted multiple actions in suppression of MAPK pathway and regulation of Akt/mTOR or AMPK pathways.	honokiol	151-159	protein kinase AMP-activated catalytic subunit alpha 2	Homo sapiens	246-250
28670854-0	2018	Honokiol attenuates diet-induced non-alcoholic steatohepatitis by regulating macrophage polarization through activating peroxisome proliferator-activated receptor gamma.	honokiol	0-8	peroxisome proliferator activated receptor gamma	Mus musculus	120-168
28670854-8	2018	Honokiol decreased M1 marker genes (TNFalpha and MCP-1) and increased M2 marker gene (YM-1, IL-10, IL-4R and IL-13) expression in mice liver compared with CL diet.	honokiol	0-8	tumor necrosis factor	Mus musculus	36-44
28670854-8	2018	Honokiol decreased M1 marker genes (TNFalpha and MCP-1) and increased M2 marker gene (YM-1, IL-10, IL-4R and IL-13) expression in mice liver compared with CL diet.	honokiol	0-8	mast cell protease 1	Mus musculus	49-54
28670854-8	2018	Honokiol decreased M1 marker genes (TNFalpha and MCP-1) and increased M2 marker gene (YM-1, IL-10, IL-4R and IL-13) expression in mice liver compared with CL diet.	honokiol	0-8	chitinase-like 3	Mus musculus	86-90
28670854-8	2018	Honokiol decreased M1 marker genes (TNFalpha and MCP-1) and increased M2 marker gene (YM-1, IL-10, IL-4R and IL-13) expression in mice liver compared with CL diet.	honokiol	0-8	interleukin 10	Mus musculus	92-97
28670854-8	2018	Honokiol decreased M1 marker genes (TNFalpha and MCP-1) and increased M2 marker gene (YM-1, IL-10, IL-4R and IL-13) expression in mice liver compared with CL diet.	honokiol	0-8	interleukin 4 receptor, alpha	Mus musculus	99-104
28670854-8	2018	Honokiol decreased M1 marker genes (TNFalpha and MCP-1) and increased M2 marker gene (YM-1, IL-10, IL-4R and IL-13) expression in mice liver compared with CL diet.	honokiol	0-8	interleukin 13	Mus musculus	109-114
28670854-10	2018	Honokiol has antioxidant function, as honokiol upregulated hepatic glutathione and superoxide dismutase level and downregulated hepatic CYP2E1 protein level.	honokiol	0-8	cytochrome P450, family 2, subfamily e, polypeptide 1	Mus musculus	136-142
28670854-10	2018	Honokiol has antioxidant function, as honokiol upregulated hepatic glutathione and superoxide dismutase level and downregulated hepatic CYP2E1 protein level.	honokiol	38-46	cytochrome P450, family 2, subfamily e, polypeptide 1	Mus musculus	136-142
28670854-11	2018	Hepatic peroxisome proliferator-activated receptor gamma (PPARgamma) and its target genes were upregulated by honokiol.	honokiol	110-118	peroxisome proliferator activated receptor gamma	Mus musculus	8-56
28670854-11	2018	Hepatic peroxisome proliferator-activated receptor gamma (PPARgamma) and its target genes were upregulated by honokiol.	honokiol	110-118	peroxisome proliferator activated receptor gamma	Mus musculus	58-67
28670854-12	2018	Furthermore, honokiol (10 muM) treatment in mouse peritoneal cells, RAW264.7 cells and ANA-1 cells, led to M2 macrophage polarization, whereas a PPARgamma antagonist, GW9662, abolished this effect of honokiol.	honokiol	13-21	peroxisome proliferator activated receptor gamma	Mus musculus	145-154
28670854-13	2018	CONCLUSIONS: Honokiol can attenuate CL diet-induced NASH and the mechanism in which possibly is polarizing macrophages to M2 phenotype via PPARgamma activation.	honokiol	13-21	peroxisome proliferator activated receptor gamma	Mus musculus	139-148
29367668-0	2018	Honokiol is a FOXM1 antagonist.	honokiol	0-8	forkhead box M1	Homo sapiens	14-19
29367668-4	2018	Here we found that honokiol inhibits FOXM1-mediated transcription and FOXM1 protein expression.	honokiol	19-27	forkhead box M1	Homo sapiens	37-42
29367668-4	2018	Here we found that honokiol inhibits FOXM1-mediated transcription and FOXM1 protein expression.	honokiol	19-27	forkhead box M1	Homo sapiens	70-75
29367668-5	2018	More importantly, we found that honokiol"s inhibitory effect on FOXM1 is a result of binding of honokiol to FOXM1.	honokiol	32-40	forkhead box M1	Homo sapiens	64-69
29367668-5	2018	More importantly, we found that honokiol"s inhibitory effect on FOXM1 is a result of binding of honokiol to FOXM1.	honokiol	32-40	forkhead box M1	Homo sapiens	108-113
29367668-5	2018	More importantly, we found that honokiol"s inhibitory effect on FOXM1 is a result of binding of honokiol to FOXM1.	honokiol	96-104	forkhead box M1	Homo sapiens	64-69
29367668-5	2018	More importantly, we found that honokiol"s inhibitory effect on FOXM1 is a result of binding of honokiol to FOXM1.	honokiol	96-104	forkhead box M1	Homo sapiens	108-113
29367668-8	2018	We thus demonstrate a novel and specific mechanism for FOXM1 inhibition by honokiol, which partially may explain its anticancer activity in cancer cells.	honokiol	75-83	forkhead box M1	Homo sapiens	55-60
29410403-0	2018	Honokiol induces apoptosis and autophagy via the ROS/ERK1/2 signaling pathway in human osteosarcoma cells in vitro and in vivo.	honokiol	0-8	mitogen-activated protein kinase 3	Homo sapiens	53-59
29410403-5	2018	Furthermore, honokiol induced G0/G1 phase arrest, elevated the levels of glucose-regulated protein (GRP)-78, an endoplasmic reticular stress (ERS)-associated protein, and increased the production of intracellular reactive oxygen species (ROS).	honokiol	13-21	heat shock protein family A (Hsp70) member 5	Homo sapiens	73-107
29410403-7	2018	Consequently, honokiol stimulated phosphorylation of extracellular signal-regulated kinase (ERK)1/2.	honokiol	14-22	mitogen-activated protein kinase 3	Homo sapiens	53-99
29410403-8	2018	Furthermore, pretreatment of osteosarcoma cells with PD98059, an inhibitor of ERK1/2, inhibited honokiol-induced apoptosis and autophagy.	honokiol	96-104	mitogen-activated protein kinase 3	Homo sapiens	78-84
29410403-10	2018	Taken together, our results revealed that honokiol caused G0/G1 phase arrest, induced apoptosis, and autophagy via the ROS/ERK1/2 signaling pathway in human osteosarcoma cells.	honokiol	42-50	mitogen-activated protein kinase 3	Homo sapiens	123-129
29675132-0	2018	Honokiol Ameliorates Myocardial Ischemia/Reperfusion Injury in Type 1 Diabetic Rats by Reducing Oxidative Stress and Apoptosis through Activating the SIRT1-Nrf2 Signaling Pathway.	honokiol	0-8	NFE2 like bZIP transcription factor 2	Rattus norvegicus	156-160
30043652-4	2018	Action mechanism studies manifested that DQA modified paclitaxel plus honokiol micelles could activate apoptotic enzymes caspase-3 and caspase-9 as well as down-regulate FAK, PI3K, MMP-2 and MMP-9.	honokiol	70-78	caspase 3	Mus musculus	121-130
29324783-0	2018	SIRT3 activator Honokiol attenuates beta-Amyloid by modulating amyloidogenic pathway.	honokiol	16-24	NAD-dependent protein deacetylase sirtuin-3, mitochondrial	Cricetulus griseus	0-5
29324783-1	2018	Honokiol (poly-phenolic lignan from Magnolia grandiflora) is a Sirtuin-3 (SIRT3) activator which exhibit antioxidant activity and augment mitochondrial functions in several experimental models.	honokiol	0-8	NAD-dependent protein deacetylase sirtuin-3, mitochondrial	Cricetulus griseus	74-79
29324783-6	2018	In the present study, we found that Honokiol significantly enhanced SIRT3 expression, reduced reactive oxygen species generation and lipid peroxidation, enhanced antioxidant activities, and mitochondrial function thereby reducing Abeta and sAPPbeta levels in Chinese Hamster Ovarian (CHO) cells (carrying the amyloid precursor protein-APP and Presenilin PS1 mutation).	honokiol	36-44	NAD-dependent protein deacetylase sirtuin-3, mitochondrial	Cricetulus griseus	68-73
29324783-9	2018	These results suggest that Honokiol is an activator of SIRT3 capable of improving antioxidant activity, mitochondrial energy regulation, while decreasing Abeta, thereby indicating it to be a lead compound for AD drug development.	honokiol	27-35	NAD-dependent protein deacetylase sirtuin-3, mitochondrial	Cricetulus griseus	55-60
29145148-0	2018	Honokiol protects pancreatic beta cell against high glucose and intermittent hypoxia-induced injury by activating Nrf2/ARE pathway in vitro and in vivo.	honokiol	0-8	NFE2 like bZIP transcription factor 2	Rattus norvegicus	114-118
29145148-11	2018	In addition, honokiol can effectively activate the Nrf2/ARE pathway and reverse this pancreatic dysfunction in vivo and in vitro.	honokiol	13-21	NFE2 like bZIP transcription factor 2	Rattus norvegicus	51-55
29145148-12	2018	These findings indicate that honokiol acts as a potent ROS scavenger via Nrf2/ARE pathway and effectively attenuates oxidative stress and improves pancreatic beta cell function of DM rats under IH treatment.	honokiol	29-37	NFE2 like bZIP transcription factor 2	Rattus norvegicus	73-77
30043652-4	2018	Action mechanism studies manifested that DQA modified paclitaxel plus honokiol micelles could activate apoptotic enzymes caspase-3 and caspase-9 as well as down-regulate FAK, PI3K, MMP-2 and MMP-9.	honokiol	70-78	caspase 9	Mus musculus	135-144
30043652-4	2018	Action mechanism studies manifested that DQA modified paclitaxel plus honokiol micelles could activate apoptotic enzymes caspase-3 and caspase-9 as well as down-regulate FAK, PI3K, MMP-2 and MMP-9.	honokiol	70-78	PTK2 protein tyrosine kinase 2	Mus musculus	170-173
30043652-4	2018	Action mechanism studies manifested that DQA modified paclitaxel plus honokiol micelles could activate apoptotic enzymes caspase-3 and caspase-9 as well as down-regulate FAK, PI3K, MMP-2 and MMP-9.	honokiol	70-78	matrix metallopeptidase 2	Mus musculus	181-186
30043652-4	2018	Action mechanism studies manifested that DQA modified paclitaxel plus honokiol micelles could activate apoptotic enzymes caspase-3 and caspase-9 as well as down-regulate FAK, PI3K, MMP-2 and MMP-9.	honokiol	70-78	matrix metallopeptidase 9	Mus musculus	191-196
28714852-8	2017	Both L1- and L1 mimetic-mediated intracellular signaling cascades in the spinal cord lesion sites were activated by trimebutine and honokiol, with trimebutine being more effective than honokiol.	honokiol	132-140	L1 cell adhesion molecule	Mus musculus	5-7
29865070-0	2018	Honokiol Alleviates Cognitive Deficits of Alzheimer"s Disease (PS1V97L) Transgenic Mice by Activating Mitochondrial SIRT3.	honokiol	0-8	sirtuin 3	Mus musculus	116-121
28983589-0	2017	Honokiol triggers receptor-interacting protein kinase 3-mediated cell death of neuroblastoma cells by upregulating reactive oxygen species.	honokiol	0-8	receptor-interacting serine-threonine kinase 3	Mus musculus	18-55
28983589-7	2017	MTT assays demonstrated that treatment of Neuro-2a neuroblastoma cells with honokiol resulted in time- and dose-dependent inhibition of cell proliferation, which was associated with upregulation of the protein expression of receptor-interacting protein kinase 3 (RIP3), as demonstrated by western blot analysis.	honokiol	76-84	receptor-interacting serine-threonine kinase 3	Mus musculus	224-261
28983589-7	2017	MTT assays demonstrated that treatment of Neuro-2a neuroblastoma cells with honokiol resulted in time- and dose-dependent inhibition of cell proliferation, which was associated with upregulation of the protein expression of receptor-interacting protein kinase 3 (RIP3), as demonstrated by western blot analysis.	honokiol	76-84	receptor-interacting serine-threonine kinase 3	Mus musculus	263-267
28983589-8	2017	Furthermore, knockdown of RIP3 by small interfering RNA, or pharmacological inhibition of RIP3 by the RIP3 specific inhibitor necrosulfonamide, reversed honokiol-induced loss of cell viability in Neuro-2a cells.	honokiol	153-161	receptor-interacting serine-threonine kinase 3	Mus musculus	26-30
28983589-8	2017	Furthermore, knockdown of RIP3 by small interfering RNA, or pharmacological inhibition of RIP3 by the RIP3 specific inhibitor necrosulfonamide, reversed honokiol-induced loss of cell viability in Neuro-2a cells.	honokiol	153-161	receptor-interacting serine-threonine kinase 3	Mus musculus	90-94
28983589-8	2017	Furthermore, knockdown of RIP3 by small interfering RNA, or pharmacological inhibition of RIP3 by the RIP3 specific inhibitor necrosulfonamide, reversed honokiol-induced loss of cell viability in Neuro-2a cells.	honokiol	153-161	receptor-interacting serine-threonine kinase 3	Mus musculus	90-94
28983589-9	2017	Importantly, honokiol significantly increased the intracellular ROS levels as determined by a 2",7"-dichlorofluorescin diacetate assay, while ROS scavenger N-acetyl cysteine significantly prevented the induction of ROS and RIP3 by honokiol.	honokiol	13-21	receptor-interacting serine-threonine kinase 3	Mus musculus	223-227
28983589-10	2017	The results of the present study indicate that honokiol may suppress the growth of neuroblastoma Neuro-2a cells, at least partially, through ROS-mediated upregulation of RIP3.	honokiol	47-55	receptor-interacting serine-threonine kinase 3	Mus musculus	170-174
29136581-5	2017	RESULTS: Honokiol treatment induced browning by elevating expression levels of brown adipocyte-specific genes such as Cidea, Cox8, Fgf21, Pgc-1alpha, and Ucp1.	honokiol	9-17	cell death inducing DFFA like effector a	Homo sapiens	118-123
29136581-5	2017	RESULTS: Honokiol treatment induced browning by elevating expression levels of brown adipocyte-specific genes such as Cidea, Cox8, Fgf21, Pgc-1alpha, and Ucp1.	honokiol	9-17	cytochrome c oxidase subunit 8A	Homo sapiens	125-129
29136581-5	2017	RESULTS: Honokiol treatment induced browning by elevating expression levels of brown adipocyte-specific genes such as Cidea, Cox8, Fgf21, Pgc-1alpha, and Ucp1.	honokiol	9-17	fibroblast growth factor 21	Homo sapiens	131-136
29136581-5	2017	RESULTS: Honokiol treatment induced browning by elevating expression levels of brown adipocyte-specific genes such as Cidea, Cox8, Fgf21, Pgc-1alpha, and Ucp1.	honokiol	9-17	PPARG coactivator 1 alpha	Homo sapiens	138-148
29136581-5	2017	RESULTS: Honokiol treatment induced browning by elevating expression levels of brown adipocyte-specific genes such as Cidea, Cox8, Fgf21, Pgc-1alpha, and Ucp1.	honokiol	9-17	uncoupling protein 1	Homo sapiens	154-158
29136581-6	2017	Honokiol promoted apoptosis of 3T3-L1 white adipocytes and inhibited apoptosis of HIB1B brown adipocytes via opposite regulation of the pro-apoptotic protein BAX and anti-apoptotic protein Bcl-2.	honokiol	0-8	BCL2 associated X, apoptosis regulator	Homo sapiens	158-161
29136581-6	2017	Honokiol promoted apoptosis of 3T3-L1 white adipocytes and inhibited apoptosis of HIB1B brown adipocytes via opposite regulation of the pro-apoptotic protein BAX and anti-apoptotic protein Bcl-2.	honokiol	0-8	BCL2 apoptosis regulator	Homo sapiens	189-194
29136581-7	2017	Honokiol also significantly increased protein expression levels of ACOX1, CPT1, p-HSL, and p-PLIN and reduced ROS levels, suggesting its possible role in fat oxidation and lipid catabolism.	honokiol	0-8	acyl-CoA oxidase 1	Homo sapiens	67-72
29136581-7	2017	Honokiol also significantly increased protein expression levels of ACOX1, CPT1, p-HSL, and p-PLIN and reduced ROS levels, suggesting its possible role in fat oxidation and lipid catabolism.	honokiol	0-8	carnitine palmitoyltransferase 1A	Homo sapiens	74-78
29136581-7	2017	Honokiol also significantly increased protein expression levels of ACOX1, CPT1, p-HSL, and p-PLIN and reduced ROS levels, suggesting its possible role in fat oxidation and lipid catabolism.	honokiol	0-8	perilipin 1	Homo sapiens	93-97
29136581-8	2017	Honokiol-induced browning could be mediated by activation of ERK, as inhibition of ERK by FR180204 abolished expression of PGC-1alpha and UCP1.	honokiol	0-8	PPARG coactivator 1 alpha	Homo sapiens	123-133
29136581-8	2017	Honokiol-induced browning could be mediated by activation of ERK, as inhibition of ERK by FR180204 abolished expression of PGC-1alpha and UCP1.	honokiol	0-8	uncoupling protein 1	Homo sapiens	138-142
28581518-0	2017	Activation of tumor suppressor LKB1 by honokiol abrogates cancer stem-like phenotype in breast cancer via inhibition of oncogenic Stat3.	honokiol	39-47	serine/threonine kinase 11	Mus musculus	31-35
28581518-0	2017	Activation of tumor suppressor LKB1 by honokiol abrogates cancer stem-like phenotype in breast cancer via inhibition of oncogenic Stat3.	honokiol	39-47	signal transducer and activator of transcription 3	Mus musculus	130-135
28581518-6	2017	Honokiol (HNK), a bioactive molecule from Magnolia grandiflora increased LKB1 expression, inhibited individual cell-motility and abrogated the stem-like phenotype of breast cancer cells by reducing the formation of mammosphere, expression of pluripotency-factors and aldehyde dehydrogenase activity.	honokiol	0-8	serine/threonine kinase 11	Mus musculus	73-77
28931882-8	2017	Furthermore, Luciferase reporter assay reveals that Honokiol modestly increased PPARgamma transcriptional activities in cultured embryonic rat cardiomyocytes (H9c2).	honokiol	52-60	peroxisome proliferator-activated receptor gamma	Rattus norvegicus	80-89
28931882-9	2017	Honokiol upregulated the expression of PPARgamma in the mouse heart.	honokiol	0-8	peroxisome proliferator activated receptor gamma	Mus musculus	39-48
28931882-12	2017	We conclude that Honokiol protects the heart from Dox-cardiotoxicity via improving mitochondrial function by not only repressing mitochondrial protein acetylation but also enhancing PPARgamma activity in the heart.	honokiol	17-25	peroxisome proliferator activated receptor gamma	Mus musculus	182-191
28714852-8	2017	Both L1- and L1 mimetic-mediated intracellular signaling cascades in the spinal cord lesion sites were activated by trimebutine and honokiol, with trimebutine being more effective than honokiol.	honokiol	132-140	L1 cell adhesion molecule	Mus musculus	13-15
28714852-8	2017	Both L1- and L1 mimetic-mediated intracellular signaling cascades in the spinal cord lesion sites were activated by trimebutine and honokiol, with trimebutine being more effective than honokiol.	honokiol	185-193	L1 cell adhesion molecule	Mus musculus	5-7
28731124-0	2017	BMP7 mediates the anticancer effect of honokiol by upregulating p53 in HCT116 cells.	honokiol	39-47	bone morphogenetic protein 7	Homo sapiens	0-4
28731124-0	2017	BMP7 mediates the anticancer effect of honokiol by upregulating p53 in HCT116 cells.	honokiol	39-47	tumor protein p53	Homo sapiens	64-67
28583810-4	2017	In this study, we developed a kind of lactoferrin (Lf) modified daunorubicin plus honokiol liposomes to transport antitumor drugs across BBB, eliminate the VM channels and block tumor cell invasion.	honokiol	82-90	lactotransferrin	Mus musculus	38-49
28583810-4	2017	In this study, we developed a kind of lactoferrin (Lf) modified daunorubicin plus honokiol liposomes to transport antitumor drugs across BBB, eliminate the VM channels and block tumor cell invasion.	honokiol	82-90	lactotransferrin	Mus musculus	51-53
28583810-7	2017	Action mechanism studies indicated that Lf modified daunorubicin plus honokiol liposomes could activate apoptotic enzymes caspase 3 as well as down-regulate VM protein indicators (PI3K, MMP-2, MMP-9, VE-Cadherin and FAK).	honokiol	70-78	lactotransferrin	Mus musculus	40-42
28583810-7	2017	Action mechanism studies indicated that Lf modified daunorubicin plus honokiol liposomes could activate apoptotic enzymes caspase 3 as well as down-regulate VM protein indicators (PI3K, MMP-2, MMP-9, VE-Cadherin and FAK).	honokiol	70-78	caspase 3	Mus musculus	122-131
28583810-7	2017	Action mechanism studies indicated that Lf modified daunorubicin plus honokiol liposomes could activate apoptotic enzymes caspase 3 as well as down-regulate VM protein indicators (PI3K, MMP-2, MMP-9, VE-Cadherin and FAK).	honokiol	70-78	matrix metallopeptidase 2	Mus musculus	186-191
28583810-7	2017	Action mechanism studies indicated that Lf modified daunorubicin plus honokiol liposomes could activate apoptotic enzymes caspase 3 as well as down-regulate VM protein indicators (PI3K, MMP-2, MMP-9, VE-Cadherin and FAK).	honokiol	70-78	matrix metallopeptidase 9	Mus musculus	193-198
28583810-7	2017	Action mechanism studies indicated that Lf modified daunorubicin plus honokiol liposomes could activate apoptotic enzymes caspase 3 as well as down-regulate VM protein indicators (PI3K, MMP-2, MMP-9, VE-Cadherin and FAK).	honokiol	70-78	cadherin 5	Mus musculus	200-211
28583810-7	2017	Action mechanism studies indicated that Lf modified daunorubicin plus honokiol liposomes could activate apoptotic enzymes caspase 3 as well as down-regulate VM protein indicators (PI3K, MMP-2, MMP-9, VE-Cadherin and FAK).	honokiol	70-78	PTK2 protein tyrosine kinase 2	Mus musculus	216-219
28851291-0	2017	Honokiol improved chondrogenesis and suppressed inflammation in human umbilical cord derived mesenchymal stem cells via blocking nuclear factor-kappaB pathway.	honokiol	0-8	nuclear factor kappa B subunit 1	Homo sapiens	129-150
28851291-4	2017	In this study, we focused on an anti-inflammatory agent, honokiol, which is isolated from an herb, investigated the potential effects on human umbilical cord derived mesenchymal stem cells (hUC-MSCs) in IL-1beta stimulation.	honokiol	57-65	interleukin 1 beta	Homo sapiens	203-211
28851291-13	2017	Honokiol relieved these negative impacts induced by IL-1beta and suppressed Nuclear factor-kappaB (NF-kappaB) pathway by downregulating expression of p-IKKalpha/beta, p-IkappaBalpha and p-p65 in dose-dependent and time-dependent manner.	honokiol	0-8	interleukin 1 beta	Homo sapiens	52-60
28851291-13	2017	Honokiol relieved these negative impacts induced by IL-1beta and suppressed Nuclear factor-kappaB (NF-kappaB) pathway by downregulating expression of p-IKKalpha/beta, p-IkappaBalpha and p-p65 in dose-dependent and time-dependent manner.	honokiol	0-8	nuclear factor kappa B subunit 1	Homo sapiens	76-97
28851291-13	2017	Honokiol relieved these negative impacts induced by IL-1beta and suppressed Nuclear factor-kappaB (NF-kappaB) pathway by downregulating expression of p-IKKalpha/beta, p-IkappaBalpha and p-p65 in dose-dependent and time-dependent manner.	honokiol	0-8	nuclear factor kappa B subunit 1	Homo sapiens	99-108
28851291-13	2017	Honokiol relieved these negative impacts induced by IL-1beta and suppressed Nuclear factor-kappaB (NF-kappaB) pathway by downregulating expression of p-IKKalpha/beta, p-IkappaBalpha and p-p65 in dose-dependent and time-dependent manner.	honokiol	0-8	RELA proto-oncogene, NF-kB subunit	Homo sapiens	188-191
28851291-14	2017	CONCLUSIONS: Honokiol improved cell survival and chondrogenesis of hUC-MSCs and inhibited IL-1beta-induced inflammatory response, which suggested that combination of anti-inflammation and stem cell can be a novel strategy for better cartilage repair.	honokiol	13-21	interleukin 1 beta	Homo sapiens	90-98
28493080-0	2017	Therapeutic Action of Honokiol on Postoperative Ileus via Downregulation of iNOS Gene Expression.	honokiol	22-30	nitric oxide synthase 2, inducible	Mus musculus	76-80
28714852-8	2017	Both L1- and L1 mimetic-mediated intracellular signaling cascades in the spinal cord lesion sites were activated by trimebutine and honokiol, with trimebutine being more effective than honokiol.	honokiol	185-193	L1 cell adhesion molecule	Mus musculus	13-15
28493080-10	2017	Honokiol significantly inhibited leukocyte infiltration and upregulation of proinflammatory cytokines (tumor necrosis factor-alpha, interleukin-1beta, and interleukin-6) and inducible nitric oxide synthase in the ileal muscle layer of postoperative ileus model mice.	honokiol	0-8	tumor necrosis factor	Mus musculus	103-130
28493080-10	2017	Honokiol significantly inhibited leukocyte infiltration and upregulation of proinflammatory cytokines (tumor necrosis factor-alpha, interleukin-1beta, and interleukin-6) and inducible nitric oxide synthase in the ileal muscle layer of postoperative ileus model mice.	honokiol	0-8	interleukin 1 beta	Mus musculus	132-149
28493080-10	2017	Honokiol significantly inhibited leukocyte infiltration and upregulation of proinflammatory cytokines (tumor necrosis factor-alpha, interleukin-1beta, and interleukin-6) and inducible nitric oxide synthase in the ileal muscle layer of postoperative ileus model mice.	honokiol	0-8	interleukin 6	Mus musculus	155-168
28751674-9	2017	Furthermore, honokiol inhibited FPR1 agonist-induced calcium mobilization as well as phosphorylation of p38 MAPK, ERK, and JNK in human neutrophils.	honokiol	13-21	formyl peptide receptor 1	Homo sapiens	32-36
28751674-0	2017	Honokiol suppresses formyl peptide-induced human neutrophil activation by blocking formyl peptide receptor 1.	honokiol	0-8	formyl peptide receptor 1	Homo sapiens	83-108
28751674-4	2017	Here, we show that honokiol exhibits an inhibitory effect on FPR1 binding in human neutrophils.	honokiol	19-27	formyl peptide receptor 1	Homo sapiens	61-65
28751674-5	2017	Honokiol inhibited superoxide anion generation, reactive oxygen species formation, and elastase release in bacterial or mitochondrial N-formyl peptides (FPR1 agonists)-activated human neutrophils.	honokiol	0-8	formyl peptide receptor 1	Homo sapiens	153-157
28751674-6	2017	Adhesion of FPR1-induced human neutrophils to cerebral endothelial cells was also reduced by honokiol.	honokiol	93-101	formyl peptide receptor 1	Homo sapiens	12-16
28751674-7	2017	The receptor-binding results revealed that honokiol repressed FPR1-specific ligand N-formyl-Nle-Leu-Phe-Nle-Tyr-Lys-fluorescein binding to FPR1 in human neutrophils, neutrophil-like THP-1 cells, and hFPR1-transfected HEK293 cells.	honokiol	43-51	formyl peptide receptor 1	Homo sapiens	62-66
28751674-7	2017	The receptor-binding results revealed that honokiol repressed FPR1-specific ligand N-formyl-Nle-Leu-Phe-Nle-Tyr-Lys-fluorescein binding to FPR1 in human neutrophils, neutrophil-like THP-1 cells, and hFPR1-transfected HEK293 cells.	honokiol	43-51	formyl peptide receptor 1	Homo sapiens	139-143
28751674-7	2017	The receptor-binding results revealed that honokiol repressed FPR1-specific ligand N-formyl-Nle-Leu-Phe-Nle-Tyr-Lys-fluorescein binding to FPR1 in human neutrophils, neutrophil-like THP-1 cells, and hFPR1-transfected HEK293 cells.	honokiol	43-51	formyl peptide receptor 1	Homo sapiens	199-204
28724911-0	2017	Honokiol inhibits c-Met-HO-1 tumor-promoting pathway and its cross-talk with calcineurin inhibitor-mediated renal cancer growth.	honokiol	0-8	MET proto-oncogene, receptor tyrosine kinase	Homo sapiens	18-23
28724911-0	2017	Honokiol inhibits c-Met-HO-1 tumor-promoting pathway and its cross-talk with calcineurin inhibitor-mediated renal cancer growth.	honokiol	0-8	heme oxygenase 1	Homo sapiens	24-28
28724911-0	2017	Honokiol inhibits c-Met-HO-1 tumor-promoting pathway and its cross-talk with calcineurin inhibitor-mediated renal cancer growth.	honokiol	0-8	calcineurin binding protein 1	Homo sapiens	77-98
28546431-6	2017	Using wild-type BRAF and BRAFV600E melanoma model systems, we demonstrate here that HKL administration rapidly reduces mitochondrial respiration by broadly inhibiting ETC complexes I, II, and V, resulting in decreased ATP levels.	honokiol	84-87	Braf transforming gene	Mus musculus	16-20
28229451-5	2017	RESULTS: Honokiol at 10 mum reduced IL-1alpha production by 3.4 folds (P &lt; 0.05) and at 10 and 20 mum reduced IL-8 by 23.9% and 53.1% (P &lt; 0.001), respectively, in HaCat keratinocytes.	honokiol	9-17	interleukin 1 alpha	Homo sapiens	36-45
28229451-5	2017	RESULTS: Honokiol at 10 mum reduced IL-1alpha production by 3.4 folds (P &lt; 0.05) and at 10 and 20 mum reduced IL-8 by 23.9% and 53.1% (P &lt; 0.001), respectively, in HaCat keratinocytes.	honokiol	9-17	C-X-C motif chemokine ligand 8	Homo sapiens	113-117
28229451-6	2017	In HFF-1, honokiol restored TIMP-2 production by 96.9% and 91.9% (P &lt; 0.001), respectively, at 10 and 20 mum, as well as reduced apoptosis by 47.1% (P &lt; 0.001) and 41.3% (P &lt; 0.01), respectively.	honokiol	10-18	TIMP metallopeptidase inhibitor 2	Homo sapiens	28-34
28229451-7	2017	Finally, honokiol reduced senescence-associated beta-galactosidase expression in HFF-1.	honokiol	9-17	galactosidase beta 1	Homo sapiens	48-66
28751674-9	2017	Furthermore, honokiol inhibited FPR1 agonist-induced calcium mobilization as well as phosphorylation of p38 MAPK, ERK, and JNK in human neutrophils.	honokiol	13-21	mitogen-activated protein kinase 1	Homo sapiens	114-117
28751674-9	2017	Furthermore, honokiol inhibited FPR1 agonist-induced calcium mobilization as well as phosphorylation of p38 MAPK, ERK, and JNK in human neutrophils.	honokiol	13-21	mitogen-activated protein kinase 8	Homo sapiens	123-126
28751674-10	2017	In conclusion, our data demonstrate that honokiol may have therapeutic potential for treating FPR1-mediated inflammatory diseases.	honokiol	41-49	formyl peptide receptor 1	Homo sapiens	94-98
28423723-0	2017	Honokiol, an activator of Sirtuin-3 (SIRT3) preserves mitochondria and protects the heart from doxorubicin-induced cardiomyopathy in mice.	honokiol	0-8	sirtuin 3	Mus musculus	26-35
28465484-7	2017	In addition, honokiol (HKL), a major bioactive compound isolated from Magnolia officinalis (Houpo), suppressed AngII-induced renal fibrosis through activating SIRT3-KLF15 signaling.	honokiol	13-21	angiotensinogen (serpin peptidase inhibitor, clade A, member 8)	Mus musculus	111-116
28465484-7	2017	In addition, honokiol (HKL), a major bioactive compound isolated from Magnolia officinalis (Houpo), suppressed AngII-induced renal fibrosis through activating SIRT3-KLF15 signaling.	honokiol	13-21	sirtuin 3	Mus musculus	159-164
28465484-7	2017	In addition, honokiol (HKL), a major bioactive compound isolated from Magnolia officinalis (Houpo), suppressed AngII-induced renal fibrosis through activating SIRT3-KLF15 signaling.	honokiol	13-21	Kruppel-like factor 15	Mus musculus	165-170
28465484-7	2017	In addition, honokiol (HKL), a major bioactive compound isolated from Magnolia officinalis (Houpo), suppressed AngII-induced renal fibrosis through activating SIRT3-KLF15 signaling.	honokiol	23-26	angiotensinogen (serpin peptidase inhibitor, clade A, member 8)	Mus musculus	111-116
28465484-7	2017	In addition, honokiol (HKL), a major bioactive compound isolated from Magnolia officinalis (Houpo), suppressed AngII-induced renal fibrosis through activating SIRT3-KLF15 signaling.	honokiol	23-26	sirtuin 3	Mus musculus	159-164
28465484-7	2017	In addition, honokiol (HKL), a major bioactive compound isolated from Magnolia officinalis (Houpo), suppressed AngII-induced renal fibrosis through activating SIRT3-KLF15 signaling.	honokiol	23-26	Kruppel-like factor 15	Mus musculus	165-170
28423723-0	2017	Honokiol, an activator of Sirtuin-3 (SIRT3) preserves mitochondria and protects the heart from doxorubicin-induced cardiomyopathy in mice.	honokiol	0-8	sirtuin 3	Mus musculus	37-42
28423723-4	2017	We have recently identified honokiol (HKL) as an activator of SIRT3, which protects the heart from developing pressure overload hypertrophy.	honokiol	28-36	sirtuin 3	Mus musculus	62-67
28423723-4	2017	We have recently identified honokiol (HKL) as an activator of SIRT3, which protects the heart from developing pressure overload hypertrophy.	honokiol	38-41	sirtuin 3	Mus musculus	62-67
28490739-4	2017	The inflammatory mediators, COX-2 and PGE2, played a key role in this effect, as indicated by honokiol inhibition of cyclooxygenase-2 (COX-2) expression and PGE2 production in the UVB-exposed skin.	honokiol	94-102	prostaglandin-endoperoxide synthase 2	Mus musculus	28-33
28490739-4	2017	The inflammatory mediators, COX-2 and PGE2, played a key role in this effect, as indicated by honokiol inhibition of cyclooxygenase-2 (COX-2) expression and PGE2 production in the UVB-exposed skin.	honokiol	94-102	prostaglandin-endoperoxide synthase 2	Mus musculus	117-133
28490739-4	2017	The inflammatory mediators, COX-2 and PGE2, played a key role in this effect, as indicated by honokiol inhibition of cyclooxygenase-2 (COX-2) expression and PGE2 production in the UVB-exposed skin.	honokiol	94-102	prostaglandin-endoperoxide synthase 2	Mus musculus	135-140
28848085-12	2017	Furthermore, AbetaO-induced NF-kappaB activation was inhibited by honokiol, as well as the upregulated amyloid precursor protein and beta-secretase.	honokiol	66-74	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	28-37
28469575-0	2017	Honokiol Alleviates Hypertrophic Scar by Targeting Transforming Growth Factor-beta/Smad2/3 Signaling Pathway.	honokiol	0-8	mothers against decapentaplegic homolog 2	Oryctolagus cuniculus	83-90
27849557-0	2017	Honokiol Decreases Lung Cancer Metastasis through Inhibition of the STAT3 Signaling Pathway.	honokiol	0-8	signal transducer and activator of transcription 3	Mus musculus	68-73
29871193-7	2017	Moreover, western blotting revealed that Honokiol treatment resulted in an increase of PTEN protein expression and a decrease of p-Akt and p-mTOR expression.Conclusion:Honokiol inhibits nasopharyngeal carcinoma cell line CNE-1 proliferation, migration and invasion via inactivation of PTEN/PI3k/Akt signaling pathway.	honokiol	41-49	phosphatase and tensin homolog	Homo sapiens	87-91
29871193-7	2017	Moreover, western blotting revealed that Honokiol treatment resulted in an increase of PTEN protein expression and a decrease of p-Akt and p-mTOR expression.Conclusion:Honokiol inhibits nasopharyngeal carcinoma cell line CNE-1 proliferation, migration and invasion via inactivation of PTEN/PI3k/Akt signaling pathway.	honokiol	41-49	mechanistic target of rapamycin kinase	Homo sapiens	141-145
29871193-7	2017	Moreover, western blotting revealed that Honokiol treatment resulted in an increase of PTEN protein expression and a decrease of p-Akt and p-mTOR expression.Conclusion:Honokiol inhibits nasopharyngeal carcinoma cell line CNE-1 proliferation, migration and invasion via inactivation of PTEN/PI3k/Akt signaling pathway.	honokiol	41-49	phosphatase and tensin homolog	Homo sapiens	285-289
29871193-7	2017	Moreover, western blotting revealed that Honokiol treatment resulted in an increase of PTEN protein expression and a decrease of p-Akt and p-mTOR expression.Conclusion:Honokiol inhibits nasopharyngeal carcinoma cell line CNE-1 proliferation, migration and invasion via inactivation of PTEN/PI3k/Akt signaling pathway.	honokiol	168-176	mechanistic target of rapamycin kinase	Homo sapiens	141-145
29871193-7	2017	Moreover, western blotting revealed that Honokiol treatment resulted in an increase of PTEN protein expression and a decrease of p-Akt and p-mTOR expression.Conclusion:Honokiol inhibits nasopharyngeal carcinoma cell line CNE-1 proliferation, migration and invasion via inactivation of PTEN/PI3k/Akt signaling pathway.	honokiol	168-176	phosphatase and tensin homolog	Homo sapiens	285-289
28054640-6	2017	Honokiol also attenuated the phosphorylation of Lyn, PLCgamma2, PKC, MAPKs, and Akt after convulxin stimulation.	honokiol	0-8	LYN proto-oncogene, Src family tyrosine kinase	Homo sapiens	48-51
28054640-6	2017	Honokiol also attenuated the phosphorylation of Lyn, PLCgamma2, PKC, MAPKs, and Akt after convulxin stimulation.	honokiol	0-8	phospholipase C gamma 2	Homo sapiens	53-62
28054640-6	2017	Honokiol also attenuated the phosphorylation of Lyn, PLCgamma2, PKC, MAPKs, and Akt after convulxin stimulation.	honokiol	0-8	AKT serine/threonine kinase 1	Homo sapiens	80-83
28054640-8	2017	Honokiol diminished the binding of anti-GP VI (FITC-JAQ1) mAb to human platelets, and it also reduced the coimmunoprecipitation of GP VI-bound Lyn after convulxin stimulation.	honokiol	0-8	glycoprotein VI platelet	Homo sapiens	40-45
28054640-8	2017	Honokiol diminished the binding of anti-GP VI (FITC-JAQ1) mAb to human platelets, and it also reduced the coimmunoprecipitation of GP VI-bound Lyn after convulxin stimulation.	honokiol	0-8	glycoprotein VI platelet	Homo sapiens	131-136
28054640-8	2017	Honokiol diminished the binding of anti-GP VI (FITC-JAQ1) mAb to human platelets, and it also reduced the coimmunoprecipitation of GP VI-bound Lyn after convulxin stimulation.	honokiol	0-8	LYN proto-oncogene, Src family tyrosine kinase	Homo sapiens	143-146
28054640-9	2017	The surface plasmon resonance results revealed that honokiol binds directly to GP VI, with a KD of 289 muM.	honokiol	52-60	glycoprotein VI platelet	Homo sapiens	79-84
28054640-11	2017	In conclusion, honokiol acts as a potent antagonist of collagen GP VI in human platelets, and it has therapeutic potential in the prevention of the pathological thrombosis.	honokiol	15-23	glycoprotein VI platelet	Homo sapiens	64-69
27906672-0	2017	Non-toxic dose of liposomal honokiol suppresses metastasis of hepatocellular carcinoma through destabilizing EGFR and inhibiting the downstream pathways.	honokiol	28-36	epidermal growth factor receptor	Homo sapiens	109-113
27906672-5	2017	In our present study, we found non-toxic dose of liposomal honokiol (LH) could inhibit the HCC metastasis by destabilizing EGFR and inhibiting the downstream pathways.	honokiol	59-67	epidermal growth factor receptor	Homo sapiens	123-127
28194418-7	2017	An elevated level of caspases and PARP were observed in both cell lines treated with honokiol.	honokiol	85-93	collagen type XI alpha 2 chain	Homo sapiens	34-38
28848085-0	2017	Honokiol Attenuates Oligomeric Amyloid beta1-42-Induced Alzheimer"s Disease in Mice Through Attenuating Mitochondrial Apoptosis and Inhibiting the Nuclear Factor Kappa-B Signaling Pathway.	honokiol	0-8	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	147-169
27593221-0	2016	Honokiol inhibits EMT-mediated motility and migration of human non-small cell lung cancer cells in vitro by targeting c-FLIP.	honokiol	0-8	CASP8 and FADD like apoptosis regulator	Homo sapiens	118-124
27714931-0	2017	Synthesis of honokiol analogues and evaluation of their modulating action on VEGF protein secretion and telomerase-related gene expressions.	honokiol	13-21	vascular endothelial growth factor A	Homo sapiens	77-81
28351375-0	2017	Erratum to: Honokiol activates AMP-activated protein kinase in breast cancer cells via LKB1-dependent pathway and inhibits breast carcinogenesis.	honokiol	12-20	serine/threonine kinase 11	Homo sapiens	87-91
28043811-0	2017	Honokiol induces proteasomal degradation of AML1-ETO oncoprotein via increasing ubiquitin conjugase UbcH8 expression in leukemia.	honokiol	0-8	runt related transcription factor 1	Mus musculus	44-48
28043811-0	2017	Honokiol induces proteasomal degradation of AML1-ETO oncoprotein via increasing ubiquitin conjugase UbcH8 expression in leukemia.	honokiol	0-8	RUNX1 translocation partner 1	Mus musculus	49-52
28043811-0	2017	Honokiol induces proteasomal degradation of AML1-ETO oncoprotein via increasing ubiquitin conjugase UbcH8 expression in leukemia.	honokiol	0-8	ubiquitin-conjugating enzyme E2L 6	Mus musculus	100-105
28043811-3	2017	Here, we report that AML1-ETO protein is rapidly degraded by Honokiol (HNK), a natural phenolic compound isolated from the plant Magnolia officinalis.	honokiol	61-69	runt related transcription factor 1	Mus musculus	21-25
28043811-3	2017	Here, we report that AML1-ETO protein is rapidly degraded by Honokiol (HNK), a natural phenolic compound isolated from the plant Magnolia officinalis.	honokiol	61-69	RUNX1 translocation partner 1	Mus musculus	26-29
28260895-3	2017	In order to improve antitumor efficiency and reduce side effects of free drugs, we prepared paclitaxel (PTX) and honokiol (HK) combination methoxy poly(ethylene glycol)-poly(caprolactone) micelles (P-H/M) by solid dispersion method against breast cancer.	honokiol	113-121	peptidylglycine alpha-amidating monooxygenase	Mus musculus	198-203
28067485-3	2017	In this study, we examined the effectiveness of honokiol to inhibit human DNA polymerase beta (pol beta), which is involved in BER, and DNA polymerase lambda (pol lambda), which is involved in NHEJ.	honokiol	48-56	DNA polymerase beta	Homo sapiens	74-93
28067485-3	2017	In this study, we examined the effectiveness of honokiol to inhibit human DNA polymerase beta (pol beta), which is involved in BER, and DNA polymerase lambda (pol lambda), which is involved in NHEJ.	honokiol	48-56	DNA polymerase beta	Homo sapiens	95-103
28067485-6	2017	The X-family polymerases, pol beta and pol lambda, were slightly more sensitive to inhibition by honokiol based on the Ki value of 4.0 muM for pol beta, and 8.3 muM for pol lambda, while the Ki values for pol eta and Kf were 20 and 26 muM, respectively.	honokiol	97-105	DNA polymerase beta	Homo sapiens	26-34
28067485-6	2017	The X-family polymerases, pol beta and pol lambda, were slightly more sensitive to inhibition by honokiol based on the Ki value of 4.0 muM for pol beta, and 8.3 muM for pol lambda, while the Ki values for pol eta and Kf were 20 and 26 muM, respectively.	honokiol	97-105	DNA polymerase beta	Homo sapiens	143-151
29358973-0	2017	Corrigendum to "Honokiol Eliminates Human Oral Cancer Stem-Like Cells Accompanied with Suppression of Wnt/beta-Catenin Signaling and Apoptosis Induction".	honokiol	16-24	catenin beta 1	Homo sapiens	106-118
27774504-1	2016	This article contains raw and processed data related to a research, "Honokiol induces autophagic cell death in malignant glioma through reactive oxygen species-mediated regulation of the p53/PI3K/Akt/mTOR signaling pathway" (C.J.	honokiol	69-77	tumor protein p53	Homo sapiens	187-190
27940017-8	2017	Moreover, honokiol treatment modulated signaling pathways including Akt/mTOR, ERK, JNK, and p38 in the studied cells.	honokiol	10-18	AKT serine/threonine kinase 1	Homo sapiens	68-71
27940017-8	2017	Moreover, honokiol treatment modulated signaling pathways including Akt/mTOR, ERK, JNK, and p38 in the studied cells.	honokiol	10-18	mechanistic target of rapamycin kinase	Homo sapiens	72-76
27940017-8	2017	Moreover, honokiol treatment modulated signaling pathways including Akt/mTOR, ERK, JNK, and p38 in the studied cells.	honokiol	10-18	mitogen-activated protein kinase 1	Homo sapiens	78-81
27940017-8	2017	Moreover, honokiol treatment modulated signaling pathways including Akt/mTOR, ERK, JNK, and p38 in the studied cells.	honokiol	10-18	mitogen-activated protein kinase 8	Homo sapiens	83-86
27940017-8	2017	Moreover, honokiol treatment modulated signaling pathways including Akt/mTOR, ERK, JNK, and p38 in the studied cells.	honokiol	10-18	mitogen-activated protein kinase 14	Homo sapiens	92-95
27633759-0	2016	Honokiol inhibits migration of renal cell carcinoma through activation of RhoA/ROCK/MLC signaling pathway.	honokiol	0-8	ras homolog family member A	Homo sapiens	74-78
27633759-0	2016	Honokiol inhibits migration of renal cell carcinoma through activation of RhoA/ROCK/MLC signaling pathway.	honokiol	0-8	modulator of VRAC current 1	Homo sapiens	84-87
27633759-6	2016	In addition, honokiol inhibited migration of highly metastatic RCC 786-0 cells and stimulated the activity of small GTPase, RhoA.	honokiol	13-21	ras homolog family member A	Homo sapiens	124-128
27633759-7	2016	Furthermore, phosphorylated myosin light chain (MLC) and excessive formation of actin stress fibers were identified in 786-0 cells treated with honokiol.	honokiol	144-152	modulator of VRAC current 1	Homo sapiens	28-46
27633759-7	2016	Furthermore, phosphorylated myosin light chain (MLC) and excessive formation of actin stress fibers were identified in 786-0 cells treated with honokiol.	honokiol	144-152	modulator of VRAC current 1	Homo sapiens	48-51
27633759-9	2016	Together these important findings suggest that honokiol suppresses the migration of highly metastatic RCC through activation of RhoA/ROCK/MLC signaling and warrants attention in the treatment of RCC metastasis as a novel therapeutic approach.	honokiol	47-55	ras homolog family member A	Homo sapiens	128-132
27633759-9	2016	Together these important findings suggest that honokiol suppresses the migration of highly metastatic RCC through activation of RhoA/ROCK/MLC signaling and warrants attention in the treatment of RCC metastasis as a novel therapeutic approach.	honokiol	47-55	modulator of VRAC current 1	Homo sapiens	138-141
27458163-0	2016	Honokiol suppresses lung tumorigenesis by targeting EGFR and its downstream effectors.	honokiol	0-8	epidermal growth factor receptor	Homo sapiens	52-56
27458163-2	2016	Here, we showed that honokiol (2.5-7.5 muM), a bioactive compound of Magnolia officinalis, differentially suppressed proliferation (up to 93%) and induced apoptosis (up to 61%) of EGFR overexpressing tumorigenic bronchial cells and these effects were paralleled by downregulation of phospho-EGFR, phospho-Akt, phospho-STAT3 and cell cycle-related proteins as early as 6-12 h post-treatment.	honokiol	21-29	epidermal growth factor receptor	Homo sapiens	180-184
27732568-2	2016	We investigated the expression of the mitochondrial deacetylase sirtuin 3 (SIRT3) and its modulation by hexafluoro, a novel fluorinated synthetic honokiol analogue, in the context of fibrosis.	honokiol	146-154	sirtuin 3	Homo sapiens	75-80
27458163-2	2016	Here, we showed that honokiol (2.5-7.5 muM), a bioactive compound of Magnolia officinalis, differentially suppressed proliferation (up to 93%) and induced apoptosis (up to 61%) of EGFR overexpressing tumorigenic bronchial cells and these effects were paralleled by downregulation of phospho-EGFR, phospho-Akt, phospho-STAT3 and cell cycle-related proteins as early as 6-12 h post-treatment.	honokiol	21-29	epidermal growth factor receptor	Homo sapiens	291-295
27458163-2	2016	Here, we showed that honokiol (2.5-7.5 muM), a bioactive compound of Magnolia officinalis, differentially suppressed proliferation (up to 93%) and induced apoptosis (up to 61%) of EGFR overexpressing tumorigenic bronchial cells and these effects were paralleled by downregulation of phospho-EGFR, phospho-Akt, phospho-STAT3 and cell cycle-related proteins as early as 6-12 h post-treatment.	honokiol	21-29	thymoma viral proto-oncogene 1	Mus musculus	305-308
27458163-2	2016	Here, we showed that honokiol (2.5-7.5 muM), a bioactive compound of Magnolia officinalis, differentially suppressed proliferation (up to 93%) and induced apoptosis (up to 61%) of EGFR overexpressing tumorigenic bronchial cells and these effects were paralleled by downregulation of phospho-EGFR, phospho-Akt, phospho-STAT3 and cell cycle-related proteins as early as 6-12 h post-treatment.	honokiol	21-29	signal transducer and activator of transcription 3	Mus musculus	318-323
27458163-4	2016	Molecular docking studies indicated that honokiol binds to the tyrosine kinase domain of EGFR although it was less efficient than erlotinib.	honokiol	41-49	epidermal growth factor receptor	Homo sapiens	89-93
27458163-7	2016	Furthermore, in a mouse lung tumor bioassay, intranasal instillation of liposomal honokiol (5 mg/kg) for 14 weeks reduced the size and multiplicity (49%) of lung tumors and the level of total- and phospho-EGFR, phospho-Akt and phospho-STAT3.	honokiol	82-90	epidermal growth factor receptor	Mus musculus	205-209
27458163-7	2016	Furthermore, in a mouse lung tumor bioassay, intranasal instillation of liposomal honokiol (5 mg/kg) for 14 weeks reduced the size and multiplicity (49%) of lung tumors and the level of total- and phospho-EGFR, phospho-Akt and phospho-STAT3.	honokiol	82-90	thymoma viral proto-oncogene 1	Mus musculus	219-222
27458163-7	2016	Furthermore, in a mouse lung tumor bioassay, intranasal instillation of liposomal honokiol (5 mg/kg) for 14 weeks reduced the size and multiplicity (49%) of lung tumors and the level of total- and phospho-EGFR, phospho-Akt and phospho-STAT3.	honokiol	82-90	signal transducer and activator of transcription 3	Mus musculus	235-240
27458163-8	2016	Overall, our results indicate that honokiol is a promising candidate to suppress the development and even progression of lung tumors driven by EGFR deregulation.	honokiol	35-43	epidermal growth factor receptor	Homo sapiens	143-147
27341160-0	2016	c-Myc is a novel target of cell cycle arrest by honokiol in prostate cancer cells.	honokiol	48-56	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	0-5
27339657-7	2016	Botanicals such as quercetin and honokiol (but not cyanidin-3-O-glucoside, 3CG) were effective in inhibiting LPS-induced nitric oxide (NO) production and phosphorylation of cPLA2.	honokiol	33-41	phospholipase A2 group IVA	Homo sapiens	173-178
27774504-1	2016	This article contains raw and processed data related to a research, "Honokiol induces autophagic cell death in malignant glioma through reactive oxygen species-mediated regulation of the p53/PI3K/Akt/mTOR signaling pathway" (C.J.	honokiol	69-77	AKT serine/threonine kinase 1	Homo sapiens	196-199
27774504-1	2016	This article contains raw and processed data related to a research, "Honokiol induces autophagic cell death in malignant glioma through reactive oxygen species-mediated regulation of the p53/PI3K/Akt/mTOR signaling pathway" (C.J.	honokiol	69-77	mechanistic target of rapamycin kinase	Homo sapiens	200-204
27774504-14	2016	The processed data show the effects of honokiol on induction of autophagy in human glioma U87 MG cells by analyzing levels of LC3-II, p62, and bectin-1, "Honokiol-induced apoptosis and autophagy in glioblastoma multiforme cells" (K.H.	honokiol	39-47	nucleoporin 62	Homo sapiens	134-137
27094504-2	2016	Recently, it was found that honokiol acted as not only a retinoid X receptor (RXR) agonist but also as a peroxisome proliferator-activated receptor gamma (PPARgamma) agonist.	honokiol	28-36	retinoid X receptor alpha	Homo sapiens	57-76
27094504-2	2016	Recently, it was found that honokiol acted as not only a retinoid X receptor (RXR) agonist but also as a peroxisome proliferator-activated receptor gamma (PPARgamma) agonist.	honokiol	28-36	retinoid X receptor alpha	Homo sapiens	78-81
27236003-0	2016	Honokiol induces autophagic cell death in malignant glioma through reactive oxygen species-mediated regulation of the p53/PI3K/Akt/mTOR signaling pathway.	honokiol	0-8	tumor protein p53	Homo sapiens	118-121
27094504-2	2016	Recently, it was found that honokiol acted as not only a retinoid X receptor (RXR) agonist but also as a peroxisome proliferator-activated receptor gamma (PPARgamma) agonist.	honokiol	28-36	peroxisome proliferator activated receptor gamma	Homo sapiens	105-153
27094504-2	2016	Recently, it was found that honokiol acted as not only a retinoid X receptor (RXR) agonist but also as a peroxisome proliferator-activated receptor gamma (PPARgamma) agonist.	honokiol	28-36	peroxisome proliferator activated receptor gamma	Homo sapiens	155-164
27094504-3	2016	Additionally, honokiol is capable of activating PPARgamma/RXR heterodimers synergistically in the presence of rosiglitazone in 3T3-L1 adipocyte and HLE human hepatoma cells.	honokiol	14-22	peroxisome proliferator activated receptor gamma	Mus musculus	48-57
27094504-3	2016	Additionally, honokiol is capable of activating PPARgamma/RXR heterodimers synergistically in the presence of rosiglitazone in 3T3-L1 adipocyte and HLE human hepatoma cells.	honokiol	14-22	retinoid X receptor alpha	Homo sapiens	58-61
27094504-9	2016	Also, treatment with honokiol and rosiglitazone induced cell cycle arrest in the G0/G1 phase; increased p21; and decreased cyclin D1, cyclin E1, and Rb expression in SK-Hep1 hepatoma cells.	honokiol	21-29	H3 histone pseudogene 16	Homo sapiens	104-107
27094504-9	2016	Also, treatment with honokiol and rosiglitazone induced cell cycle arrest in the G0/G1 phase; increased p21; and decreased cyclin D1, cyclin E1, and Rb expression in SK-Hep1 hepatoma cells.	honokiol	21-29	cyclin D1	Homo sapiens	123-132
27094504-9	2016	Also, treatment with honokiol and rosiglitazone induced cell cycle arrest in the G0/G1 phase; increased p21; and decreased cyclin D1, cyclin E1, and Rb expression in SK-Hep1 hepatoma cells.	honokiol	21-29	cyclin E1	Homo sapiens	134-143
27094504-9	2016	Also, treatment with honokiol and rosiglitazone induced cell cycle arrest in the G0/G1 phase; increased p21; and decreased cyclin D1, cyclin E1, and Rb expression in SK-Hep1 hepatoma cells.	honokiol	21-29	DNL-type zinc finger	Homo sapiens	169-173
27094504-10	2016	CONCLUSION: Honokiol combined with rosiglitazone showed more effective growth inhibition in hepatoma cells mediated through the regulation of G0/G1 phase-related proteins p21, cyclin D1, cyclin E1, and Rb and cell cycle progression.	honokiol	12-20	H3 histone pseudogene 16	Homo sapiens	171-174
27094504-10	2016	CONCLUSION: Honokiol combined with rosiglitazone showed more effective growth inhibition in hepatoma cells mediated through the regulation of G0/G1 phase-related proteins p21, cyclin D1, cyclin E1, and Rb and cell cycle progression.	honokiol	12-20	cyclin D1	Homo sapiens	176-185
27094504-10	2016	CONCLUSION: Honokiol combined with rosiglitazone showed more effective growth inhibition in hepatoma cells mediated through the regulation of G0/G1 phase-related proteins p21, cyclin D1, cyclin E1, and Rb and cell cycle progression.	honokiol	12-20	cyclin E1	Homo sapiens	187-196
27236003-0	2016	Honokiol induces autophagic cell death in malignant glioma through reactive oxygen species-mediated regulation of the p53/PI3K/Akt/mTOR signaling pathway.	honokiol	0-8	AKT serine/threonine kinase 1	Homo sapiens	127-130
27236003-0	2016	Honokiol induces autophagic cell death in malignant glioma through reactive oxygen species-mediated regulation of the p53/PI3K/Akt/mTOR signaling pathway.	honokiol	0-8	mechanistic target of rapamycin kinase	Homo sapiens	131-135
27236003-5	2016	Administration of honokiol to mice with an intracranial glioma increased expressions of cleaved caspase 3 and light chain 3 (LC3)-II.	honokiol	18-26	microtubule-associated protein 1 light chain 3 alpha	Mus musculus	110-123
27236003-5	2016	Administration of honokiol to mice with an intracranial glioma increased expressions of cleaved caspase 3 and light chain 3 (LC3)-II.	honokiol	18-26	microtubule-associated protein 1 light chain 3 alpha	Mus musculus	125-128
27236003-8	2016	Honokiol decreased protein levels of PI3K, phosphorylated (p)-Akt, and p-mammalian target of rapamycin (mTOR) in vitro and in vivo.	honokiol	0-8	AKT serine/threonine kinase 1	Homo sapiens	62-65
27236003-8	2016	Honokiol decreased protein levels of PI3K, phosphorylated (p)-Akt, and p-mammalian target of rapamycin (mTOR) in vitro and in vivo.	honokiol	0-8	mechanistic target of rapamycin kinase	Homo sapiens	71-102
27236003-8	2016	Honokiol decreased protein levels of PI3K, phosphorylated (p)-Akt, and p-mammalian target of rapamycin (mTOR) in vitro and in vivo.	honokiol	0-8	mechanistic target of rapamycin kinase	Homo sapiens	104-108
27236003-9	2016	Pretreatment with a p53 inhibitor or transfection with p53 small interfering (si)RNA suppressed honokiol-induced autophagy by reversing downregulation of p-Akt and p-mTOR expressions.	honokiol	96-104	tumor protein p53	Homo sapiens	20-23
27236003-9	2016	Pretreatment with a p53 inhibitor or transfection with p53 small interfering (si)RNA suppressed honokiol-induced autophagy by reversing downregulation of p-Akt and p-mTOR expressions.	honokiol	96-104	tumor protein p53	Homo sapiens	55-58
27236003-9	2016	Pretreatment with a p53 inhibitor or transfection with p53 small interfering (si)RNA suppressed honokiol-induced autophagy by reversing downregulation of p-Akt and p-mTOR expressions.	honokiol	96-104	AKT serine/threonine kinase 1	Homo sapiens	156-159
27236003-9	2016	Pretreatment with a p53 inhibitor or transfection with p53 small interfering (si)RNA suppressed honokiol-induced autophagy by reversing downregulation of p-Akt and p-mTOR expressions.	honokiol	96-104	mechanistic target of rapamycin kinase	Homo sapiens	166-170
27236003-12	2016	Concurrently, honokiol-induced alterations in levels of p-p53, p53, p-Akt, and p-mTOR were attenuated following vitamin C administration.	honokiol	14-22	tumor protein p53	Homo sapiens	58-61
27236003-12	2016	Concurrently, honokiol-induced alterations in levels of p-p53, p53, p-Akt, and p-mTOR were attenuated following vitamin C administration.	honokiol	14-22	tumor protein p53	Homo sapiens	63-66
27236003-12	2016	Concurrently, honokiol-induced alterations in levels of p-p53, p53, p-Akt, and p-mTOR were attenuated following vitamin C administration.	honokiol	14-22	AKT serine/threonine kinase 1	Homo sapiens	70-73
27236003-12	2016	Concurrently, honokiol-induced alterations in levels of p-p53, p53, p-Akt, and p-mTOR were attenuated following vitamin C administration.	honokiol	14-22	mechanistic target of rapamycin kinase	Homo sapiens	81-85
27236003-13	2016	Taken together, our data indicated that honokiol induced ROS-mediated autophagic cell death through regulating the p53/PI3K/Akt/mTOR signaling pathway.	honokiol	40-48	tumor protein p53	Homo sapiens	115-118
27236003-13	2016	Taken together, our data indicated that honokiol induced ROS-mediated autophagic cell death through regulating the p53/PI3K/Akt/mTOR signaling pathway.	honokiol	40-48	AKT serine/threonine kinase 1	Homo sapiens	124-127
27236003-13	2016	Taken together, our data indicated that honokiol induced ROS-mediated autophagic cell death through regulating the p53/PI3K/Akt/mTOR signaling pathway.	honokiol	40-48	mechanistic target of rapamycin kinase	Homo sapiens	128-132
27212040-0	2016	Honokiol suppresses TNF-alpha-induced neutrophil adhesion on cerebral endothelial cells by disrupting polyubiquitination and degradation of IkappaBalpha.	honokiol	0-8	tumor necrosis factor	Mus musculus	20-29
27131736-0	2016	Neuroprotective effects of honokiol against beta-amyloid-induced neurotoxicity via GSK-3beta and beta-catenin signaling pathway in PC12 cells.	honokiol	27-35	catenin beta 1	Rattus norvegicus	97-109
27131736-5	2016	The results revealed that honokiol protected PC12 cells from Abeta1-42 induced cytotoxicity with increases in cell viability, GSH production and Bcl-2 expression, but decreases in the release of lactate dehydrogenase and cytochrome c, the amount of DNA fragmentation and MDA level, as well as Bax expression.	honokiol	26-34	BCL2, apoptosis regulator	Rattus norvegicus	145-150
27131736-5	2016	The results revealed that honokiol protected PC12 cells from Abeta1-42 induced cytotoxicity with increases in cell viability, GSH production and Bcl-2 expression, but decreases in the release of lactate dehydrogenase and cytochrome c, the amount of DNA fragmentation and MDA level, as well as Bax expression.	honokiol	26-34	BCL2 associated X, apoptosis regulator	Rattus norvegicus	293-296
27131736-6	2016	Mechanistic study showed that honokiol could inhibit the activation of glycogen synthase kinase (GSK)-3beta, attenuate the nuclear accumulation of beta-catenin and suppress the phosphorylation of beta-catenin (Ser33/Ser37/Thr41 site) in the Abeta1-42-treated PC12 cells.	honokiol	30-38	catenin beta 1	Rattus norvegicus	147-159
27131736-6	2016	Mechanistic study showed that honokiol could inhibit the activation of glycogen synthase kinase (GSK)-3beta, attenuate the nuclear accumulation of beta-catenin and suppress the phosphorylation of beta-catenin (Ser33/Ser37/Thr41 site) in the Abeta1-42-treated PC12 cells.	honokiol	30-38	catenin beta 1	Rattus norvegicus	196-208
27131736-7	2016	These results indicate that the anti-oxidative and anti-apoptotic effects of honokiol in Abeta1-42-treated PC12 cells may be mediated, at least in part, by regulation the GSK-3beta and beta-catenin signaling pathways.	honokiol	77-85	glycogen synthase kinase 3 beta	Rattus norvegicus	171-180
27131736-7	2016	These results indicate that the anti-oxidative and anti-apoptotic effects of honokiol in Abeta1-42-treated PC12 cells may be mediated, at least in part, by regulation the GSK-3beta and beta-catenin signaling pathways.	honokiol	77-85	catenin beta 1	Rattus norvegicus	185-197
27212040-0	2016	Honokiol suppresses TNF-alpha-induced neutrophil adhesion on cerebral endothelial cells by disrupting polyubiquitination and degradation of IkappaBalpha.	honokiol	0-8	nuclear factor of kappa light polypeptide gene enhancer in B cells inhibitor, alpha	Mus musculus	140-152
27212040-4	2016	Here, we investigated the inhibitory effect of honokiol on neutrophil adhesion and vascular cell adhesion molecule-1 (VCAM-1) expression, which underlie its molecular target, and mechanisms for inactivating nuclear factor kappa enhancer binding protein (NF-kappaB) in mouse cerebral ECs.	honokiol	47-55	vascular cell adhesion molecule 1	Mus musculus	83-116
27212040-4	2016	Here, we investigated the inhibitory effect of honokiol on neutrophil adhesion and vascular cell adhesion molecule-1 (VCAM-1) expression, which underlie its molecular target, and mechanisms for inactivating nuclear factor kappa enhancer binding protein (NF-kappaB) in mouse cerebral ECs.	honokiol	47-55	vascular cell adhesion molecule 1	Mus musculus	118-124
27212040-5	2016	Honokiol inhibited tumour necrosis factor-alpha (TNF-alpha)-induced neutrophil adhesion and VCAM-1 gene expression in cerebral ECs.	honokiol	0-8	tumor necrosis factor	Mus musculus	49-58
27212040-5	2016	Honokiol inhibited tumour necrosis factor-alpha (TNF-alpha)-induced neutrophil adhesion and VCAM-1 gene expression in cerebral ECs.	honokiol	0-8	vascular cell adhesion molecule 1	Mus musculus	92-98
27212040-6	2016	The inflammatory transcription factor NF-kappaB was downregulated by honokiol.	honokiol	69-77	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	38-47
27212040-7	2016	Honokiol significantly blocked TNF-alpha-induced NF-kappaB p65 nuclear translocation and degradation of the proteasome-dependent inhibitor of NF-kappaB alpha (IkappaBalpha).	honokiol	0-8	tumor necrosis factor	Mus musculus	31-40
27212040-7	2016	Honokiol significantly blocked TNF-alpha-induced NF-kappaB p65 nuclear translocation and degradation of the proteasome-dependent inhibitor of NF-kappaB alpha (IkappaBalpha).	honokiol	0-8	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	49-58
27212040-7	2016	Honokiol significantly blocked TNF-alpha-induced NF-kappaB p65 nuclear translocation and degradation of the proteasome-dependent inhibitor of NF-kappaB alpha (IkappaBalpha).	honokiol	0-8	v-rel reticuloendotheliosis viral oncogene homolog A (avian)	Mus musculus	59-62
27212040-7	2016	Honokiol significantly blocked TNF-alpha-induced NF-kappaB p65 nuclear translocation and degradation of the proteasome-dependent inhibitor of NF-kappaB alpha (IkappaBalpha).	honokiol	0-8	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	142-151
27212040-7	2016	Honokiol significantly blocked TNF-alpha-induced NF-kappaB p65 nuclear translocation and degradation of the proteasome-dependent inhibitor of NF-kappaB alpha (IkappaBalpha).	honokiol	0-8	nuclear factor of kappa light polypeptide gene enhancer in B cells inhibitor, alpha	Mus musculus	159-171
27212040-9	2016	Moreover, honokiol prevented the TNF-alpha-induced Lys48-linked polyubiquitination, including IkappaBalpha-polyubiquitin interaction.	honokiol	10-18	tumor necrosis factor	Mus musculus	33-42
27212040-9	2016	Moreover, honokiol prevented the TNF-alpha-induced Lys48-linked polyubiquitination, including IkappaBalpha-polyubiquitin interaction.	honokiol	10-18	nuclear factor of kappa light polypeptide gene enhancer in B cells inhibitor, alpha	Mus musculus	94-106
27212040-10	2016	Honokiol has protective anti-inflammatory effects on TNF-alpha-induced neutrophil adhesion and VCAM-1 gene expression in cerebral ECs, at least in part by directly inhibiting ubiquitination-mediated IkappaBalpha degradation and then preventing NF-kappaB nuclear translocation.	honokiol	0-8	tumor necrosis factor	Mus musculus	53-62
27212040-10	2016	Honokiol has protective anti-inflammatory effects on TNF-alpha-induced neutrophil adhesion and VCAM-1 gene expression in cerebral ECs, at least in part by directly inhibiting ubiquitination-mediated IkappaBalpha degradation and then preventing NF-kappaB nuclear translocation.	honokiol	0-8	vascular cell adhesion molecule 1	Mus musculus	95-101
27212040-10	2016	Honokiol has protective anti-inflammatory effects on TNF-alpha-induced neutrophil adhesion and VCAM-1 gene expression in cerebral ECs, at least in part by directly inhibiting ubiquitination-mediated IkappaBalpha degradation and then preventing NF-kappaB nuclear translocation.	honokiol	0-8	nuclear factor of kappa light polypeptide gene enhancer in B cells inhibitor, alpha	Mus musculus	199-211
27212040-10	2016	Honokiol has protective anti-inflammatory effects on TNF-alpha-induced neutrophil adhesion and VCAM-1 gene expression in cerebral ECs, at least in part by directly inhibiting ubiquitination-mediated IkappaBalpha degradation and then preventing NF-kappaB nuclear translocation.	honokiol	0-8	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	244-253
26871475-8	2016	Gene arrays comparing treated with vehicle control tumors demonstrated induction of the respiratory enzyme succinate dehydrogenase B (SDHB) by treatment, suggesting that our honokiol analogs induce respiration in vivo.	honokiol	174-182	succinate dehydrogenase complex iron sulfur subunit B	Homo sapiens	107-132
26936128-0	2016	mTOR signaling pathway is inhibited downstream of the cyclophilin D-mediated mitochondrial permeability transition in honokiol-triggered regulated necrosis.	honokiol	118-126	mechanistic target of rapamycin kinase	Homo sapiens	0-4
26936128-0	2016	mTOR signaling pathway is inhibited downstream of the cyclophilin D-mediated mitochondrial permeability transition in honokiol-triggered regulated necrosis.	honokiol	118-126	peptidylprolyl isomerase F	Homo sapiens	54-67
27012679-8	2016	Treatment of these SP-derived spheres with honokiol resulted in apoptosis induction via Bax/Bcl-2 and caspase-3-dependent pathway.	honokiol	43-51	BCL2 associated X, apoptosis regulator	Homo sapiens	88-91
27012679-8	2016	Treatment of these SP-derived spheres with honokiol resulted in apoptosis induction via Bax/Bcl-2 and caspase-3-dependent pathway.	honokiol	43-51	BCL2 apoptosis regulator	Homo sapiens	92-97
27012679-8	2016	Treatment of these SP-derived spheres with honokiol resulted in apoptosis induction via Bax/Bcl-2 and caspase-3-dependent pathway.	honokiol	43-51	caspase 3	Homo sapiens	102-111
27012679-9	2016	This apoptosis induction was associated with marked suppression of JAK2/STAT3, Akt and Erk signaling pathways in honokiol-treated SAS spheres.	honokiol	113-121	Janus kinase 2	Homo sapiens	67-71
27012679-9	2016	This apoptosis induction was associated with marked suppression of JAK2/STAT3, Akt and Erk signaling pathways in honokiol-treated SAS spheres.	honokiol	113-121	signal transducer and activator of transcription 3	Homo sapiens	72-77
27012679-9	2016	This apoptosis induction was associated with marked suppression of JAK2/STAT3, Akt and Erk signaling pathways in honokiol-treated SAS spheres.	honokiol	113-121	AKT serine/threonine kinase 1	Homo sapiens	79-82
27012679-9	2016	This apoptosis induction was associated with marked suppression of JAK2/STAT3, Akt and Erk signaling pathways in honokiol-treated SAS spheres.	honokiol	113-121	mitogen-activated protein kinase 1	Homo sapiens	87-90
27012679-10	2016	Consistent with its effect on JAK2/STAT3 suppression, honokiol also markedly inhibited IL-6-mediated migration of SAS cells.	honokiol	54-62	interleukin 6	Homo sapiens	87-91
27012679-11	2016	Accordingly, honokiol dose-dependently inhibited the growth of SAS SP xenograft and markedly reduced the immunohistochemical staining of PCNA and endothelial marker CD31 in the xenograft tumor.	honokiol	13-21	proliferating cell nuclear antigen	Homo sapiens	137-141
27012679-11	2016	Accordingly, honokiol dose-dependently inhibited the growth of SAS SP xenograft and markedly reduced the immunohistochemical staining of PCNA and endothelial marker CD31 in the xenograft tumor.	honokiol	13-21	platelet and endothelial cell adhesion molecule 1	Homo sapiens	165-169
27074557-3	2016	In comparison with Hono or Mag alone, co-treatment with Hono and Mag (Hono-Mag) decreased cyclin A, D1 and cyclin-dependent kinase 2, 4, 6 significantly, leading to cell cycle arrest in U87MG and LN229 human glioma cells.	honokiol	56-60	cyclin dependent kinase 2	Homo sapiens	90-132
27064011-8	2016	In parallel, honokiol induced activations of caspase-8, -9, and -3, apoptosis, and G1 cell cycle arrest.	honokiol	13-21	caspase 8	Homo sapiens	45-66
27064011-9	2016	Treatment of U87 MG cells with honokiol increased p53 phosphorylation and p21 levels.	honokiol	31-39	tumor protein p53	Homo sapiens	50-53
27064011-9	2016	Treatment of U87 MG cells with honokiol increased p53 phosphorylation and p21 levels.	honokiol	31-39	H3 histone pseudogene 16	Homo sapiens	74-77
27064011-10	2016	Honokiol provoked signal-transducing downregulation of CDK6, CDK4, cyclin D1, phosphorylated (p)RB, and E2F1.	honokiol	0-8	cyclin-dependent kinase 6 L homeolog	Xenopus laevis	55-59
27064011-10	2016	Honokiol provoked signal-transducing downregulation of CDK6, CDK4, cyclin D1, phosphorylated (p)RB, and E2F1.	honokiol	0-8	cyclin-dependent kinase 4 S homeolog	Xenopus laevis	61-65
27064011-10	2016	Honokiol provoked signal-transducing downregulation of CDK6, CDK4, cyclin D1, phosphorylated (p)RB, and E2F1.	honokiol	0-8	cyclin D1	Homo sapiens	67-76
27064011-10	2016	Honokiol provoked signal-transducing downregulation of CDK6, CDK4, cyclin D1, phosphorylated (p)RB, and E2F1.	honokiol	0-8	E2F transcription factor 1 L homeolog	Xenopus laevis	104-108
27064011-11	2016	Pretreatment of U87 MG cells with PFN-alpha significantly reversed honokiol-induced p53 phosphorylation and p21 augmentation.	honokiol	67-75	tumor protein p53	Homo sapiens	84-87
27064011-11	2016	Pretreatment of U87 MG cells with PFN-alpha significantly reversed honokiol-induced p53 phosphorylation and p21 augmentation.	honokiol	67-75	H3 histone pseudogene 16	Homo sapiens	108-111
27064011-12	2016	Honokiol-induced alterations in levels of CDK6, CDK4, cyclin D1, p-RB, and E2F1 were attenuated by PFN-alpha.	honokiol	0-8	cyclin dependent kinase 6	Homo sapiens	42-46
27064011-12	2016	Honokiol-induced alterations in levels of CDK6, CDK4, cyclin D1, p-RB, and E2F1 were attenuated by PFN-alpha.	honokiol	0-8	cyclin dependent kinase 4	Homo sapiens	48-52
27064011-12	2016	Honokiol-induced alterations in levels of CDK6, CDK4, cyclin D1, p-RB, and E2F1 were attenuated by PFN-alpha.	honokiol	0-8	cyclin D1	Homo sapiens	54-63
27064011-12	2016	Honokiol-induced alterations in levels of CDK6, CDK4, cyclin D1, p-RB, and E2F1 were attenuated by PFN-alpha.	honokiol	0-8	RB transcriptional corepressor 1	Homo sapiens	65-69
27064011-12	2016	Honokiol-induced alterations in levels of CDK6, CDK4, cyclin D1, p-RB, and E2F1 were attenuated by PFN-alpha.	honokiol	0-8	E2F transcription factor 1	Homo sapiens	75-79
27064011-14	2016	In our in vivo model, administration of honokiol prolonged the survival rate of nude mice implanted with U87 MG cells and induced caspase-3 activation and chronological changes in p53, p21, CDK6, CDK4, cyclin D1, p-RB, and E2F1.	honokiol	40-48	caspase 3	Homo sapiens	130-139
27064011-14	2016	In our in vivo model, administration of honokiol prolonged the survival rate of nude mice implanted with U87 MG cells and induced caspase-3 activation and chronological changes in p53, p21, CDK6, CDK4, cyclin D1, p-RB, and E2F1.	honokiol	40-48	tumor protein p53	Homo sapiens	180-183
27064011-14	2016	In our in vivo model, administration of honokiol prolonged the survival rate of nude mice implanted with U87 MG cells and induced caspase-3 activation and chronological changes in p53, p21, CDK6, CDK4, cyclin D1, p-RB, and E2F1.	honokiol	40-48	H3 histone pseudogene 16	Homo sapiens	185-188
27064011-14	2016	In our in vivo model, administration of honokiol prolonged the survival rate of nude mice implanted with U87 MG cells and induced caspase-3 activation and chronological changes in p53, p21, CDK6, CDK4, cyclin D1, p-RB, and E2F1.	honokiol	40-48	cyclin dependent kinase 6	Homo sapiens	190-194
27064011-14	2016	In our in vivo model, administration of honokiol prolonged the survival rate of nude mice implanted with U87 MG cells and induced caspase-3 activation and chronological changes in p53, p21, CDK6, CDK4, cyclin D1, p-RB, and E2F1.	honokiol	40-48	cyclin dependent kinase 4	Homo sapiens	196-200
27064011-14	2016	In our in vivo model, administration of honokiol prolonged the survival rate of nude mice implanted with U87 MG cells and induced caspase-3 activation and chronological changes in p53, p21, CDK6, CDK4, cyclin D1, p-RB, and E2F1.	honokiol	40-48	cyclin D1	Homo sapiens	202-211
27064011-14	2016	In our in vivo model, administration of honokiol prolonged the survival rate of nude mice implanted with U87 MG cells and induced caspase-3 activation and chronological changes in p53, p21, CDK6, CDK4, cyclin D1, p-RB, and E2F1.	honokiol	40-48	RB transcriptional corepressor 1	Homo sapiens	213-217
27064011-14	2016	In our in vivo model, administration of honokiol prolonged the survival rate of nude mice implanted with U87 MG cells and induced caspase-3 activation and chronological changes in p53, p21, CDK6, CDK4, cyclin D1, p-RB, and E2F1.	honokiol	40-48	E2F transcription factor 1	Homo sapiens	223-227
27064011-15	2016	CONCLUSIONS: Honokiol can repress human glioma growth by inducing apoptosis and cell cycle arrest in tumor cells though activating a p53/cyclin D1/CDK6/CDK4/E2F1-dependent pathway.	honokiol	13-21	tumor protein p53	Homo sapiens	133-136
27064011-15	2016	CONCLUSIONS: Honokiol can repress human glioma growth by inducing apoptosis and cell cycle arrest in tumor cells though activating a p53/cyclin D1/CDK6/CDK4/E2F1-dependent pathway.	honokiol	13-21	cyclin D1	Homo sapiens	137-146
27064011-15	2016	CONCLUSIONS: Honokiol can repress human glioma growth by inducing apoptosis and cell cycle arrest in tumor cells though activating a p53/cyclin D1/CDK6/CDK4/E2F1-dependent pathway.	honokiol	13-21	cyclin dependent kinase 6	Homo sapiens	147-151
27064011-15	2016	CONCLUSIONS: Honokiol can repress human glioma growth by inducing apoptosis and cell cycle arrest in tumor cells though activating a p53/cyclin D1/CDK6/CDK4/E2F1-dependent pathway.	honokiol	13-21	cyclin dependent kinase 4	Homo sapiens	152-156
27064011-15	2016	CONCLUSIONS: Honokiol can repress human glioma growth by inducing apoptosis and cell cycle arrest in tumor cells though activating a p53/cyclin D1/CDK6/CDK4/E2F1-dependent pathway.	honokiol	13-21	E2F transcription factor 1	Homo sapiens	157-161
26912655-7	2016	Inhibiting SIRT3 using SIRT3 siRNA exacerbated HSC activation via the SDH-succinate-GPR91 pathway, and SIRT3 overexpression or honokiol treatment attenuated HSC activation in vitro In isolated liver and HSCs from methionine- and choline-deficient (MCD) diet-induced NAFLD, the expression of SIRT3 and SDH activity was decreased, and the succinate concentrations and GPR91 expression were increased.	honokiol	127-135	aminoadipate-semialdehyde synthase	Mus musculus	301-304
26912655-7	2016	Inhibiting SIRT3 using SIRT3 siRNA exacerbated HSC activation via the SDH-succinate-GPR91 pathway, and SIRT3 overexpression or honokiol treatment attenuated HSC activation in vitro In isolated liver and HSCs from methionine- and choline-deficient (MCD) diet-induced NAFLD, the expression of SIRT3 and SDH activity was decreased, and the succinate concentrations and GPR91 expression were increased.	honokiol	127-135	succinate receptor 1	Mus musculus	366-371
27569089-0	2016	Anticancer activity of Honokiol against lymphoid malignant cells via activation of ROS-JNK and attenuation of Nrf2 and NF-kappaB.	honokiol	23-31	mitogen-activated protein kinase 8	Homo sapiens	87-90
27569089-0	2016	Anticancer activity of Honokiol against lymphoid malignant cells via activation of ROS-JNK and attenuation of Nrf2 and NF-kappaB.	honokiol	23-31	NFE2 like bZIP transcription factor 2	Homo sapiens	110-114
27569089-0	2016	Anticancer activity of Honokiol against lymphoid malignant cells via activation of ROS-JNK and attenuation of Nrf2 and NF-kappaB.	honokiol	23-31	nuclear factor kappa B subunit 1	Homo sapiens	119-128
27569089-1	2016	PURPOSE: To evaluate the effect of Honokiol (HK) in the ROS-JNK pro-apoptotic pathway and NF-kappaB, Nrf2 anti-apoptotic pathways, in order to seek a possible explanation for its anticancer efficacy.	honokiol	35-43	mitogen-activated protein kinase 8	Homo sapiens	60-63
26871475-8	2016	Gene arrays comparing treated with vehicle control tumors demonstrated induction of the respiratory enzyme succinate dehydrogenase B (SDHB) by treatment, suggesting that our honokiol analogs induce respiration in vivo.	honokiol	174-182	succinate dehydrogenase complex iron sulfur subunit B	Homo sapiens	134-138
26871475-11	2016	Honokiol DCA and hexafluoro inhibited the phosphorylation of DRP1, thus stimulating a phenotype suggestive of respiration through mitochondrial normalization.	honokiol	0-8	collapsin response mediator protein 1	Homo sapiens	61-65
26760964-3	2016	Using an in vitro cell migration assay, we observed that treatment of different melanoma cell lines with honokiol for 24 h resulted in a dose-dependent inhibition of cell migration that was associated with reduction in Nox1 expression and reduced levels of oxidative stress.	honokiol	105-113	NADPH oxidase 1	Homo sapiens	219-223
26760964-6	2016	Further, we examined the effect of honokiol on the levels of core proteins (p22(phox) and p47(phox)) of the NADPH oxidase complex.	honokiol	35-43	calcineurin like EF-hand protein 1	Homo sapiens	76-79
26760964-7	2016	Treatment of Hs294t and SK-Mel28 cells with honokiol resulted in accumulation of the cytosolic p47(phox) protein and decreased levels of the membrane-bound p22(phox) protein, thus blocking their interaction and inhibiting Nox1 activation.	honokiol	44-52	pleckstrin	Homo sapiens	95-98
26760964-7	2016	Treatment of Hs294t and SK-Mel28 cells with honokiol resulted in accumulation of the cytosolic p47(phox) protein and decreased levels of the membrane-bound p22(phox) protein, thus blocking their interaction and inhibiting Nox1 activation.	honokiol	44-52	calcineurin like EF-hand protein 1	Homo sapiens	156-159
26760964-7	2016	Treatment of Hs294t and SK-Mel28 cells with honokiol resulted in accumulation of the cytosolic p47(phox) protein and decreased levels of the membrane-bound p22(phox) protein, thus blocking their interaction and inhibiting Nox1 activation.	honokiol	44-52	NADPH oxidase 1	Homo sapiens	222-226
26760964-8	2016	Our in vivo bioluminescence imaging data indicate that oral administration of honokiol inhibited the migration/extravasation and growth of intravenously injected melanoma cells in internal body organs, such as liver, lung and kidney in nude mice, and that this was associated with an inhibitory effect on Nox1 activity in these internal organs/tissues.	honokiol	78-86	NADPH oxidase 1	Mus musculus	305-309
26647858-8	2016	Pretreatment with honokiol significantly reduced the levels of serum creatinine, BUN, ALT, AST and ALP, and the level of nitrite in the kidney of the IRI group, compared with the control group.	honokiol	18-26	glutamic-oxaloacetic transaminase 2	Rattus norvegicus	91-94
26647858-10	2016	In addition, the expression levels of tumor necrosis factor-alpha and interleukin-6 in the IRI rats were increased by honokiol.	honokiol	118-126	tumor necrosis factor	Rattus norvegicus	38-65
26647858-10	2016	In addition, the expression levels of tumor necrosis factor-alpha and interleukin-6 in the IRI rats were increased by honokiol.	honokiol	118-126	interleukin 6	Rattus norvegicus	70-83
26647858-11	2016	Treatment with honokiol suppressed the protein expression levels of p-STAT3 and caspase-3 in the IRI rats.	honokiol	15-23	signal transducer and activator of transcription 3	Rattus norvegicus	70-75
26647858-11	2016	Treatment with honokiol suppressed the protein expression levels of p-STAT3 and caspase-3 in the IRI rats.	honokiol	15-23	caspase 3	Rattus norvegicus	80-89
26647858-12	2016	These findings indicated that honokiol protects against renal IRI via the suppression of oxidative stress, iNOS, inflammation and STAT3 in the rat.	honokiol	30-38	nitric oxide synthase 2	Rattus norvegicus	107-111
26647858-12	2016	These findings indicated that honokiol protects against renal IRI via the suppression of oxidative stress, iNOS, inflammation and STAT3 in the rat.	honokiol	30-38	signal transducer and activator of transcription 3	Rattus norvegicus	130-135
26723916-6	2016	Pretreatment with honokiol prior to MG exposure reduced MG-induced mitochondrial dysfunction and alleviated MG-induced reduction of nitric oxide and PGC1alpha levels, suggesting that honokiol may induce mitochondrial biogenesis.	honokiol	18-26	peroxisome proliferative activated receptor, gamma, coactivator 1 alpha	Mus musculus	149-158
26647858-0	2016	Honokiol protects against renal ischemia/reperfusion injury via the suppression of oxidative stress, iNOS, inflammation and STAT3 in rats.	honokiol	0-8	nitric oxide synthase 2	Rattus norvegicus	101-105
26647858-0	2016	Honokiol protects against renal ischemia/reperfusion injury via the suppression of oxidative stress, iNOS, inflammation and STAT3 in rats.	honokiol	0-8	signal transducer and activator of transcription 3	Rattus norvegicus	124-129
26723916-6	2016	Pretreatment with honokiol prior to MG exposure reduced MG-induced mitochondrial dysfunction and alleviated MG-induced reduction of nitric oxide and PGC1alpha levels, suggesting that honokiol may induce mitochondrial biogenesis.	honokiol	183-191	peroxisome proliferative activated receptor, gamma, coactivator 1 alpha	Mus musculus	149-158
26454217-0	2016	Honokiol induces autophagy of neuroblastoma cells through activating the PI3K/Akt/mTOR and endoplasmic reticular stress/ERK1/2 signaling pathways and suppressing cell migration.	honokiol	0-8	thymoma viral proto-oncogene 1	Mus musculus	78-81
26828978-0	2016	Protective effect of Honokiol against endometriosis in Rats via attenuating Survivin and Bcl-2: A mechanistic study.	honokiol	21-29	BCL2, apoptosis regulator	Rattus norvegicus	89-94
27671820-4	2016	Honokiol affects multiple signaling pathways, molecular and cellular targets including nuclear factor-kappaB (NF-kappaB), STAT3, epidermal growth factor receptor (EGFR), cell survival signaling, cell cycle, cyclooxygenase and other inflammatory mediators, etc.	honokiol	0-8	signal transducer and activator of transcription 3	Homo sapiens	122-127
27671820-4	2016	Honokiol affects multiple signaling pathways, molecular and cellular targets including nuclear factor-kappaB (NF-kappaB), STAT3, epidermal growth factor receptor (EGFR), cell survival signaling, cell cycle, cyclooxygenase and other inflammatory mediators, etc.	honokiol	0-8	epidermal growth factor receptor	Homo sapiens	129-161
27671820-4	2016	Honokiol affects multiple signaling pathways, molecular and cellular targets including nuclear factor-kappaB (NF-kappaB), STAT3, epidermal growth factor receptor (EGFR), cell survival signaling, cell cycle, cyclooxygenase and other inflammatory mediators, etc.	honokiol	0-8	epidermal growth factor receptor	Homo sapiens	163-167
26505879-0	2016	Honokiol sensitizes breast cancer cells to TNF-alpha induction of apoptosis by inhibiting Nur77 expression.	honokiol	0-8	tumor necrosis factor	Homo sapiens	43-52
26505879-0	2016	Honokiol sensitizes breast cancer cells to TNF-alpha induction of apoptosis by inhibiting Nur77 expression.	honokiol	0-8	nuclear receptor subfamily 4 group A member 1	Homo sapiens	90-95
26505879-9	2016	Our in vitro and animal studies also identified honokiol as an effective sensitizer of TNF-alpha-induced apoptosis by inhibiting TNF-alpha-induced Nur77 mRNA expression, which could be attributed to its interference of TNFR1"s interaction with receptor-interacting protein 1 (RIPK1).	honokiol	48-56	tumor necrosis factor	Homo sapiens	87-96
26505879-9	2016	Our in vitro and animal studies also identified honokiol as an effective sensitizer of TNF-alpha-induced apoptosis by inhibiting TNF-alpha-induced Nur77 mRNA expression, which could be attributed to its interference of TNFR1"s interaction with receptor-interacting protein 1 (RIPK1).	honokiol	48-56	tumor necrosis factor	Homo sapiens	129-138
26505879-9	2016	Our in vitro and animal studies also identified honokiol as an effective sensitizer of TNF-alpha-induced apoptosis by inhibiting TNF-alpha-induced Nur77 mRNA expression, which could be attributed to its interference of TNFR1"s interaction with receptor-interacting protein 1 (RIPK1).	honokiol	48-56	nuclear receptor subfamily 4 group A member 1	Homo sapiens	147-152
26505879-9	2016	Our in vitro and animal studies also identified honokiol as an effective sensitizer of TNF-alpha-induced apoptosis by inhibiting TNF-alpha-induced Nur77 mRNA expression, which could be attributed to its interference of TNFR1"s interaction with receptor-interacting protein 1 (RIPK1).	honokiol	48-56	TNF receptor superfamily member 1A	Homo sapiens	219-224
26505879-9	2016	Our in vitro and animal studies also identified honokiol as an effective sensitizer of TNF-alpha-induced apoptosis by inhibiting TNF-alpha-induced Nur77 mRNA expression, which could be attributed to its interference of TNFR1"s interaction with receptor-interacting protein 1 (RIPK1).	honokiol	48-56	receptor interacting serine/threonine kinase 1	Homo sapiens	244-274
26505879-9	2016	Our in vitro and animal studies also identified honokiol as an effective sensitizer of TNF-alpha-induced apoptosis by inhibiting TNF-alpha-induced Nur77 mRNA expression, which could be attributed to its interference of TNFR1"s interaction with receptor-interacting protein 1 (RIPK1).	honokiol	48-56	receptor interacting serine/threonine kinase 1	Homo sapiens	276-281
26454217-0	2016	Honokiol induces autophagy of neuroblastoma cells through activating the PI3K/Akt/mTOR and endoplasmic reticular stress/ERK1/2 signaling pathways and suppressing cell migration.	honokiol	0-8	mechanistic target of rapamycin kinase	Mus musculus	82-86
26454217-0	2016	Honokiol induces autophagy of neuroblastoma cells through activating the PI3K/Akt/mTOR and endoplasmic reticular stress/ERK1/2 signaling pathways and suppressing cell migration.	honokiol	0-8	mitogen-activated protein kinase 3	Mus musculus	120-126
26454217-7	2016	Sequentially, honokiol downregulated phosphorylation of protein kinase B (Akt) and mammalian target of rapamycin (mTOR) in neuro-2a cells.	honokiol	14-22	AKT serine/threonine kinase 1	Homo sapiens	74-77
26454217-7	2016	Sequentially, honokiol downregulated phosphorylation of protein kinase B (Akt) and mammalian target of rapamycin (mTOR) in neuro-2a cells.	honokiol	14-22	mechanistic target of rapamycin kinase	Homo sapiens	83-112
26454217-7	2016	Sequentially, honokiol downregulated phosphorylation of protein kinase B (Akt) and mammalian target of rapamycin (mTOR) in neuro-2a cells.	honokiol	14-22	mechanistic target of rapamycin kinase	Homo sapiens	114-118
26454217-10	2016	Consequently, honokiol stimulated phosphorylation of extracellular signal-regulated kinase (ERK)1/2.	honokiol	14-22	mitogen-activated protein kinase 3	Mus musculus	53-99
26454217-11	2016	However, pretreatment of neuro-2a cells with PD98059, an inhibitor of ERK1/2, lowered honokiol-induced autophagy.	honokiol	86-94	mitogen-activated protein kinase 3	Mus musculus	70-76
26454217-14	2016	Taken together, this study showed that honokiol can induce autophagy of neuroblastoma cells and consequent apoptosis through activating the PI3K/Akt/mTOR and ERS/ROS/ERK1/2 signaling pathways and suppressing cell migration.	honokiol	39-47	thymoma viral proto-oncogene 1	Mus musculus	145-148
26454217-14	2016	Taken together, this study showed that honokiol can induce autophagy of neuroblastoma cells and consequent apoptosis through activating the PI3K/Akt/mTOR and ERS/ROS/ERK1/2 signaling pathways and suppressing cell migration.	honokiol	39-47	mechanistic target of rapamycin kinase	Mus musculus	149-153
26454217-14	2016	Taken together, this study showed that honokiol can induce autophagy of neuroblastoma cells and consequent apoptosis through activating the PI3K/Akt/mTOR and ERS/ROS/ERK1/2 signaling pathways and suppressing cell migration.	honokiol	39-47	mitogen-activated protein kinase 3	Mus musculus	166-172
26674084-8	2015	The inhibitory potencies of honokiol on the protein tyrosine phosphatase 1B (PTP1B) activity were performed in reaction buffer.	honokiol	28-36	protein tyrosine phosphatase, non-receptor type 1	Mus musculus	44-75
26723916-5	2016	Furthermore, honokiol increased the levels of Nrf2 and increased the levels of glutathione and the activity of glyoxalase I.	honokiol	13-21	nuclear factor, erythroid derived 2, like 2	Mus musculus	46-50
26723916-5	2016	Furthermore, honokiol increased the levels of Nrf2 and increased the levels of glutathione and the activity of glyoxalase I.	honokiol	13-21	glyoxalase 1	Mus musculus	111-123
26674084-8	2015	The inhibitory potencies of honokiol on the protein tyrosine phosphatase 1B (PTP1B) activity were performed in reaction buffer.	honokiol	28-36	protein tyrosine phosphatase, non-receptor type 1	Mus musculus	77-82
26674084-11	2015	The phosphorylations of the IRbeta and the downstream insulin signaling factors including AKT and ERK1/2 significantly increase in adipose, skeletal muscle, and liver tissue of the honokiol-treated mice.	honokiol	181-189	thymoma viral proto-oncogene 1	Mus musculus	90-93
26674084-11	2015	The phosphorylations of the IRbeta and the downstream insulin signaling factors including AKT and ERK1/2 significantly increase in adipose, skeletal muscle, and liver tissue of the honokiol-treated mice.	honokiol	181-189	mitogen-activated protein kinase 3	Mus musculus	98-104
26674084-12	2015	Moreover, honokiol enhanced the insulin-stimulated phosphorylations of IRbeta, AKT, and ERK1/2 in a dose-dependent manner in C2C12 myotube cells.	honokiol	10-18	thymoma viral proto-oncogene 1	Mus musculus	79-82
26674084-12	2015	Moreover, honokiol enhanced the insulin-stimulated phosphorylations of IRbeta, AKT, and ERK1/2 in a dose-dependent manner in C2C12 myotube cells.	honokiol	10-18	mitogen-activated protein kinase 3	Mus musculus	88-94
26674084-13	2015	Meanwhile, honokiol enhanced insulin-stimulated GLUT4 translocation.	honokiol	11-19	solute carrier family 2 (facilitated glucose transporter), member 4	Mus musculus	48-53
26674084-14	2015	Importantly, honokiol exhibited reversible competitive inhibitory activity against PTP1B with good selectivity in vitro and in vivo.	honokiol	13-21	protein tyrosine phosphatase, non-receptor type 1	Mus musculus	83-88
26674084-15	2015	Furthermore, using molecular docking and dynamic simulation approaches, we determined the potential binding mode of honokiol to PTP1B at an atomic level.	honokiol	116-124	protein tyrosine phosphatase, non-receptor type 1	Mus musculus	128-133
26674084-16	2015	CONCLUSION: These findings indicated the hypoglycemic effects of honokiol and its mechanism that honokiol improved the insulin sensitivity by targeting PTP1B.	honokiol	65-73	protein tyrosine phosphatase, non-receptor type 1	Mus musculus	152-157
26674084-16	2015	CONCLUSION: These findings indicated the hypoglycemic effects of honokiol and its mechanism that honokiol improved the insulin sensitivity by targeting PTP1B.	honokiol	97-105	protein tyrosine phosphatase, non-receptor type 1	Mus musculus	152-157
26020804-0	2015	Honokiol inhibits the growth of head and neck squamous cell carcinoma by targeting epidermal growth factor receptor.	honokiol	0-8	epidermal growth factor receptor	Homo sapiens	83-115
26445991-6	2015	TNF-alpha release assays were performed to elucidate the biological relevance of changes in LLO and p60 secretion induced by honokiol.	honokiol	125-133	tumor necrosis factor	Mus musculus	0-9
26445991-9	2015	Our results indicate that TNF-alpha production by RAW264.7 cells stimulated with L. monocytogenes supernatants was inhibited by honokiol.	honokiol	128-136	tumor necrosis factor	Mus musculus	26-35
26454249-7	2015	Cellular uptake study demonstrated that rhodamine123 uptake rate was enhanced by honokiol-loaded micelles, indicating substantial P-gp inhibition action by honokiol and mPEG-PLA-based micelles.	honokiol	81-89	phosphoglycolate phosphatase	Homo sapiens	130-134
26454249-7	2015	Cellular uptake study demonstrated that rhodamine123 uptake rate was enhanced by honokiol-loaded micelles, indicating substantial P-gp inhibition action by honokiol and mPEG-PLA-based micelles.	honokiol	156-164	phosphoglycolate phosphatase	Homo sapiens	130-134
26454249-8	2015	CONCLUSION: Oral transport of sirolimus was significantly improved by coadministration with honokiol, an inhibitor of the P-gp, in polymeric micelles formulation.	honokiol	92-100	phosphoglycolate phosphatase	Homo sapiens	122-126
25491779-0	2015	Honokiol inhibits melanoma stem cells by targeting notch signaling.	honokiol	0-8	notch receptor 2	Homo sapiens	51-56
26539813-7	2015	Honokiol treatment normalized hippocampal and thalamic c-Fos and hippocampal alveus substance P receptor expression relative to controls at P21.	honokiol	0-8	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	55-60
26539813-7	2015	Honokiol treatment normalized hippocampal and thalamic c-Fos and hippocampal alveus substance P receptor expression relative to controls at P21.	honokiol	0-8	tachykinin receptor 1	Rattus norvegicus	84-104
26484567-0	2015	Honokiol inhibits bladder tumor growth by suppressing EZH2/miR-143 axis.	honokiol	0-8	enhancer of zeste 2 polycomb repressive complex 2 subunit	Homo sapiens	54-58
26484567-0	2015	Honokiol inhibits bladder tumor growth by suppressing EZH2/miR-143 axis.	honokiol	0-8	microRNA 143	Homo sapiens	59-66
26484567-3	2015	Herein, we reported that honokiol, a biologically active biphenolic compound isolated from the Magnolia officinalis inhibited human UBC cell proliferation, survival, cancer stemness, migration, and invasion, through downregulation of EZH2 expression level, along with the reductions of MMP9, CD44, Sox2 and the induction of tumor suppressor miR-143.	honokiol	25-33	enhancer of zeste 2 polycomb repressive complex 2 subunit	Homo sapiens	234-238
26484567-3	2015	Herein, we reported that honokiol, a biologically active biphenolic compound isolated from the Magnolia officinalis inhibited human UBC cell proliferation, survival, cancer stemness, migration, and invasion, through downregulation of EZH2 expression level, along with the reductions of MMP9, CD44, Sox2 and the induction of tumor suppressor miR-143.	honokiol	25-33	matrix metallopeptidase 9	Homo sapiens	286-290
26484567-3	2015	Herein, we reported that honokiol, a biologically active biphenolic compound isolated from the Magnolia officinalis inhibited human UBC cell proliferation, survival, cancer stemness, migration, and invasion, through downregulation of EZH2 expression level, along with the reductions of MMP9, CD44, Sox2 and the induction of tumor suppressor miR-143.	honokiol	25-33	CD44 molecule (Indian blood group)	Homo sapiens	292-296
26484567-3	2015	Herein, we reported that honokiol, a biologically active biphenolic compound isolated from the Magnolia officinalis inhibited human UBC cell proliferation, survival, cancer stemness, migration, and invasion, through downregulation of EZH2 expression level, along with the reductions of MMP9, CD44, Sox2 and the induction of tumor suppressor miR-143.	honokiol	25-33	SRY-box transcription factor 2	Homo sapiens	298-302
26484567-3	2015	Herein, we reported that honokiol, a biologically active biphenolic compound isolated from the Magnolia officinalis inhibited human UBC cell proliferation, survival, cancer stemness, migration, and invasion, through downregulation of EZH2 expression level, along with the reductions of MMP9, CD44, Sox2 and the induction of tumor suppressor miR-143.	honokiol	25-33	microRNA 143	Homo sapiens	341-348
26484567-4	2015	Either EZH2 overexpression or miR-143 inhibition could partially reverse honokiol-induced cell growth arrest and impaired clonogenicity.	honokiol	73-81	enhancer of zeste 2 polycomb repressive complex 2 subunit	Homo sapiens	7-11
26484567-4	2015	Either EZH2 overexpression or miR-143 inhibition could partially reverse honokiol-induced cell growth arrest and impaired clonogenicity.	honokiol	73-81	microRNA 143	Homo sapiens	30-37
26484567-6	2015	Furthermore, honokiol treatment on T24 tumor xenografts confirmed its anticancer effects in vivo, including suppression tumor growth and tumor stemness, accompanied by the dysregulation of EZH2 and miR-143 expressions.	honokiol	13-21	enhancer of zeste 2 polycomb repressive complex 2 subunit	Homo sapiens	189-193
26484567-6	2015	Furthermore, honokiol treatment on T24 tumor xenografts confirmed its anticancer effects in vivo, including suppression tumor growth and tumor stemness, accompanied by the dysregulation of EZH2 and miR-143 expressions.	honokiol	13-21	microRNA 143	Homo sapiens	198-205
26484567-7	2015	Our data suggest a promising therapeutic option to develop drugs targeting EZH2/miR-143 axis, such as honokiol, for bladder cancer treatment.	honokiol	102-110	enhancer of zeste 2 polycomb repressive complex 2 subunit	Homo sapiens	75-79
26484567-7	2015	Our data suggest a promising therapeutic option to develop drugs targeting EZH2/miR-143 axis, such as honokiol, for bladder cancer treatment.	honokiol	102-110	microRNA 143	Homo sapiens	80-87
26466521-0	2015	Honokiol Inhibits Constitutive and Inducible STAT3 Signaling via PU.1-Induced SHP1 Expression in Acute Myeloid Leukemia Cells.	honokiol	0-8	signal transducer and activator of transcription 3	Homo sapiens	45-50
26466521-0	2015	Honokiol Inhibits Constitutive and Inducible STAT3 Signaling via PU.1-Induced SHP1 Expression in Acute Myeloid Leukemia Cells.	honokiol	0-8	Spi-1 proto-oncogene	Homo sapiens	65-69
26466521-0	2015	Honokiol Inhibits Constitutive and Inducible STAT3 Signaling via PU.1-Induced SHP1 Expression in Acute Myeloid Leukemia Cells.	honokiol	0-8	protein tyrosine phosphatase non-receptor type 6	Homo sapiens	78-82
26466521-3	2015	In this study, we investigated the effect of honokiol (HNK), a constituent of Magnolia officinalis, on the STAT3 signaling.	honokiol	45-53	signal transducer and activator of transcription 3	Homo sapiens	107-112
26020804-2	2015	Treatment of HNSCC cell lines from different sub-sites, SCC-1 (oral cavity), SCC-5 (larynx), OSC-19 (tongue) and FaDu (pharynx) with honokiol inhibited their cell viability, which was associated with the: (i) induction of apoptosis, (ii) correction of dysregulatory cell cycle proteins of G0/G1 phase.	honokiol	133-141	protein tyrosine phosphatase receptor type J	Homo sapiens	56-61
26020804-3	2015	Honokiol decreased the expression levels of epidermal growth factor receptor (EGFR), mTOR and their downstream signaling molecules.	honokiol	0-8	epidermal growth factor receptor	Homo sapiens	44-76
26410663-3	2015	We have previously identified a nitrogen-containing honokiol derivative (3-acetylamino-4"-O-methylhonokiol, AMH) as a high efficient modulator of GABAA receptors.	honokiol	52-60	anti-Mullerian hormone	Homo sapiens	108-111
26020804-3	2015	Honokiol decreased the expression levels of epidermal growth factor receptor (EGFR), mTOR and their downstream signaling molecules.	honokiol	0-8	epidermal growth factor receptor	Homo sapiens	78-82
26020804-3	2015	Honokiol decreased the expression levels of epidermal growth factor receptor (EGFR), mTOR and their downstream signaling molecules.	honokiol	0-8	mechanistic target of rapamycin kinase	Homo sapiens	85-89
26020804-5	2015	Administration of honokiol by oral gavage (100 mg/kg body weight) significantly (P &lt; 0.01-0.001) inhibited the growth of SCC-1 and FaDu xenografts in athymic nude mice, which was associated with: (i) inhibition of tumor cell proliferation, (ii) induction of apoptosis, (iii) reduced expressions of cyclins and Cdks, and (iv) inhibition of EGFR signaling pathway.	honokiol	18-26	protein tyrosine phosphatase, receptor type, J	Mus musculus	124-129
26020804-5	2015	Administration of honokiol by oral gavage (100 mg/kg body weight) significantly (P &lt; 0.01-0.001) inhibited the growth of SCC-1 and FaDu xenografts in athymic nude mice, which was associated with: (i) inhibition of tumor cell proliferation, (ii) induction of apoptosis, (iii) reduced expressions of cyclins and Cdks, and (iv) inhibition of EGFR signaling pathway.	honokiol	18-26	epidermal growth factor receptor	Mus musculus	342-346
26020804-6	2015	Molecular docking analysis of honokiol in EGFR binding site indicated that the chemotherapeutic effect of honokiol against HNSCC is mediated through its firm binding with EGFR, which is better than that of gefitinib, a commonly used drug for HNSCC treatment.	honokiol	30-38	epidermal growth factor receptor	Homo sapiens	42-46
26020804-6	2015	Molecular docking analysis of honokiol in EGFR binding site indicated that the chemotherapeutic effect of honokiol against HNSCC is mediated through its firm binding with EGFR, which is better than that of gefitinib, a commonly used drug for HNSCC treatment.	honokiol	106-114	epidermal growth factor receptor	Homo sapiens	42-46
25912802-6	2015	In addition, treatment with honokiol significantly decreased the protein and mRNA levels of interleukin (IL)-1beta and the activity of acetylcholinesterase (AChE), while significantly increased the protein and mRNA levels of IL-10, and the level of acetylcholine (Ach) in the brain of the SCOP-treated mice.	honokiol	28-36	interleukin 1 beta	Mus musculus	92-114
26020804-6	2015	Molecular docking analysis of honokiol in EGFR binding site indicated that the chemotherapeutic effect of honokiol against HNSCC is mediated through its firm binding with EGFR, which is better than that of gefitinib, a commonly used drug for HNSCC treatment.	honokiol	106-114	epidermal growth factor receptor	Homo sapiens	171-175
25912802-6	2015	In addition, treatment with honokiol significantly decreased the protein and mRNA levels of interleukin (IL)-1beta and the activity of acetylcholinesterase (AChE), while significantly increased the protein and mRNA levels of IL-10, and the level of acetylcholine (Ach) in the brain of the SCOP-treated mice.	honokiol	28-36	acetylcholinesterase	Mus musculus	135-155
26253493-5	2015	Our results indicated that the drug screen model was established successfully and that both honokiol and hyperoside induced P19 differentiation into neurons, with the possible molecular mechanism being modulating the Wnt signaling pathway.	honokiol	92-100	interleukin 23 subunit alpha	Homo sapiens	124-127
25912802-6	2015	In addition, treatment with honokiol significantly decreased the protein and mRNA levels of interleukin (IL)-1beta and the activity of acetylcholinesterase (AChE), while significantly increased the protein and mRNA levels of IL-10, and the level of acetylcholine (Ach) in the brain of the SCOP-treated mice.	honokiol	28-36	acetylcholinesterase	Mus musculus	157-161
25912802-6	2015	In addition, treatment with honokiol significantly decreased the protein and mRNA levels of interleukin (IL)-1beta and the activity of acetylcholinesterase (AChE), while significantly increased the protein and mRNA levels of IL-10, and the level of acetylcholine (Ach) in the brain of the SCOP-treated mice.	honokiol	28-36	interleukin 10	Mus musculus	225-230
25912802-7	2015	Moreover, honokiol also significantly suppressed the production of prostaglandin E 2 (PGE2) and mRNA expression of cyclooxygenase-2 (COX-2) in the brain of the SCOP-treated mice.	honokiol	10-18	prostaglandin-endoperoxide synthase 2	Mus musculus	115-131
25912802-7	2015	Moreover, honokiol also significantly suppressed the production of prostaglandin E 2 (PGE2) and mRNA expression of cyclooxygenase-2 (COX-2) in the brain of the SCOP-treated mice.	honokiol	10-18	prostaglandin-endoperoxide synthase 2	Mus musculus	133-138
25912802-8	2015	Mechanistic investigations revealed that honokiol could markedly reverse the amount of phosphorylated Akt and extracellular regulated kinases 1/2 (ERK1/2) changes in the brain of the SCOP-treated mice.	honokiol	41-49	thymoma viral proto-oncogene 1	Mus musculus	102-105
25912802-8	2015	Mechanistic investigations revealed that honokiol could markedly reverse the amount of phosphorylated Akt and extracellular regulated kinases 1/2 (ERK1/2) changes in the brain of the SCOP-treated mice.	honokiol	41-49	mitogen-activated protein kinase 3	Mus musculus	147-153
25912802-9	2015	These results amply demonstrated that honokiol could improve learning and memory impairments induced by SCOP in mice, and the protective action may be mediated, at least in part, by inhibition of AChE activity, and amelioration of the neuroinflammatory processes in the SCOP-treated mice.	honokiol	38-46	acetylcholinesterase	Mus musculus	196-200
25980585-6	2015	Further, honokiol specifically suppresses fMLP-induced Lyn (a member of the Src kinase family) phosphorylation, by inhibiting Lyn kinase activity.	honokiol	9-17	LYN proto-oncogene, Src family tyrosine kinase	Homo sapiens	126-129
25980585-7	2015	Consequently, honokiol attenuated the downstream targets of Lyn kinase, such as Tec translocation from the cytosol to the inner leaflet of the plasma membrane, phosphorylation of AKT, P38, PLCgamma2, protein kinase C and membrane localization of p47(phox).	honokiol	14-22	LYN proto-oncogene, Src family tyrosine kinase	Homo sapiens	60-63
25980585-7	2015	Consequently, honokiol attenuated the downstream targets of Lyn kinase, such as Tec translocation from the cytosol to the inner leaflet of the plasma membrane, phosphorylation of AKT, P38, PLCgamma2, protein kinase C and membrane localization of p47(phox).	honokiol	14-22	AKT serine/threonine kinase 1	Homo sapiens	179-182
25980585-7	2015	Consequently, honokiol attenuated the downstream targets of Lyn kinase, such as Tec translocation from the cytosol to the inner leaflet of the plasma membrane, phosphorylation of AKT, P38, PLCgamma2, protein kinase C and membrane localization of p47(phox).	honokiol	14-22	mitogen-activated protein kinase 14	Homo sapiens	184-187
25980585-7	2015	Consequently, honokiol attenuated the downstream targets of Lyn kinase, such as Tec translocation from the cytosol to the inner leaflet of the plasma membrane, phosphorylation of AKT, P38, PLCgamma2, protein kinase C and membrane localization of p47(phox).	honokiol	14-22	phospholipase C gamma 2	Homo sapiens	189-198
25980585-7	2015	Consequently, honokiol attenuated the downstream targets of Lyn kinase, such as Tec translocation from the cytosol to the inner leaflet of the plasma membrane, phosphorylation of AKT, P38, PLCgamma2, protein kinase C and membrane localization of p47(phox).	honokiol	14-22	pleckstrin	Homo sapiens	246-249
25980585-11	2015	In conclusion, honokiol specifically modulates fMLP-mediated neutrophil activation by inhibiting Lyn activation which subsequently interferes with the activation of PLCgamma2, AKT, p38, protein kinase C, and p47(phox).	honokiol	15-23	formyl peptide receptor 1	Homo sapiens	47-51
25980585-11	2015	In conclusion, honokiol specifically modulates fMLP-mediated neutrophil activation by inhibiting Lyn activation which subsequently interferes with the activation of PLCgamma2, AKT, p38, protein kinase C, and p47(phox).	honokiol	15-23	LYN proto-oncogene, Src family tyrosine kinase	Homo sapiens	97-100
25980585-11	2015	In conclusion, honokiol specifically modulates fMLP-mediated neutrophil activation by inhibiting Lyn activation which subsequently interferes with the activation of PLCgamma2, AKT, p38, protein kinase C, and p47(phox).	honokiol	15-23	phospholipase C gamma 2	Homo sapiens	165-174
25980585-11	2015	In conclusion, honokiol specifically modulates fMLP-mediated neutrophil activation by inhibiting Lyn activation which subsequently interferes with the activation of PLCgamma2, AKT, p38, protein kinase C, and p47(phox).	honokiol	15-23	AKT serine/threonine kinase 1	Homo sapiens	176-179
25980585-11	2015	In conclusion, honokiol specifically modulates fMLP-mediated neutrophil activation by inhibiting Lyn activation which subsequently interferes with the activation of PLCgamma2, AKT, p38, protein kinase C, and p47(phox).	honokiol	15-23	mitogen-activated protein kinase 14	Homo sapiens	181-184
25980585-11	2015	In conclusion, honokiol specifically modulates fMLP-mediated neutrophil activation by inhibiting Lyn activation which subsequently interferes with the activation of PLCgamma2, AKT, p38, protein kinase C, and p47(phox).	honokiol	15-23	pleckstrin	Homo sapiens	208-211
26138903-0	2015	Honokiol ameliorates endothelial dysfunction through suppression of PTX3 expression, a key mediator of IKK/IkappaB/NF-kappaB, in atherosclerotic cell model.	honokiol	0-8	pentraxin 3	Homo sapiens	68-72
26138903-6	2015	Honokiol significantly suppressed the overexpression of PTX3 in PA-inducted HUVECs by inhibiting IkappaB phosphorylation and the expression of two NF-kappaB subunits (p50 and p65) in the IKK/IkappaB/NF-kappaB signaling pathway.	honokiol	0-8	pentraxin 3	Homo sapiens	56-60
26138903-6	2015	Honokiol significantly suppressed the overexpression of PTX3 in PA-inducted HUVECs by inhibiting IkappaB phosphorylation and the expression of two NF-kappaB subunits (p50 and p65) in the IKK/IkappaB/NF-kappaB signaling pathway.	honokiol	0-8	nuclear factor kappa B subunit 1	Homo sapiens	147-156
26138903-6	2015	Honokiol significantly suppressed the overexpression of PTX3 in PA-inducted HUVECs by inhibiting IkappaB phosphorylation and the expression of two NF-kappaB subunits (p50 and p65) in the IKK/IkappaB/NF-kappaB signaling pathway.	honokiol	0-8	nuclear factor kappa B subunit 1	Homo sapiens	167-170
26138903-6	2015	Honokiol significantly suppressed the overexpression of PTX3 in PA-inducted HUVECs by inhibiting IkappaB phosphorylation and the expression of two NF-kappaB subunits (p50 and p65) in the IKK/IkappaB/NF-kappaB signaling pathway.	honokiol	0-8	RELA proto-oncogene, NF-kB subunit	Homo sapiens	175-178
26138903-6	2015	Honokiol significantly suppressed the overexpression of PTX3 in PA-inducted HUVECs by inhibiting IkappaB phosphorylation and the expression of two NF-kappaB subunits (p50 and p65) in the IKK/IkappaB/NF-kappaB signaling pathway.	honokiol	0-8	nuclear factor kappa B subunit 1	Homo sapiens	199-208
26138903-7	2015	Furthermore, honokiol reduced endothelial cell injury and apoptosis by regulating the expression of inducible NO synthase and endothelial NO synthase, as well as the generation of NO.	honokiol	13-21	nitric oxide synthase 2	Homo sapiens	100-121
26138903-8	2015	Honokiol showed an anti-inflammatory effect in PA-inducted HUVECs by significantly inhibiting the generation of interleukin-6 (IL-6), IL-8 and monocyte chemoattractant protein-1.	honokiol	0-8	interleukin 6	Homo sapiens	112-125
26138903-8	2015	Honokiol showed an anti-inflammatory effect in PA-inducted HUVECs by significantly inhibiting the generation of interleukin-6 (IL-6), IL-8 and monocyte chemoattractant protein-1.	honokiol	0-8	interleukin 6	Homo sapiens	127-131
26138903-8	2015	Honokiol showed an anti-inflammatory effect in PA-inducted HUVECs by significantly inhibiting the generation of interleukin-6 (IL-6), IL-8 and monocyte chemoattractant protein-1.	honokiol	0-8	C-X-C motif chemokine ligand 8	Homo sapiens	134-138
26138903-8	2015	Honokiol showed an anti-inflammatory effect in PA-inducted HUVECs by significantly inhibiting the generation of interleukin-6 (IL-6), IL-8 and monocyte chemoattractant protein-1.	honokiol	0-8	C-C motif chemokine ligand 2	Homo sapiens	143-177
26138903-9	2015	In summary, honokiol repaired endothelial dysfunction by suppressing PTX3 overexpression in an atherosclerotic cell model.	honokiol	12-20	pentraxin 3	Homo sapiens	69-73
26138903-0	2015	Honokiol ameliorates endothelial dysfunction through suppression of PTX3 expression, a key mediator of IKK/IkappaB/NF-kappaB, in atherosclerotic cell model.	honokiol	0-8	nuclear factor kappa B subunit 1	Homo sapiens	115-124
26339358-0	2015	Honokiol possesses potential anti-inflammatory effects on rheumatoid arthritis and GM-CSF can be a target for its treatment.	honokiol	0-8	colony stimulating factor 2	Homo sapiens	83-89
26339358-5	2015	Honokiol inhibited the expression levels of IL-1beta, TNF-alpha, GM-CSF and IL-8 in PBMCs with a dose-dependent manner.	honokiol	0-8	interleukin 1 beta	Homo sapiens	44-52
26339358-5	2015	Honokiol inhibited the expression levels of IL-1beta, TNF-alpha, GM-CSF and IL-8 in PBMCs with a dose-dependent manner.	honokiol	0-8	tumor necrosis factor	Homo sapiens	54-63
26339358-5	2015	Honokiol inhibited the expression levels of IL-1beta, TNF-alpha, GM-CSF and IL-8 in PBMCs with a dose-dependent manner.	honokiol	0-8	colony stimulating factor 2	Homo sapiens	65-71
26339358-5	2015	Honokiol inhibited the expression levels of IL-1beta, TNF-alpha, GM-CSF and IL-8 in PBMCs with a dose-dependent manner.	honokiol	0-8	C-X-C motif chemokine ligand 8	Homo sapiens	76-80
26339358-7	2015	Furthermore, the mRNA and protein expression of IL-1beta, GM-CSF and IL-8 were up-regulated when the PBMCs exposure to TNF-alpha, however, honokiol treatment significantly reversed the expression of IL-1beta, TNF-alpha and GM-CSF in response to TNF-alpha with a dose-dependent manner.	honokiol	139-147	interleukin 1 beta	Homo sapiens	48-56
26339358-7	2015	Furthermore, the mRNA and protein expression of IL-1beta, GM-CSF and IL-8 were up-regulated when the PBMCs exposure to TNF-alpha, however, honokiol treatment significantly reversed the expression of IL-1beta, TNF-alpha and GM-CSF in response to TNF-alpha with a dose-dependent manner.	honokiol	139-147	colony stimulating factor 2	Homo sapiens	58-64
26339358-7	2015	Furthermore, the mRNA and protein expression of IL-1beta, GM-CSF and IL-8 were up-regulated when the PBMCs exposure to TNF-alpha, however, honokiol treatment significantly reversed the expression of IL-1beta, TNF-alpha and GM-CSF in response to TNF-alpha with a dose-dependent manner.	honokiol	139-147	C-X-C motif chemokine ligand 8	Homo sapiens	69-73
26339358-7	2015	Furthermore, the mRNA and protein expression of IL-1beta, GM-CSF and IL-8 were up-regulated when the PBMCs exposure to TNF-alpha, however, honokiol treatment significantly reversed the expression of IL-1beta, TNF-alpha and GM-CSF in response to TNF-alpha with a dose-dependent manner.	honokiol	139-147	tumor necrosis factor	Homo sapiens	119-128
26339358-7	2015	Furthermore, the mRNA and protein expression of IL-1beta, GM-CSF and IL-8 were up-regulated when the PBMCs exposure to TNF-alpha, however, honokiol treatment significantly reversed the expression of IL-1beta, TNF-alpha and GM-CSF in response to TNF-alpha with a dose-dependent manner.	honokiol	139-147	interleukin 1 beta	Homo sapiens	199-207
26339358-7	2015	Furthermore, the mRNA and protein expression of IL-1beta, GM-CSF and IL-8 were up-regulated when the PBMCs exposure to TNF-alpha, however, honokiol treatment significantly reversed the expression of IL-1beta, TNF-alpha and GM-CSF in response to TNF-alpha with a dose-dependent manner.	honokiol	139-147	tumor necrosis factor	Homo sapiens	209-218
26339358-7	2015	Furthermore, the mRNA and protein expression of IL-1beta, GM-CSF and IL-8 were up-regulated when the PBMCs exposure to TNF-alpha, however, honokiol treatment significantly reversed the expression of IL-1beta, TNF-alpha and GM-CSF in response to TNF-alpha with a dose-dependent manner.	honokiol	139-147	colony stimulating factor 2	Homo sapiens	223-229
26339358-7	2015	Furthermore, the mRNA and protein expression of IL-1beta, GM-CSF and IL-8 were up-regulated when the PBMCs exposure to TNF-alpha, however, honokiol treatment significantly reversed the expression of IL-1beta, TNF-alpha and GM-CSF in response to TNF-alpha with a dose-dependent manner.	honokiol	139-147	tumor necrosis factor	Homo sapiens	209-218
26339358-8	2015	CONCLUSIONS: This study demonstrates that honokiol could possess potential anti-inflammatory effects and inhibits TNF-alpha-induced IL-1beta, GM-CSF and IL-8 production in PBMCs from rheumatoid arthritis patients.	honokiol	42-50	tumor necrosis factor	Homo sapiens	114-123
26339358-8	2015	CONCLUSIONS: This study demonstrates that honokiol could possess potential anti-inflammatory effects and inhibits TNF-alpha-induced IL-1beta, GM-CSF and IL-8 production in PBMCs from rheumatoid arthritis patients.	honokiol	42-50	interleukin 1 beta	Homo sapiens	132-140
26339358-8	2015	CONCLUSIONS: This study demonstrates that honokiol could possess potential anti-inflammatory effects and inhibits TNF-alpha-induced IL-1beta, GM-CSF and IL-8 production in PBMCs from rheumatoid arthritis patients.	honokiol	42-50	colony stimulating factor 2	Homo sapiens	142-148
26339358-8	2015	CONCLUSIONS: This study demonstrates that honokiol could possess potential anti-inflammatory effects and inhibits TNF-alpha-induced IL-1beta, GM-CSF and IL-8 production in PBMCs from rheumatoid arthritis patients.	honokiol	42-50	C-X-C motif chemokine ligand 8	Homo sapiens	153-157
26131123-8	2015	Moreover, Cyclin B1, CDC2 and cdc25C were downregulated, and the expression of p-CDC2 and p-cdc25c was significantly upregulated upon honokiol treatment.	honokiol	134-142	cyclin B1	Homo sapiens	10-19
25980585-4	2015	Signaling pathways regulated by honokiol which modulate fMLP-induced respiratory burst and cathepsin G release were evaluated by phosphorylation of Src family kinase induced by fMLP, Src family kinases activities and by immunoblotting analysis of the downstream targets of Src kinase.	honokiol	32-40	formyl peptide receptor 1	Homo sapiens	56-60
25980585-4	2015	Signaling pathways regulated by honokiol which modulate fMLP-induced respiratory burst and cathepsin G release were evaluated by phosphorylation of Src family kinase induced by fMLP, Src family kinases activities and by immunoblotting analysis of the downstream targets of Src kinase.	honokiol	32-40	formyl peptide receptor 1	Homo sapiens	177-181
25980585-5	2015	Briefly, honokiol inhibited fMLP-induced superoxide anion production (IC50 = 9.80 +- 0.21 muM, n = 4), cathepsin G release (IC50 = 14.23 +- 1.43 muM, n = 4) and migration (IC50 = 5.69 +- 1.51 muM, n = 4) in a concentration dependent manner.	honokiol	9-17	formyl peptide receptor 1	Homo sapiens	28-32
25980585-6	2015	Further, honokiol specifically suppresses fMLP-induced Lyn (a member of the Src kinase family) phosphorylation, by inhibiting Lyn kinase activity.	honokiol	9-17	formyl peptide receptor 1	Homo sapiens	42-46
25980585-6	2015	Further, honokiol specifically suppresses fMLP-induced Lyn (a member of the Src kinase family) phosphorylation, by inhibiting Lyn kinase activity.	honokiol	9-17	LYN proto-oncogene, Src family tyrosine kinase	Homo sapiens	55-58
26220468-0	2015	Anti-psoriatic effects of Honokiol through the inhibition of NF-kappaB and VEGFR-2 in animal model of K14-VEGF transgenic mouse.	honokiol	26-34	kinase insert domain protein receptor	Mus musculus	75-82
26220468-0	2015	Anti-psoriatic effects of Honokiol through the inhibition of NF-kappaB and VEGFR-2 in animal model of K14-VEGF transgenic mouse.	honokiol	26-34	keratin 14	Mus musculus	102-110
26036628-0	2015	Honokiol abrogates leptin-induced tumor progression by inhibiting Wnt1-MTA1-beta-catenin signaling axis in a microRNA-34a dependent manner.	honokiol	0-8	wingless-type MMTV integration site family, member 1	Mus musculus	66-70
26036628-0	2015	Honokiol abrogates leptin-induced tumor progression by inhibiting Wnt1-MTA1-beta-catenin signaling axis in a microRNA-34a dependent manner.	honokiol	0-8	metastasis associated 1	Mus musculus	71-75
26036628-0	2015	Honokiol abrogates leptin-induced tumor progression by inhibiting Wnt1-MTA1-beta-catenin signaling axis in a microRNA-34a dependent manner.	honokiol	0-8	catenin (cadherin associated protein), beta 1	Mus musculus	76-88
25771451-5	2015	Magnolol and honokiol increased the Cl(-) and K(+) concentrations, further, upregulated the CaM, BKalpha1 and BKbeta3 mRNA levels but downregulated the IP3 receptors 1, PKC, SK1, SK2, SK3, SK4 and BKbeta4 mRNA expressions.	honokiol	13-21	calmodulin 1	Mus musculus	92-95
25771451-5	2015	Magnolol and honokiol increased the Cl(-) and K(+) concentrations, further, upregulated the CaM, BKalpha1 and BKbeta3 mRNA levels but downregulated the IP3 receptors 1, PKC, SK1, SK2, SK3, SK4 and BKbeta4 mRNA expressions.	honokiol	13-21	skin antigen 1	Mus musculus	174-177
25771451-5	2015	Magnolol and honokiol increased the Cl(-) and K(+) concentrations, further, upregulated the CaM, BKalpha1 and BKbeta3 mRNA levels but downregulated the IP3 receptors 1, PKC, SK1, SK2, SK3, SK4 and BKbeta4 mRNA expressions.	honokiol	13-21	skin antigen 2	Mus musculus	179-182
25771451-5	2015	Magnolol and honokiol increased the Cl(-) and K(+) concentrations, further, upregulated the CaM, BKalpha1 and BKbeta3 mRNA levels but downregulated the IP3 receptors 1, PKC, SK1, SK2, SK3, SK4 and BKbeta4 mRNA expressions.	honokiol	13-21	potassium intermediate/small conductance calcium-activated channel, subfamily N, member 3	Mus musculus	184-187
25771451-5	2015	Magnolol and honokiol increased the Cl(-) and K(+) concentrations, further, upregulated the CaM, BKalpha1 and BKbeta3 mRNA levels but downregulated the IP3 receptors 1, PKC, SK1, SK2, SK3, SK4 and BKbeta4 mRNA expressions.	honokiol	13-21	potassium intermediate/small conductance calcium-activated channel, subfamily N, member 4	Mus musculus	189-192
25771451-5	2015	Magnolol and honokiol increased the Cl(-) and K(+) concentrations, further, upregulated the CaM, BKalpha1 and BKbeta3 mRNA levels but downregulated the IP3 receptors 1, PKC, SK1, SK2, SK3, SK4 and BKbeta4 mRNA expressions.	honokiol	13-21	potassium large conductance calcium-activated channel, subfamily M, beta member 4	Mus musculus	197-204
25771451-7	2015	These results clarify that magnolol and honokiol, acting through Ca(2+) channel blockade, inhibit the activation of IP3 receptor 1 to regulate the IP3-Ca(2+) store release, activate CaM to inhibit SK channels, and effectively suppress PKC kinases to promote BKalpha1 and BKbeta3 channels opening and BKbeta4 channel closing, which modulates the intestinal ion secretion.	honokiol	40-48	inositol 1,4,5-triphosphate receptor 3	Mus musculus	116-128
25771451-7	2015	These results clarify that magnolol and honokiol, acting through Ca(2+) channel blockade, inhibit the activation of IP3 receptor 1 to regulate the IP3-Ca(2+) store release, activate CaM to inhibit SK channels, and effectively suppress PKC kinases to promote BKalpha1 and BKbeta3 channels opening and BKbeta4 channel closing, which modulates the intestinal ion secretion.	honokiol	40-48	calmodulin 1	Mus musculus	182-185
25771451-7	2015	These results clarify that magnolol and honokiol, acting through Ca(2+) channel blockade, inhibit the activation of IP3 receptor 1 to regulate the IP3-Ca(2+) store release, activate CaM to inhibit SK channels, and effectively suppress PKC kinases to promote BKalpha1 and BKbeta3 channels opening and BKbeta4 channel closing, which modulates the intestinal ion secretion.	honokiol	40-48	potassium large conductance calcium-activated channel, subfamily M, beta member 4	Mus musculus	300-307
26131123-8	2015	Moreover, Cyclin B1, CDC2 and cdc25C were downregulated, and the expression of p-CDC2 and p-cdc25c was significantly upregulated upon honokiol treatment.	honokiol	134-142	cyclin dependent kinase 1	Homo sapiens	21-25
26131123-8	2015	Moreover, Cyclin B1, CDC2 and cdc25C were downregulated, and the expression of p-CDC2 and p-cdc25c was significantly upregulated upon honokiol treatment.	honokiol	134-142	cell division cycle 25C	Homo sapiens	30-36
26131123-8	2015	Moreover, Cyclin B1, CDC2 and cdc25C were downregulated, and the expression of p-CDC2 and p-cdc25c was significantly upregulated upon honokiol treatment.	honokiol	134-142	cyclin dependent kinase 1	Homo sapiens	81-85
26131123-8	2015	Moreover, Cyclin B1, CDC2 and cdc25C were downregulated, and the expression of p-CDC2 and p-cdc25c was significantly upregulated upon honokiol treatment.	honokiol	134-142	cell division cycle 25C	Homo sapiens	92-98
26131123-9	2015	P53 and p21 were significantly upregulated by honokiol treatment.	honokiol	46-54	tumor protein p53	Homo sapiens	0-3
26131123-9	2015	P53 and p21 were significantly upregulated by honokiol treatment.	honokiol	46-54	H3 histone pseudogene 16	Homo sapiens	8-11
26131123-10	2015	Treatment of MGC-803 cells with honokiol significantly increased the pro-apoptotic Bax level and decreased the anti-apoptotic Bcl-2 level.	honokiol	32-40	BCL2 associated X, apoptosis regulator	Homo sapiens	83-86
26131123-10	2015	Treatment of MGC-803 cells with honokiol significantly increased the pro-apoptotic Bax level and decreased the anti-apoptotic Bcl-2 level.	honokiol	32-40	BCL2 apoptosis regulator	Homo sapiens	126-131
26131123-11	2015	CONCLUSIONS: These results confirmed that honokiol could induce apoptosis and cell cycle arrest, the underlying molecular mechanisms, at least partially, through activation p53 signaling and downregulation CDC2/cdc25C expression.	honokiol	42-50	tumor protein p53	Homo sapiens	173-176
26131123-11	2015	CONCLUSIONS: These results confirmed that honokiol could induce apoptosis and cell cycle arrest, the underlying molecular mechanisms, at least partially, through activation p53 signaling and downregulation CDC2/cdc25C expression.	honokiol	42-50	cyclin dependent kinase 1	Homo sapiens	206-210
26131123-11	2015	CONCLUSIONS: These results confirmed that honokiol could induce apoptosis and cell cycle arrest, the underlying molecular mechanisms, at least partially, through activation p53 signaling and downregulation CDC2/cdc25C expression.	honokiol	42-50	cell division cycle 25C	Homo sapiens	211-217
25737164-0	2015	Honokiol activates the LKB1-AMPK signaling pathway and attenuates the lipid accumulation in hepatocytes.	honokiol	0-8	serine/threonine kinase 11	Homo sapiens	23-27
25737164-7	2015	Honokiol significantly inhibited sterol regulatory element-binding protein-1c (SREBP-1c) maturation and the induction of lipogenic proteins, stearoyl-CoA desaturase-1 (SCD-1) and fatty acid synthase (FAS) in FFA-exposed HepG2 cells, but these effects were blocked by pretreatment of an AMPK inhibitor.	honokiol	0-8	sterol regulatory element binding transcription factor 1	Homo sapiens	33-77
25737164-7	2015	Honokiol significantly inhibited sterol regulatory element-binding protein-1c (SREBP-1c) maturation and the induction of lipogenic proteins, stearoyl-CoA desaturase-1 (SCD-1) and fatty acid synthase (FAS) in FFA-exposed HepG2 cells, but these effects were blocked by pretreatment of an AMPK inhibitor.	honokiol	0-8	sterol regulatory element binding transcription factor 1	Homo sapiens	79-87
25737164-7	2015	Honokiol significantly inhibited sterol regulatory element-binding protein-1c (SREBP-1c) maturation and the induction of lipogenic proteins, stearoyl-CoA desaturase-1 (SCD-1) and fatty acid synthase (FAS) in FFA-exposed HepG2 cells, but these effects were blocked by pretreatment of an AMPK inhibitor.	honokiol	0-8	stearoyl-CoA desaturase	Homo sapiens	141-166
25737164-7	2015	Honokiol significantly inhibited sterol regulatory element-binding protein-1c (SREBP-1c) maturation and the induction of lipogenic proteins, stearoyl-CoA desaturase-1 (SCD-1) and fatty acid synthase (FAS) in FFA-exposed HepG2 cells, but these effects were blocked by pretreatment of an AMPK inhibitor.	honokiol	0-8	stearoyl-CoA desaturase	Homo sapiens	168-173
25737164-8	2015	Honokiol induced AMPK phosphorylation and subsequent acetyl-CoA carboxylase (ACC) phosphorylation, which were inhibited by genetic deletion of liver kinase B1 (LKB1).	honokiol	0-8	serine/threonine kinase 11	Homo sapiens	143-158
25737164-8	2015	Honokiol induced AMPK phosphorylation and subsequent acetyl-CoA carboxylase (ACC) phosphorylation, which were inhibited by genetic deletion of liver kinase B1 (LKB1).	honokiol	0-8	serine/threonine kinase 11	Homo sapiens	160-164
25737164-9	2015	Honokiol stimulated LKB1 phosphorylation, and genetic deletion of LKB1 blocked the effect of honokiol on SREBP-1c maturation and the induction of SCD-1 and FAS proteins in FFA-exposed HepG2 cells.	honokiol	0-8	serine/threonine kinase 11	Homo sapiens	20-24
25737164-9	2015	Honokiol stimulated LKB1 phosphorylation, and genetic deletion of LKB1 blocked the effect of honokiol on SREBP-1c maturation and the induction of SCD-1 and FAS proteins in FFA-exposed HepG2 cells.	honokiol	93-101	serine/threonine kinase 11	Homo sapiens	66-70
25737164-9	2015	Honokiol stimulated LKB1 phosphorylation, and genetic deletion of LKB1 blocked the effect of honokiol on SREBP-1c maturation and the induction of SCD-1 and FAS proteins in FFA-exposed HepG2 cells.	honokiol	93-101	sterol regulatory element binding transcription factor 1	Homo sapiens	105-113
25737164-10	2015	Honokiol attenuated the increases in hepatic TG and lipogenic protein levels and fat accumulation in the mice fed with high-fat diet, while significantly induced LKB1 and AMPK phosphorylation.	honokiol	0-8	serine/threonine kinase 11	Mus musculus	162-166
25737164-11	2015	Taken together, our findings suggest that honokiol has an anti-lipogenic effect in hepatocytes, and this effect may be mediated by the LKB1-AMPK signaling pathway, which induces ACC phosphorylation and inhibits SREBP-1c maturation in hepatocytes.	honokiol	42-50	serine/threonine kinase 11	Homo sapiens	135-139
25737164-11	2015	Taken together, our findings suggest that honokiol has an anti-lipogenic effect in hepatocytes, and this effect may be mediated by the LKB1-AMPK signaling pathway, which induces ACC phosphorylation and inhibits SREBP-1c maturation in hepatocytes.	honokiol	42-50	sterol regulatory element binding transcription factor 1	Homo sapiens	211-219
25871545-0	2015	Honokiol blocks and reverses cardiac hypertrophy in mice by activating mitochondrial Sirt3.	honokiol	0-8	sirtuin 3	Mus musculus	85-90
25871545-3	2015	Our data suggest that the anti-hypertrophic effects of HKL depend on activation of the deacetylase Sirt3.	honokiol	55-58	sirtuin 3	Mus musculus	99-104
25871545-7	2015	Moreover, HKL-treatment blocks cardiac fibroblast proliferation and differentiation to myofibroblasts in a Sirt3-dependent manner.	honokiol	10-13	sirtuin 3	Mus musculus	107-112
25871545-8	2015	These results suggest that HKL is a pharmacological activator of Sirt3 capable of blocking, and even reversing, the cardiac hypertrophic response.	honokiol	27-30	sirtuin 3	Mus musculus	65-70
25774462-0	2015	Honokiol downregulates Kruppel-like factor 4 expression, attenuates inflammation, and reduces histopathology after spinal cord injury in rats.	honokiol	0-8	Kruppel like factor 4	Rattus norvegicus	23-44
26221255-0	2015	Honokiol induces cell cycle arrest and apoptosis via p53 activation in H4 human neuroglioma cells.	honokiol	0-8	tumor protein p53	Homo sapiens	53-56
26221255-1	2015	OBJECTIVE: To investigate the signal pathway of honokiol-induced apoptosis in H4 human neuroglioma cells and to evaluate whether p53 signaling and cell cycle arrest were involved in honokiol-treated H4 human neuroglioma cells.	honokiol	182-190	tumor protein p53	Homo sapiens	129-132
26221255-9	2015	The expression of Cyclin B1, CDC2 and cdc25C were downregulated, however, the expression of p-CDC2 and p-cdc25c was significantly upregulated when the neuroglioma cells were exposed to honokiol.	honokiol	185-193	cyclin B1	Homo sapiens	18-27
26221255-9	2015	The expression of Cyclin B1, CDC2 and cdc25C were downregulated, however, the expression of p-CDC2 and p-cdc25c was significantly upregulated when the neuroglioma cells were exposed to honokiol.	honokiol	185-193	cyclin dependent kinase 1	Homo sapiens	29-33
26221255-9	2015	The expression of Cyclin B1, CDC2 and cdc25C were downregulated, however, the expression of p-CDC2 and p-cdc25c was significantly upregulated when the neuroglioma cells were exposed to honokiol.	honokiol	185-193	cell division cycle 25C	Homo sapiens	38-44
26221255-9	2015	The expression of Cyclin B1, CDC2 and cdc25C were downregulated, however, the expression of p-CDC2 and p-cdc25c was significantly upregulated when the neuroglioma cells were exposed to honokiol.	honokiol	185-193	cyclin dependent kinase 1	Homo sapiens	94-98
26221255-9	2015	The expression of Cyclin B1, CDC2 and cdc25C were downregulated, however, the expression of p-CDC2 and p-cdc25c was significantly upregulated when the neuroglioma cells were exposed to honokiol.	honokiol	185-193	cell division cycle 25C	Homo sapiens	105-111
26221255-10	2015	Moreover, p53, p21 and Bax/Bcl-2 were significantly upregulated by honokiol treatment.	honokiol	67-75	tumor protein p53	Homo sapiens	10-13
26221255-10	2015	Moreover, p53, p21 and Bax/Bcl-2 were significantly upregulated by honokiol treatment.	honokiol	67-75	H3 histone pseudogene 16	Homo sapiens	15-18
26221255-10	2015	Moreover, p53, p21 and Bax/Bcl-2 were significantly upregulated by honokiol treatment.	honokiol	67-75	BCL2 associated X, apoptosis regulator	Homo sapiens	23-26
26221255-10	2015	Moreover, p53, p21 and Bax/Bcl-2 were significantly upregulated by honokiol treatment.	honokiol	67-75	BCL2 apoptosis regulator	Homo sapiens	27-32
26221255-11	2015	CONCLUSIONS: These results confirmed that honokiol could induce apoptosis in human neuroglioma cells, the underlying molecular mechanisms, at least partially, through activation p53 signaling and induction of cell cycle arrest.	honokiol	42-50	tumor protein p53	Homo sapiens	178-181
25125496-0	2015	Combination of honokiol and magnolol inhibits hepatic steatosis through AMPK-SREBP-1 c pathway.	honokiol	15-23	sterol regulatory element binding transcription factor 1	Mus musculus	77-86
25125496-3	2015	In the present study, we investigated the effects of a combination of honokiol and magnolol on SREBP-1 c-dependent lipogenesis in hepatocytes as well as in mice with fatty liver due to consumption of high-fat diet (HFD).	honokiol	70-78	sterol regulatory element binding transcription factor 1	Mus musculus	95-104
25125496-4	2015	Liver X receptor alpha (LXRalpha) agonists induced activation of SREBP-1 c and expression of lipogenic genes, which were blocked by co-treatment of honokiol and magnolol (HM).	honokiol	148-156	nuclear receptor subfamily 1, group H, member 3	Mus musculus	0-22
25125496-4	2015	Liver X receptor alpha (LXRalpha) agonists induced activation of SREBP-1 c and expression of lipogenic genes, which were blocked by co-treatment of honokiol and magnolol (HM).	honokiol	148-156	nuclear receptor subfamily 1, group H, member 3	Mus musculus	24-32
25125496-4	2015	Liver X receptor alpha (LXRalpha) agonists induced activation of SREBP-1 c and expression of lipogenic genes, which were blocked by co-treatment of honokiol and magnolol (HM).	honokiol	148-156	sterol regulatory element binding transcription factor 1	Mus musculus	65-74
25619450-0	2015	Honokiol confers immunogenicity by dictating calreticulin exposure, activating ER stress and inhibiting epithelial-to-mesenchymal transition.	honokiol	0-8	calreticulin	Homo sapiens	45-57
25619450-4	2015	CRT was significantly down-regulated in highly metastatic gastric cancer cell lines and metastatic animal by Honokiol-treated.	honokiol	109-117	calreticulin	Homo sapiens	0-3
25619450-5	2015	Small RNA interference blocking CRT by siRNA-CRT was translocated to the cells in the early immunogenic response to Honokiol.	honokiol	116-124	calreticulin	Homo sapiens	32-35
25619450-5	2015	Small RNA interference blocking CRT by siRNA-CRT was translocated to the cells in the early immunogenic response to Honokiol.	honokiol	116-124	calreticulin	Homo sapiens	45-48
25619450-6	2015	Honokiol activated endoplasmic reticulum (ER) stress and down-regulated peroxisome proliferator-activated receptor-gamma (PPARgamma) activity resulting in PPARgamma and CRT degradation through calpain-II activity, which could be reversed by siRNA-calpain-II.	honokiol	0-8	peroxisome proliferator activated receptor gamma	Homo sapiens	72-120
25619450-6	2015	Honokiol activated endoplasmic reticulum (ER) stress and down-regulated peroxisome proliferator-activated receptor-gamma (PPARgamma) activity resulting in PPARgamma and CRT degradation through calpain-II activity, which could be reversed by siRNA-calpain-II.	honokiol	0-8	peroxisome proliferator activated receptor gamma	Homo sapiens	122-131
25619450-6	2015	Honokiol activated endoplasmic reticulum (ER) stress and down-regulated peroxisome proliferator-activated receptor-gamma (PPARgamma) activity resulting in PPARgamma and CRT degradation through calpain-II activity, which could be reversed by siRNA-calpain-II.	honokiol	0-8	peroxisome proliferator activated receptor gamma	Homo sapiens	155-164
25619450-6	2015	Honokiol activated endoplasmic reticulum (ER) stress and down-regulated peroxisome proliferator-activated receptor-gamma (PPARgamma) activity resulting in PPARgamma and CRT degradation through calpain-II activity, which could be reversed by siRNA-calpain-II.	honokiol	0-8	calreticulin	Homo sapiens	169-172
25619450-7	2015	The Calpain-II/PPARgamma/CRT axis and interaction evoked by Honokiol could be blocked by gene silencing or pharmacological agents.	honokiol	60-68	peroxisome proliferator activated receptor gamma	Homo sapiens	15-24
25619450-7	2015	The Calpain-II/PPARgamma/CRT axis and interaction evoked by Honokiol could be blocked by gene silencing or pharmacological agents.	honokiol	60-68	calreticulin	Homo sapiens	25-28
25619450-9	2015	Moreover, Honokiol significantly suppressed MNNG-induced gastrointestinal tumor growth and over-expression of CRT in mice.	honokiol	10-18	calreticulin	Homo sapiens	110-113
25619450-12	2015	Taken together, our results suggest that the therapeutic inhibition of CRT by Honokiol suppresses both gastric tumor growth and peritoneal dissemination by dictating early translocation of CRT in immunogenic cell death, activating ER stress, and blocking EMT.	honokiol	78-86	calreticulin	Homo sapiens	71-74
25619450-12	2015	Taken together, our results suggest that the therapeutic inhibition of CRT by Honokiol suppresses both gastric tumor growth and peritoneal dissemination by dictating early translocation of CRT in immunogenic cell death, activating ER stress, and blocking EMT.	honokiol	78-86	calreticulin	Homo sapiens	189-192
25763821-4	2015	Honokiol inhibited the proliferation of both GBM8401 parental cells and SP cells in a dose-dependent manner, the IC50 were 5.3+-0.72 and 11+-1.1 muM, respectively.	honokiol	0-8	latexin	Homo sapiens	145-148
25763821-5	2015	The proportions of SP in GBM8401 cells were diminished by Honokiol from 1.5+-0.22% down to 0.3+-0.02% and 0.2+-0.01% at doses of 2.5 muM and 5 muM, respectively.	honokiol	58-66	latexin	Homo sapiens	133-136
25776492-4	2015	The accumulation of daunorubicin or rhodamine 123, fluorescent substrates of P-glycoprotein, in KB/MDR1 cells increased in the presence of caffeic acid phenetyl ester (CAPE), licochalcone A, anacardic acid, celastrol, xanthohumol, magnolol, and honokiol in a concentration-dependent manner.	honokiol	245-253	ATP binding cassette subfamily B member 1	Homo sapiens	77-91
25776492-6	2015	The ATPase activities of P-glycoprotein were stimulated by CAPE, licochalcone A, anacardic acid, celastrol, xanthohumol, magnolol, and honokiol.	honokiol	135-143	ATP binding cassette subfamily B member 1	Homo sapiens	25-39
25776492-8	2015	KB/MDR1 cells were sensitized to vinblastine cytotoxicity by CAPE, licochalcone A, anacardic acid, xanthohumol, magnolol, and honokiol, showing that these natural NF-kappaB inhibitors reverse multidrug resistance.	honokiol	126-134	ATP binding cassette subfamily B member 1	Homo sapiens	3-7
25890726-1	2015	The aim of this study was to investigate anti-inflammatory and anti-cancer effects of honokiol (HK) in two oral squamous cancer cell carcinoma (OSCC) cell lines, HN22 and HSC4, through the regulation of inducible nitric oxide synthase (iNOS) and endoplasmic reticulum resident protein 44 (ERp44).	honokiol	86-94	nitric oxide synthase 2	Homo sapiens	203-234
25187418-5	2015	Importantly, honokiol increased the levels of p21/waf1 and Bax via triggering acetylation of histone in the regions of p21/waf1 and Bax promoter.	honokiol	13-21	cyclin dependent kinase inhibitor 1A	Homo sapiens	46-49
25187418-5	2015	Importantly, honokiol increased the levels of p21/waf1 and Bax via triggering acetylation of histone in the regions of p21/waf1 and Bax promoter.	honokiol	13-21	cyclin dependent kinase inhibitor 1A	Homo sapiens	50-54
25187418-5	2015	Importantly, honokiol increased the levels of p21/waf1 and Bax via triggering acetylation of histone in the regions of p21/waf1 and Bax promoter.	honokiol	13-21	BCL2 associated X, apoptosis regulator	Homo sapiens	59-62
25187418-5	2015	Importantly, honokiol increased the levels of p21/waf1 and Bax via triggering acetylation of histone in the regions of p21/waf1 and Bax promoter.	honokiol	13-21	cyclin dependent kinase inhibitor 1A	Homo sapiens	46-54
25187418-5	2015	Importantly, honokiol increased the levels of p21/waf1 and Bax via triggering acetylation of histone in the regions of p21/waf1 and Bax promoter.	honokiol	13-21	BCL2 associated X, apoptosis regulator	Homo sapiens	132-135
25890726-1	2015	The aim of this study was to investigate anti-inflammatory and anti-cancer effects of honokiol (HK) in two oral squamous cancer cell carcinoma (OSCC) cell lines, HN22 and HSC4, through the regulation of inducible nitric oxide synthase (iNOS) and endoplasmic reticulum resident protein 44 (ERp44).	honokiol	86-94	nitric oxide synthase 2	Homo sapiens	236-240
25890726-1	2015	The aim of this study was to investigate anti-inflammatory and anti-cancer effects of honokiol (HK) in two oral squamous cancer cell carcinoma (OSCC) cell lines, HN22 and HSC4, through the regulation of inducible nitric oxide synthase (iNOS) and endoplasmic reticulum resident protein 44 (ERp44).	honokiol	86-94	endoplasmic reticulum protein 44	Homo sapiens	246-287
25890726-1	2015	The aim of this study was to investigate anti-inflammatory and anti-cancer effects of honokiol (HK) in two oral squamous cancer cell carcinoma (OSCC) cell lines, HN22 and HSC4, through the regulation of inducible nitric oxide synthase (iNOS) and endoplasmic reticulum resident protein 44 (ERp44).	honokiol	86-94	endoplasmic reticulum protein 44	Homo sapiens	289-294
25890726-1	2015	The aim of this study was to investigate anti-inflammatory and anti-cancer effects of honokiol (HK) in two oral squamous cancer cell carcinoma (OSCC) cell lines, HN22 and HSC4, through the regulation of inducible nitric oxide synthase (iNOS) and endoplasmic reticulum resident protein 44 (ERp44).	honokiol	96-98	nitric oxide synthase 2	Homo sapiens	203-234
25890726-1	2015	The aim of this study was to investigate anti-inflammatory and anti-cancer effects of honokiol (HK) in two oral squamous cancer cell carcinoma (OSCC) cell lines, HN22 and HSC4, through the regulation of inducible nitric oxide synthase (iNOS) and endoplasmic reticulum resident protein 44 (ERp44).	honokiol	96-98	nitric oxide synthase 2	Homo sapiens	236-240
25395831-3	2014	Honokiol treatment at the highest concentration tested (50 muM) increased the CYP2B6 mRNA level and CYP2B6-catalyzed bupropion hydroxylase activity more than two-fold in three different hepatocyte cultures, indicating that honokiol induces CYP2B6 at higher concentrations.	honokiol	0-8	latexin	Homo sapiens	59-62
25890726-1	2015	The aim of this study was to investigate anti-inflammatory and anti-cancer effects of honokiol (HK) in two oral squamous cancer cell carcinoma (OSCC) cell lines, HN22 and HSC4, through the regulation of inducible nitric oxide synthase (iNOS) and endoplasmic reticulum resident protein 44 (ERp44).	honokiol	96-98	endoplasmic reticulum protein 44	Homo sapiens	246-287
25890726-1	2015	The aim of this study was to investigate anti-inflammatory and anti-cancer effects of honokiol (HK) in two oral squamous cancer cell carcinoma (OSCC) cell lines, HN22 and HSC4, through the regulation of inducible nitric oxide synthase (iNOS) and endoplasmic reticulum resident protein 44 (ERp44).	honokiol	96-98	endoplasmic reticulum protein 44	Homo sapiens	289-294
25846316-0	2015	Honokiol suppresses metastasis of renal cell carcinoma by targeting KISS1/KISS1R signaling.	honokiol	0-8	KiSS-1 metastasis suppressor	Homo sapiens	68-73
25846316-0	2015	Honokiol suppresses metastasis of renal cell carcinoma by targeting KISS1/KISS1R signaling.	honokiol	0-8	KISS1 receptor	Homo sapiens	74-80
25846316-9	2015	Taken together, the results first indicate that activation of KISS1/KISS1R signaling by honokiol suppresses multistep process of metastasis, including invasion and colony formation, in RCC cells 786-0.	honokiol	88-96	KiSS-1 metastasis suppressor	Homo sapiens	62-67
25846316-9	2015	Taken together, the results first indicate that activation of KISS1/KISS1R signaling by honokiol suppresses multistep process of metastasis, including invasion and colony formation, in RCC cells 786-0.	honokiol	88-96	KISS1 receptor	Homo sapiens	68-74
25450590-0	2014	Honokiol affects melanoma cell growth by targeting the AMP-activated protein kinase signaling pathway.	honokiol	0-8	protein kinase AMP-activated catalytic subunit alpha 2	Homo sapiens	55-83
25422886-6	2014	Using chromatin immunoprecipitation experiments, we demonstrate that honokiol inhibits binding of HIF to hypoxia-response elements present on VEGF promoter.	honokiol	69-77	vascular endothelial growth factor A	Homo sapiens	142-146
25395831-3	2014	Honokiol treatment at the highest concentration tested (50 muM) increased the CYP2B6 mRNA level and CYP2B6-catalyzed bupropion hydroxylase activity more than two-fold in three different hepatocyte cultures, indicating that honokiol induces CYP2B6 at higher concentrations.	honokiol	0-8	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	78-84
25395831-3	2014	Honokiol treatment at the highest concentration tested (50 muM) increased the CYP2B6 mRNA level and CYP2B6-catalyzed bupropion hydroxylase activity more than two-fold in three different hepatocyte cultures, indicating that honokiol induces CYP2B6 at higher concentrations.	honokiol	0-8	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	100-106
25395831-3	2014	Honokiol treatment at the highest concentration tested (50 muM) increased the CYP2B6 mRNA level and CYP2B6-catalyzed bupropion hydroxylase activity more than two-fold in three different hepatocyte cultures, indicating that honokiol induces CYP2B6 at higher concentrations.	honokiol	0-8	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	100-106
25395831-6	2014	These results indicate that honokiol is a weak CYP2B6 inducer and is unlikely to increase the metabolism of concomitant CYP2B6 substrates and cause pharmacokinetic-based drug interactions in humans.	honokiol	28-36	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	47-53
25245764-6	2014	Administration of honokiol significantly reduced the percentage of bronchial that exhibit abnormal lung SCC histology from 24.4% bronchial in control to 11.0% bronchial in honokiol-treated group (P = 0.01) while protecting normal bronchial histology (present in 20.5% of bronchial in control group and 38.5% of bronchial in honokiol-treated group.	honokiol	18-26	serpin family B member 3	Homo sapiens	104-107
25083916-5	2014	Those natural PPARgamma ligands have different binding modes to the receptor in comparison to the full thiazolidinedione agonists, and on some occasions activate in addition PPARalpha (e.g. genistein, biochanin A, sargaquinoic acid, sargahydroquinoic acid, resveratrol, amorphastilbol) or the PPARgamma-dimer partner retinoid X receptor (RXR; e.g. the neolignans magnolol and honokiol).	honokiol	376-384	peroxisome proliferator activated receptor gamma	Homo sapiens	14-23
25083916-6	2014	A number of in vivo studies suggest that some of the natural product activators of PPARgamma (e.g. honokiol, amorfrutin 1, amorfrutin B, amorphastilbol) improve metabolic parameters in diabetic animal models, partly with reduced side effects in comparison to full thiazolidinedione agonists.	honokiol	99-107	peroxisome proliferator activated receptor gamma	Homo sapiens	83-92
25245764-9	2014	In vitro studies revealed that honokiol inhibited lung SCC cells proliferation, arrested cells at the G1-S cell-cycle checkpoint, while also leading to increased apoptosis.	honokiol	31-39	serpin family B member 3	Homo sapiens	55-58
25245764-10	2014	Our study showed that interfering with mitochondrial respiration is a novel mechanism by which honokiol changed redox status in the mitochondria, triggered apoptosis, and finally leads to the inhibition of lung SCC.	honokiol	95-103	serpin family B member 3	Homo sapiens	211-214
25245764-11	2014	This novel mechanism of targeting mitochondrial suggests honokiol as a potential lung SCC chemopreventive agent.	honokiol	57-65	serpin family B member 3	Homo sapiens	86-89
24973706-8	2014	Furthermore, the expression of some of the key cell cycle proteins such as cyclin D1 and E2F1 and the associated apoptosis in neurons were both remarkably attenuated by Honokiol treatment.	honokiol	169-177	cyclin D1	Rattus norvegicus	75-84
24973706-8	2014	Furthermore, the expression of some of the key cell cycle proteins such as cyclin D1 and E2F1 and the associated apoptosis in neurons were both remarkably attenuated by Honokiol treatment.	honokiol	169-177	E2F transcription factor 1	Rattus norvegicus	89-93
25106108-10	2014	Inhibition of phospholipase C (PLC) with U73122 abolished honokiol-induced [Ca(2+)]i rise.	honokiol	58-66	heparan sulfate proteoglycan 2	Homo sapiens	31-34
25442261-8	2014	To gain insight into possible modes of collateral sensitivity, we performed in silico molecular docking studies of honokiol to EGFR and EGFR-related downstream signal proteins.	honokiol	115-123	epidermal growth factor receptor	Homo sapiens	127-131
25442261-8	2014	To gain insight into possible modes of collateral sensitivity, we performed in silico molecular docking studies of honokiol to EGFR and EGFR-related downstream signal proteins.	honokiol	115-123	epidermal growth factor receptor	Homo sapiens	136-140
25442261-9	2014	Honokiol bound with comparable binding energies to EGFR (-7.30 +- 0.01 kcal/mol) as the control drugs erlotinib (-7.50 +- 0.30 kcal/mol) and gefitinib (-8.30 +- 0.10 kcal/mol).	honokiol	0-8	epidermal growth factor receptor	Homo sapiens	51-55
25442261-11	2014	This indicates that collateral sensitivity of EGFR-transfectant cells towards honokiol may be due to binding to EGFR and downstream signal transducers.	honokiol	78-86	epidermal growth factor receptor	Homo sapiens	46-50
25442261-11	2014	This indicates that collateral sensitivity of EGFR-transfectant cells towards honokiol may be due to binding to EGFR and downstream signal transducers.	honokiol	78-86	epidermal growth factor receptor	Homo sapiens	112-116
24905183-0	2014	Expression of survivin and p53 modulates honokiol-induced apoptosis in colorectal cancer cells.	honokiol	41-49	tumor protein p53	Homo sapiens	27-30
24905183-2	2014	Here, we show that survivin and p53 display the opposite role on the regulation of honokiol-induced apoptosis in the human colorectal cancer cells.	honokiol	83-91	tumor protein p53	Homo sapiens	32-35
24905183-4	2014	Moreover, honokiol elicited the extrinsic death receptor pathway of DR5 and caspase 8 and the intrinsic pathway of caspase 9.	honokiol	10-18	TNF receptor superfamily member 10b	Homo sapiens	68-71
24905183-4	2014	Moreover, honokiol elicited the extrinsic death receptor pathway of DR5 and caspase 8 and the intrinsic pathway of caspase 9.	honokiol	10-18	caspase 8	Homo sapiens	76-85
24905183-4	2014	Moreover, honokiol elicited the extrinsic death receptor pathway of DR5 and caspase 8 and the intrinsic pathway of caspase 9.	honokiol	10-18	caspase 9	Homo sapiens	115-124
24905183-5	2014	The common intrinsic and extrinsic downstream targets of activated caspase 3 and PARP protein cleavage were induced by honokiol.	honokiol	119-127	caspase 3	Homo sapiens	67-76
24905183-5	2014	The common intrinsic and extrinsic downstream targets of activated caspase 3 and PARP protein cleavage were induced by honokiol.	honokiol	119-127	poly(ADP-ribose) polymerase 1	Homo sapiens	81-85
24905183-8	2014	Meantime, honokiol increased total p53 and the phosphorylated p53 proteins at Ser15 and Ser46.	honokiol	10-18	tumor protein p53	Homo sapiens	35-38
24905183-8	2014	Meantime, honokiol increased total p53 and the phosphorylated p53 proteins at Ser15 and Ser46.	honokiol	10-18	tumor protein p53	Homo sapiens	62-65
24905183-9	2014	The p53-wild type colorectal cancer cells were exhibited greater cytotoxicity, apoptosis and survivin reduction than the p53-null cancer cells after treatment with honokiol.	honokiol	164-172	tumor protein p53	Homo sapiens	4-7
24905183-9	2014	The p53-wild type colorectal cancer cells were exhibited greater cytotoxicity, apoptosis and survivin reduction than the p53-null cancer cells after treatment with honokiol.	honokiol	164-172	tumor protein p53	Homo sapiens	121-124
24905183-10	2014	Together, these findings demonstrate that the existence of survivin and p53 can modulate the honokiol-induced apoptosis in the human colorectal cancer cells.	honokiol	93-101	tumor protein p53	Homo sapiens	72-75
25043291-1	2014	BACKGROUND: Honokiol (HNK), derived from the bark of an oriental medicinal plant (Magnolia officinalis), is a promising anticancer agent with preclinical in vitro (PC-3 and LNCaP cells) and in vivo (PC-3 xenografts) efficacy against prostate cancer.	honokiol	12-20	chromobox 8	Homo sapiens	164-168
25043291-1	2014	BACKGROUND: Honokiol (HNK), derived from the bark of an oriental medicinal plant (Magnolia officinalis), is a promising anticancer agent with preclinical in vitro (PC-3 and LNCaP cells) and in vivo (PC-3 xenografts) efficacy against prostate cancer.	honokiol	12-20	chromobox 8	Homo sapiens	199-203
27508182-8	2014	Notably, a novel PPARgamma agonist, honokiol, has recently been found to activate the PPARgamma/RXR heterodimer, and has also exhibited significant anti-cancer effects in hepatoma cells.	honokiol	36-44	peroxisome proliferator activated receptor gamma	Homo sapiens	17-26
27508182-8	2014	Notably, a novel PPARgamma agonist, honokiol, has recently been found to activate the PPARgamma/RXR heterodimer, and has also exhibited significant anti-cancer effects in hepatoma cells.	honokiol	36-44	peroxisome proliferator activated receptor gamma	Homo sapiens	86-95
27508182-8	2014	Notably, a novel PPARgamma agonist, honokiol, has recently been found to activate the PPARgamma/RXR heterodimer, and has also exhibited significant anti-cancer effects in hepatoma cells.	honokiol	36-44	retinoid X receptor alpha	Homo sapiens	96-99
25106108-12	2014	Honokiol (20-60muM) enhanced reactive oxygen species (ROS) production, decreased mitochondrial membrane potential, released cytochrome c, and activated caspase-9/caspase-3.	honokiol	0-8	latexin	Homo sapiens	15-18
25106108-12	2014	Honokiol (20-60muM) enhanced reactive oxygen species (ROS) production, decreased mitochondrial membrane potential, released cytochrome c, and activated caspase-9/caspase-3.	honokiol	0-8	cytochrome c, somatic	Homo sapiens	124-136
25106108-12	2014	Honokiol (20-60muM) enhanced reactive oxygen species (ROS) production, decreased mitochondrial membrane potential, released cytochrome c, and activated caspase-9/caspase-3.	honokiol	0-8	caspase 9	Homo sapiens	152-161
25106108-12	2014	Honokiol (20-60muM) enhanced reactive oxygen species (ROS) production, decreased mitochondrial membrane potential, released cytochrome c, and activated caspase-9/caspase-3.	honokiol	0-8	caspase 3	Homo sapiens	162-171
25106108-13	2014	Together, honokiol induced a [Ca(2+)]i rise by inducing PLC-dependent Ca(2+) release from the endoplasmic reticulum and Ca(2+) entry via PKC-dependent, non store-operated Ca(2+) channels.	honokiol	10-18	heparan sulfate proteoglycan 2	Homo sapiens	56-59
24360976-0	2014	Honokiol suppresses TNF-alpha-induced migration and matrix metalloproteinase expression by blocking NF-kappaB activation via the ERK signaling pathway in rat aortic smooth muscle cells.	honokiol	0-8	tumor necrosis factor	Rattus norvegicus	20-29
24360976-0	2014	Honokiol suppresses TNF-alpha-induced migration and matrix metalloproteinase expression by blocking NF-kappaB activation via the ERK signaling pathway in rat aortic smooth muscle cells.	honokiol	0-8	Eph receptor B1	Rattus norvegicus	129-132
24360976-2	2014	In the present study, we aimed to investigate the effects of honokiol on tumor necrosis factor-alpha (TNF-alpha)-induced migration in rat aortic smooth muscle cells (RASMCs).	honokiol	61-69	tumor necrosis factor	Rattus norvegicus	73-100
24360976-2	2014	In the present study, we aimed to investigate the effects of honokiol on tumor necrosis factor-alpha (TNF-alpha)-induced migration in rat aortic smooth muscle cells (RASMCs).	honokiol	61-69	tumor necrosis factor	Rattus norvegicus	102-111
24360976-3	2014	We found that honokiol inhibited TNF-alpha-induced RASMC proliferation and migration in a dose-dependent manner.	honokiol	14-22	tumor necrosis factor	Rattus norvegicus	33-42
24360976-4	2014	At the molecular level, pretreatment with honokiol blocked TNF-alpha-induced protein expression of matrix metalloproteinase (MMP)-2 and MMP-9, nuclear factor (NF)-kappaB activation, and extracellular signal-regulated kinase 1/2 (ERK1/2) phosphorylation.	honokiol	42-50	tumor necrosis factor	Rattus norvegicus	59-68
24360976-4	2014	At the molecular level, pretreatment with honokiol blocked TNF-alpha-induced protein expression of matrix metalloproteinase (MMP)-2 and MMP-9, nuclear factor (NF)-kappaB activation, and extracellular signal-regulated kinase 1/2 (ERK1/2) phosphorylation.	honokiol	42-50	matrix metallopeptidase 2	Rattus norvegicus	99-131
24360976-4	2014	At the molecular level, pretreatment with honokiol blocked TNF-alpha-induced protein expression of matrix metalloproteinase (MMP)-2 and MMP-9, nuclear factor (NF)-kappaB activation, and extracellular signal-regulated kinase 1/2 (ERK1/2) phosphorylation.	honokiol	42-50	matrix metallopeptidase 9	Rattus norvegicus	136-141
24360976-4	2014	At the molecular level, pretreatment with honokiol blocked TNF-alpha-induced protein expression of matrix metalloproteinase (MMP)-2 and MMP-9, nuclear factor (NF)-kappaB activation, and extracellular signal-regulated kinase 1/2 (ERK1/2) phosphorylation.	honokiol	42-50	mitogen activated protein kinase 3	Rattus norvegicus	186-227
24360976-4	2014	At the molecular level, pretreatment with honokiol blocked TNF-alpha-induced protein expression of matrix metalloproteinase (MMP)-2 and MMP-9, nuclear factor (NF)-kappaB activation, and extracellular signal-regulated kinase 1/2 (ERK1/2) phosphorylation.	honokiol	42-50	mitogen activated protein kinase 3	Rattus norvegicus	229-235
24508063-0	2014	Honokiol inhibits epithelial-mesenchymal transition in breast cancer cells by targeting signal transducer and activator of transcription 3/Zeb1/E-cadherin axis.	honokiol	0-8	signal transducer and activator of transcription 3	Homo sapiens	88-138
24360976-5	2014	Moreover, NF-kappaB inhibitor (BAY 11-7028) and ERK inhibitor (U0126) also mimicked the inhibitory effects of honokiol in TNF-alpha-treated RASMCs.	honokiol	110-118	Eph receptor B1	Rattus norvegicus	48-51
24360976-5	2014	Moreover, NF-kappaB inhibitor (BAY 11-7028) and ERK inhibitor (U0126) also mimicked the inhibitory effects of honokiol in TNF-alpha-treated RASMCs.	honokiol	110-118	tumor necrosis factor	Rattus norvegicus	122-131
24360976-6	2014	In conclusion, these results indicate that honokiol suppresses TNF-alpha-induced migration and MMP expression by blocking NF-kappaB activation via the ERK signaling pathway in RASMCs.	honokiol	43-51	tumor necrosis factor	Rattus norvegicus	63-72
24360976-6	2014	In conclusion, these results indicate that honokiol suppresses TNF-alpha-induced migration and MMP expression by blocking NF-kappaB activation via the ERK signaling pathway in RASMCs.	honokiol	43-51	Eph receptor B1	Rattus norvegicus	151-154
24375705-8	2014	Our data showed that IL-1beta markedly stimulated the expressions of iNOS and COX-2 and the productions of NO, PGE2 , and IL-6, which could be significantly reversed by honokiol.	honokiol	169-177	interleukin 1 beta	Homo sapiens	21-29
24375705-8	2014	Our data showed that IL-1beta markedly stimulated the expressions of iNOS and COX-2 and the productions of NO, PGE2 , and IL-6, which could be significantly reversed by honokiol.	honokiol	169-177	nitric oxide synthase 2	Homo sapiens	69-73
24375705-8	2014	Our data showed that IL-1beta markedly stimulated the expressions of iNOS and COX-2 and the productions of NO, PGE2 , and IL-6, which could be significantly reversed by honokiol.	honokiol	169-177	prostaglandin-endoperoxide synthase 2	Homo sapiens	78-83
24375705-8	2014	Our data showed that IL-1beta markedly stimulated the expressions of iNOS and COX-2 and the productions of NO, PGE2 , and IL-6, which could be significantly reversed by honokiol.	honokiol	169-177	interleukin 6	Homo sapiens	122-126
24375705-9	2014	Honokiol could also suppress the IL-1beta-triggered activation of IKK/IkappaBalpha/NF-kappaB signaling pathway.	honokiol	0-8	interleukin 1 beta	Homo sapiens	33-41
24375705-9	2014	Honokiol could also suppress the IL-1beta-triggered activation of IKK/IkappaBalpha/NF-kappaB signaling pathway.	honokiol	0-8	NFKB inhibitor alpha	Homo sapiens	70-82
24375705-9	2014	Honokiol could also suppress the IL-1beta-triggered activation of IKK/IkappaBalpha/NF-kappaB signaling pathway.	honokiol	0-8	nuclear factor kappa B subunit 1	Homo sapiens	83-92
24375705-10	2014	Moreover, honokiol significantly inhibited the IL-1beta-induced MMP-13 production and collagen II reduction.	honokiol	10-18	interleukin 1 beta	Homo sapiens	47-55
24375705-10	2014	Moreover, honokiol significantly inhibited the IL-1beta-induced MMP-13 production and collagen II reduction.	honokiol	10-18	matrix metallopeptidase 13	Homo sapiens	64-70
24338950-0	2014	Honokiol inhibits androgen receptor activity in prostate cancer cells.	honokiol	0-8	androgen receptor	Homo sapiens	18-35
24810210-0	2014	Honokiol suppresses renal cancer cells" metastasis via dual-blocking epithelial-mesenchymal transition and cancer stem cell properties through modulating miR-141/ZEB2 signaling.	honokiol	0-8	microRNA 141	Homo sapiens	154-161
24810210-0	2014	Honokiol suppresses renal cancer cells" metastasis via dual-blocking epithelial-mesenchymal transition and cancer stem cell properties through modulating miR-141/ZEB2 signaling.	honokiol	0-8	zinc finger E-box binding homeobox 2	Homo sapiens	162-166
24810210-7	2014	It was found that honokiol could upregulate miR-141, which targeted ZEB2 and modulated ZEB2 expression.	honokiol	18-26	microRNA 141	Homo sapiens	44-51
24810210-7	2014	It was found that honokiol could upregulate miR-141, which targeted ZEB2 and modulated ZEB2 expression.	honokiol	18-26	zinc finger E-box binding homeobox 2	Homo sapiens	68-72
24810210-7	2014	It was found that honokiol could upregulate miR-141, which targeted ZEB2 and modulated ZEB2 expression.	honokiol	18-26	zinc finger E-box binding homeobox 2	Homo sapiens	87-91
24810210-8	2014	Honokiol reversed EMT and suppressed CSC properties partly through the miR-141/ZEB2 axis.	honokiol	0-8	microRNA 141	Homo sapiens	71-78
24810210-8	2014	Honokiol reversed EMT and suppressed CSC properties partly through the miR-141/ZEB2 axis.	honokiol	0-8	zinc finger E-box binding homeobox 2	Homo sapiens	79-83
24508063-0	2014	Honokiol inhibits epithelial-mesenchymal transition in breast cancer cells by targeting signal transducer and activator of transcription 3/Zeb1/E-cadherin axis.	honokiol	0-8	zinc finger E-box binding homeobox 1	Homo sapiens	139-143
24508063-0	2014	Honokiol inhibits epithelial-mesenchymal transition in breast cancer cells by targeting signal transducer and activator of transcription 3/Zeb1/E-cadherin axis.	honokiol	0-8	cadherin 1	Homo sapiens	144-154
24309146-3	2014	Honokiol and beta-amyrin acetate, isolated from Magnolia officinalis and Acer mandshuricum, respectively, displayed strong inhibition of sEH activity, with respective IC50 values of 0.57 muM and 3.4 muM determined using the fluorescent substrate, and 1.7 muM and 6.1 muM determined using 14,15-epoxyeicosatrienoic acid.	honokiol	0-8	epoxide hydrolase 2	Homo sapiens	137-140
24586249-4	2014	Honokiol induced mitochondria-dependent and death receptor-mediated apoptosis in MDR KB cells, which was associated with inhibition of EGFR-STAT3 signaling and downregulation of STAT3 target genes.	honokiol	0-8	epidermal growth factor receptor	Homo sapiens	135-139
24586249-4	2014	Honokiol induced mitochondria-dependent and death receptor-mediated apoptosis in MDR KB cells, which was associated with inhibition of EGFR-STAT3 signaling and downregulation of STAT3 target genes.	honokiol	0-8	signal transducer and activator of transcription 3	Homo sapiens	140-145
24586249-4	2014	Honokiol induced mitochondria-dependent and death receptor-mediated apoptosis in MDR KB cells, which was associated with inhibition of EGFR-STAT3 signaling and downregulation of STAT3 target genes.	honokiol	0-8	signal transducer and activator of transcription 3	Homo sapiens	178-183
23933846-1	2014	This study aims to investigate the effects of honokiol on proliferation, cell cycle, and apoptosis in tumor necrosis factor (TNF)-alpha-induced rat aortic smooth muscle cells (RASMCs).	honokiol	46-54	tumor necrosis factor	Rattus norvegicus	102-135
23933846-2	2014	We found that honokiol treatment showed potent inhibitory effects on TNF-alpha-induced RASMC proliferation, which were associated with G0/G1 cell cycle arrest and downregulation of cell cycle-related proteins, including cyclin D1, cyclin E, cyclin-dependent kinase (CDK)2 and CDK4.	honokiol	14-22	tumor necrosis factor	Rattus norvegicus	69-78
23933846-2	2014	We found that honokiol treatment showed potent inhibitory effects on TNF-alpha-induced RASMC proliferation, which were associated with G0/G1 cell cycle arrest and downregulation of cell cycle-related proteins, including cyclin D1, cyclin E, cyclin-dependent kinase (CDK)2 and CDK4.	honokiol	14-22	cyclin D1	Rattus norvegicus	220-229
23933846-2	2014	We found that honokiol treatment showed potent inhibitory effects on TNF-alpha-induced RASMC proliferation, which were associated with G0/G1 cell cycle arrest and downregulation of cell cycle-related proteins, including cyclin D1, cyclin E, cyclin-dependent kinase (CDK)2 and CDK4.	honokiol	14-22	cyclin E1	Rattus norvegicus	231-239
23933846-2	2014	We found that honokiol treatment showed potent inhibitory effects on TNF-alpha-induced RASMC proliferation, which were associated with G0/G1 cell cycle arrest and downregulation of cell cycle-related proteins, including cyclin D1, cyclin E, cyclin-dependent kinase (CDK)2 and CDK4.	honokiol	14-22	cyclin dependent kinase 2	Rattus norvegicus	266-271
23933846-2	2014	We found that honokiol treatment showed potent inhibitory effects on TNF-alpha-induced RASMC proliferation, which were associated with G0/G1 cell cycle arrest and downregulation of cell cycle-related proteins, including cyclin D1, cyclin E, cyclin-dependent kinase (CDK)2 and CDK4.	honokiol	14-22	cyclin-dependent kinase 4	Rattus norvegicus	276-280
23933846-3	2014	Furthermore, honokiol treatment led to the release of cytochrome c into cytosol and a loss of mitochondrial membrane potential (DeltaPsim), as well as a decrease in the expression of Bcl-2 and an increase in the expression of Bax.	honokiol	13-21	BCL2, apoptosis regulator	Rattus norvegicus	183-188
23933846-3	2014	Furthermore, honokiol treatment led to the release of cytochrome c into cytosol and a loss of mitochondrial membrane potential (DeltaPsim), as well as a decrease in the expression of Bcl-2 and an increase in the expression of Bax.	honokiol	13-21	BCL2 associated X, apoptosis regulator	Rattus norvegicus	226-229
23933846-4	2014	Treatment with honokiol also reduced TNF-alpha-induced phosphorylation of p38, extracellular signal-regulated kinase 1/2, and c-Jun N-terminal kinase.	honokiol	15-23	tumor necrosis factor	Rattus norvegicus	37-46
23933846-4	2014	Treatment with honokiol also reduced TNF-alpha-induced phosphorylation of p38, extracellular signal-regulated kinase 1/2, and c-Jun N-terminal kinase.	honokiol	15-23	mitogen activated protein kinase 14	Rattus norvegicus	74-77
23933846-4	2014	Treatment with honokiol also reduced TNF-alpha-induced phosphorylation of p38, extracellular signal-regulated kinase 1/2, and c-Jun N-terminal kinase.	honokiol	15-23	mitogen activated protein kinase 3	Rattus norvegicus	79-149
23933846-5	2014	Taken together, our results suggest that honokiol suppresses TNF-alpha-stimulated RASMC proliferation via caspase- and mitochondria-dependent apoptosis and highlight the therapeutic potential of honokiol in the prevention of cardiovascular diseases.	honokiol	41-49	tumor necrosis factor	Rattus norvegicus	61-70
23933846-5	2014	Taken together, our results suggest that honokiol suppresses TNF-alpha-stimulated RASMC proliferation via caspase- and mitochondria-dependent apoptosis and highlight the therapeutic potential of honokiol in the prevention of cardiovascular diseases.	honokiol	195-203	tumor necrosis factor	Rattus norvegicus	61-70
24309146-4	2014	mEH activity was decreased to 49% or 61% of control activity by 25 muM honokiol or beta-amyrin acetate, respectively.	honokiol	71-79	epoxide hydrolase 1, microsomal	Mus musculus	0-3
24309146-5	2014	These results suggest that beta-amyrin acetate and honokiol exhibit sEH inhibitory activity, although their sEH selectivity should be improved.	honokiol	51-59	epoxide hydrolase 2	Homo sapiens	68-71
24598658-6	2014	It is concluded that Honokiol combined Gemcitabine can synergistically inhibit the proliferation, induce cell apoptosis, and down-regulate the expression of BCL-2 in Raji cells.	honokiol	21-29	BCL2 apoptosis regulator	Homo sapiens	157-162
24247297-11	2014	Honokiol reduced the expression levels of Snail, N-cadherin and beta-catenin, which are mesenchymal markers, but increased E-cadherin, an epithelial marker.	honokiol	0-8	catenin beta 1	Homo sapiens	64-76
24247297-11	2014	Honokiol reduced the expression levels of Snail, N-cadherin and beta-catenin, which are mesenchymal markers, but increased E-cadherin, an epithelial marker.	honokiol	0-8	cadherin 1	Homo sapiens	123-133
24247297-12	2014	In conclusion, these results suggest that honokiol inhibits metastasis by targeting the interaction between U87MG and BMECs, regulating the adhesion of U87MG to BMECs by inhibiting VCAM-1, and regulating the invasion of U87MG through BMECs by reducing membrane permeability and EMT processes of U87MG cells.	honokiol	42-50	vascular cell adhesion molecule 1	Homo sapiens	181-187
23828905-0	2013	Honokiol thwarts gastric tumor growth and peritoneal dissemination by inhibiting Tpl2 in an orthotopic model.	honokiol	0-8	mitogen-activated protein kinase kinase kinase 8	Mus musculus	81-85
24247297-0	2014	Honokiol inhibits U87MG human glioblastoma cell invasion through endothelial cells by regulating membrane permeability and the epithelial-mesenchymal transition.	honokiol	0-8	small nucleolar RNA, C/D box 87	Homo sapiens	18-21
24247297-7	2014	Honokiol dose-dependently inhibited TNF-alpha-induced VCAM-1 expression in BMECs and adhesion of U87MG to BMECs.	honokiol	0-8	tumor necrosis factor	Homo sapiens	36-45
24247297-7	2014	Honokiol dose-dependently inhibited TNF-alpha-induced VCAM-1 expression in BMECs and adhesion of U87MG to BMECs.	honokiol	0-8	vascular cell adhesion molecule 1	Homo sapiens	54-60
24247297-9	2014	Increased phosphorylation of VE-cadherin and membrane permeability by TNF-alpha were suppressed by honokiol in BMECs.	honokiol	99-107	cadherin 5	Homo sapiens	29-40
24247297-9	2014	Increased phosphorylation of VE-cadherin and membrane permeability by TNF-alpha were suppressed by honokiol in BMECs.	honokiol	99-107	tumor necrosis factor	Homo sapiens	70-79
24247297-11	2014	Honokiol reduced the expression levels of Snail, N-cadherin and beta-catenin, which are mesenchymal markers, but increased E-cadherin, an epithelial marker.	honokiol	0-8	snail family transcriptional repressor 1	Homo sapiens	42-47
24247297-11	2014	Honokiol reduced the expression levels of Snail, N-cadherin and beta-catenin, which are mesenchymal markers, but increased E-cadherin, an epithelial marker.	honokiol	0-8	cadherin 2	Homo sapiens	49-59
23828905-4	2013	Honokiol-treated tumors showed increased epithelial signatures such as E-cadherin, cytokeratin-18 and ER stress marker.	honokiol	0-8	cadherin 1	Mus musculus	71-81
23828905-4	2013	Honokiol-treated tumors showed increased epithelial signatures such as E-cadherin, cytokeratin-18 and ER stress marker.	honokiol	0-8	keratin 18	Mus musculus	83-97
23828905-6	2013	TGFbeta1 and MNNG-induced downregulation of E-cadherin and upregulation of Tpl2 were abrogated by Honokiol treatment.	honokiol	98-106	transforming growth factor, beta 1	Mus musculus	0-8
23828905-6	2013	TGFbeta1 and MNNG-induced downregulation of E-cadherin and upregulation of Tpl2 were abrogated by Honokiol treatment.	honokiol	98-106	cadherin 1	Mus musculus	44-54
23828905-6	2013	TGFbeta1 and MNNG-induced downregulation of E-cadherin and upregulation of Tpl2 were abrogated by Honokiol treatment.	honokiol	98-106	mitogen-activated protein kinase kinase kinase 8	Mus musculus	75-79
23828905-10	2013	Taken together, our results suggest that the therapeutic inhibition of Tpl2 by Honokiol thwarts both gastric tumor growth and peritoneal dissemination by inducing ER stress and inhibiting EMT.	honokiol	79-87	mitogen-activated protein kinase kinase kinase 8	Mus musculus	71-75
24179537-7	2013	At a dose of 50 muM, honokiol markedly decreased the expression of Rb protein and led to the cleavage of poly(ADP-ribose) polymerase and Bcl-xL to promote apoptosis in the cancer cells.	honokiol	21-29	latexin	Homo sapiens	16-19
24179537-7	2013	At a dose of 50 muM, honokiol markedly decreased the expression of Rb protein and led to the cleavage of poly(ADP-ribose) polymerase and Bcl-xL to promote apoptosis in the cancer cells.	honokiol	21-29	poly(ADP-ribose) polymerase 1	Homo sapiens	105-132
24179537-7	2013	At a dose of 50 muM, honokiol markedly decreased the expression of Rb protein and led to the cleavage of poly(ADP-ribose) polymerase and Bcl-xL to promote apoptosis in the cancer cells.	honokiol	21-29	BCL2 like 1	Homo sapiens	137-143
23877711-0	2013	Anti-proliferative effect of honokiol in oral squamous cancer through the regulation of specificity protein 1.	honokiol	29-37	Sp1 transcription factor	Homo sapiens	88-109
23811337-0	2013	Honokiol: a non-adipogenic PPARgamma agonist from nature.	honokiol	0-8	peroxisome proliferator activated receptor gamma	Mus musculus	27-36
23811337-4	2013	RESULTS: The natural product honokiol from the traditional Chinese herbal drug Magnolia bark was in silico predicted to bind into the PPARgamma ligand binding pocket as dimer.	honokiol	29-37	peroxisome proliferator activated receptor gamma	Mus musculus	134-143
23811337-5	2013	Honokiol indeed directly bound to purified PPARgamma ligand-binding domain (LBD) and acted as partial agonist in a PPARgamma-mediated luciferase reporter assay.	honokiol	0-8	peroxisome proliferator activated receptor gamma	Mus musculus	43-52
23811337-5	2013	Honokiol indeed directly bound to purified PPARgamma ligand-binding domain (LBD) and acted as partial agonist in a PPARgamma-mediated luciferase reporter assay.	honokiol	0-8	peroxisome proliferator activated receptor gamma	Mus musculus	115-124
23811337-9	2013	CONCLUSION: We identified honokiol as a partial non-adipogenic PPARgamma agonist in vitro which prevented hyperglycemia and weight gain in vivo.	honokiol	26-34	peroxisome proliferator activated receptor gamma	Mus musculus	63-72
23651094-3	2013	Honokiol and its analogs target multiple signaling pathways including NF-kappaB, STAT3, EGFR, mTOR and caspase-mediated common pathway, which regulate cancer initiation and progression.	honokiol	0-8	signal transducer and activator of transcription 3	Homo sapiens	81-86
23752066-3	2013	Here, we show that the natural product honokiol significantly inhibited CsA-induced and Ras-mediated survival of renal cancer cells through the down-regulations of VEGF and HO-1.	honokiol	39-47	vascular endothelial growth factor A	Homo sapiens	164-168
23921228-9	2013	Since honokiol suppresses multiple pathways activated by HIF, in addition to the VEGF signaling, it may provide advantages over current treatments utilizing specific VEGF antagonists for ocular neovascular diseases and cancers.	honokiol	6-14	vascular endothelial growth factor A	Mus musculus	166-170
24005963-4	2013	Honokiol also moderately inhibited CYP2B6-mediated bupropion hydroxylation and CYP2D6-mediated bufuralol 1"-hydroxylation with K(i) values of 17.5 and 12.0 muM, respectively.	honokiol	0-8	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	35-41
24005963-4	2013	Honokiol also moderately inhibited CYP2B6-mediated bupropion hydroxylation and CYP2D6-mediated bufuralol 1"-hydroxylation with K(i) values of 17.5 and 12.0 muM, respectively.	honokiol	0-8	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	79-85
24005963-4	2013	Honokiol also moderately inhibited CYP2B6-mediated bupropion hydroxylation and CYP2D6-mediated bufuralol 1"-hydroxylation with K(i) values of 17.5 and 12.0 muM, respectively.	honokiol	0-8	latexin	Homo sapiens	156-159
24005963-5	2013	These in vitro results indicate that honokiol has the potential to cause pharmacokinetic drug interactions with other co-administered drugs metabolized by CYP1A2, CYP2C8, CYP2C9, CYP2C19, and UGT1A9.	honokiol	37-45	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	155-161
24005963-5	2013	These in vitro results indicate that honokiol has the potential to cause pharmacokinetic drug interactions with other co-administered drugs metabolized by CYP1A2, CYP2C8, CYP2C9, CYP2C19, and UGT1A9.	honokiol	37-45	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	163-169
24005963-5	2013	These in vitro results indicate that honokiol has the potential to cause pharmacokinetic drug interactions with other co-administered drugs metabolized by CYP1A2, CYP2C8, CYP2C9, CYP2C19, and UGT1A9.	honokiol	37-45	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	171-177
24005963-5	2013	These in vitro results indicate that honokiol has the potential to cause pharmacokinetic drug interactions with other co-administered drugs metabolized by CYP1A2, CYP2C8, CYP2C9, CYP2C19, and UGT1A9.	honokiol	37-45	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	179-186
24005963-5	2013	These in vitro results indicate that honokiol has the potential to cause pharmacokinetic drug interactions with other co-administered drugs metabolized by CYP1A2, CYP2C8, CYP2C9, CYP2C19, and UGT1A9.	honokiol	37-45	UDP glucuronosyltransferase family 1 member A9	Homo sapiens	192-198
23786838-8	2013	Oxaliplatin combined with honokiol improved the apoptosis rate of HT-29 cell and reduced PGE2 and VEGF secretion levels.	honokiol	26-34	vascular endothelial growth factor A	Homo sapiens	98-102
23786838-10	2013	Caspase-3 levels were upregulated after honokiol treatment.	honokiol	40-48	caspase 3	Homo sapiens	0-9
23454146-6	2013	The neuroprotective effects of obovatol and honokiol were attributable to the inhibition of intracellular reactive oxygen species production, followed by protection of the mitochondrial membrane potential (DeltaPsim), recovery of Bcl-2 and Bid levels, inhibition of apoptosis-inducing factor expression, and phosphorylation of mitogen-activated protein kinases such as p38 kinases, extracellular signal-regulated kinases, and c-Jun N-terminal kinases.	honokiol	44-52	B cell leukemia/lymphoma 2	Mus musculus	230-235
23454146-6	2013	The neuroprotective effects of obovatol and honokiol were attributable to the inhibition of intracellular reactive oxygen species production, followed by protection of the mitochondrial membrane potential (DeltaPsim), recovery of Bcl-2 and Bid levels, inhibition of apoptosis-inducing factor expression, and phosphorylation of mitogen-activated protein kinases such as p38 kinases, extracellular signal-regulated kinases, and c-Jun N-terminal kinases.	honokiol	44-52	BH3 interacting domain death agonist	Mus musculus	240-243
23454146-6	2013	The neuroprotective effects of obovatol and honokiol were attributable to the inhibition of intracellular reactive oxygen species production, followed by protection of the mitochondrial membrane potential (DeltaPsim), recovery of Bcl-2 and Bid levels, inhibition of apoptosis-inducing factor expression, and phosphorylation of mitogen-activated protein kinases such as p38 kinases, extracellular signal-regulated kinases, and c-Jun N-terminal kinases.	honokiol	44-52	mitogen-activated protein kinase 14	Mus musculus	369-372
23454146-6	2013	The neuroprotective effects of obovatol and honokiol were attributable to the inhibition of intracellular reactive oxygen species production, followed by protection of the mitochondrial membrane potential (DeltaPsim), recovery of Bcl-2 and Bid levels, inhibition of apoptosis-inducing factor expression, and phosphorylation of mitogen-activated protein kinases such as p38 kinases, extracellular signal-regulated kinases, and c-Jun N-terminal kinases.	honokiol	44-52	jun proto-oncogene	Mus musculus	426-431
23651094-3	2013	Honokiol and its analogs target multiple signaling pathways including NF-kappaB, STAT3, EGFR, mTOR and caspase-mediated common pathway, which regulate cancer initiation and progression.	honokiol	0-8	epidermal growth factor receptor	Homo sapiens	88-92
23651094-3	2013	Honokiol and its analogs target multiple signaling pathways including NF-kappaB, STAT3, EGFR, mTOR and caspase-mediated common pathway, which regulate cancer initiation and progression.	honokiol	0-8	mechanistic target of rapamycin kinase	Homo sapiens	94-98
23525116-0	2013	Cyclophilin D modulates cell death transition from early apoptosis to programmed necrosis induced by honokiol.	honokiol	101-109	peptidylprolyl isomerase F	Homo sapiens	0-13
23525116-8	2013	These data indicated that honokiol-induced programmed necrosis and death mode transition are potentially RIP3-dependent, cyclophilin D-regulated.	honokiol	26-34	receptor interacting serine/threonine kinase 3	Homo sapiens	105-109
23525116-8	2013	These data indicated that honokiol-induced programmed necrosis and death mode transition are potentially RIP3-dependent, cyclophilin D-regulated.	honokiol	26-34	peptidylprolyl isomerase F	Homo sapiens	121-134
23525116-11	2013	In conclusion, honokiol triggers a potential RIP3-dependent cell death mode transition from early-stage apoptosis to programmed necrosis, which is highly regulated by cyclophilin D.	honokiol	15-23	receptor interacting serine/threonine kinase 3	Homo sapiens	45-49
23525116-11	2013	In conclusion, honokiol triggers a potential RIP3-dependent cell death mode transition from early-stage apoptosis to programmed necrosis, which is highly regulated by cyclophilin D.	honokiol	15-23	peptidylprolyl isomerase F	Homo sapiens	167-180
23242346-8	2013	Co-incubation with honokiol and etoposide (VP-16) activated a complex death modality, which was composed of necrotic cell death and apoptosis.	honokiol	19-27	host cell factor C1	Homo sapiens	43-48
23580348-0	2013	Honokiol inhibits non-small cell lung cancer cell migration by targeting PGE2-mediated activation of beta-catenin signaling.	honokiol	0-8	catenin beta 1	Homo sapiens	101-113
23580348-3	2013	Using an in vitro cell migration assay, we found that treatment of A549, H1299, H460 and H226 NSCLC cells with honokiol resulted in inhibition of migration of these cells in a dose-dependent manner, which was associated with a reduction in the levels of cyclooxygenase-2 (COX-2) and prostaglandin E2 (PGE2).	honokiol	111-119	prostaglandin-endoperoxide synthase 2	Homo sapiens	254-270
23580348-3	2013	Using an in vitro cell migration assay, we found that treatment of A549, H1299, H460 and H226 NSCLC cells with honokiol resulted in inhibition of migration of these cells in a dose-dependent manner, which was associated with a reduction in the levels of cyclooxygenase-2 (COX-2) and prostaglandin E2 (PGE2).	honokiol	111-119	prostaglandin-endoperoxide synthase 2	Homo sapiens	272-277
23580348-5	2013	Honokiol inhibited PGE2-enhanced migration of NSCLC cells, inhibited the activation of NF-kappaB/p65, an upstream regulator of COX-2, in A549 and H1299 cells, and treatment of cells with caffeic acid phenethyl ester, an inhibitor of NF-kappaB, also inhibited migration of NSCLC cells.	honokiol	0-8	nuclear factor kappa B subunit 1	Homo sapiens	87-96
23580348-5	2013	Honokiol inhibited PGE2-enhanced migration of NSCLC cells, inhibited the activation of NF-kappaB/p65, an upstream regulator of COX-2, in A549 and H1299 cells, and treatment of cells with caffeic acid phenethyl ester, an inhibitor of NF-kappaB, also inhibited migration of NSCLC cells.	honokiol	0-8	RELA proto-oncogene, NF-kB subunit	Homo sapiens	97-100
23580348-5	2013	Honokiol inhibited PGE2-enhanced migration of NSCLC cells, inhibited the activation of NF-kappaB/p65, an upstream regulator of COX-2, in A549 and H1299 cells, and treatment of cells with caffeic acid phenethyl ester, an inhibitor of NF-kappaB, also inhibited migration of NSCLC cells.	honokiol	0-8	prostaglandin-endoperoxide synthase 2	Homo sapiens	127-132
23580348-5	2013	Honokiol inhibited PGE2-enhanced migration of NSCLC cells, inhibited the activation of NF-kappaB/p65, an upstream regulator of COX-2, in A549 and H1299 cells, and treatment of cells with caffeic acid phenethyl ester, an inhibitor of NF-kappaB, also inhibited migration of NSCLC cells.	honokiol	0-8	nuclear factor kappa B subunit 1	Homo sapiens	233-242
23580348-7	2013	Therefore, we checked the effect of honokiol on beta-catenin signaling.	honokiol	36-44	catenin beta 1	Homo sapiens	48-60
23580348-8	2013	It was observed that treatment of NSCLC cells with honokiol degraded cytosolic beta-catenin, reduced nuclear accumulation of beta-catenin and down-regulated matrix metalloproteinase (MMP)-2 and MMP-9, which are the down-stream targets of beta-catenin and play a crucial role in cancer cell metastasis.	honokiol	51-59	catenin beta 1	Homo sapiens	79-91
23580348-8	2013	It was observed that treatment of NSCLC cells with honokiol degraded cytosolic beta-catenin, reduced nuclear accumulation of beta-catenin and down-regulated matrix metalloproteinase (MMP)-2 and MMP-9, which are the down-stream targets of beta-catenin and play a crucial role in cancer cell metastasis.	honokiol	51-59	catenin beta 1	Homo sapiens	125-137
23580348-8	2013	It was observed that treatment of NSCLC cells with honokiol degraded cytosolic beta-catenin, reduced nuclear accumulation of beta-catenin and down-regulated matrix metalloproteinase (MMP)-2 and MMP-9, which are the down-stream targets of beta-catenin and play a crucial role in cancer cell metastasis.	honokiol	51-59	matrix metallopeptidase 2	Homo sapiens	157-189
23580348-8	2013	It was observed that treatment of NSCLC cells with honokiol degraded cytosolic beta-catenin, reduced nuclear accumulation of beta-catenin and down-regulated matrix metalloproteinase (MMP)-2 and MMP-9, which are the down-stream targets of beta-catenin and play a crucial role in cancer cell metastasis.	honokiol	51-59	matrix metallopeptidase 9	Homo sapiens	194-199
23580348-8	2013	It was observed that treatment of NSCLC cells with honokiol degraded cytosolic beta-catenin, reduced nuclear accumulation of beta-catenin and down-regulated matrix metalloproteinase (MMP)-2 and MMP-9, which are the down-stream targets of beta-catenin and play a crucial role in cancer cell metastasis.	honokiol	51-59	catenin beta 1	Homo sapiens	125-137
23580348-9	2013	Honokiol enhanced: (i) the levels of casein kinase-1alpha, glycogen synthase kinase-3beta, and (ii) phosphorylation of beta-catenin on critical residues Ser(45), Ser(33/37) and Thr(41).	honokiol	0-8	glycogen synthase kinase 3 beta	Homo sapiens	59-89
23580348-9	2013	Honokiol enhanced: (i) the levels of casein kinase-1alpha, glycogen synthase kinase-3beta, and (ii) phosphorylation of beta-catenin on critical residues Ser(45), Ser(33/37) and Thr(41).	honokiol	0-8	catenin beta 1	Homo sapiens	119-131
23580348-13	2013	These results indicate that honokiol inhibits non-small cell lung cancer cells migration by targeting PGE2-mediated activation of beta-catenin signaling.	honokiol	28-36	catenin beta 1	Homo sapiens	130-142
23262090-3	2013	Honokiol (0.1-10muM) significantly reduced the p65 subunit level of NF-kappaB in the nucleus of primary culture-microglia.	honokiol	0-8	v-rel reticuloendotheliosis viral oncogene homolog A (avian)	Mus musculus	47-50
23262090-5	2013	Honokiol (0.01-10muM) significantly decreased the level of TNF-alpha in the microglia medium or coculture cell medium.	honokiol	0-8	tumor necrosis factor	Mus musculus	59-68
23262090-6	2013	Honokiol (10muM) decreased the level of Regulated upon Activation Normal T-cell Expressed and Secreted (RANTES/CCL5) protein in medium of microglia or astrocytes.	honokiol	0-8	chemokine (C-C motif) ligand 5	Mus musculus	104-110
23262090-6	2013	Honokiol (10muM) decreased the level of Regulated upon Activation Normal T-cell Expressed and Secreted (RANTES/CCL5) protein in medium of microglia or astrocytes.	honokiol	0-8	chemokine (C-C motif) ligand 5	Mus musculus	111-115
23262090-7	2013	In conclusion, Honokiol has a potent anti-inflammatory effect in cerebral ischemia-reperfusion mice and this effect might be attributed to its inhibition ability on the NF-kappaB activation, consequently blocking the production of inflammatory factors including: NO, tumor necrosis factor-alpha (TNF-alpha) and RANTES/CCL5 in glial cells.	honokiol	15-23	tumor necrosis factor	Mus musculus	267-294
23262090-7	2013	In conclusion, Honokiol has a potent anti-inflammatory effect in cerebral ischemia-reperfusion mice and this effect might be attributed to its inhibition ability on the NF-kappaB activation, consequently blocking the production of inflammatory factors including: NO, tumor necrosis factor-alpha (TNF-alpha) and RANTES/CCL5 in glial cells.	honokiol	15-23	tumor necrosis factor	Mus musculus	296-305
23262090-7	2013	In conclusion, Honokiol has a potent anti-inflammatory effect in cerebral ischemia-reperfusion mice and this effect might be attributed to its inhibition ability on the NF-kappaB activation, consequently blocking the production of inflammatory factors including: NO, tumor necrosis factor-alpha (TNF-alpha) and RANTES/CCL5 in glial cells.	honokiol	15-23	chemokine (C-C motif) ligand 5	Mus musculus	311-317
23262090-7	2013	In conclusion, Honokiol has a potent anti-inflammatory effect in cerebral ischemia-reperfusion mice and this effect might be attributed to its inhibition ability on the NF-kappaB activation, consequently blocking the production of inflammatory factors including: NO, tumor necrosis factor-alpha (TNF-alpha) and RANTES/CCL5 in glial cells.	honokiol	15-23	chemokine (C-C motif) ligand 5	Mus musculus	318-322
23242346-10	2013	Western blot analysis results proved that honokiol also enhanced VP-16-induced apoptosis potentially via blocking nuclear factor-kappaB (NF-kappaB) activation.	honokiol	42-50	host cell factor C1	Homo sapiens	65-70
23401389-9	2013	Results showed that the retention fractions were honokiol and magnolol and the inhibition rate on MDA-MB-231 cell growth were 23 and 64 muM, respectively.	honokiol	49-57	latexin	Homo sapiens	136-139
23148950-0	2013	Honokiol protects brain against ischemia-reperfusion injury in rats through disrupting PSD95-nNOS interaction.	honokiol	0-8	discs large MAGUK scaffold protein 4	Rattus norvegicus	87-92
23148950-0	2013	Honokiol protects brain against ischemia-reperfusion injury in rats through disrupting PSD95-nNOS interaction.	honokiol	0-8	nitric oxide synthase 1	Rattus norvegicus	93-97
23148950-5	2013	In co-immunoprecipitation and western blot test, honokiol decreased the intensity of nNOS related to PSD95 but failed to affect that of PSD95 related to NR2B in NR2B-PSD95-nNOS complex, and it also inhibited the translocation of nNOS from cytosol to membrane without affecting total nNOS expression, and then markedly decreased NO production in cortical neurons.	honokiol	49-57	nitric oxide synthase 1	Rattus norvegicus	85-89
23148950-5	2013	In co-immunoprecipitation and western blot test, honokiol decreased the intensity of nNOS related to PSD95 but failed to affect that of PSD95 related to NR2B in NR2B-PSD95-nNOS complex, and it also inhibited the translocation of nNOS from cytosol to membrane without affecting total nNOS expression, and then markedly decreased NO production in cortical neurons.	honokiol	49-57	discs large MAGUK scaffold protein 4	Rattus norvegicus	101-106
23148950-5	2013	In co-immunoprecipitation and western blot test, honokiol decreased the intensity of nNOS related to PSD95 but failed to affect that of PSD95 related to NR2B in NR2B-PSD95-nNOS complex, and it also inhibited the translocation of nNOS from cytosol to membrane without affecting total nNOS expression, and then markedly decreased NO production in cortical neurons.	honokiol	49-57	nitric oxide synthase 1	Rattus norvegicus	172-176
23148950-5	2013	In co-immunoprecipitation and western blot test, honokiol decreased the intensity of nNOS related to PSD95 but failed to affect that of PSD95 related to NR2B in NR2B-PSD95-nNOS complex, and it also inhibited the translocation of nNOS from cytosol to membrane without affecting total nNOS expression, and then markedly decreased NO production in cortical neurons.	honokiol	49-57	nitric oxide synthase 1	Rattus norvegicus	172-176
23148950-5	2013	In co-immunoprecipitation and western blot test, honokiol decreased the intensity of nNOS related to PSD95 but failed to affect that of PSD95 related to NR2B in NR2B-PSD95-nNOS complex, and it also inhibited the translocation of nNOS from cytosol to membrane without affecting total nNOS expression, and then markedly decreased NO production in cortical neurons.	honokiol	49-57	nitric oxide synthase 1	Rattus norvegicus	172-176
23148950-7	2013	In conclusion, honokiol has a therapeutic window of at least 5h after the onset of cerebral ischemia or 3h after reperfusion in rats, which may be in part ascribed to the disruption of the PSD95-nNOS interaction leading to the inhibition of neurotoxic NO production.	honokiol	15-23	discs large MAGUK scaffold protein 4	Rattus norvegicus	189-194
23148950-7	2013	In conclusion, honokiol has a therapeutic window of at least 5h after the onset of cerebral ischemia or 3h after reperfusion in rats, which may be in part ascribed to the disruption of the PSD95-nNOS interaction leading to the inhibition of neurotoxic NO production.	honokiol	15-23	nitric oxide synthase 1	Rattus norvegicus	195-199
23221619-7	2013	Treatment of A549 and H1299 cells with honokiol resulted in an increase in G 1 phase arrest, and a decrease in the levels of cyclin D1, D2 and cyclin dependent kinases.	honokiol	39-47	cyclin D1	Homo sapiens	125-134
23251290-8	2013	The malondialdehyde (MDA) level, myeloperoxidase (MPO) activity, concentrations of tumor necrosis factor (TNF)-alpha and interleukin (IL)-6 and expression level of NF-kappaB were all reduced by honokiol pretreatment, while honokiol inhibited the decreases in superoxide dismutase (SOD) and catalase (CAT) activities.	honokiol	194-202	tumor necrosis factor	Rattus norvegicus	83-116
23251290-8	2013	The malondialdehyde (MDA) level, myeloperoxidase (MPO) activity, concentrations of tumor necrosis factor (TNF)-alpha and interleukin (IL)-6 and expression level of NF-kappaB were all reduced by honokiol pretreatment, while honokiol inhibited the decreases in superoxide dismutase (SOD) and catalase (CAT) activities.	honokiol	194-202	interleukin 6	Rattus norvegicus	121-139
23662112-0	2013	Honokiol Eliminates Human Oral Cancer Stem-Like Cells Accompanied with Suppression of Wnt/ beta -Catenin Signaling and Apoptosis Induction.	honokiol	0-8	catenin beta 1	Homo sapiens	91-104
23662112-5	2013	Apoptosis of honokiol-treated SP cells was evidenced by increased annexin V staining and cleaved caspase-3 as well as decreased Survivin and Bcl-2.	honokiol	13-21	annexin A5	Homo sapiens	66-75
23662112-5	2013	Apoptosis of honokiol-treated SP cells was evidenced by increased annexin V staining and cleaved caspase-3 as well as decreased Survivin and Bcl-2.	honokiol	13-21	BCL2 apoptosis regulator	Homo sapiens	141-146
23662112-6	2013	Mechanistically, honokiol inhibited the CD44 and Wnt/ beta -catenin signaling of SP cells.	honokiol	17-25	CD44 molecule (Indian blood group)	Homo sapiens	40-44
23662112-6	2013	Mechanistically, honokiol inhibited the CD44 and Wnt/ beta -catenin signaling of SP cells.	honokiol	17-25	catenin beta 1	Homo sapiens	54-67
23662112-7	2013	The Wnt signaling transducers such as beta -catenin and TCF-4 were decreased in honokiol-treated SP cells, while the beta -catenin degradation promoting kinase GSK-3 alpha / beta was increased.	honokiol	80-88	catenin beta 1	Homo sapiens	38-51
23662112-7	2013	The Wnt signaling transducers such as beta -catenin and TCF-4 were decreased in honokiol-treated SP cells, while the beta -catenin degradation promoting kinase GSK-3 alpha / beta was increased.	honokiol	80-88	transcription factor 4	Homo sapiens	56-61
23662112-9	2013	Furthermore, the beta -catenin-related EMT markers such as Slug and Snail were markedly suppressed by honokiol.	honokiol	102-110	catenin beta 1	Homo sapiens	17-30
23662112-9	2013	Furthermore, the beta -catenin-related EMT markers such as Slug and Snail were markedly suppressed by honokiol.	honokiol	102-110	IL2 inducible T cell kinase	Homo sapiens	39-42
23662112-9	2013	Furthermore, the beta -catenin-related EMT markers such as Slug and Snail were markedly suppressed by honokiol.	honokiol	102-110	snail family transcriptional repressor 2	Homo sapiens	59-63
23662112-9	2013	Furthermore, the beta -catenin-related EMT markers such as Slug and Snail were markedly suppressed by honokiol.	honokiol	102-110	snail family transcriptional repressor 1	Homo sapiens	68-73
23662112-10	2013	Our findings indicate honokiol may be able to eliminate oral cancer stem cells through apoptosis induction, suppression of Wnt/ beta -catenin signaling, and inhibition of EMT.	honokiol	22-30	catenin beta 1	Homo sapiens	128-141
23662112-10	2013	Our findings indicate honokiol may be able to eliminate oral cancer stem cells through apoptosis induction, suppression of Wnt/ beta -catenin signaling, and inhibition of EMT.	honokiol	22-30	IL2 inducible T cell kinase	Homo sapiens	171-174
23231930-10	2012	Honokiol also decreased phosphorylation of AKT (known as protein kinase B) and mammalian target of rapamycin, and inhibited gamma-secretase activity by down-regulating the expression of gamma-secretase complex proteins, especially anterior pharynx-defective 1.	honokiol	0-8	AKT serine/threonine kinase 1	Homo sapiens	43-46
23231930-10	2012	Honokiol also decreased phosphorylation of AKT (known as protein kinase B) and mammalian target of rapamycin, and inhibited gamma-secretase activity by down-regulating the expression of gamma-secretase complex proteins, especially anterior pharynx-defective 1.	honokiol	0-8	protein tyrosine kinase 2 beta	Homo sapiens	57-73
23231930-10	2012	Honokiol also decreased phosphorylation of AKT (known as protein kinase B) and mammalian target of rapamycin, and inhibited gamma-secretase activity by down-regulating the expression of gamma-secretase complex proteins, especially anterior pharynx-defective 1.	honokiol	0-8	mechanistic target of rapamycin kinase	Homo sapiens	79-108
23231930-11	2012	CONCLUSIONS: Honokiol is highly effective in inhibiting melanoma cancer cells by attenuating AKT/mammalian target of rapamycin and Notch signaling.	honokiol	13-21	AKT serine/threonine kinase 1	Homo sapiens	93-96
23231930-11	2012	CONCLUSIONS: Honokiol is highly effective in inhibiting melanoma cancer cells by attenuating AKT/mammalian target of rapamycin and Notch signaling.	honokiol	13-21	mechanistic target of rapamycin kinase	Homo sapiens	97-126
22537192-8	2012	The effects of honokiol were measured by EEG and electromyogram (EMG), c-Fos expression and in vitro electrophysiology.	honokiol	15-23	FBJ osteosarcoma oncogene	Mus musculus	71-76
22834827-3	2012	Honokiol targets multiple signaling pathways including nuclear factor kappa B (NF-kappaB), signal transducers and activator of transcription 3 (STAT3), epidermal growth factor receptor (EGFR) and mammalian target of rapamycin (m-TOR), which have great relevance during cancer initiation and progression.	honokiol	0-8	nuclear factor kappa B subunit 1	Homo sapiens	55-77
22834827-3	2012	Honokiol targets multiple signaling pathways including nuclear factor kappa B (NF-kappaB), signal transducers and activator of transcription 3 (STAT3), epidermal growth factor receptor (EGFR) and mammalian target of rapamycin (m-TOR), which have great relevance during cancer initiation and progression.	honokiol	0-8	nuclear factor kappa B subunit 1	Homo sapiens	79-88
22834827-3	2012	Honokiol targets multiple signaling pathways including nuclear factor kappa B (NF-kappaB), signal transducers and activator of transcription 3 (STAT3), epidermal growth factor receptor (EGFR) and mammalian target of rapamycin (m-TOR), which have great relevance during cancer initiation and progression.	honokiol	0-8	signal transducer and activator of transcription 3	Homo sapiens	91-142
22834827-3	2012	Honokiol targets multiple signaling pathways including nuclear factor kappa B (NF-kappaB), signal transducers and activator of transcription 3 (STAT3), epidermal growth factor receptor (EGFR) and mammalian target of rapamycin (m-TOR), which have great relevance during cancer initiation and progression.	honokiol	0-8	signal transducer and activator of transcription 3	Homo sapiens	144-149
22834827-3	2012	Honokiol targets multiple signaling pathways including nuclear factor kappa B (NF-kappaB), signal transducers and activator of transcription 3 (STAT3), epidermal growth factor receptor (EGFR) and mammalian target of rapamycin (m-TOR), which have great relevance during cancer initiation and progression.	honokiol	0-8	epidermal growth factor receptor	Homo sapiens	152-184
22834827-3	2012	Honokiol targets multiple signaling pathways including nuclear factor kappa B (NF-kappaB), signal transducers and activator of transcription 3 (STAT3), epidermal growth factor receptor (EGFR) and mammalian target of rapamycin (m-TOR), which have great relevance during cancer initiation and progression.	honokiol	0-8	epidermal growth factor receptor	Homo sapiens	186-190
22834827-3	2012	Honokiol targets multiple signaling pathways including nuclear factor kappa B (NF-kappaB), signal transducers and activator of transcription 3 (STAT3), epidermal growth factor receptor (EGFR) and mammalian target of rapamycin (m-TOR), which have great relevance during cancer initiation and progression.	honokiol	0-8	mechanistic target of rapamycin kinase	Homo sapiens	196-225
22834827-3	2012	Honokiol targets multiple signaling pathways including nuclear factor kappa B (NF-kappaB), signal transducers and activator of transcription 3 (STAT3), epidermal growth factor receptor (EGFR) and mammalian target of rapamycin (m-TOR), which have great relevance during cancer initiation and progression.	honokiol	0-8	RAR related orphan receptor C	Homo sapiens	229-232
23160676-0	2012	Comparative inhibitory effects of magnolol, honokiol, eugenol and bis-eugenol on cyclooxygenase-2 expression and nuclear factor-kappa B activation in RAW264.7 macrophage-like cells stimulated with fimbriae of Porphyromonas gingivalis.	honokiol	44-52	prostaglandin-endoperoxide synthase 2	Mus musculus	81-97
23160676-9	2012	Magnolol and honokiol significantly inhibited the fimbria-induced expression of COX-2 at non-cytotoxic concentrations.	honokiol	13-21	cytochrome c oxidase II, mitochondrial	Mus musculus	80-85
23160676-10	2012	Both the fimbria-stimulated binding of NF-kappaB to its consensus sequence and phosphorylation-dependent proteolysis of inhibitor kappaB-alpha were markedly inhibited by magnilol and honokiol, whereas eugenol and bis-eugenol did not inhibit COX-2 expression and NF-kappaB activation.	honokiol	183-191	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	39-48
23160676-10	2012	Both the fimbria-stimulated binding of NF-kappaB to its consensus sequence and phosphorylation-dependent proteolysis of inhibitor kappaB-alpha were markedly inhibited by magnilol and honokiol, whereas eugenol and bis-eugenol did not inhibit COX-2 expression and NF-kappaB activation.	honokiol	183-191	cytochrome c oxidase II, mitochondrial	Mus musculus	241-246
23160676-10	2012	Both the fimbria-stimulated binding of NF-kappaB to its consensus sequence and phosphorylation-dependent proteolysis of inhibitor kappaB-alpha were markedly inhibited by magnilol and honokiol, whereas eugenol and bis-eugenol did not inhibit COX-2 expression and NF-kappaB activation.	honokiol	183-191	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	262-271
23060571-0	2012	Modulation of P-glycoprotein expression by honokiol, magnolol and 4-O-methylhonokiol, the bioactive components of Magnolia officinalis.	honokiol	43-51	ATP binding cassette subfamily B member 1	Homo sapiens	14-28
23060571-1	2012	AIM: This study aimed to evaluate the effect of honokiol and its structural analogs on the functional activity and gene expression of P-glycoprotein (P-gp) in order to identify effective P-gp inhibitors from natural products which have additional health-promoting effects.	honokiol	48-56	ATP binding cassette subfamily B member 1	Homo sapiens	134-148
23060571-1	2012	AIM: This study aimed to evaluate the effect of honokiol and its structural analogs on the functional activity and gene expression of P-glycoprotein (P-gp) in order to identify effective P-gp inhibitors from natural products which have additional health-promoting effects.	honokiol	48-56	ATP binding cassette subfamily B member 1	Homo sapiens	150-154
23060571-1	2012	AIM: This study aimed to evaluate the effect of honokiol and its structural analogs on the functional activity and gene expression of P-glycoprotein (P-gp) in order to identify effective P-gp inhibitors from natural products which have additional health-promoting effects.	honokiol	48-56	ATP binding cassette subfamily B member 1	Homo sapiens	187-191
23060571-2	2012	MATERIALS AND METHODS: The interaction characteristics of honokiol, magnolol and 4-O-methylhonokiol with P-gp were determined in NCI/ADR-RES cells overexpressing P-gp.	honokiol	58-66	ATP binding cassette subfamily B member 1	Homo sapiens	105-109
23060571-6	2012	CONCLUSION: The present study suggests that honokiol, magnolol and 4-O-methylhonokiol could be promising agents for reducing the multidrug resistance of cancer cells to anticancer drugs via the down-regulation of P-gp expression.	honokiol	44-52	ATP binding cassette subfamily B member 1	Homo sapiens	213-217
22537192-12	2012	Honokiol increased c-Fos expression in ventrolateral preoptic area (VLPO) neurons, as examined by immunostaining, and excited sleep-promoting neurons in the VLPO by whole-cell patch clamping in the brain slice.	honokiol	0-8	FBJ osteosarcoma oncogene	Mus musculus	19-24
22895699-3	2012	Thus, we investigated the effects of honokiol on the expression of adhesion molecules in TNF-alpha-stimulated endothelial cells, and cancer growth and invasion were determined in T98G human glioblastoma cells.	honokiol	37-45	tumor necrosis factor	Homo sapiens	89-98
22895699-4	2012	Honokiol dose-dependently inhibited the expression of intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1) in human umbilical vein endothelial cells (HUVECs) stimulated with TNF-alpha for 6 h. Pretreatment with honokiol significantly reduced the adhesion of T98G cells to HUVECs.	honokiol	0-8	intercellular adhesion molecule 1	Homo sapiens	54-87
22895699-4	2012	Honokiol dose-dependently inhibited the expression of intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1) in human umbilical vein endothelial cells (HUVECs) stimulated with TNF-alpha for 6 h. Pretreatment with honokiol significantly reduced the adhesion of T98G cells to HUVECs.	honokiol	0-8	intercellular adhesion molecule 1	Homo sapiens	89-95
22895699-4	2012	Honokiol dose-dependently inhibited the expression of intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1) in human umbilical vein endothelial cells (HUVECs) stimulated with TNF-alpha for 6 h. Pretreatment with honokiol significantly reduced the adhesion of T98G cells to HUVECs.	honokiol	0-8	vascular cell adhesion molecule 1	Homo sapiens	101-134
22895699-4	2012	Honokiol dose-dependently inhibited the expression of intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1) in human umbilical vein endothelial cells (HUVECs) stimulated with TNF-alpha for 6 h. Pretreatment with honokiol significantly reduced the adhesion of T98G cells to HUVECs.	honokiol	0-8	vascular cell adhesion molecule 1	Homo sapiens	136-142
22895699-4	2012	Honokiol dose-dependently inhibited the expression of intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1) in human umbilical vein endothelial cells (HUVECs) stimulated with TNF-alpha for 6 h. Pretreatment with honokiol significantly reduced the adhesion of T98G cells to HUVECs.	honokiol	0-8	tumor necrosis factor	Homo sapiens	211-220
22895699-4	2012	Honokiol dose-dependently inhibited the expression of intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1) in human umbilical vein endothelial cells (HUVECs) stimulated with TNF-alpha for 6 h. Pretreatment with honokiol significantly reduced the adhesion of T98G cells to HUVECs.	honokiol	248-256	vascular cell adhesion molecule 1	Homo sapiens	136-142
22465179-10	2012	Honokiol induced G1 cell cycle arrest by reducing the expression of cyclins D1, D2, E, CDK2, CDK4, CDK6 and c-Myc, while apoptosis was induced via reduced expression of cIAP-2, XIAP and survivin.	honokiol	0-8	iodothyronine deiodinase 2	Homo sapiens	68-85
22744336-0	2012	Targeting the intrinsic inflammatory pathway: honokiol exerts proapoptotic effects through STAT3 inhibition in transformed Barrett"s cells.	honokiol	46-54	signal transducer and activator of transcription 3	Homo sapiens	91-96
22744336-3	2012	In human tumors, honokiol (a polyphenol in herbal teas) has growth-inhibitory and proapoptotic effects associated with suppressed activation of STAT3.	honokiol	17-25	signal transducer and activator of transcription 3	Homo sapiens	144-149
22744336-6	2012	Cells were infected with constitutively active Stat3-C to assess effects of honokiol-induced STAT3 inhibition on apoptosis.	honokiol	76-84	signal transducer and activator of transcription 3	Homo sapiens	93-98
22744336-9	2012	Within 30 min of honokiol treatment, transformed Barrett"s cells decreased expression of phosphorylated STAT3; decreases in Ras activity and phosphorylated ERK1/2 expression were detected at 24 h. Infection with Stat3-C significantly reduced apoptosis after honokiol treatment.	honokiol	17-25	signal transducer and activator of transcription 3	Homo sapiens	104-109
22744336-9	2012	Within 30 min of honokiol treatment, transformed Barrett"s cells decreased expression of phosphorylated STAT3; decreases in Ras activity and phosphorylated ERK1/2 expression were detected at 24 h. Infection with Stat3-C significantly reduced apoptosis after honokiol treatment.	honokiol	17-25	mitogen-activated protein kinase 3	Homo sapiens	156-162
22744336-9	2012	Within 30 min of honokiol treatment, transformed Barrett"s cells decreased expression of phosphorylated STAT3; decreases in Ras activity and phosphorylated ERK1/2 expression were detected at 24 h. Infection with Stat3-C significantly reduced apoptosis after honokiol treatment.	honokiol	17-25	signal transducer and activator of transcription 3	Homo sapiens	212-217
22744336-9	2012	Within 30 min of honokiol treatment, transformed Barrett"s cells decreased expression of phosphorylated STAT3; decreases in Ras activity and phosphorylated ERK1/2 expression were detected at 24 h. Infection with Stat3-C significantly reduced apoptosis after honokiol treatment.	honokiol	258-266	signal transducer and activator of transcription 3	Homo sapiens	212-217
22744336-10	2012	Honokiol causes necrosis and apoptosis in transformed Barrett"s and esophageal adenocarcinoma cells, but not in nontransformed Barrett"s cells, and the proapoptotic effects of honokiol are mediated by its inhibition of STAT3 signaling.	honokiol	176-184	signal transducer and activator of transcription 3	Homo sapiens	219-224
22465179-10	2012	Honokiol induced G1 cell cycle arrest by reducing the expression of cyclins D1, D2, E, CDK2, CDK4, CDK6 and c-Myc, while apoptosis was induced via reduced expression of cIAP-2, XIAP and survivin.	honokiol	0-8	cyclin dependent kinase 2	Homo sapiens	87-91
22465179-10	2012	Honokiol induced G1 cell cycle arrest by reducing the expression of cyclins D1, D2, E, CDK2, CDK4, CDK6 and c-Myc, while apoptosis was induced via reduced expression of cIAP-2, XIAP and survivin.	honokiol	0-8	cyclin dependent kinase 4	Homo sapiens	93-97
22465179-10	2012	Honokiol induced G1 cell cycle arrest by reducing the expression of cyclins D1, D2, E, CDK2, CDK4, CDK6 and c-Myc, while apoptosis was induced via reduced expression of cIAP-2, XIAP and survivin.	honokiol	0-8	cyclin dependent kinase 6	Homo sapiens	99-103
22465179-10	2012	Honokiol induced G1 cell cycle arrest by reducing the expression of cyclins D1, D2, E, CDK2, CDK4, CDK6 and c-Myc, while apoptosis was induced via reduced expression of cIAP-2, XIAP and survivin.	honokiol	0-8	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	108-113
22465179-10	2012	Honokiol induced G1 cell cycle arrest by reducing the expression of cyclins D1, D2, E, CDK2, CDK4, CDK6 and c-Myc, while apoptosis was induced via reduced expression of cIAP-2, XIAP and survivin.	honokiol	0-8	baculoviral IAP repeat containing 3	Homo sapiens	169-175
22465179-10	2012	Honokiol induced G1 cell cycle arrest by reducing the expression of cyclins D1, D2, E, CDK2, CDK4, CDK6 and c-Myc, while apoptosis was induced via reduced expression of cIAP-2, XIAP and survivin.	honokiol	0-8	X-linked inhibitor of apoptosis	Homo sapiens	177-181
22465179-12	2012	In addition, honokiol suppressed the phosphorylation of IkappaBalpha, IKKalpha, IKKbeta, STAT3, STAT5 and Akt, down-regulated JunB and JunD, and inhibited DNA binding of NF-kappaB, AP-1, STAT3 and STAT5.	honokiol	13-21	NFKB inhibitor alpha	Homo sapiens	56-68
22465179-12	2012	In addition, honokiol suppressed the phosphorylation of IkappaBalpha, IKKalpha, IKKbeta, STAT3, STAT5 and Akt, down-regulated JunB and JunD, and inhibited DNA binding of NF-kappaB, AP-1, STAT3 and STAT5.	honokiol	13-21	component of inhibitor of nuclear factor kappa B kinase complex	Homo sapiens	70-78
22465179-12	2012	In addition, honokiol suppressed the phosphorylation of IkappaBalpha, IKKalpha, IKKbeta, STAT3, STAT5 and Akt, down-regulated JunB and JunD, and inhibited DNA binding of NF-kappaB, AP-1, STAT3 and STAT5.	honokiol	13-21	inhibitor of nuclear factor kappa B kinase subunit beta	Homo sapiens	80-87
22465179-12	2012	In addition, honokiol suppressed the phosphorylation of IkappaBalpha, IKKalpha, IKKbeta, STAT3, STAT5 and Akt, down-regulated JunB and JunD, and inhibited DNA binding of NF-kappaB, AP-1, STAT3 and STAT5.	honokiol	13-21	signal transducer and activator of transcription 3	Homo sapiens	89-94
22465179-12	2012	In addition, honokiol suppressed the phosphorylation of IkappaBalpha, IKKalpha, IKKbeta, STAT3, STAT5 and Akt, down-regulated JunB and JunD, and inhibited DNA binding of NF-kappaB, AP-1, STAT3 and STAT5.	honokiol	13-21	signal transducer and activator of transcription 5A	Homo sapiens	96-101
22465179-12	2012	In addition, honokiol suppressed the phosphorylation of IkappaBalpha, IKKalpha, IKKbeta, STAT3, STAT5 and Akt, down-regulated JunB and JunD, and inhibited DNA binding of NF-kappaB, AP-1, STAT3 and STAT5.	honokiol	13-21	AKT serine/threonine kinase 1	Homo sapiens	106-109
22465179-12	2012	In addition, honokiol suppressed the phosphorylation of IkappaBalpha, IKKalpha, IKKbeta, STAT3, STAT5 and Akt, down-regulated JunB and JunD, and inhibited DNA binding of NF-kappaB, AP-1, STAT3 and STAT5.	honokiol	13-21	JunB proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	126-130
22465179-12	2012	In addition, honokiol suppressed the phosphorylation of IkappaBalpha, IKKalpha, IKKbeta, STAT3, STAT5 and Akt, down-regulated JunB and JunD, and inhibited DNA binding of NF-kappaB, AP-1, STAT3 and STAT5.	honokiol	13-21	JunD proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	135-139
22465179-12	2012	In addition, honokiol suppressed the phosphorylation of IkappaBalpha, IKKalpha, IKKbeta, STAT3, STAT5 and Akt, down-regulated JunB and JunD, and inhibited DNA binding of NF-kappaB, AP-1, STAT3 and STAT5.	honokiol	13-21	signal transducer and activator of transcription 3	Homo sapiens	187-192
22465179-12	2012	In addition, honokiol suppressed the phosphorylation of IkappaBalpha, IKKalpha, IKKbeta, STAT3, STAT5 and Akt, down-regulated JunB and JunD, and inhibited DNA binding of NF-kappaB, AP-1, STAT3 and STAT5.	honokiol	13-21	signal transducer and activator of transcription 5A	Homo sapiens	197-202
22098176-8	2012	The expression levels of components of replication complex, NS3, NS5A and NS5B, were down-regulated by honokiol in a dose-dependent manner.	honokiol	103-111	KRAS proto-oncogene, GTPase	Homo sapiens	60-63
22258232-8	2012	Honokiol significantly reduced the increases in serum tumor necrosis factor-alpha, interleukin 1, and nitric oxide levels 3 h and serum high-mobility group box 1 24 h after acute pancreatitis induction.	honokiol	0-8	tumor necrosis factor	Mus musculus	54-81
21792937-0	2012	Honokiol inhibits signal transducer and activator of transcription-3 signaling, proliferation, and survival of hepatocellular carcinoma cells via the protein tyrosine phosphatase SHP-1.	honokiol	0-8	signal transducer and activator of transcription 3	Homo sapiens	18-68
21792937-0	2012	Honokiol inhibits signal transducer and activator of transcription-3 signaling, proliferation, and survival of hepatocellular carcinoma cells via the protein tyrosine phosphatase SHP-1.	honokiol	0-8	protein tyrosine phosphatase non-receptor type 6	Homo sapiens	179-184
21792937-2	2012	In the present report, we investigated whether honokiol mediates its effect through interference with the STAT3 activation pathway.	honokiol	47-55	signal transducer and activator of transcription 3	Homo sapiens	106-111
21792937-3	2012	The effect of honokiol on STAT3 activation, associated protein kinases, and phosphatase, STAT3-regulated gene products and apoptosis was investigated using both functional proteomics tumor pathway technology platform and different HCC cell lines.	honokiol	14-22	signal transducer and activator of transcription 3	Homo sapiens	26-31
21792937-3	2012	The effect of honokiol on STAT3 activation, associated protein kinases, and phosphatase, STAT3-regulated gene products and apoptosis was investigated using both functional proteomics tumor pathway technology platform and different HCC cell lines.	honokiol	14-22	signal transducer and activator of transcription 3	Homo sapiens	89-94
21792937-4	2012	We found that honokiol inhibited both constitutive and inducible STAT3 activation in a dose- and time-dependent manner in HCC cells.	honokiol	14-22	signal transducer and activator of transcription 3	Homo sapiens	65-70
21792937-6	2012	Vanadate treatment reversed honokiol-induced down-regulation of STAT3, suggesting the involvement of a tyrosine phosphatase.	honokiol	28-36	signal transducer and activator of transcription 3	Homo sapiens	64-69
21792937-7	2012	Indeed, we found that honokiol induced the expression of tyrosine phosphatase SHP-1 that correlated with the down-regulation of constitutive STAT3 activation.	honokiol	22-30	protein tyrosine phosphatase non-receptor type 6	Homo sapiens	78-83
21792937-7	2012	Indeed, we found that honokiol induced the expression of tyrosine phosphatase SHP-1 that correlated with the down-regulation of constitutive STAT3 activation.	honokiol	22-30	signal transducer and activator of transcription 3	Homo sapiens	141-146
21792937-8	2012	Moreover, deletion of SHP-1 gene by siRNA abolished the ability of honokiol to inhibit STAT3 activation.	honokiol	67-75	protein tyrosine phosphatase non-receptor type 6	Homo sapiens	22-27
21792937-8	2012	Moreover, deletion of SHP-1 gene by siRNA abolished the ability of honokiol to inhibit STAT3 activation.	honokiol	67-75	signal transducer and activator of transcription 3	Homo sapiens	87-92
21792937-9	2012	The inhibition of STAT3 activation by honokiol led to the suppression of various gene products involved in proliferation, survival, and angiogenesis.	honokiol	38-46	signal transducer and activator of transcription 3	Homo sapiens	18-23
21792937-11	2012	Overall, the results suggest that honokiol is a novel blocker of STAT3 activation and may have a great potential for the treatment of HCC and other cancers.	honokiol	34-42	signal transducer and activator of transcription 3	Homo sapiens	65-70
22258232-7	2012	Honokiol protected against the severity of acute pancreatitis in terms of increased serum amylase and lipase levels, pancreas pathological injury, and associated acute lung injury.	honokiol	0-8	lipase, endothelial	Mus musculus	102-108
21908486-7	2011	Honokiol down-regulated the expression of cyclin D1, cyclin D2, Cdk2, Cdk4 and Cdk6 proteins and up-regulated the expression of Cdk"s inhibitor proteins p21 and p27.	honokiol	0-8	cyclin D1	Homo sapiens	42-51
21935912-3	2012	METHODS: The antineoplastic activity of honokiol, which was demonstrated previously in numerous malignancies, was studied in vivo in C3H mice subcutaneously injected with syngeneic beta-galactosidase bacterial gene (lacZ)-expressing LM8 osteosarcoma (LM8-lacZ) cells.	honokiol	40-48	galactosidase, beta 1	Mus musculus	181-199
22319203-0	2012	Honokiol in combination with radiation targets notch signaling to inhibit colon cancer stem cells.	honokiol	0-8	notch 1	Mus musculus	47-52
22319203-6	2012	Flow cytometry studies confirmed that the honokiol-IR combination reduced the number of DCLK1+ cells.	honokiol	42-50	doublecortin-like kinase 1	Mus musculus	88-93
22319203-13	2012	Together, these data suggest that honokiol is a potent inhibitor of colon cancer growth that targets the stem cells by inhibiting the gamma-secretase complex and the Notch signaling pathway.	honokiol	34-42	notch 1	Mus musculus	166-171
22259050-0	2012	Honokiol traverses the blood-brain barrier and induces apoptosis of neuroblastoma cells via an intrinsic bax-mitochondrion-cytochrome c-caspase protease pathway.	honokiol	0-8	BCL2-associated X protein	Mus musculus	105-108
22259050-0	2012	Honokiol traverses the blood-brain barrier and induces apoptosis of neuroblastoma cells via an intrinsic bax-mitochondrion-cytochrome c-caspase protease pathway.	honokiol	0-8	caspase 6	Mus musculus	136-143
22259050-9	2012	Sequential treatment of neuro-2a cells with honokiol increased the expression of the proapoptotic Bax protein and its translocation from the cytoplasm to mitochondria.	honokiol	44-52	BCL2-associated X protein	Mus musculus	98-101
22259050-11	2012	Consequently, honokiol induced cascade activation of caspases-9, -3, and -6.	honokiol	14-22	caspase 9	Mus musculus	53-75
22259050-12	2012	In comparison, reducing caspase-6 activity by Z-VEID-FMK, an inhibitor of caspase-6, simultaneously attenuated honokiol-induced DNA fragmentation and cell apoptosis.	honokiol	111-119	caspase 6	Mus musculus	24-33
22353783-0	2012	Honokiol activates AMP-activated protein kinase in breast cancer cells via an LKB1-dependent pathway and inhibits breast carcinogenesis.	honokiol	0-8	serine/threonine kinase 11	Mus musculus	78-82
22353783-7	2012	Functional importance of AMPK activation and LKB1 overexpression in the biologic effects of honokiol was examined by using AMPK-null and AMPK-wild type (WT) immortalized mouse embryonic fibroblasts (MEFs) and isogenic LKB1-knockdown cell line pairs.	honokiol	92-100	serine/threonine kinase 11	Mus musculus	45-49
22353783-9	2012	RESULTS: Analysis of the underlying molecular mechanisms revealed that honokiol treatment increases AMP-activated protein kinase (AMPK) phosphorylation and activity, as evidenced by increased phosphorylation of the downstream target of AMPK, acetyl-coenzyme A carboxylase (ACC) and inhibition of phosphorylation of p70S6kinase (pS6K) and eukaryotic translation initiation factor 4E binding protein 1 (4EBP1).	honokiol	71-79	eukaryotic translation initiation factor 4E binding protein 1	Mus musculus	379-399
22353783-9	2012	RESULTS: Analysis of the underlying molecular mechanisms revealed that honokiol treatment increases AMP-activated protein kinase (AMPK) phosphorylation and activity, as evidenced by increased phosphorylation of the downstream target of AMPK, acetyl-coenzyme A carboxylase (ACC) and inhibition of phosphorylation of p70S6kinase (pS6K) and eukaryotic translation initiation factor 4E binding protein 1 (4EBP1).	honokiol	71-79	eukaryotic translation initiation factor 4E binding protein 1	Mus musculus	401-406
22353783-11	2012	Intriguingly, we discovered that honokiol treatment increased the expression and cytoplasmic translocation of tumor-suppressor LKB1 in breast cancer cells.	honokiol	33-41	serine/threonine kinase 11	Mus musculus	127-131
22353783-12	2012	LKB1 knockdown inhibited honokiol-mediated activation of AMPK and, more important, inhibition of migration and invasion of breast cancer cells.	honokiol	25-33	serine/threonine kinase 11	Mus musculus	0-4
22353783-14	2012	Analysis of tumors showed significant increases in the levels of cytoplasmic LKB1 and phospho-AMPK in honokiol-treated tumors.	honokiol	102-110	serine/threonine kinase 11	Mus musculus	77-81
22353783-15	2012	CONCLUSIONS: Taken together, these data provide the first in vitro and in vivo evidence of the integral role of the LKB1-AMPK axis in honokiol-mediated inhibition of the invasion and migration of breast cancer cells.	honokiol	134-142	serine/threonine kinase 11	Mus musculus	116-120
22890153-0	2012	Honokiol inhibits vascular vessel formation of mouse embryonic stem cell-derived endothelial cells via the suppression of PECAM and MAPK/mTOR signaling pathway.	honokiol	0-8	platelet/endothelial cell adhesion molecule 1	Mus musculus	122-127
22890153-0	2012	Honokiol inhibits vascular vessel formation of mouse embryonic stem cell-derived endothelial cells via the suppression of PECAM and MAPK/mTOR signaling pathway.	honokiol	0-8	mechanistic target of rapamycin kinase	Mus musculus	137-141
22890153-8	2012	Honokiol also inhibited the vascular formation of mES cells on 3-D collagen gel and decreased the expression of endothelial biomarkers VEGFR2 and PECAM in the differentiated EB-derived endothelial cells.	honokiol	0-8	kinase insert domain protein receptor	Mus musculus	135-141
22890153-8	2012	Honokiol also inhibited the vascular formation of mES cells on 3-D collagen gel and decreased the expression of endothelial biomarkers VEGFR2 and PECAM in the differentiated EB-derived endothelial cells.	honokiol	0-8	platelet/endothelial cell adhesion molecule 1	Mus musculus	146-151
22890153-9	2012	In addition, honokiol suppressed the MAPK and mTOR signaling pathways in the EB-derived endothelial cells.	honokiol	13-21	mechanistic target of rapamycin kinase	Mus musculus	46-50
22890153-10	2012	Therefore, the anti-angiogenic activity of honokiol is associated in part with the suppression of PECAM and MAPK/mTOR pathways in EB-derived endothelial cells.	honokiol	43-51	platelet/endothelial cell adhesion molecule 1	Mus musculus	98-103
22890153-10	2012	Therefore, the anti-angiogenic activity of honokiol is associated in part with the suppression of PECAM and MAPK/mTOR pathways in EB-derived endothelial cells.	honokiol	43-51	mechanistic target of rapamycin kinase	Mus musculus	113-117
21999396-4	2012	Among the constituents, matrine, baicalin, ursolic acid, sodium danshensu, magnolol, honokiol, hesperidin and andrographolide significantly reduced IL-8 and TNF-alpha by human HaCaT keratinocyte cells pretreated with heat-killed P. acnes.	honokiol	85-93	C-X-C motif chemokine ligand 8	Homo sapiens	148-152
21999396-4	2012	Among the constituents, matrine, baicalin, ursolic acid, sodium danshensu, magnolol, honokiol, hesperidin and andrographolide significantly reduced IL-8 and TNF-alpha by human HaCaT keratinocyte cells pretreated with heat-killed P. acnes.	honokiol	85-93	tumor necrosis factor	Homo sapiens	157-166
22937084-0	2012	Calpain/SHP-1 interaction by honokiol dampening peritoneal dissemination of gastric cancer in nu/nu mice.	honokiol	29-37	protein tyrosine phosphatase, non-receptor type 6	Mus musculus	8-13
22937084-7	2012	Furthermore, honokiol effectively enhanced signal transducer and activator of transcription (STAT-3) dephosphorylation and inhibited STAT-3 DNA binding activity in human gastric cancer cells and HUVECs, which was correlated with the up-regulation of the activity and protein expression of Src homology 2 (SH2)-containing tyrosine phosphatase-1 (SHP-1).	honokiol	13-21	signal transducer and activator of transcription 3	Homo sapiens	93-99
22937084-7	2012	Furthermore, honokiol effectively enhanced signal transducer and activator of transcription (STAT-3) dephosphorylation and inhibited STAT-3 DNA binding activity in human gastric cancer cells and HUVECs, which was correlated with the up-regulation of the activity and protein expression of Src homology 2 (SH2)-containing tyrosine phosphatase-1 (SHP-1).	honokiol	13-21	signal transducer and activator of transcription 3	Homo sapiens	133-139
22937084-7	2012	Furthermore, honokiol effectively enhanced signal transducer and activator of transcription (STAT-3) dephosphorylation and inhibited STAT-3 DNA binding activity in human gastric cancer cells and HUVECs, which was correlated with the up-regulation of the activity and protein expression of Src homology 2 (SH2)-containing tyrosine phosphatase-1 (SHP-1).	honokiol	13-21	protein tyrosine phosphatase non-receptor type 6	Homo sapiens	345-350
22937084-8	2012	Calpain-II inhibitor and siRNA transfection significantly reversed the honokiol-induced SHP-1 activity.	honokiol	71-79	protein tyrosine phosphatase, non-receptor type 6	Mus musculus	88-93
22937084-10	2012	Honokiol was also capable of inhibiting VEGF generation, which could be reversed by SHP-1 siRNA transfection.	honokiol	0-8	vascular endothelial growth factor A	Mus musculus	40-44
22937084-10	2012	Honokiol was also capable of inhibiting VEGF generation, which could be reversed by SHP-1 siRNA transfection.	honokiol	0-8	protein tyrosine phosphatase, non-receptor type 6	Mus musculus	84-89
22937084-11	2012	CONCLUSIONS/SIGNIFICANCE: Honokiol increases expression and activity of SPH-1 that further deactivates STAT3 pathway.	honokiol	26-34	signal transducer and activator of transcription 3	Mus musculus	103-108
22429472-3	2012	Our current study focuses on finding the molecular mechanism of the anti-inflammatory activities of honokiol in lipopolysaccharide-treated microglia with emphasis on the regulation of Klf4.	honokiol	100-108	Kruppel-like factor 4 (gut)	Mus musculus	184-188
22429472-10	2012	In addition, honokiol downregulates lipopolysaccharide-induced upregulation of both Klf4 and phospho-nuclear factor-kappa B in these cells.	honokiol	13-21	Kruppel-like factor 4 (gut)	Mus musculus	84-88
22429472-11	2012	We also found that overexpression of Klf4 in BV-2 cells suppresses the anti-inflammatory action of honokiol.	honokiol	99-107	Kruppel-like factor 4 (gut)	Mus musculus	37-41
22429472-12	2012	CONCLUSIONS: Honokiol potentially reduces inflammation in activated microglia in a Klf4-dependent manner.	honokiol	13-21	Kruppel-like factor 4 (gut)	Mus musculus	83-87
22259050-12	2012	In comparison, reducing caspase-6 activity by Z-VEID-FMK, an inhibitor of caspase-6, simultaneously attenuated honokiol-induced DNA fragmentation and cell apoptosis.	honokiol	111-119	caspase 6	Mus musculus	74-83
22259050-13	2012	Taken together, this study showed that honokiol can pass through the BBB and induce apoptotic insults to neuroblastoma cells through a Bax-mitochondrion-cytochrome c-caspase protease pathway.	honokiol	39-47	BCL2-associated X protein	Mus musculus	135-138
22223330-0	2012	A naturally occurring rexinoid, honokiol, can serve as a regulator of various retinoid x receptor heterodimers.	honokiol	32-40	retinoid X receptor alpha	Homo sapiens	78-97
22223330-1	2012	We investigated the properties of honokiol, a natural rexinoid, as a regulator of retinoid X receptor (RXR) heterodimers with various partner nuclear receptors (NRs), in comparison with those of the synthetic rexinoid bexarotene.	honokiol	34-42	retinoid X receptor alpha	Homo sapiens	82-101
22223330-1	2012	We investigated the properties of honokiol, a natural rexinoid, as a regulator of retinoid X receptor (RXR) heterodimers with various partner nuclear receptors (NRs), in comparison with those of the synthetic rexinoid bexarotene.	honokiol	34-42	retinoid X receptor alpha	Homo sapiens	103-106
22223330-2	2012	Honokiol alone was hardly capable of activating peroxisome proliferator-activated receptor (PPAR) gamma/RXR, RXR/liver X receptor (LXR), and RXR/vitamin D receptor (VDR) heterodimers, whereas it effectively potentiated their activation by agonists for the partner NRs of the RXR heterodimers.	honokiol	0-8	peroxisome proliferator activated receptor alpha	Homo sapiens	48-90
22223330-2	2012	Honokiol alone was hardly capable of activating peroxisome proliferator-activated receptor (PPAR) gamma/RXR, RXR/liver X receptor (LXR), and RXR/vitamin D receptor (VDR) heterodimers, whereas it effectively potentiated their activation by agonists for the partner NRs of the RXR heterodimers.	honokiol	0-8	vitamin D receptor	Homo sapiens	145-163
22223330-2	2012	Honokiol alone was hardly capable of activating peroxisome proliferator-activated receptor (PPAR) gamma/RXR, RXR/liver X receptor (LXR), and RXR/vitamin D receptor (VDR) heterodimers, whereas it effectively potentiated their activation by agonists for the partner NRs of the RXR heterodimers.	honokiol	0-8	vitamin D receptor	Homo sapiens	165-168
22223330-5	2012	When the potencies of honokiol and bexarotene were compared, honokiol was able to serve as a subsidiary agonist in the activation of RXR heterodimers in a similar manner to bexarotene.	honokiol	61-69	retinoid X receptor alpha	Homo sapiens	133-136
22223330-7	2012	In conclusion, we have demonstrated that honokiol is a rexinoid that possesses distinct properties from bexarotene, and mainly has subsidiary roles in the activation of RXR heterodimers by potentiating the activation of RXR heterodimers by agonists for the partner NRs.	honokiol	41-49	retinoid X receptor alpha	Homo sapiens	169-172
22223330-7	2012	In conclusion, we have demonstrated that honokiol is a rexinoid that possesses distinct properties from bexarotene, and mainly has subsidiary roles in the activation of RXR heterodimers by potentiating the activation of RXR heterodimers by agonists for the partner NRs.	honokiol	41-49	retinoid X receptor alpha	Homo sapiens	220-223
22057812-7	2012	Western blot analysis was used to assess the potential inhibition of extracellular signal-regulated kinase (ERK) and AKT signaling by honokiol.	honokiol	134-142	mitogen-activated protein kinase 1	Homo sapiens	69-106
22057812-7	2012	Western blot analysis was used to assess the potential inhibition of extracellular signal-regulated kinase (ERK) and AKT signaling by honokiol.	honokiol	134-142	mitogen-activated protein kinase 1	Homo sapiens	108-111
22057812-11	2012	CONCLUSIONS: Honokiol, a low molecular weight natural product, inhibits cell proliferation and promotes apoptosis in schwannoma cells by targeting the ERK pathway.	honokiol	13-21	mitogen-activated protein kinase 1	Homo sapiens	151-154
21800176-5	2011	In addition, the effects of honokiol on the activation of PI3K (phosphoinositide 3-kinase) and CREB (cAMP-responsive element-binding protein) were examined in MC3T3-E1 cells.	honokiol	28-36	phosphoinositide-3-kinase regulatory subunit 1	Mus musculus	64-89
21800176-5	2011	In addition, the effects of honokiol on the activation of PI3K (phosphoinositide 3-kinase) and CREB (cAMP-responsive element-binding protein) were examined in MC3T3-E1 cells.	honokiol	28-36	cAMP responsive element binding protein 1	Mus musculus	101-140
21800176-8	2011	Honokiol also induced the activation of PI3K and CREB inhibited by antimycin A, which demonstrates that honokiol utilizes the PI3K and CREB pathway to augment metabolic activity inhibited by antimycin A.	honokiol	0-8	cAMP responsive element binding protein 1	Mus musculus	49-53
21800176-8	2011	Honokiol also induced the activation of PI3K and CREB inhibited by antimycin A, which demonstrates that honokiol utilizes the PI3K and CREB pathway to augment metabolic activity inhibited by antimycin A.	honokiol	0-8	cAMP responsive element binding protein 1	Mus musculus	135-139
21800176-8	2011	Honokiol also induced the activation of PI3K and CREB inhibited by antimycin A, which demonstrates that honokiol utilizes the PI3K and CREB pathway to augment metabolic activity inhibited by antimycin A.	honokiol	104-112	cAMP responsive element binding protein 1	Mus musculus	49-53
21800176-8	2011	Honokiol also induced the activation of PI3K and CREB inhibited by antimycin A, which demonstrates that honokiol utilizes the PI3K and CREB pathway to augment metabolic activity inhibited by antimycin A.	honokiol	104-112	cAMP responsive element binding protein 1	Mus musculus	135-139
22126780-8	2011	Caspase 8 activity in Raji cells was significantly enhanced by honokiol (P&lt;0.05).	honokiol	63-71	caspase 8	Homo sapiens	0-9
22126780-10	2011	CONCLUSION: Honokiol can induce apoptosis in Raji cells possibly in relation to enhancement of caspase 8 activity and Bad gene expression.	honokiol	12-20	caspase 8	Homo sapiens	95-104
21561750-0	2011	Effect of honokiol on activity of GAD(65) and GAD(67) in the cortex and hippocampus of mice.	honokiol	10-18	glutamic acid decarboxylase 2	Mus musculus	34-41
21561750-3	2011	This study was to investigate the change in two forms of glutamic acid decarboxylase (GABA synthesized enzymes) GAD(65) and GAD(67) in the cortex and hippocampus areas while the anxiolytic actions induced by chronic administration of honokiol in mice.	honokiol	234-242	glutamic acid decarboxylase 2	Mus musculus	112-119
21561750-7	2011	In addition, the activity of hippocampal GAD(65) of honokiol treated mice was significantly increased than that of the vehicle or diazepam treated groups.	honokiol	52-60	glutamic acid decarboxylase 2	Mus musculus	41-48
21908486-7	2011	Honokiol down-regulated the expression of cyclin D1, cyclin D2, Cdk2, Cdk4 and Cdk6 proteins and up-regulated the expression of Cdk"s inhibitor proteins p21 and p27.	honokiol	0-8	cyclin D2	Homo sapiens	53-62
21908486-7	2011	Honokiol down-regulated the expression of cyclin D1, cyclin D2, Cdk2, Cdk4 and Cdk6 proteins and up-regulated the expression of Cdk"s inhibitor proteins p21 and p27.	honokiol	0-8	cyclin dependent kinase 2	Homo sapiens	64-68
21908486-7	2011	Honokiol down-regulated the expression of cyclin D1, cyclin D2, Cdk2, Cdk4 and Cdk6 proteins and up-regulated the expression of Cdk"s inhibitor proteins p21 and p27.	honokiol	0-8	cyclin dependent kinase 4	Homo sapiens	70-74
21908486-7	2011	Honokiol down-regulated the expression of cyclin D1, cyclin D2, Cdk2, Cdk4 and Cdk6 proteins and up-regulated the expression of Cdk"s inhibitor proteins p21 and p27.	honokiol	0-8	cyclin dependent kinase 6	Homo sapiens	79-83
21908486-7	2011	Honokiol down-regulated the expression of cyclin D1, cyclin D2, Cdk2, Cdk4 and Cdk6 proteins and up-regulated the expression of Cdk"s inhibitor proteins p21 and p27.	honokiol	0-8	H3 histone pseudogene 16	Homo sapiens	153-156
21908486-7	2011	Honokiol down-regulated the expression of cyclin D1, cyclin D2, Cdk2, Cdk4 and Cdk6 proteins and up-regulated the expression of Cdk"s inhibitor proteins p21 and p27.	honokiol	0-8	dynactin subunit 6	Homo sapiens	161-164
21827498-0	2011	Honokiol attenuates vascular contraction through the inhibition of the RhoA/Rho-kinase signalling pathway in rat aortic rings.	honokiol	0-8	ras homolog family member A	Rattus norvegicus	71-75
21827498-2	2011	We hypothesized that honokiol attenuated vascular contractions through the inhibition of the RhoA/Rho-kinase signalling pathway.	honokiol	21-29	ras homolog family member A	Rattus norvegicus	93-97
21827498-7	2011	Honokiol decreased the phosphorylation levels of MLC(20) , MYPT1(Thr855) and CPI17(Thr38) as well as the activation of RhoA induced by 8.0mm NaF or 30nm U46619.	honokiol	0-8	myosin light chain 12B	Rattus norvegicus	49-56
21827498-7	2011	Honokiol decreased the phosphorylation levels of MLC(20) , MYPT1(Thr855) and CPI17(Thr38) as well as the activation of RhoA induced by 8.0mm NaF or 30nm U46619.	honokiol	0-8	protein phosphatase 1, regulatory subunit 12A	Rattus norvegicus	59-64
21827498-7	2011	Honokiol decreased the phosphorylation levels of MLC(20) , MYPT1(Thr855) and CPI17(Thr38) as well as the activation of RhoA induced by 8.0mm NaF or 30nm U46619.	honokiol	0-8	protein phosphatase 1, regulatory (inhibitor) subunit 14A	Rattus norvegicus	77-82
21827498-7	2011	Honokiol decreased the phosphorylation levels of MLC(20) , MYPT1(Thr855) and CPI17(Thr38) as well as the activation of RhoA induced by 8.0mm NaF or 30nm U46619.	honokiol	0-8	ras homolog family member A	Rattus norvegicus	119-123
21827498-8	2011	CONCLUSIONS: These results demonstrated that honokiol attenuated vascular contraction through the inhibition of the RhoA/Rho-kinase signalling pathway.	honokiol	45-53	ras homolog family member A	Rattus norvegicus	116-120
21511450-0	2011	Magnolia dealbata Zucc and its active principles honokiol and magnolol stimulate glucose uptake in murine and human adipocytes using the insulin-signaling pathway.	honokiol	49-57	insulin	Homo sapiens	137-144
21511450-4	2011	The simultaneous application of HK and MG stimulated 2-NBDG uptake by 70% in hormone-sensitive cells, on which Magnolia preparations exerted synergic effects with insulin.	honokiol	32-34	insulin	Homo sapiens	163-170
21147091-7	2011	Moreover, honokiol almost completely reversed IL-1beta, CCL3, and NO expression at 10 mumol/l, and IL-18, TNF-alpha, TGF-beta1, and COX-2 expression at 20 mumol/l.	honokiol	10-18	interleukin 1 beta	Homo sapiens	46-54
21473672-2	2011	In this study, we examined the inhibitory effect of a natural compound, honokiol, on HIF-1alpha activity and tumour growth in combination with radiation.	honokiol	72-80	hypoxia inducible factor 1, alpha subunit	Mus musculus	85-95
21473672-4	2011	Effect of honokiol on HIF-1alpha levels within hypoxic tumour microenvironment was investigated by immunohistochemical and in vivo bioluminescent studies.	honokiol	10-18	hypoxia inducible factor 1, alpha subunit	Mus musculus	22-32
21473672-7	2011	In CT26-HRE-luc tumour-bearing mice, the inhibitory effect of intraperitoneally injected honokiol on HIF-1alpha-regulated luciferase activities induced by either CoCl(2) or radiation could be monitored non-invasively.	honokiol	89-97	hypoxia inducible factor 1, alpha subunit	Mus musculus	101-111
21473672-9	2011	CONCLUSIONS: Our data suggest that honokiol can exert its anticancer activity as a HIF-1alpha inhibitor by reducing HIF-1alpha protein level and suppressing the hypoxia-related signaling pathway.	honokiol	35-43	hypoxia inducible factor 1, alpha subunit	Mus musculus	83-93
21473672-9	2011	CONCLUSIONS: Our data suggest that honokiol can exert its anticancer activity as a HIF-1alpha inhibitor by reducing HIF-1alpha protein level and suppressing the hypoxia-related signaling pathway.	honokiol	35-43	hypoxia inducible factor 1, alpha subunit	Mus musculus	116-126
21511722-0	2011	Honokiol: an effective inhibitor of tumor necrosis factor-alpha-induced up-regulation of inflammatory cytokine and chemokine production in human synovial fibroblasts.	honokiol	0-8	tumor necrosis factor	Homo sapiens	36-63
21511722-1	2011	In this study, we investigated the mechanisms underlying the anti-inflammatory effects of honokiol in tumor necrosis factor (TNF)-alpha-stimulated rheumatoid arthritis synovial fibroblasts (RASFs).	honokiol	90-98	tumor necrosis factor	Homo sapiens	102-135
21511722-2	2011	RASFs pre-treated with honokiol (0-20 muM) were stimulated with TNF-alpha (20 ng/ml).	honokiol	23-31	tumor necrosis factor	Homo sapiens	64-73
21511722-7	2011	TNF-alpha-induced expression of these molecules was inhibited in a dose-dependent manner by pre-treatment with honokiol.	honokiol	111-119	tumor necrosis factor	Homo sapiens	0-9
21511722-8	2011	The inhibitory effect of honokiol on NFkappaB-p65 activity was also confirmed by immunocytochemical analysis.	honokiol	25-33	RELA proto-oncogene, NF-kB subunit	Homo sapiens	46-49
21511722-9	2011	In conclusion, honokiol is a potential inhibitor of TNF-alpha-induced expression of inflammatory factors in RASFs, which holds promise as a potential anti-inflammatory drug.	honokiol	15-23	tumor necrosis factor	Homo sapiens	52-61
21837966-12	2011	CONCLUSION: Honokiol is transported through the intestinal mucosa via a passive diffusion mechanism primarily, coexisting with a carrier-mediated transport, at the same time effected by P-gp.	honokiol	12-20	phosphoglycolate phosphatase	Homo sapiens	186-190
21225228-0	2011	Honokiol, a phytochemical from Magnolia spp., inhibits breast cancer cell migration by targeting nitric oxide and cyclooxygenase-2.	honokiol	0-8	prostaglandin-endoperoxide synthase 2	Mus musculus	114-130
21225228-6	2011	Honokiol also inhibited the levels of cyclooxygenase-2 (COX-2) and prostaglandin (PG) E2 in 4T1 cells.	honokiol	0-8	prostaglandin-endoperoxide synthase 2	Mus musculus	38-54
21225228-6	2011	Honokiol also inhibited the levels of cyclooxygenase-2 (COX-2) and prostaglandin (PG) E2 in 4T1 cells.	honokiol	0-8	prostaglandin-endoperoxide synthase 2	Mus musculus	56-61
21225228-9	2011	Moreover, honokiol inhibited the activation of nuclear factor kappaB (NF-kappaB), an upstream regulator of COX-2 and iNOS, in 4T1 cells.	honokiol	10-18	prostaglandin-endoperoxide synthase 2	Mus musculus	107-112
21225228-9	2011	Moreover, honokiol inhibited the activation of nuclear factor kappaB (NF-kappaB), an upstream regulator of COX-2 and iNOS, in 4T1 cells.	honokiol	10-18	nitric oxide synthase 2, inducible	Mus musculus	117-121
21225228-10	2011	These results indicate that NO and COX-2 are the key targets of honokiol in the inhibition of breast cancer cell migration, an essential step in invasion and metastasis.	honokiol	64-72	prostaglandin-endoperoxide synthase 2	Mus musculus	35-40
21699169-2	2011	Honokiol enhanced chloride currents (I(GABA)) through GABA(A) receptors of seven different subunit compositions with EC(50) values ranging from 23.4 muM (alpha(5)beta(2)) to 59.6 muM (alpha(1)beta(3)).	honokiol	0-8	latexin	Homo sapiens	149-152
21699169-2	2011	Honokiol enhanced chloride currents (I(GABA)) through GABA(A) receptors of seven different subunit compositions with EC(50) values ranging from 23.4 muM (alpha(5)beta(2)) to 59.6 muM (alpha(1)beta(3)).	honokiol	0-8	latexin	Homo sapiens	179-182
21265825-9	2011	Honokiol also decreased expression of the mRNA for the chemokine CCL2 and for the intracellular adhesion molecule-1, as well as accumulation of type I (alpha1) collagen and fibronectin in UUO kidneys.	honokiol	0-8	C-C motif chemokine ligand 2	Rattus norvegicus	65-69
21265825-9	2011	Honokiol also decreased expression of the mRNA for the chemokine CCL2 and for the intracellular adhesion molecule-1, as well as accumulation of type I (alpha1) collagen and fibronectin in UUO kidneys.	honokiol	0-8	collagen type I alpha 1 chain	Rattus norvegicus	144-168
21265825-9	2011	Honokiol also decreased expression of the mRNA for the chemokine CCL2 and for the intracellular adhesion molecule-1, as well as accumulation of type I (alpha1) collagen and fibronectin in UUO kidneys.	honokiol	0-8	fibronectin 1	Rattus norvegicus	173-184
21265825-10	2011	Phosphorylation of Smad-2/3 induced by TGF-beta1 and CTGF luciferase activity in renal tubular cells were also inhibited by honokiol.	honokiol	124-132	SMAD family member 2	Rattus norvegicus	19-27
21265825-10	2011	Phosphorylation of Smad-2/3 induced by TGF-beta1 and CTGF luciferase activity in renal tubular cells were also inhibited by honokiol.	honokiol	124-132	transforming growth factor, beta 1	Rattus norvegicus	39-48
21265825-10	2011	Phosphorylation of Smad-2/3 induced by TGF-beta1 and CTGF luciferase activity in renal tubular cells were also inhibited by honokiol.	honokiol	124-132	cellular communication network factor 2	Rattus norvegicus	53-57
21147091-7	2011	Moreover, honokiol almost completely reversed IL-1beta, CCL3, and NO expression at 10 mumol/l, and IL-18, TNF-alpha, TGF-beta1, and COX-2 expression at 20 mumol/l.	honokiol	10-18	C-C motif chemokine ligand 3	Homo sapiens	56-60
21147091-8	2011	In addition, phospho-NF-kappaB p65 at Ser536, phospho-Akt, and phospho-p42/44 were dramatically suppressed by honokiol in LPS-treated HRMCs.	honokiol	110-118	RELA proto-oncogene, NF-kB subunit	Homo sapiens	31-34
21147091-10	2011	The anti-inflammatory mechanisms of honokiol are partly due to the suppression of the phospho-NF-kappaB p65, phospho-Akt and phospho-p42/44 pathways.	honokiol	36-44	RELA proto-oncogene, NF-kB subunit	Homo sapiens	104-107
21720559-9	2011	Importantly, honokiol also potentiated the cytotoxic effects of gemcitabine, in part, by restricting the gemcitabine-induced nuclear accumulation of NF-kappaB in the treated pancreatic cancer cell lines.	honokiol	13-21	nuclear factor kappa B subunit 1	Homo sapiens	149-158
21720559-5	2011	At the molecular level, honokiol markedly decreased the expression of cyclins (D1 and E) and cyclin-dependent kinases (Cdk2 and Cdk4), and caused an increase in Cdk inhibitors, p21 and p27.	honokiol	24-32	leiomodin 1	Homo sapiens	70-87
21279327-5	2011	RESULTS: The productions of serum tumor necrosis factor-alpha (TNF-alpha), nitric oxide (NO), and high mobility group box 1 (HMGB 1) were increased in mice during sepsis, which could be reversed by honokiol.	honokiol	198-206	tumor necrosis factor	Mus musculus	34-61
21279327-5	2011	RESULTS: The productions of serum tumor necrosis factor-alpha (TNF-alpha), nitric oxide (NO), and high mobility group box 1 (HMGB 1) were increased in mice during sepsis, which could be reversed by honokiol.	honokiol	198-206	tumor necrosis factor	Mus musculus	63-72
21279327-5	2011	RESULTS: The productions of serum tumor necrosis factor-alpha (TNF-alpha), nitric oxide (NO), and high mobility group box 1 (HMGB 1) were increased in mice during sepsis, which could be reversed by honokiol.	honokiol	198-206	high mobility group box 1	Mus musculus	98-123
21279327-5	2011	RESULTS: The productions of serum tumor necrosis factor-alpha (TNF-alpha), nitric oxide (NO), and high mobility group box 1 (HMGB 1) were increased in mice during sepsis, which could be reversed by honokiol.	honokiol	198-206	high mobility group box 1	Mus musculus	125-131
21279327-7	2011	Honokiol significantly reversed the inductions of inducible NO synthase and nuclear factor-kappaB (NF-kappaB) activation in the lungs of mice during sepsis.	honokiol	0-8	nitric oxide synthase 2, inducible	Mus musculus	50-71
21279327-7	2011	Honokiol significantly reversed the inductions of inducible NO synthase and nuclear factor-kappaB (NF-kappaB) activation in the lungs of mice during sepsis.	honokiol	0-8	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	76-97
21279327-7	2011	Honokiol significantly reversed the inductions of inducible NO synthase and nuclear factor-kappaB (NF-kappaB) activation in the lungs of mice during sepsis.	honokiol	0-8	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	99-108
20965163-0	2011	Honokiol inhibits H(2)O(2)-induced apoptosis in human lens epithelial cells via inhibition of the mitogen-activated protein kinase and Akt pathways.	honokiol	0-8	AKT serine/threonine kinase 1	Homo sapiens	135-138
20965163-4	2011	The results demonstrated that pretreatment of honokiol inhibited the activation of caspase-3 and caspase-9 and downregulated the expression of Bcl-2.	honokiol	46-54	caspase 3	Homo sapiens	83-92
20965163-4	2011	The results demonstrated that pretreatment of honokiol inhibited the activation of caspase-3 and caspase-9 and downregulated the expression of Bcl-2.	honokiol	46-54	caspase 9	Homo sapiens	97-106
20965163-4	2011	The results demonstrated that pretreatment of honokiol inhibited the activation of caspase-3 and caspase-9 and downregulated the expression of Bcl-2.	honokiol	46-54	BCL2 apoptosis regulator	Homo sapiens	143-148
20965163-5	2011	Mechanistically, honokiol suppressed H(2)O(2)-induced phosphorylation of ERK1/2, p38 mitogen-activated protein kinase (MAPK), JNK and Akt.	honokiol	17-25	mitogen-activated protein kinase 3	Homo sapiens	73-79
20965163-5	2011	Mechanistically, honokiol suppressed H(2)O(2)-induced phosphorylation of ERK1/2, p38 mitogen-activated protein kinase (MAPK), JNK and Akt.	honokiol	17-25	mitogen-activated protein kinase 14	Homo sapiens	81-117
20965163-5	2011	Mechanistically, honokiol suppressed H(2)O(2)-induced phosphorylation of ERK1/2, p38 mitogen-activated protein kinase (MAPK), JNK and Akt.	honokiol	17-25	mitogen-activated protein kinase 3	Homo sapiens	119-123
20965163-5	2011	Mechanistically, honokiol suppressed H(2)O(2)-induced phosphorylation of ERK1/2, p38 mitogen-activated protein kinase (MAPK), JNK and Akt.	honokiol	17-25	mitogen-activated protein kinase 8	Homo sapiens	126-129
20965163-5	2011	Mechanistically, honokiol suppressed H(2)O(2)-induced phosphorylation of ERK1/2, p38 mitogen-activated protein kinase (MAPK), JNK and Akt.	honokiol	17-25	AKT serine/threonine kinase 1	Homo sapiens	134-137
20965163-6	2011	Honokiol also inhibited H(2)O(2)-induced nuclear factor-kappaB (NF-kappaB)/p65 phosphorylation and translocation in HLE cells.	honokiol	0-8	RELA proto-oncogene, NF-kB subunit	Homo sapiens	75-78
20965163-7	2011	These results demonstrate that honokiol suppresses H(2)O(2)-induced HLE cell apoptosis via interference with the MAPKs, Akt and NF-kappaB signaling, suggesting that honokiol might have a potential effect against cataract formation.	honokiol	31-39	AKT serine/threonine kinase 1	Homo sapiens	120-123
20965163-7	2011	These results demonstrate that honokiol suppresses H(2)O(2)-induced HLE cell apoptosis via interference with the MAPKs, Akt and NF-kappaB signaling, suggesting that honokiol might have a potential effect against cataract formation.	honokiol	165-173	AKT serine/threonine kinase 1	Homo sapiens	120-123
21720559-5	2011	At the molecular level, honokiol markedly decreased the expression of cyclins (D1 and E) and cyclin-dependent kinases (Cdk2 and Cdk4), and caused an increase in Cdk inhibitors, p21 and p27.	honokiol	24-32	cyclin dependent kinase 2	Homo sapiens	119-123
21720559-5	2011	At the molecular level, honokiol markedly decreased the expression of cyclins (D1 and E) and cyclin-dependent kinases (Cdk2 and Cdk4), and caused an increase in Cdk inhibitors, p21 and p27.	honokiol	24-32	cyclin dependent kinase 4	Homo sapiens	128-132
21720559-5	2011	At the molecular level, honokiol markedly decreased the expression of cyclins (D1 and E) and cyclin-dependent kinases (Cdk2 and Cdk4), and caused an increase in Cdk inhibitors, p21 and p27.	honokiol	24-32	cyclin dependent kinase inhibitor 1A	Homo sapiens	177-180
21720559-5	2011	At the molecular level, honokiol markedly decreased the expression of cyclins (D1 and E) and cyclin-dependent kinases (Cdk2 and Cdk4), and caused an increase in Cdk inhibitors, p21 and p27.	honokiol	24-32	interferon alpha inducible protein 27	Homo sapiens	185-188
21720559-6	2011	Furthermore, honokiol treatment led to augmentation of Bax/Bcl-2 and Bax/Bcl-xL ratios to favor apoptosis in pancreatic cancer cells.	honokiol	13-21	BCL2 associated X, apoptosis regulator	Homo sapiens	55-58
21720559-6	2011	Furthermore, honokiol treatment led to augmentation of Bax/Bcl-2 and Bax/Bcl-xL ratios to favor apoptosis in pancreatic cancer cells.	honokiol	13-21	BCL2 apoptosis regulator	Homo sapiens	59-64
21720559-6	2011	Furthermore, honokiol treatment led to augmentation of Bax/Bcl-2 and Bax/Bcl-xL ratios to favor apoptosis in pancreatic cancer cells.	honokiol	13-21	BCL2 associated X, apoptosis regulator	Homo sapiens	69-72
21720559-6	2011	Furthermore, honokiol treatment led to augmentation of Bax/Bcl-2 and Bax/Bcl-xL ratios to favor apoptosis in pancreatic cancer cells.	honokiol	13-21	BCL2 like 1	Homo sapiens	73-79
20878707-4	2010	Only two of the studied compounds, honokiol and magnolol, significantly decreased Abeta-induced cell death.	honokiol	35-43	amyloid beta precursor protein	Rattus norvegicus	82-87
20582713-6	2010	Honokiol (~20 mumol/L) treatment inhibited the HG-induced expression of inflammatory cytokines such as IL-1beta, IL-18, TNF-alpha, PGE2, NO, and TGF-beta1 in a dose-dependent manner.	honokiol	0-8	interleukin 1 beta	Homo sapiens	103-111
20582713-6	2010	Honokiol (~20 mumol/L) treatment inhibited the HG-induced expression of inflammatory cytokines such as IL-1beta, IL-18, TNF-alpha, PGE2, NO, and TGF-beta1 in a dose-dependent manner.	honokiol	0-8	interleukin 18	Homo sapiens	113-118
20582713-6	2010	Honokiol (~20 mumol/L) treatment inhibited the HG-induced expression of inflammatory cytokines such as IL-1beta, IL-18, TNF-alpha, PGE2, NO, and TGF-beta1 in a dose-dependent manner.	honokiol	0-8	tumor necrosis factor	Homo sapiens	120-129
20582713-6	2010	Honokiol (~20 mumol/L) treatment inhibited the HG-induced expression of inflammatory cytokines such as IL-1beta, IL-18, TNF-alpha, PGE2, NO, and TGF-beta1 in a dose-dependent manner.	honokiol	0-8	transforming growth factor beta 1	Homo sapiens	145-154
20823108-5	2010	Treatment with honokiol significantly inhibited UVB-induced expression of cyclooxygenase-2, prostaglandin E(2) (P &lt; 0.001), proliferating cell nuclear antigen and proinflammatory cytokines, such as tumor necrosis factor-alpha (P &lt; 0.001), interleukin (IL)-1beta (P &lt; 0.01) and IL-6 (P &lt; 0.001) in the skin as well as in skin tumors.	honokiol	15-23	prostaglandin-endoperoxide synthase 2	Mus musculus	74-90
20823108-5	2010	Treatment with honokiol significantly inhibited UVB-induced expression of cyclooxygenase-2, prostaglandin E(2) (P &lt; 0.001), proliferating cell nuclear antigen and proinflammatory cytokines, such as tumor necrosis factor-alpha (P &lt; 0.001), interleukin (IL)-1beta (P &lt; 0.01) and IL-6 (P &lt; 0.001) in the skin as well as in skin tumors.	honokiol	15-23	tumor necrosis factor	Mus musculus	201-228
20823108-5	2010	Treatment with honokiol significantly inhibited UVB-induced expression of cyclooxygenase-2, prostaglandin E(2) (P &lt; 0.001), proliferating cell nuclear antigen and proinflammatory cytokines, such as tumor necrosis factor-alpha (P &lt; 0.001), interleukin (IL)-1beta (P &lt; 0.01) and IL-6 (P &lt; 0.001) in the skin as well as in skin tumors.	honokiol	15-23	interleukin 1 beta	Mus musculus	245-267
20823108-5	2010	Treatment with honokiol significantly inhibited UVB-induced expression of cyclooxygenase-2, prostaglandin E(2) (P &lt; 0.001), proliferating cell nuclear antigen and proinflammatory cytokines, such as tumor necrosis factor-alpha (P &lt; 0.001), interleukin (IL)-1beta (P &lt; 0.01) and IL-6 (P &lt; 0.001) in the skin as well as in skin tumors.	honokiol	15-23	interleukin 6	Mus musculus	286-290
20823108-6	2010	Western blot analysis revealed that honokiol: (i) inhibited the levels of cyclins D1, D2 and E and associated cyclin-dependent kinases (CDKs)2, CDK4 and CDK6, (ii) upregulated Cip/p21 and Kip/p27 and (iii) inhibited the levels of phosphatidylinositol 3-kinase and the phosphorylation of Akt at Ser(473) in UVB-induced skin tumors.	honokiol	36-44	cyclin-dependent kinase 4	Mus musculus	144-148
20823108-6	2010	Western blot analysis revealed that honokiol: (i) inhibited the levels of cyclins D1, D2 and E and associated cyclin-dependent kinases (CDKs)2, CDK4 and CDK6, (ii) upregulated Cip/p21 and Kip/p27 and (iii) inhibited the levels of phosphatidylinositol 3-kinase and the phosphorylation of Akt at Ser(473) in UVB-induced skin tumors.	honokiol	36-44	cyclin-dependent kinase 6	Mus musculus	153-157
20823108-6	2010	Western blot analysis revealed that honokiol: (i) inhibited the levels of cyclins D1, D2 and E and associated cyclin-dependent kinases (CDKs)2, CDK4 and CDK6, (ii) upregulated Cip/p21 and Kip/p27 and (iii) inhibited the levels of phosphatidylinositol 3-kinase and the phosphorylation of Akt at Ser(473) in UVB-induced skin tumors.	honokiol	36-44	cyclin-dependent kinase inhibitor 1A (P21)	Mus musculus	180-183
20823108-6	2010	Western blot analysis revealed that honokiol: (i) inhibited the levels of cyclins D1, D2 and E and associated cyclin-dependent kinases (CDKs)2, CDK4 and CDK6, (ii) upregulated Cip/p21 and Kip/p27 and (iii) inhibited the levels of phosphatidylinositol 3-kinase and the phosphorylation of Akt at Ser(473) in UVB-induced skin tumors.	honokiol	36-44	calcium and integrin binding 1 (calmyrin)	Mus musculus	188-191
20823108-6	2010	Western blot analysis revealed that honokiol: (i) inhibited the levels of cyclins D1, D2 and E and associated cyclin-dependent kinases (CDKs)2, CDK4 and CDK6, (ii) upregulated Cip/p21 and Kip/p27 and (iii) inhibited the levels of phosphatidylinositol 3-kinase and the phosphorylation of Akt at Ser(473) in UVB-induced skin tumors.	honokiol	36-44	cyclin-dependent kinase inhibitor 1B	Mus musculus	192-195
19880244-4	2010	Honokiol also induces upregulation of Bax and Bak, downregulation of Bcl-XL and dysfunction of mitochondria in chondrosarcoma cells.	honokiol	0-8	BCL2 associated X, apoptosis regulator	Homo sapiens	38-41
20695472-4	2010	Honokiol (1) is capable of activating a RXR/LXR heterodimer, resulting in the induction of ATP-binding cassette transporter A1 mRNA and protein expression in RAW264.7 cells, as well as an increase in [(3)H]cholesterol efflux from peritoneal macrophages.	honokiol	0-8	nuclear receptor subfamily 1, group H, member 3	Mus musculus	44-47
20649594-0	2010	Honokiol inhibits gastric tumourigenesis by activation of 15-lipoxygenase-1 and consequent inhibition of peroxisome proliferator-activated receptor-gamma and COX-2-dependent signals.	honokiol	0-8	peroxisome proliferator activated receptor gamma	Mus musculus	105-153
20649594-0	2010	Honokiol inhibits gastric tumourigenesis by activation of 15-lipoxygenase-1 and consequent inhibition of peroxisome proliferator-activated receptor-gamma and COX-2-dependent signals.	honokiol	0-8	cytochrome c oxidase II, mitochondrial	Mus musculus	158-163
20649594-3	2010	Here, we investigate the role of 15-LOX-1 induction by honokiol, a small-molecular weight natural product, in PPAR-gamma and COX-2 signalling during gastric tumourigenesis.	honokiol	55-63	peroxisome proliferator activated receptor gamma	Mus musculus	110-120
20649594-3	2010	Here, we investigate the role of 15-LOX-1 induction by honokiol, a small-molecular weight natural product, in PPAR-gamma and COX-2 signalling during gastric tumourigenesis.	honokiol	55-63	cytochrome c oxidase II, mitochondrial	Mus musculus	125-130
20649594-10	2010	Honokiol markedly inhibited PPAR-gamma and COX-2 expressions in gastric cancer cells and tumours of xenograft mice, and induced apoptosis and cell death.	honokiol	0-8	peroxisome proliferator activated receptor gamma	Mus musculus	28-38
20649594-10	2010	Honokiol markedly inhibited PPAR-gamma and COX-2 expressions in gastric cancer cells and tumours of xenograft mice, and induced apoptosis and cell death.	honokiol	0-8	cytochrome c oxidase II, mitochondrial	Mus musculus	43-48
20649594-12	2010	15-LOX-1 siRNA could reverse the honokiol-induced down-regulation of PPAR-gamma and COX-2, and cell apoptosis.	honokiol	33-41	peroxisome proliferator activated receptor gamma	Mus musculus	69-79
20649594-12	2010	15-LOX-1 siRNA could reverse the honokiol-induced down-regulation of PPAR-gamma and COX-2, and cell apoptosis.	honokiol	33-41	cytochrome c oxidase II, mitochondrial	Mus musculus	84-89
20649594-14	2010	CONCLUSIONS AND IMPLICATIONS: These findings suggest that induction of 15-LOX-1-mediated down-regulation of a PPAR-gamma and COX-2 pathway by honokiol may be a promising therapeutic strategy for gastric cancer.	honokiol	142-150	peroxisome proliferator activated receptor gamma	Mus musculus	110-120
20649594-14	2010	CONCLUSIONS AND IMPLICATIONS: These findings suggest that induction of 15-LOX-1-mediated down-regulation of a PPAR-gamma and COX-2 pathway by honokiol may be a promising therapeutic strategy for gastric cancer.	honokiol	142-150	cytochrome c oxidase II, mitochondrial	Mus musculus	125-130
20388852-0	2010	Honokiol inhibits epidermal growth factor receptor signaling and enhances the antitumor effects of epidermal growth factor receptor inhibitors.	honokiol	0-8	epidermal growth factor receptor	Homo sapiens	18-50
20388852-0	2010	Honokiol inhibits epidermal growth factor receptor signaling and enhances the antitumor effects of epidermal growth factor receptor inhibitors.	honokiol	0-8	epidermal growth factor receptor	Homo sapiens	99-131
20388852-5	2010	Furthermore, honokiol enhanced the growth inhibitory and anti-invasion activity of the EGFR-targeting agent erlotinib.	honokiol	13-21	epidermal growth factor receptor	Homo sapiens	87-91
20388852-8	2010	CONCLUSIONS: These results suggest that honokiol may be an effective therapeutic agent in HNSCC, in which it can augment the effects of EGFR inhibitors and overcome drug resistance.	honokiol	40-48	epidermal growth factor receptor	Homo sapiens	136-140
19880244-4	2010	Honokiol also induces upregulation of Bax and Bak, downregulation of Bcl-XL and dysfunction of mitochondria in chondrosarcoma cells.	honokiol	0-8	BCL2 antagonist/killer 1	Homo sapiens	46-49
19880244-4	2010	Honokiol also induces upregulation of Bax and Bak, downregulation of Bcl-XL and dysfunction of mitochondria in chondrosarcoma cells.	honokiol	0-8	BCL2 like 1	Homo sapiens	69-75
19880244-6	2010	We also found that honokiol increased the expression and activities of glucose-regulated protein 78 (GRP78) and calpain.	honokiol	19-27	heat shock protein family A (Hsp70) member 5	Homo sapiens	71-99
19880244-6	2010	We also found that honokiol increased the expression and activities of glucose-regulated protein 78 (GRP78) and calpain.	honokiol	19-27	heat shock protein family A (Hsp70) member 5	Homo sapiens	101-106
19880244-7	2010	Transfection of cells with GRP78 or calpain siRNA reduced honokiol-mediated cell apoptosis in JJ012 cells.	honokiol	58-66	heat shock protein family A (Hsp70) member 5	Homo sapiens	27-32
20127691-0	2010	Honokiol inhibits HepG2 migration via down-regulation of IQGAP1 expression discovered by a quantitative pharmaceutical proteomic analysis.	honokiol	0-8	IQ motif containing GTPase activating protein 1	Homo sapiens	57-63
20192217-0	2010	Anti-inflammatory bioactivities of honokiol through inhibition of protein kinase C, mitogen-activated protein kinase, and the NF-kappaB pathway to reduce LPS-induced TNFalpha and NO expression.	honokiol	35-43	tumor necrosis factor	Mus musculus	166-174
20192217-3	2010	At the same time, honokiol not only inhibited nitric oxide expression in LPS-stimulated murine macrophages but also inhibited the LPS-induced phosphorylation of ERK1/2, JNK1/2, and p38.	honokiol	18-26	mitogen-activated protein kinase 3	Mus musculus	161-167
20192217-3	2010	At the same time, honokiol not only inhibited nitric oxide expression in LPS-stimulated murine macrophages but also inhibited the LPS-induced phosphorylation of ERK1/2, JNK1/2, and p38.	honokiol	18-26	mitogen-activated protein kinase 8	Mus musculus	169-175
20192217-3	2010	At the same time, honokiol not only inhibited nitric oxide expression in LPS-stimulated murine macrophages but also inhibited the LPS-induced phosphorylation of ERK1/2, JNK1/2, and p38.	honokiol	18-26	mitogen-activated protein kinase 14	Mus musculus	181-184
20703013-3	2010	The oral administration of honokiol inhibited the progression and severity of type II collagen (CII)-induced arthritis (CIA) by reducing clinical arthritis scores and paw swelling.	honokiol	27-35	nuclear receptor coactivator 5	Mus musculus	120-123
20487633-0	2010	Modulation of multidrug resistance p-glycoprotein activity by flavonoids and honokiol in human doxorubicin- resistant sarcoma cells (MES-SA/DX-5): implications for natural sedatives as chemosensitizing agents in cancer therapy.	honokiol	77-85	ATP binding cassette subfamily B member 1	Homo sapiens	35-49
20190414-2	2010	This study investigated the effects of honokiol on the differentiation and function of osteoclasts induced by receptor activator of nuclear factor-kappaB ligand (RANKL).	honokiol	39-47	tumor necrosis factor (ligand) superfamily, member 11	Mus musculus	110-160
20190414-2	2010	This study investigated the effects of honokiol on the differentiation and function of osteoclasts induced by receptor activator of nuclear factor-kappaB ligand (RANKL).	honokiol	39-47	tumor necrosis factor (ligand) superfamily, member 11	Mus musculus	162-167
20190414-3	2010	Honokiol markedly inhibited RANKL-induced tartrate-resistant acid phosphatase (TRAP) activity and the formation of TRAP-positive multinucleated cells in both bone marrow-derived monocytes and RAW264 cells.	honokiol	0-8	tumor necrosis factor (ligand) superfamily, member 11	Mus musculus	28-33
20190414-3	2010	Honokiol markedly inhibited RANKL-induced tartrate-resistant acid phosphatase (TRAP) activity and the formation of TRAP-positive multinucleated cells in both bone marrow-derived monocytes and RAW264 cells.	honokiol	0-8	acid phosphatase 5, tartrate resistant	Mus musculus	42-77
20190414-3	2010	Honokiol markedly inhibited RANKL-induced tartrate-resistant acid phosphatase (TRAP) activity and the formation of TRAP-positive multinucleated cells in both bone marrow-derived monocytes and RAW264 cells.	honokiol	0-8	acid phosphatase 5, tartrate resistant	Mus musculus	79-83
20190414-3	2010	Honokiol markedly inhibited RANKL-induced tartrate-resistant acid phosphatase (TRAP) activity and the formation of TRAP-positive multinucleated cells in both bone marrow-derived monocytes and RAW264 cells.	honokiol	0-8	acid phosphatase 5, tartrate resistant	Mus musculus	115-119
20190414-4	2010	In experiments to elucidate its mechanism of action, honokiol was found to suppress RANKL-induced phosphorylation of p38 mitogen-activated protein kinase (MAPK), extracellular signal-regulated kinase (ERK), and c-Jun N-terminal kinase (JNK).	honokiol	53-61	tumor necrosis factor (ligand) superfamily, member 11	Mus musculus	84-89
20190414-4	2010	In experiments to elucidate its mechanism of action, honokiol was found to suppress RANKL-induced phosphorylation of p38 mitogen-activated protein kinase (MAPK), extracellular signal-regulated kinase (ERK), and c-Jun N-terminal kinase (JNK).	honokiol	53-61	mitogen-activated protein kinase 1	Mus musculus	155-159
20190414-4	2010	In experiments to elucidate its mechanism of action, honokiol was found to suppress RANKL-induced phosphorylation of p38 mitogen-activated protein kinase (MAPK), extracellular signal-regulated kinase (ERK), and c-Jun N-terminal kinase (JNK).	honokiol	53-61	mitogen-activated protein kinase 1	Mus musculus	162-199
20190414-4	2010	In experiments to elucidate its mechanism of action, honokiol was found to suppress RANKL-induced phosphorylation of p38 mitogen-activated protein kinase (MAPK), extracellular signal-regulated kinase (ERK), and c-Jun N-terminal kinase (JNK).	honokiol	53-61	mitogen-activated protein kinase 1	Mus musculus	201-204
20190414-4	2010	In experiments to elucidate its mechanism of action, honokiol was found to suppress RANKL-induced phosphorylation of p38 mitogen-activated protein kinase (MAPK), extracellular signal-regulated kinase (ERK), and c-Jun N-terminal kinase (JNK).	honokiol	53-61	mitogen-activated protein kinase 8	Mus musculus	211-234
20190414-4	2010	In experiments to elucidate its mechanism of action, honokiol was found to suppress RANKL-induced phosphorylation of p38 mitogen-activated protein kinase (MAPK), extracellular signal-regulated kinase (ERK), and c-Jun N-terminal kinase (JNK).	honokiol	53-61	mitogen-activated protein kinase 8	Mus musculus	236-239
20190414-5	2010	The RANKL-induced expressions of c-Fos and nuclear factor of activated T cells-c1 (NFATc1), which are crucial transcriptional factors for osteoclastogenesis, were also reduced by treatment with honokiol.	honokiol	194-202	tumor necrosis factor (ligand) superfamily, member 11	Mus musculus	4-9
20190414-5	2010	The RANKL-induced expressions of c-Fos and nuclear factor of activated T cells-c1 (NFATc1), which are crucial transcriptional factors for osteoclastogenesis, were also reduced by treatment with honokiol.	honokiol	194-202	FBJ osteosarcoma oncogene	Mus musculus	33-38
20190414-5	2010	The RANKL-induced expressions of c-Fos and nuclear factor of activated T cells-c1 (NFATc1), which are crucial transcriptional factors for osteoclastogenesis, were also reduced by treatment with honokiol.	honokiol	194-202	nuclear factor of activated T cells, cytoplasmic, calcineurin dependent 1	Mus musculus	43-81
20190414-5	2010	The RANKL-induced expressions of c-Fos and nuclear factor of activated T cells-c1 (NFATc1), which are crucial transcriptional factors for osteoclastogenesis, were also reduced by treatment with honokiol.	honokiol	194-202	nuclear factor of activated T cells, cytoplasmic, calcineurin dependent 1	Mus musculus	83-89
20190414-7	2010	Taken together, these results suggest that honokiol inhibits osteoclast differentiation by suppressing the activation of MAPKs (p38 MAPK, ERK and JNK), decreasing the expressions of c-Fos and NFATc1, and attenuates bone resorption by disrupting the actin rings in mOCs.	honokiol	43-51	mitogen-activated protein kinase 14	Mus musculus	128-136
20190414-7	2010	Taken together, these results suggest that honokiol inhibits osteoclast differentiation by suppressing the activation of MAPKs (p38 MAPK, ERK and JNK), decreasing the expressions of c-Fos and NFATc1, and attenuates bone resorption by disrupting the actin rings in mOCs.	honokiol	43-51	mitogen-activated protein kinase 1	Mus musculus	138-141
20190414-7	2010	Taken together, these results suggest that honokiol inhibits osteoclast differentiation by suppressing the activation of MAPKs (p38 MAPK, ERK and JNK), decreasing the expressions of c-Fos and NFATc1, and attenuates bone resorption by disrupting the actin rings in mOCs.	honokiol	43-51	mitogen-activated protein kinase 8	Mus musculus	146-149
20190414-7	2010	Taken together, these results suggest that honokiol inhibits osteoclast differentiation by suppressing the activation of MAPKs (p38 MAPK, ERK and JNK), decreasing the expressions of c-Fos and NFATc1, and attenuates bone resorption by disrupting the actin rings in mOCs.	honokiol	43-51	FBJ osteosarcoma oncogene	Mus musculus	182-187
20190414-7	2010	Taken together, these results suggest that honokiol inhibits osteoclast differentiation by suppressing the activation of MAPKs (p38 MAPK, ERK and JNK), decreasing the expressions of c-Fos and NFATc1, and attenuates bone resorption by disrupting the actin rings in mOCs.	honokiol	43-51	nuclear factor of activated T cells, cytoplasmic, calcineurin dependent 1	Mus musculus	192-198
20606297-0	2010	Honokiol increases ABCA1 expression level by activating retinoid X receptor beta.	honokiol	0-8	ATP binding cassette subfamily A member 1	Homo sapiens	19-24
20606297-0	2010	Honokiol increases ABCA1 expression level by activating retinoid X receptor beta.	honokiol	0-8	retinoid X receptor beta	Homo sapiens	56-80
20606297-4	2010	Using this system, we identified honokiol, a compound extracted from Magnolia officinalis, as an activator of the ABCA1 promoter.	honokiol	33-41	ATP binding cassette subfamily A member 1	Homo sapiens	114-119
20606297-5	2010	We found that honokiol also increased ABCA1 mRNA and protein expression levels in a dose-dependent manner in U251-MG cells without significant cell death and also increased ABCA1, ABCG1 and apolipoprotein E (apoE) expression levels in THP-1 macrophages.	honokiol	14-22	ATP binding cassette subfamily A member 1	Homo sapiens	38-43
20606297-5	2010	We found that honokiol also increased ABCA1 mRNA and protein expression levels in a dose-dependent manner in U251-MG cells without significant cell death and also increased ABCA1, ABCG1 and apolipoprotein E (apoE) expression levels in THP-1 macrophages.	honokiol	14-22	ATP binding cassette subfamily A member 1	Homo sapiens	173-178
20606297-5	2010	We found that honokiol also increased ABCA1 mRNA and protein expression levels in a dose-dependent manner in U251-MG cells without significant cell death and also increased ABCA1, ABCG1 and apolipoprotein E (apoE) expression levels in THP-1 macrophages.	honokiol	14-22	ATP binding cassette subfamily G member 1	Homo sapiens	180-185
20606297-5	2010	We found that honokiol also increased ABCA1 mRNA and protein expression levels in a dose-dependent manner in U251-MG cells without significant cell death and also increased ABCA1, ABCG1 and apolipoprotein E (apoE) expression levels in THP-1 macrophages.	honokiol	14-22	apolipoprotein E	Homo sapiens	190-206
20606297-5	2010	We found that honokiol also increased ABCA1 mRNA and protein expression levels in a dose-dependent manner in U251-MG cells without significant cell death and also increased ABCA1, ABCG1 and apolipoprotein E (apoE) expression levels in THP-1 macrophages.	honokiol	14-22	apolipoprotein E	Homo sapiens	208-212
20606297-5	2010	We found that honokiol also increased ABCA1 mRNA and protein expression levels in a dose-dependent manner in U251-MG cells without significant cell death and also increased ABCA1, ABCG1 and apolipoprotein E (apoE) expression levels in THP-1 macrophages.	honokiol	14-22	GLI family zinc finger 2	Homo sapiens	235-240
20606297-7	2010	Cotreatment of the cells with honokiol and T0901317 (synthetic LXR ligand) further increased the ABCA1 expression level, whereas cotreatment with 9-cis retinoic acid had no additive effect compared with treatment with honokiol alone.	honokiol	30-38	ATP binding cassette subfamily A member 1	Homo sapiens	97-102
20606297-8	2010	We also found that honokiol has binding affinity to RXRbeta.	honokiol	19-27	retinoid X receptor beta	Homo sapiens	52-59
20606297-9	2010	In this study, we identified for the first time honokiol as an upregulator of ABCA1 expression, which is mediated by the binding of honokiol to RXRbeta as a ligand.	honokiol	48-56	ATP binding cassette subfamily A member 1	Homo sapiens	78-83
20606297-9	2010	In this study, we identified for the first time honokiol as an upregulator of ABCA1 expression, which is mediated by the binding of honokiol to RXRbeta as a ligand.	honokiol	48-56	retinoid X receptor beta	Homo sapiens	144-151
20606297-9	2010	In this study, we identified for the first time honokiol as an upregulator of ABCA1 expression, which is mediated by the binding of honokiol to RXRbeta as a ligand.	honokiol	132-140	ATP binding cassette subfamily A member 1	Homo sapiens	78-83
20606297-9	2010	In this study, we identified for the first time honokiol as an upregulator of ABCA1 expression, which is mediated by the binding of honokiol to RXRbeta as a ligand.	honokiol	132-140	retinoid X receptor beta	Homo sapiens	144-151
20703013-5	2010	The elevated serum levels of tumor necrosis factor-alpha and IL-1beta in the CIA mice were also restored to control levels via honokiol treatment.	honokiol	127-135	interleukin 1 beta	Mus musculus	61-69
20703013-5	2010	The elevated serum levels of tumor necrosis factor-alpha and IL-1beta in the CIA mice were also restored to control levels via honokiol treatment.	honokiol	127-135	nuclear receptor coactivator 5	Mus musculus	77-80
20703013-6	2010	In the CIA mice, honokiol inhibited CII- or lipopolysaccharide-stimulated cytokine secretion in spleen cells, as well as CII-stimulated spleen cell proliferation.	honokiol	17-25	nuclear receptor coactivator 5	Mus musculus	7-10
20703013-7	2010	Furthermore, honokiol treatment reduced CIA-induced oxidative damage in the liver and kidney tissues of CIA mice.	honokiol	13-21	nuclear receptor coactivator 5	Mus musculus	40-43
20703013-7	2010	Furthermore, honokiol treatment reduced CIA-induced oxidative damage in the liver and kidney tissues of CIA mice.	honokiol	13-21	nuclear receptor coactivator 5	Mus musculus	104-107
20703013-8	2010	Collectively, the oral administration of honokiol inhibited CIA development by reducing the production of pro-inflammatory cytokines, MMP expressions, and oxidative stress.	honokiol	41-49	nuclear receptor coactivator 5	Mus musculus	60-63
19815000-12	2009	A 14-day treatment with either magnolol (10 mg/kg) or honokiol (1 mg/kg) enhanced phosphorylation of Akt in the forebrain at 2 months of age.	honokiol	54-62	thymoma viral proto-oncogene 1	Mus musculus	101-104
19219913-0	2009	Liposomal honokiol inhibits VEGF-D-induced lymphangiogenesis and metastasis in xenograft tumor model.	honokiol	10-18	vascular endothelial growth factor D	Homo sapiens	28-34
19483651-0	2009	Honokiol-mediated inhibition of PI3K/mTOR pathway: a potential strategy to overcome immunoresistance in glioma, breast, and prostate carcinoma without impacting T cell function.	honokiol	0-8	mechanistic target of rapamycin kinase	Homo sapiens	37-41
19483651-4	2009	Here we show that Honokiol, a natural dietary product isolated from an extract of seed cones from Magnolia grandiflora, can decrease PI3K/mTOR pathway-mediated immunoresistance of glioma, breast and prostate cancer cell lines, without affecting critical proinflammatory T cell functions.	honokiol	18-26	mechanistic target of rapamycin kinase	Homo sapiens	138-142
19483651-6	2009	In contrast to classic inhibitors, including LY294002, wortmannin, AKT inhibitor III and rapamycin, Honokiol specifically decreases the PI3K/mTOR pathway activity in tumor cells, but not in freshly stimulated T cells.	honokiol	100-108	mechanistic target of rapamycin kinase	Homo sapiens	141-145
19706287-3	2009	AKR1B10 was inhibited by curcuminoids, magnolol, honokiol and resveratrol, with IC(50) values of 0.06-5 microM, which were lower than their values for AR.	honokiol	49-57	aldo-keto reductase family 1 member B10	Homo sapiens	0-7
19832997-4	2009	Consistently, honokiol and magnolol significantly decreased glutamate-induced c-Fos protein expression in superficial (I-II) laminae of the L4-L5 lumbar dorsal horn.	honokiol	14-22	FBJ osteosarcoma oncogene	Mus musculus	78-83
19788858-4	2009	In addition, honokiol appeared to block the production of cytotoxic cytokines such as interleukin (IL)-1beta and tumor necrosis factor (TNF)-alpha, nitric oxide (NO), and reactive oxygen species (ROS).	honokiol	13-21	interleukin 1 beta	Mus musculus	86-108
19788858-4	2009	In addition, honokiol appeared to block the production of cytotoxic cytokines such as interleukin (IL)-1beta and tumor necrosis factor (TNF)-alpha, nitric oxide (NO), and reactive oxygen species (ROS).	honokiol	13-21	tumor necrosis factor	Mus musculus	113-146
21783988-0	2009	Reactive oxygen species production and Bax/Bcl-2 regulation in honokiol-induced apoptosis in human hepatocellular carcinoma SMMC-7721 cells.	honokiol	63-71	BCL2 associated X, apoptosis regulator	Homo sapiens	39-42
21783988-0	2009	Reactive oxygen species production and Bax/Bcl-2 regulation in honokiol-induced apoptosis in human hepatocellular carcinoma SMMC-7721 cells.	honokiol	63-71	BCL2 apoptosis regulator	Homo sapiens	43-48
21783988-6	2009	Up-regulation of Bax and down-regulation of Bcl-2 were observed, suggesting that honokiol-induced apoptosis was associated with reactive oxygen species (ROS) production and an increase of Bax/Bcl-2 ratios.	honokiol	81-89	BCL2 associated X, apoptosis regulator	Homo sapiens	17-20
21783988-6	2009	Up-regulation of Bax and down-regulation of Bcl-2 were observed, suggesting that honokiol-induced apoptosis was associated with reactive oxygen species (ROS) production and an increase of Bax/Bcl-2 ratios.	honokiol	81-89	BCL2 apoptosis regulator	Homo sapiens	44-49
21783988-6	2009	Up-regulation of Bax and down-regulation of Bcl-2 were observed, suggesting that honokiol-induced apoptosis was associated with reactive oxygen species (ROS) production and an increase of Bax/Bcl-2 ratios.	honokiol	81-89	BCL2 associated X, apoptosis regulator	Homo sapiens	188-191
21783988-6	2009	Up-regulation of Bax and down-regulation of Bcl-2 were observed, suggesting that honokiol-induced apoptosis was associated with reactive oxygen species (ROS) production and an increase of Bax/Bcl-2 ratios.	honokiol	81-89	BCL2 apoptosis regulator	Homo sapiens	192-197
19219913-9	2009	In in vitro study, honokiol inhibited VEGF-D-induced survival, proliferation and tube-formation of both human umbilical vein endothelial cells (HUVECs) and lymphatic vascular endothelial cells (HLECs).	honokiol	19-27	vascular endothelial growth factor D	Homo sapiens	38-44
19219913-10	2009	Western blotting analysis showed that liposomal honokiol-inhibited Akt and MAPK phosphorylation in 2 endothelial cells, and downregulated expressions of VEGFR-2 of human vascular endothelial cells and VEGFR-3 of lymphatic endothelial cells.	honokiol	48-56	AKT serine/threonine kinase 1	Homo sapiens	67-70
19219913-10	2009	Western blotting analysis showed that liposomal honokiol-inhibited Akt and MAPK phosphorylation in 2 endothelial cells, and downregulated expressions of VEGFR-2 of human vascular endothelial cells and VEGFR-3 of lymphatic endothelial cells.	honokiol	48-56	kinase insert domain receptor	Homo sapiens	153-160
19219913-10	2009	Western blotting analysis showed that liposomal honokiol-inhibited Akt and MAPK phosphorylation in 2 endothelial cells, and downregulated expressions of VEGFR-2 of human vascular endothelial cells and VEGFR-3 of lymphatic endothelial cells.	honokiol	48-56	fms related receptor tyrosine kinase 4	Homo sapiens	201-208
19219913-11	2009	Thus, we identified for the first time that honokiol provided therapeutic benefit not only by direct effects on tumor cells and antiangiogenesis but also by inhibiting lymphangiogenesis and metastasis via the VEGFR-3 pathway.	honokiol	44-52	fms related receptor tyrosine kinase 4	Homo sapiens	209-216
19371623-5	2009	Honokiol inhibited the maturation of SREBP-1c and its translocation to the nucleus, the binding of nSREBP-1c to SRE or SRE-related sequences of its lipogenic target genes, and the expression of genes for fatty acid synthesis.	honokiol	0-8	sterol regulatory element binding transcription factor 1	Rattus norvegicus	37-45
19203212-10	2009	Second, honokiol induces cyclophilin D, thus potentiating the mitochondrial permeability transition pore, and causing death in cells with wild-type p53.	honokiol	8-16	peptidylprolyl isomerase D	Homo sapiens	25-38
19203212-10	2009	Second, honokiol induces cyclophilin D, thus potentiating the mitochondrial permeability transition pore, and causing death in cells with wild-type p53.	honokiol	8-16	tumor protein p53	Homo sapiens	148-151
19371623-10	2009	A chromatin immunoprecipitation assay demonstrated inhibition of specific binding of SREBP-1c to the Fas promoter by honokiol in vivo.	honokiol	117-125	sterol regulatory element binding transcription factor 1	Rattus norvegicus	85-93
19371623-11	2009	These results demonstrate that honokiol has the potential to ameliorate alcoholic steatosis by blocking fatty acid synthesis regulated by SREBP-1c.	honokiol	31-39	sterol regulatory element binding transcription factor 1	Rattus norvegicus	138-146
19303869-6	2009	Both honokiol treatments (HK5 x 1 and HK1 x 5) significantly ameliorated eccentric exercise-induced muscle damage as revealed by suppression of cell fragmentation, protein nitrotyrosylation and PARP upregulation, as well as reductions in lipid peroxidation and leukocyte infiltration, possibly through downregulating gene expression for COX-2, iNOS, and the proinflammatory cytokines by modulation of NF-kappaB activation.	honokiol	5-13	poly (ADP-ribose) polymerase 1	Rattus norvegicus	194-198
19303869-6	2009	Both honokiol treatments (HK5 x 1 and HK1 x 5) significantly ameliorated eccentric exercise-induced muscle damage as revealed by suppression of cell fragmentation, protein nitrotyrosylation and PARP upregulation, as well as reductions in lipid peroxidation and leukocyte infiltration, possibly through downregulating gene expression for COX-2, iNOS, and the proinflammatory cytokines by modulation of NF-kappaB activation.	honokiol	5-13	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	337-342
19303869-6	2009	Both honokiol treatments (HK5 x 1 and HK1 x 5) significantly ameliorated eccentric exercise-induced muscle damage as revealed by suppression of cell fragmentation, protein nitrotyrosylation and PARP upregulation, as well as reductions in lipid peroxidation and leukocyte infiltration, possibly through downregulating gene expression for COX-2, iNOS, and the proinflammatory cytokines by modulation of NF-kappaB activation.	honokiol	5-13	nitric oxide synthase 2	Rattus norvegicus	344-348
19135778-0	2009	Down-regulation of c-Src/EGFR-mediated signaling activation is involved in the honokiol-induced cell cycle arrest and apoptosis in MDA-MB-231 human breast cancer cells.	honokiol	79-87	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	19-24
19135778-0	2009	Down-regulation of c-Src/EGFR-mediated signaling activation is involved in the honokiol-induced cell cycle arrest and apoptosis in MDA-MB-231 human breast cancer cells.	honokiol	79-87	epidermal growth factor receptor	Homo sapiens	25-29
19135778-5	2009	The honokiol-induced cell cycle arrest was well correlated with the suppressive expression of CDK4, cyclin D1, CDK2, cyclin E, c-Myc, and phosphorylated retinoblastoma protein (pRb) at Ser780.	honokiol	4-12	cyclin dependent kinase 4	Homo sapiens	94-98
19135778-5	2009	The honokiol-induced cell cycle arrest was well correlated with the suppressive expression of CDK4, cyclin D1, CDK2, cyclin E, c-Myc, and phosphorylated retinoblastoma protein (pRb) at Ser780.	honokiol	4-12	cyclin D1	Homo sapiens	100-109
19135778-5	2009	The honokiol-induced cell cycle arrest was well correlated with the suppressive expression of CDK4, cyclin D1, CDK2, cyclin E, c-Myc, and phosphorylated retinoblastoma protein (pRb) at Ser780.	honokiol	4-12	cyclin dependent kinase 2	Homo sapiens	111-115
19135778-5	2009	The honokiol-induced cell cycle arrest was well correlated with the suppressive expression of CDK4, cyclin D1, CDK2, cyclin E, c-Myc, and phosphorylated retinoblastoma protein (pRb) at Ser780.	honokiol	4-12	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	127-132
19135778-5	2009	The honokiol-induced cell cycle arrest was well correlated with the suppressive expression of CDK4, cyclin D1, CDK2, cyclin E, c-Myc, and phosphorylated retinoblastoma protein (pRb) at Ser780.	honokiol	4-12	RB transcriptional corepressor 1	Homo sapiens	177-180
19135778-6	2009	Apoptosis caused by honokiol was also concomitant with the cleavage of caspases (caspase-3, -8, and -9) and Bid along with the suppressive expression of Bcl-2, but it was independent on the expression of Bax and p53.	honokiol	20-28	caspase 8	Homo sapiens	71-79
19135778-6	2009	Apoptosis caused by honokiol was also concomitant with the cleavage of caspases (caspase-3, -8, and -9) and Bid along with the suppressive expression of Bcl-2, but it was independent on the expression of Bax and p53.	honokiol	20-28	caspase 3	Homo sapiens	81-102
19135778-6	2009	Apoptosis caused by honokiol was also concomitant with the cleavage of caspases (caspase-3, -8, and -9) and Bid along with the suppressive expression of Bcl-2, but it was independent on the expression of Bax and p53.	honokiol	20-28	BH3 interacting domain death agonist	Homo sapiens	108-111
19135778-6	2009	Apoptosis caused by honokiol was also concomitant with the cleavage of caspases (caspase-3, -8, and -9) and Bid along with the suppressive expression of Bcl-2, but it was independent on the expression of Bax and p53.	honokiol	20-28	BCL2 apoptosis regulator	Homo sapiens	153-158
19135778-6	2009	Apoptosis caused by honokiol was also concomitant with the cleavage of caspases (caspase-3, -8, and -9) and Bid along with the suppressive expression of Bcl-2, but it was independent on the expression of Bax and p53.	honokiol	20-28	BCL2 associated X, apoptosis regulator	Homo sapiens	204-207
19135778-6	2009	Apoptosis caused by honokiol was also concomitant with the cleavage of caspases (caspase-3, -8, and -9) and Bid along with the suppressive expression of Bcl-2, but it was independent on the expression of Bax and p53.	honokiol	20-28	tumor protein p53	Homo sapiens	212-215
19135778-7	2009	In addition, honokiol-treated cells exhibited the cleavage of poly (ADP-ribose) polymerase (PARP) and DNA fragmentation.	honokiol	13-21	poly(ADP-ribose) polymerase 1	Homo sapiens	62-90
19135778-7	2009	In addition, honokiol-treated cells exhibited the cleavage of poly (ADP-ribose) polymerase (PARP) and DNA fragmentation.	honokiol	13-21	poly(ADP-ribose) polymerase 1	Homo sapiens	92-96
19135778-8	2009	In the analysis of signal transduction pathway, honokiol down-regulated the expression and phosphorylation of c-Src, epidermal growth factor receptor (EGFR), and Akt, and consequently led to the inactivation of mTOR and its downstream signal molecules including 4E-binding protein (4E-BP) and p70 S6 kinase.	honokiol	48-56	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	110-115
19135778-8	2009	In the analysis of signal transduction pathway, honokiol down-regulated the expression and phosphorylation of c-Src, epidermal growth factor receptor (EGFR), and Akt, and consequently led to the inactivation of mTOR and its downstream signal molecules including 4E-binding protein (4E-BP) and p70 S6 kinase.	honokiol	48-56	epidermal growth factor receptor	Homo sapiens	117-149
19135778-8	2009	In the analysis of signal transduction pathway, honokiol down-regulated the expression and phosphorylation of c-Src, epidermal growth factor receptor (EGFR), and Akt, and consequently led to the inactivation of mTOR and its downstream signal molecules including 4E-binding protein (4E-BP) and p70 S6 kinase.	honokiol	48-56	epidermal growth factor receptor	Homo sapiens	151-155
19135778-8	2009	In the analysis of signal transduction pathway, honokiol down-regulated the expression and phosphorylation of c-Src, epidermal growth factor receptor (EGFR), and Akt, and consequently led to the inactivation of mTOR and its downstream signal molecules including 4E-binding protein (4E-BP) and p70 S6 kinase.	honokiol	48-56	AKT serine/threonine kinase 1	Homo sapiens	162-165
19135778-8	2009	In the analysis of signal transduction pathway, honokiol down-regulated the expression and phosphorylation of c-Src, epidermal growth factor receptor (EGFR), and Akt, and consequently led to the inactivation of mTOR and its downstream signal molecules including 4E-binding protein (4E-BP) and p70 S6 kinase.	honokiol	48-56	mechanistic target of rapamycin kinase	Homo sapiens	211-215
19371623-8	2009	Daily administration of honokiol (10 mg/kg body weight) by gavage during the final 2 weeks of ethanol treatment completely reversed these effects on hepatotoxicity markers, including hepatic triglyceride, hepatic glutathione, and serum TNF-alpha, with efficacious abrogation of fat accumulation in the liver.	honokiol	24-32	tumor necrosis factor	Rattus norvegicus	236-245
18507762-0	2008	Involvement of p38 mitogen-activated protein kinase pathway in honokiol-induced apoptosis in a human hepatoma cell line (hepG2).	honokiol	63-71	mitogen-activated protein kinase 14	Homo sapiens	15-18
18507762-7	2008	RESULTS: Honokiol induced apoptosis with a decreased expression of procaspase-3 and -9 and an increased expression of active caspase-3.	honokiol	9-17	caspase 3	Homo sapiens	67-86
18507762-7	2008	RESULTS: Honokiol induced apoptosis with a decreased expression of procaspase-3 and -9 and an increased expression of active caspase-3.	honokiol	9-17	caspase 3	Homo sapiens	70-79
18507762-8	2008	Exposure of hepG2 cells to honokiol resulted in the downregulation of Bcl-X(L) and Bcl-2 expression and the release of mitochondrial cytochrome c to the cytosol.	honokiol	27-35	BCL2 like 1	Homo sapiens	70-78
18507762-8	2008	Exposure of hepG2 cells to honokiol resulted in the downregulation of Bcl-X(L) and Bcl-2 expression and the release of mitochondrial cytochrome c to the cytosol.	honokiol	27-35	BCL2 apoptosis regulator	Homo sapiens	83-88
18507762-8	2008	Exposure of hepG2 cells to honokiol resulted in the downregulation of Bcl-X(L) and Bcl-2 expression and the release of mitochondrial cytochrome c to the cytosol.	honokiol	27-35	cytochrome c, somatic	Homo sapiens	133-145
18507762-9	2008	In addition, honokiol activated the p38 mitogen-activated protein kinase (MAPK) pathway, and the inhibition of this pathway by SB203580 reduced honokiol-induced apoptosis and activation of caspase-3.	honokiol	13-21	mitogen-activated protein kinase 14	Homo sapiens	36-72
18507762-9	2008	In addition, honokiol activated the p38 mitogen-activated protein kinase (MAPK) pathway, and the inhibition of this pathway by SB203580 reduced honokiol-induced apoptosis and activation of caspase-3.	honokiol	144-152	caspase 3	Homo sapiens	189-198
18507762-10	2008	CONCLUSION: Honokiol induces apoptosis of hepG2 human hepatocellular carcinoma cells through activation of the p38 MAPK pathway, and, in turn, activation of caspase-3.	honokiol	12-20	mitogen-activated protein kinase 14	Homo sapiens	111-114
18507762-10	2008	CONCLUSION: Honokiol induces apoptosis of hepG2 human hepatocellular carcinoma cells through activation of the p38 MAPK pathway, and, in turn, activation of caspase-3.	honokiol	12-20	caspase 3	Homo sapiens	157-166
18640101-2	2008	Among the downstream pathways inhibited by honokiol is nuclear factor kappa beta (NFkappabeta).	honokiol	43-51	nuclear factor kappa B subunit 1	Homo sapiens	82-93
18588872-4	2008	The effects of honokiol might be reversely related to the expression level of human epidermal growth receptor 2, (HER-2, also known as erbB2, c-erbB2) since knockdown of her-2 expression by siRNA significantly enhanced the sensitivity of the her-2 over-expressed BT-474 cells to the honokiol-induced apoptosis.	honokiol	15-23	erb-b2 receptor tyrosine kinase 2	Homo sapiens	114-119
18588872-4	2008	The effects of honokiol might be reversely related to the expression level of human epidermal growth receptor 2, (HER-2, also known as erbB2, c-erbB2) since knockdown of her-2 expression by siRNA significantly enhanced the sensitivity of the her-2 over-expressed BT-474 cells to the honokiol-induced apoptosis.	honokiol	15-23	erb-b2 receptor tyrosine kinase 2	Homo sapiens	135-140
18588872-4	2008	The effects of honokiol might be reversely related to the expression level of human epidermal growth receptor 2, (HER-2, also known as erbB2, c-erbB2) since knockdown of her-2 expression by siRNA significantly enhanced the sensitivity of the her-2 over-expressed BT-474 cells to the honokiol-induced apoptosis.	honokiol	15-23	erb-b2 receptor tyrosine kinase 2	Homo sapiens	142-149
18588872-4	2008	The effects of honokiol might be reversely related to the expression level of human epidermal growth receptor 2, (HER-2, also known as erbB2, c-erbB2) since knockdown of her-2 expression by siRNA significantly enhanced the sensitivity of the her-2 over-expressed BT-474 cells to the honokiol-induced apoptosis.	honokiol	15-23	erb-b2 receptor tyrosine kinase 2	Homo sapiens	170-175
18588872-4	2008	The effects of honokiol might be reversely related to the expression level of human epidermal growth receptor 2, (HER-2, also known as erbB2, c-erbB2) since knockdown of her-2 expression by siRNA significantly enhanced the sensitivity of the her-2 over-expressed BT-474 cells to the honokiol-induced apoptosis.	honokiol	15-23	erb-b2 receptor tyrosine kinase 2	Homo sapiens	242-247
18588872-4	2008	The effects of honokiol might be reversely related to the expression level of human epidermal growth receptor 2, (HER-2, also known as erbB2, c-erbB2) since knockdown of her-2 expression by siRNA significantly enhanced the sensitivity of the her-2 over-expressed BT-474 cells to the honokiol-induced apoptosis.	honokiol	283-291	erb-b2 receptor tyrosine kinase 2	Homo sapiens	114-119
18588872-4	2008	The effects of honokiol might be reversely related to the expression level of human epidermal growth receptor 2, (HER-2, also known as erbB2, c-erbB2) since knockdown of her-2 expression by siRNA significantly enhanced the sensitivity of the her-2 over-expressed BT-474 cells to the honokiol-induced apoptosis.	honokiol	283-291	erb-b2 receptor tyrosine kinase 2	Homo sapiens	135-140
18588872-4	2008	The effects of honokiol might be reversely related to the expression level of human epidermal growth receptor 2, (HER-2, also known as erbB2, c-erbB2) since knockdown of her-2 expression by siRNA significantly enhanced the sensitivity of the her-2 over-expressed BT-474 cells to the honokiol-induced apoptosis.	honokiol	283-291	erb-b2 receptor tyrosine kinase 2	Homo sapiens	142-149
18588872-4	2008	The effects of honokiol might be reversely related to the expression level of human epidermal growth receptor 2, (HER-2, also known as erbB2, c-erbB2) since knockdown of her-2 expression by siRNA significantly enhanced the sensitivity of the her-2 over-expressed BT-474 cells to the honokiol-induced apoptosis.	honokiol	283-291	erb-b2 receptor tyrosine kinase 2	Homo sapiens	170-175
18588872-5	2008	Furthermore, inhibition of HER-2 signalling by specific human epidermal growth receptor 1/HER-2 (EGFR/HER-2) kinase inhibitor lapatinib synergistically enhanced the anti-cancer effects of honokiol in her-2 over-expressed breast cancer cells.	honokiol	188-196	erb-b2 receptor tyrosine kinase 2	Homo sapiens	27-32
18588872-5	2008	Furthermore, inhibition of HER-2 signalling by specific human epidermal growth receptor 1/HER-2 (EGFR/HER-2) kinase inhibitor lapatinib synergistically enhanced the anti-cancer effects of honokiol in her-2 over-expressed breast cancer cells.	honokiol	188-196	erb-b2 receptor tyrosine kinase 2	Homo sapiens	90-95
18588872-5	2008	Furthermore, inhibition of HER-2 signalling by specific human epidermal growth receptor 1/HER-2 (EGFR/HER-2) kinase inhibitor lapatinib synergistically enhanced the anti-cancer effects of honokiol in her-2 over-expressed breast cancer cells.	honokiol	188-196	epidermal growth factor receptor	Homo sapiens	97-101
18588872-5	2008	Furthermore, inhibition of HER-2 signalling by specific human epidermal growth receptor 1/HER-2 (EGFR/HER-2) kinase inhibitor lapatinib synergistically enhanced the anti-cancer effects of honokiol in her-2 over-expressed breast cancer cells.	honokiol	188-196	erb-b2 receptor tyrosine kinase 2	Homo sapiens	90-95
18588872-5	2008	Furthermore, inhibition of HER-2 signalling by specific human epidermal growth receptor 1/HER-2 (EGFR/HER-2) kinase inhibitor lapatinib synergistically enhanced the anti-cancer effects of honokiol in her-2 over-expressed breast cancer cells.	honokiol	188-196	erb-b2 receptor tyrosine kinase 2	Homo sapiens	200-205
18588872-6	2008	Finally, we showed that honokiol was able to attenuate the PI3K/Akt/mTOR (Phosphoinositide 3-kinases/Akt/mammalian target of rapamycin) signalling by down-regulation of Akt phosphorylation and upregulation of PTEN (Phosphatase and Tensin homolog deleted on chromosome Ten) expression.	honokiol	24-32	AKT serine/threonine kinase 1	Homo sapiens	64-67
18588872-6	2008	Finally, we showed that honokiol was able to attenuate the PI3K/Akt/mTOR (Phosphoinositide 3-kinases/Akt/mammalian target of rapamycin) signalling by down-regulation of Akt phosphorylation and upregulation of PTEN (Phosphatase and Tensin homolog deleted on chromosome Ten) expression.	honokiol	24-32	mechanistic target of rapamycin kinase	Homo sapiens	68-72
18588872-6	2008	Finally, we showed that honokiol was able to attenuate the PI3K/Akt/mTOR (Phosphoinositide 3-kinases/Akt/mammalian target of rapamycin) signalling by down-regulation of Akt phosphorylation and upregulation of PTEN (Phosphatase and Tensin homolog deleted on chromosome Ten) expression.	honokiol	24-32	AKT serine/threonine kinase 1	Homo sapiens	101-104
18588872-6	2008	Finally, we showed that honokiol was able to attenuate the PI3K/Akt/mTOR (Phosphoinositide 3-kinases/Akt/mammalian target of rapamycin) signalling by down-regulation of Akt phosphorylation and upregulation of PTEN (Phosphatase and Tensin homolog deleted on chromosome Ten) expression.	honokiol	24-32	mechanistic target of rapamycin kinase	Homo sapiens	105-134
18588872-6	2008	Finally, we showed that honokiol was able to attenuate the PI3K/Akt/mTOR (Phosphoinositide 3-kinases/Akt/mammalian target of rapamycin) signalling by down-regulation of Akt phosphorylation and upregulation of PTEN (Phosphatase and Tensin homolog deleted on chromosome Ten) expression.	honokiol	24-32	AKT serine/threonine kinase 1	Homo sapiens	101-104
18588872-6	2008	Finally, we showed that honokiol was able to attenuate the PI3K/Akt/mTOR (Phosphoinositide 3-kinases/Akt/mammalian target of rapamycin) signalling by down-regulation of Akt phosphorylation and upregulation of PTEN (Phosphatase and Tensin homolog deleted on chromosome Ten) expression.	honokiol	24-32	phosphatase and tensin homolog	Homo sapiens	209-213
18640101-6	2008	Honokiol efficiently scavenged superoxide radicals in xanthine oxidase and cytochrome P-450 cell-free systems with the rate constant 3.2x10(5)M(-1)s(-1), which is similar to reactivity of ascorbic acid but 20-times higher than reactivity of vitamin E analog trolox.	honokiol	0-8	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	75-91
18440692-5	2008	RESULTS: Honokiol significantly inhibited proliferation and induced apoptosis, with alteration of Bcl-2 members and caspase-3.	honokiol	9-17	BCL2 apoptosis regulator	Homo sapiens	98-103
18440692-5	2008	RESULTS: Honokiol significantly inhibited proliferation and induced apoptosis, with alteration of Bcl-2 members and caspase-3.	honokiol	9-17	caspase 3	Homo sapiens	116-125
18594009-0	2008	Honokiol suppresses survival signals mediated by Ras-dependent phospholipase D activity in human cancer cells.	honokiol	0-8	glycosylphosphatidylinositol specific phospholipase D1	Homo sapiens	63-78
18594009-4	2008	The purpose of this study was to investigate the effect of honokiol on PLD survival signals and the Ras dependence of these signals.	honokiol	59-67	glycosylphosphatidylinositol specific phospholipase D1	Homo sapiens	71-74
18594009-5	2008	EXPERIMENTAL DESIGN: The effect of honokiol upon PLD activity was examined in human cancer cell lines where PLD activity provides a survival signal.	honokiol	35-43	glycosylphosphatidylinositol specific phospholipase D1	Homo sapiens	49-52
18594009-5	2008	EXPERIMENTAL DESIGN: The effect of honokiol upon PLD activity was examined in human cancer cell lines where PLD activity provides a survival signal.	honokiol	35-43	glycosylphosphatidylinositol specific phospholipase D1	Homo sapiens	108-111
18594009-7	2008	RESULTS: We report here that honokiol suppresses PLD activity in human cancer cells where PLD has been shown to suppress apoptosis.	honokiol	29-37	glycosylphosphatidylinositol specific phospholipase D1	Homo sapiens	49-52
18594009-7	2008	RESULTS: We report here that honokiol suppresses PLD activity in human cancer cells where PLD has been shown to suppress apoptosis.	honokiol	29-37	glycosylphosphatidylinositol specific phospholipase D1	Homo sapiens	90-93
18594009-8	2008	PLD activity is commonly elevated in response to the stress of serum withdrawal, and, importantly, the stress-induced increase in PLD activity is selectively suppressed by honokiol.	honokiol	172-180	glycosylphosphatidylinositol specific phospholipase D1	Homo sapiens	0-3
18594009-8	2008	PLD activity is commonly elevated in response to the stress of serum withdrawal, and, importantly, the stress-induced increase in PLD activity is selectively suppressed by honokiol.	honokiol	172-180	glycosylphosphatidylinositol specific phospholipase D1	Homo sapiens	130-133
18594009-12	2008	CONCLUSION: The data provided here indicate that honokiol may be a valuable therapeutic reagent for targeting a large number of human cancers that depend on Ras and PLD for their survival.	honokiol	49-57	glycosylphosphatidylinositol specific phospholipase D1	Homo sapiens	165-168
18281560-4	2008	Honokiol was administered by oral gavage to male nude mice s.c. implanted with PC-3 cells.	honokiol	0-8	proprotein convertase subtilisin/kexin type 1	Mus musculus	79-83
18706101-7	2008	In addition, the combination of honokiol and DDP apparently reduced the number of vessels by immunolabeling of CD31 in the tissue sections, compared with control groups.	honokiol	32-40	platelet and endothelial cell adhesion molecule 1	Homo sapiens	111-115
17914455-10	2008	Tumor growth in vivo was strongly reduced in the Shb-knockdown cells upon honokiol treatment.	honokiol	74-82	src homology 2 domain-containing transforming protein B	Mus musculus	49-52
18645030-0	2008	The natural product honokiol preferentially inhibits cellular FLICE-inhibitory protein and augments death receptor-induced apoptosis.	honokiol	20-28	CASP8 and FADD like apoptosis regulator	Homo sapiens	53-86
18645030-4	2008	Honokiol alone moderately inhibited the growth of human lung cancer cells; however, when combined with tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), greater effects on decreasing cell survival and inducing apoptosis than TRAIL alone were observed, indicating that honokiol cooperates with TRAIL to enhance apoptosis.	honokiol	283-291	TNF superfamily member 10	Homo sapiens	103-158
18645030-4	2008	Honokiol alone moderately inhibited the growth of human lung cancer cells; however, when combined with tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), greater effects on decreasing cell survival and inducing apoptosis than TRAIL alone were observed, indicating that honokiol cooperates with TRAIL to enhance apoptosis.	honokiol	283-291	TNF superfamily member 10	Homo sapiens	160-165
18645030-6	2008	Among several apoptosis-associated proteins tested, cellular FLICE-inhibitory protein (c-FLIP) was the only one that was rapidly down-regulated by honokiol in all of the tested cell lines.	honokiol	147-155	CASP8 and FADD like apoptosis regulator	Homo sapiens	52-85
18645030-6	2008	Among several apoptosis-associated proteins tested, cellular FLICE-inhibitory protein (c-FLIP) was the only one that was rapidly down-regulated by honokiol in all of the tested cell lines.	honokiol	147-155	CASP8 and FADD like apoptosis regulator	Homo sapiens	87-93
18645030-7	2008	The down-regulation of c-FLIP by honokiol could be prevented by the proteasome inhibitor MG132.	honokiol	33-41	CASP8 and FADD like apoptosis regulator	Homo sapiens	23-29
18645030-8	2008	Moreover, honokiol increased c-FLIP ubiquitination.	honokiol	10-18	CASP8 and FADD like apoptosis regulator	Homo sapiens	29-35
18645030-9	2008	These results indicate that honokiol down-regulates c-FLIP by facilitating its degradation through a ubiquitin/proteasome-mediated mechanism.	honokiol	28-36	CASP8 and FADD like apoptosis regulator	Homo sapiens	52-58
18645030-10	2008	Enforced expression of ectopic c-FLIP abolished the ability of honokiol to enhance TRAIL-induced apoptosis.	honokiol	63-71	CASP8 and FADD like apoptosis regulator	Homo sapiens	31-37
18645030-10	2008	Enforced expression of ectopic c-FLIP abolished the ability of honokiol to enhance TRAIL-induced apoptosis.	honokiol	63-71	TNF superfamily member 10	Homo sapiens	83-88
18645030-11	2008	Several honokiol derivatives, which exhibited more potent effects on down-regulation of c-FLIP than honokiol, showed better efficacy than honokiol in inhibiting the growth and enhancing TRAIL-induced apoptosis as well.	honokiol	8-16	CASP8 and FADD like apoptosis regulator	Homo sapiens	88-94
18645030-11	2008	Several honokiol derivatives, which exhibited more potent effects on down-regulation of c-FLIP than honokiol, showed better efficacy than honokiol in inhibiting the growth and enhancing TRAIL-induced apoptosis as well.	honokiol	8-16	TNF superfamily member 10	Homo sapiens	186-191
18645030-12	2008	Collectively, we conclude that c-FLIP down-regulation is a key event for honokiol to modulate the death receptor-induced apoptosis.	honokiol	73-81	CASP8 and FADD like apoptosis regulator	Homo sapiens	31-37
18423412-4	2008	Here we explored the efficacy of honokiol, a small molecular weight natural product, on NADPH oxidase-related oxidative stress-mediated NF-kappaB-regulated signaling and apoptosis in human umbilical vein endothelial cells (HUVECs) under hyperglycemic conditions.	honokiol	33-41	nuclear factor kappa B subunit 1	Homo sapiens	136-145
18423412-6	2008	Submicromolar concentrations of honokiol suppressed the increases of NADPH oxidase activity, Rac-1 phosphorylation, p22(phox) protein expression, and reactive oxygen species production in high glucose (HG)-stimulated HUVECs.	honokiol	32-40	Rac family small GTPase 1	Homo sapiens	93-98
18423412-6	2008	Submicromolar concentrations of honokiol suppressed the increases of NADPH oxidase activity, Rac-1 phosphorylation, p22(phox) protein expression, and reactive oxygen species production in high glucose (HG)-stimulated HUVECs.	honokiol	32-40	calcineurin like EF-hand protein 1	Homo sapiens	116-119
18423412-7	2008	The degradation of IkappaBalpha and increase of NF-kappaB activity were inhibited by honokiol in HG-treated HUVECs.	honokiol	85-93	NFKB inhibitor alpha	Homo sapiens	19-31
18423412-7	2008	The degradation of IkappaBalpha and increase of NF-kappaB activity were inhibited by honokiol in HG-treated HUVECs.	honokiol	85-93	nuclear factor kappa B subunit 1	Homo sapiens	48-57
18423412-9	2008	Honokiol could reduce increased caspase-3 activity and the subsequent apoptosis and cell death triggered by HG.	honokiol	0-8	caspase 3	Homo sapiens	32-41
18423412-10	2008	These results imply that inhibition of NADPH oxidase-related oxidative stress by honokiol suppresses the HG-induced NF-kappaB-regulated COX-2 upregulation, apoptosis, and cell death in HUVECs, which has the potential to be developed as a therapeutic agent to prevent hyperglycemia-induced endothelial damage.	honokiol	81-89	nuclear factor kappa B subunit 1	Homo sapiens	116-125
18423412-10	2008	These results imply that inhibition of NADPH oxidase-related oxidative stress by honokiol suppresses the HG-induced NF-kappaB-regulated COX-2 upregulation, apoptosis, and cell death in HUVECs, which has the potential to be developed as a therapeutic agent to prevent hyperglycemia-induced endothelial damage.	honokiol	81-89	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	136-141
18281560-7	2008	RESULTS: Exposure of human prostate cancer cells (PC-3, LNCaP, and C4-2) to honokiol resulted in apoptotic DNA fragmentation in a concentration- and time-dependent manner irrespective of their androgen responsiveness or p53 status.	honokiol	76-84	proprotein convertase subtilisin/kexin type 1	Homo sapiens	50-54
18281560-7	2008	RESULTS: Exposure of human prostate cancer cells (PC-3, LNCaP, and C4-2) to honokiol resulted in apoptotic DNA fragmentation in a concentration- and time-dependent manner irrespective of their androgen responsiveness or p53 status.	honokiol	76-84	CDK5 regulatory subunit associated protein 1	Homo sapiens	67-71
18281560-7	2008	RESULTS: Exposure of human prostate cancer cells (PC-3, LNCaP, and C4-2) to honokiol resulted in apoptotic DNA fragmentation in a concentration- and time-dependent manner irrespective of their androgen responsiveness or p53 status.	honokiol	76-84	tumor protein p53	Homo sapiens	220-223
18281560-8	2008	Honokiol-induced apoptosis correlated with induction of Bax, Bak, and Bad and a decrease in Bcl-xL and Mcl-1 protein levels.	honokiol	0-8	BCL2-associated X protein	Mus musculus	56-59
18281560-8	2008	Honokiol-induced apoptosis correlated with induction of Bax, Bak, and Bad and a decrease in Bcl-xL and Mcl-1 protein levels.	honokiol	0-8	BCL2-antagonist/killer 1	Mus musculus	61-64
18281560-8	2008	Honokiol-induced apoptosis correlated with induction of Bax, Bak, and Bad and a decrease in Bcl-xL and Mcl-1 protein levels.	honokiol	0-8	BCL2-like 1	Mus musculus	92-98
18281560-8	2008	Honokiol-induced apoptosis correlated with induction of Bax, Bak, and Bad and a decrease in Bcl-xL and Mcl-1 protein levels.	honokiol	0-8	myeloid cell leukemia sequence 1	Mus musculus	103-108
18281560-9	2008	Transient transfection of PC-3 cells with Bak- and Bax-targeted siRNAs and Bcl-xL plasmid conferred partial yet significant protection against honokiol-induced apoptosis.	honokiol	143-151	proprotein convertase subtilisin/kexin type 1	Mus musculus	26-30
18281560-9	2008	Transient transfection of PC-3 cells with Bak- and Bax-targeted siRNAs and Bcl-xL plasmid conferred partial yet significant protection against honokiol-induced apoptosis.	honokiol	143-151	BCL2-antagonist/killer 1	Mus musculus	42-45
18281560-9	2008	Transient transfection of PC-3 cells with Bak- and Bax-targeted siRNAs and Bcl-xL plasmid conferred partial yet significant protection against honokiol-induced apoptosis.	honokiol	143-151	BCL2-associated X protein	Mus musculus	51-54
18281560-9	2008	Transient transfection of PC-3 cells with Bak- and Bax-targeted siRNAs and Bcl-xL plasmid conferred partial yet significant protection against honokiol-induced apoptosis.	honokiol	143-151	BCL2-like 1	Mus musculus	75-81
18281560-10	2008	Oral gavage of 2 mg honokiol/mouse (thrice a week) significantly retarded growth of PC-3 xenografts without causing weight loss.	honokiol	20-28	proprotein convertase subtilisin/kexin type 1	Mus musculus	84-88
18158873-0	2008	Anti-inflammatory effect of honokiol is mediated by PI3K/Akt pathway suppression.	honokiol	28-36	thymoma viral proto-oncogene 1	Mus musculus	57-60
18158873-4	2008	These anti-inflammatory effects of honokiol seem to be mediated by interrupting the early activated intracellular signaling molecule phosphoinositide 3-kinase (PI3K)/Akt, but not Src, the extracellular signal-regulated kinase, and p38, according to pharmacological, biochemical, and functional analyses.	honokiol	35-43	phosphoinositide-3-kinase regulatory subunit 1	Mus musculus	133-158
18158873-4	2008	These anti-inflammatory effects of honokiol seem to be mediated by interrupting the early activated intracellular signaling molecule phosphoinositide 3-kinase (PI3K)/Akt, but not Src, the extracellular signal-regulated kinase, and p38, according to pharmacological, biochemical, and functional analyses.	honokiol	35-43	thymoma viral proto-oncogene 1	Mus musculus	166-169
18158873-4	2008	These anti-inflammatory effects of honokiol seem to be mediated by interrupting the early activated intracellular signaling molecule phosphoinositide 3-kinase (PI3K)/Akt, but not Src, the extracellular signal-regulated kinase, and p38, according to pharmacological, biochemical, and functional analyses.	honokiol	35-43	mitogen-activated protein kinase 14	Mus musculus	231-234
18158873-5	2008	CONCLUSION: These results suggest that honokiol may act as a potent anti-inflammatory agent with multipotential activities due to an inhibitory effect on the PI3K/Akt pathway.	honokiol	39-47	thymoma viral proto-oncogene 1	Mus musculus	163-166
17510419-7	2007	We further showed that honokiol induced a CypD-regulated death in primary human acute myelogenous leukemia cells, overcame Bcl-2 and Bcl-X(L)-mediated apoptotic resistance, and was effective against HL60 cells in a pilot in vivo study.	honokiol	23-31	peptidylprolyl isomerase D	Homo sapiens	42-46
17971859-5	2007	METHODOLOGY AND PRINCIPAL FINDINGS: Treatment of various human gastric cancer cells with honokiol led to the induction of GRP94 cleavage, but did not affect GRP78.	honokiol	89-97	heat shock protein 90 beta family member 1	Homo sapiens	122-127
17971859-7	2007	Treatment of cells with honokiol or chemotherapeutics agent etoposide enhanced the increase in apoptosis and GRP94 degradation.	honokiol	24-32	heat shock protein 90 beta family member 1	Homo sapiens	109-114
17971859-9	2007	Honokiol-induced GRP94 down-regulation and apoptosis in gastric cancer cells could be reversed by siRNA targeting calpain-II and calpain inhibitors.	honokiol	0-8	heat shock protein 90 beta family member 1	Homo sapiens	17-22
17971859-10	2007	Furthermore, the results of immunofluorescence staining and immunoprecipitation revealed a specific interaction of GRP94 with calpain-II in cells following honokiol treatment.	honokiol	156-164	heat shock protein 90 beta family member 1	Homo sapiens	115-120
17971859-11	2007	We next observed that tumor GRP94 over-expression and tumor growth in BALB/c nude mice, which were inoculated with human gastric cancer cells MKN45, are markedly decreased by honokiol treatment.	honokiol	175-183	heat shock protein 90, beta (Grp94), member 1	Mus musculus	28-33
17971859-12	2007	CONCLUSIONS AND SIGNIFICANCE: These results provide the first evidence that honokiol-induced calpain-II-mediated GRP94 cleavage causes human gastric cancer cell apoptosis.	honokiol	76-84	heat shock protein 90 beta family member 1	Homo sapiens	113-118
17938262-0	2007	Honokiol causes G0-G1 phase cell cycle arrest in human prostate cancer cells in association with suppression of retinoblastoma protein level/phosphorylation and inhibition of E2F1 transcriptional activity.	honokiol	0-8	E2F transcription factor 1	Homo sapiens	175-179
17938262-2	2007	The honokiol treatment decreased the viability of PC-3 and LNCaP human prostate cancer cells in a concentration- and time-dependent manner, which correlated with G0-G1 phase cell cycle arrest.	honokiol	4-12	keratin 6A	Homo sapiens	50-54
17938262-3	2007	The honokiol-mediated cell cycle arrest was associated with a decrease in protein levels of cyclin D1, cyclin-dependent kinase 4 (Cdk4), Cdk6, and/or cyclin E and suppression of complex formation between cyclin D1 and Cdk4 as revealed by immunoprecipitation using anti-cyclin D1 antibody followed by immunoblotting for Cdk4 protein.	honokiol	4-12	cyclin D1	Homo sapiens	92-101
17938262-3	2007	The honokiol-mediated cell cycle arrest was associated with a decrease in protein levels of cyclin D1, cyclin-dependent kinase 4 (Cdk4), Cdk6, and/or cyclin E and suppression of complex formation between cyclin D1 and Cdk4 as revealed by immunoprecipitation using anti-cyclin D1 antibody followed by immunoblotting for Cdk4 protein.	honokiol	4-12	cyclin dependent kinase 4	Homo sapiens	103-128
17938262-3	2007	The honokiol-mediated cell cycle arrest was associated with a decrease in protein levels of cyclin D1, cyclin-dependent kinase 4 (Cdk4), Cdk6, and/or cyclin E and suppression of complex formation between cyclin D1 and Cdk4 as revealed by immunoprecipitation using anti-cyclin D1 antibody followed by immunoblotting for Cdk4 protein.	honokiol	4-12	cyclin dependent kinase 4	Homo sapiens	130-134
17938262-3	2007	The honokiol-mediated cell cycle arrest was associated with a decrease in protein levels of cyclin D1, cyclin-dependent kinase 4 (Cdk4), Cdk6, and/or cyclin E and suppression of complex formation between cyclin D1 and Cdk4 as revealed by immunoprecipitation using anti-cyclin D1 antibody followed by immunoblotting for Cdk4 protein.	honokiol	4-12	cyclin dependent kinase 6	Homo sapiens	137-141
17938262-3	2007	The honokiol-mediated cell cycle arrest was associated with a decrease in protein levels of cyclin D1, cyclin-dependent kinase 4 (Cdk4), Cdk6, and/or cyclin E and suppression of complex formation between cyclin D1 and Cdk4 as revealed by immunoprecipitation using anti-cyclin D1 antibody followed by immunoblotting for Cdk4 protein.	honokiol	4-12	cyclin D1	Homo sapiens	204-213
17938262-3	2007	The honokiol-mediated cell cycle arrest was associated with a decrease in protein levels of cyclin D1, cyclin-dependent kinase 4 (Cdk4), Cdk6, and/or cyclin E and suppression of complex formation between cyclin D1 and Cdk4 as revealed by immunoprecipitation using anti-cyclin D1 antibody followed by immunoblotting for Cdk4 protein.	honokiol	4-12	cyclin dependent kinase 4	Homo sapiens	218-222
17938262-3	2007	The honokiol-mediated cell cycle arrest was associated with a decrease in protein levels of cyclin D1, cyclin-dependent kinase 4 (Cdk4), Cdk6, and/or cyclin E and suppression of complex formation between cyclin D1 and Cdk4 as revealed by immunoprecipitation using anti-cyclin D1 antibody followed by immunoblotting for Cdk4 protein.	honokiol	4-12	cyclin D1	Homo sapiens	204-213
17938262-3	2007	The honokiol-mediated cell cycle arrest was associated with a decrease in protein levels of cyclin D1, cyclin-dependent kinase 4 (Cdk4), Cdk6, and/or cyclin E and suppression of complex formation between cyclin D1 and Cdk4 as revealed by immunoprecipitation using anti-cyclin D1 antibody followed by immunoblotting for Cdk4 protein.	honokiol	4-12	cyclin dependent kinase 4	Homo sapiens	218-222
17938262-4	2007	The honokiol-treated PC-3 and LNCaP cells exhibited a marked decrease in the levels of total and phosphorylated retinoblastoma protein (Rb), which correlated with the suppression of transcriptional activity of E2F1.	honokiol	4-12	keratin 6A	Homo sapiens	21-25
17938262-4	2007	The honokiol-treated PC-3 and LNCaP cells exhibited a marked decrease in the levels of total and phosphorylated retinoblastoma protein (Rb), which correlated with the suppression of transcriptional activity of E2F1.	honokiol	4-12	E2F transcription factor 1	Homo sapiens	210-214
17938262-5	2007	Exposure of PC-3 and LNCaP cells to honokiol resulted in the induction of p21 (PC-3 and LNCaP) and p53 protein expression (LNCaP).	honokiol	36-44	keratin 6A	Homo sapiens	12-16
17938262-5	2007	Exposure of PC-3 and LNCaP cells to honokiol resulted in the induction of p21 (PC-3 and LNCaP) and p53 protein expression (LNCaP).	honokiol	36-44	H3 histone pseudogene 16	Homo sapiens	74-77
17938262-5	2007	Exposure of PC-3 and LNCaP cells to honokiol resulted in the induction of p21 (PC-3 and LNCaP) and p53 protein expression (LNCaP).	honokiol	36-44	keratin 6A	Homo sapiens	79-83
17938262-5	2007	Exposure of PC-3 and LNCaP cells to honokiol resulted in the induction of p21 (PC-3 and LNCaP) and p53 protein expression (LNCaP).	honokiol	36-44	tumor protein p53	Homo sapiens	99-102
17938262-8	2007	In conclusion, the present study reveals that the honokiol-mediated G0-G1 phase cell cycle arrest in human prostate cancer cells is associated with the suppression of protein level/phosphorylation of Rb leading to inhibition of transcriptional activity of E2F1.	honokiol	50-58	E2F transcription factor 1	Homo sapiens	256-260
17826802-5	2007	Consistently, honokiol and magnolol significantly decreased formalin-induced c-Fos protein expression in superficial (I-II) laminae of the L4-L5 lumbar dorsal horn.	honokiol	14-22	FBJ osteosarcoma oncogene	Mus musculus	77-82
17510419-7	2007	We further showed that honokiol induced a CypD-regulated death in primary human acute myelogenous leukemia cells, overcame Bcl-2 and Bcl-X(L)-mediated apoptotic resistance, and was effective against HL60 cells in a pilot in vivo study.	honokiol	23-31	BCL2 apoptosis regulator	Homo sapiens	123-128
17510419-7	2007	We further showed that honokiol induced a CypD-regulated death in primary human acute myelogenous leukemia cells, overcame Bcl-2 and Bcl-X(L)-mediated apoptotic resistance, and was effective against HL60 cells in a pilot in vivo study.	honokiol	23-31	BCL2 like 1	Homo sapiens	133-140
17109844-11	2007	In addition, at lower concentration (0.376-3.76 microM), honokiol significantly decreased the percentage of apoptotic endothelial cells induced by oxidized low-density lipoprotein (ox-LDL) and significantly lowered the activity of caspase-3 stimulated by ox-LDL.	honokiol	57-65	caspase 3	Rattus norvegicus	231-240
17326044-4	2007	Honokiol-induced activation of caspases was evaluated by Western blot and FACS analysis.	honokiol	0-8	caspase 8	Homo sapiens	31-39
17326044-9	2007	In PCa cells honokiol induced apoptosis via the activation of caspases 3, 8, and 9 and the cleavage of poly-adenosine diphosphate ribose polymerase in a dose- and time-dependent manner.	honokiol	13-21	caspase 3	Homo sapiens	62-82
17326044-10	2007	Honokiol was shown to inhibit the growth and depress serum PSA in mice harboring C4-2 xenografts in the skeleton and the combination with docetaxel showed additive effects that inhibited further growth without evidence of systemic toxicity.	honokiol	0-8	kallikrein B, plasma 1	Mus musculus	59-62
16732532-6	2006	Pretreatment with honokiol at concentrations of 40, 20 and 10 microM significantly inhibited the generation of intracellular reactive oxygen species and reduced activation of caspases-8, -9, and -3 and cleavage of poly-(ADP-ribose) polymerase.	honokiol	18-26	caspase 8	Rattus norvegicus	175-197
16966432-2	2006	In this report, we found that honokiol potentiated the apoptosis induced by tumor necrosis factor (TNF) and chemotherapeutic agents, suppressed TNF-induced tumor cell invasion, and inhibited RANKL-induced osteoclastogenesis, all of which are known to require nuclear factor-kappaB (NF-kappaB) activation.	honokiol	30-38	tumor necrosis factor	Mus musculus	76-97
16966432-2	2006	In this report, we found that honokiol potentiated the apoptosis induced by tumor necrosis factor (TNF) and chemotherapeutic agents, suppressed TNF-induced tumor cell invasion, and inhibited RANKL-induced osteoclastogenesis, all of which are known to require nuclear factor-kappaB (NF-kappaB) activation.	honokiol	30-38	tumor necrosis factor	Mus musculus	99-102
16966432-2	2006	In this report, we found that honokiol potentiated the apoptosis induced by tumor necrosis factor (TNF) and chemotherapeutic agents, suppressed TNF-induced tumor cell invasion, and inhibited RANKL-induced osteoclastogenesis, all of which are known to require nuclear factor-kappaB (NF-kappaB) activation.	honokiol	30-38	tumor necrosis factor	Mus musculus	144-147
16966432-2	2006	In this report, we found that honokiol potentiated the apoptosis induced by tumor necrosis factor (TNF) and chemotherapeutic agents, suppressed TNF-induced tumor cell invasion, and inhibited RANKL-induced osteoclastogenesis, all of which are known to require nuclear factor-kappaB (NF-kappaB) activation.	honokiol	30-38	tumor necrosis factor (ligand) superfamily, member 11	Mus musculus	191-196
16966432-4	2006	Further studies showed that honokiol blocked TNF-induced phosphorylation, ubiquitination, and degradation of IkappaBalpha through the inhibition of activation of IkappaBalpha kinase and of Akt.	honokiol	28-36	tumor necrosis factor	Mus musculus	45-48
16966432-4	2006	Further studies showed that honokiol blocked TNF-induced phosphorylation, ubiquitination, and degradation of IkappaBalpha through the inhibition of activation of IkappaBalpha kinase and of Akt.	honokiol	28-36	nuclear factor of kappa light polypeptide gene enhancer in B cells inhibitor, alpha	Mus musculus	109-121
16966432-4	2006	Further studies showed that honokiol blocked TNF-induced phosphorylation, ubiquitination, and degradation of IkappaBalpha through the inhibition of activation of IkappaBalpha kinase and of Akt.	honokiol	28-36	nuclear factor of kappa light polypeptide gene enhancer in B cells inhibitor, alpha	Mus musculus	162-174
16966432-4	2006	Further studies showed that honokiol blocked TNF-induced phosphorylation, ubiquitination, and degradation of IkappaBalpha through the inhibition of activation of IkappaBalpha kinase and of Akt.	honokiol	28-36	thymoma viral proto-oncogene 1	Mus musculus	189-192
16406853-0	2006	Down-regulation of P-glycoprotein expression in MDR breast cancer cell MCF-7/ADR by honokiol.	honokiol	84-92	ATP binding cassette subfamily B member 1	Homo sapiens	19-33
16406853-4	2006	Here, we show that honokiol down-regulated the expression of P-glycoprotein at mRNA and protein levels in MCF-7/ADR, a human breast MDR cancer cell line.	honokiol	19-27	ATP binding cassette subfamily B member 1	Homo sapiens	61-75
16807544-5	2006	In this study, we first investigated the in vivo effects of honokiol on rat anti-Thy1 nephritis.	honokiol	60-68	Thy-1 cell surface antigen	Rattus norvegicus	81-85
16807544-12	2006	The increased intraglomerular proliferating cell nuclear antigen and Akt phosphorylation in nephritic rats could be abolished by the treatment of honokiol.	honokiol	146-154	AKT serine/threonine kinase 1	Rattus norvegicus	69-72
16807544-13	2006	Honokiol also alleviated glomerular monocyte chemoattractant protein-1 and intracellular adhesion molecule-1, similar to type I (alpha1) collagen and fibronectin mRNA levels of nephritic rats.	honokiol	0-8	C-C motif chemokine ligand 2	Rattus norvegicus	36-108
16732532-6	2006	Pretreatment with honokiol at concentrations of 40, 20 and 10 microM significantly inhibited the generation of intracellular reactive oxygen species and reduced activation of caspases-8, -9, and -3 and cleavage of poly-(ADP-ribose) polymerase.	honokiol	18-26	poly (ADP-ribose) polymerase 1	Rattus norvegicus	214-242
16181613-0	2005	Honokiol inhibits TNF-alpha-stimulated NF-kappaB activation and NF-kappaB-regulated gene expression through suppression of IKK activation.	honokiol	0-8	tumor necrosis factor	Homo sapiens	18-27
16580656-11	2006	Furthermore, honokiol attenuated the oxLDL-induced cytotoxicity, apoptotic features, ROS generation, intracellular calcium accumulation and the subsequent mitochondrial membrane potential collapse, cytochrome c release and activation of caspase-3.	honokiol	13-21	cytochrome c, somatic	Homo sapiens	198-210
16580656-11	2006	Furthermore, honokiol attenuated the oxLDL-induced cytotoxicity, apoptotic features, ROS generation, intracellular calcium accumulation and the subsequent mitochondrial membrane potential collapse, cytochrome c release and activation of caspase-3.	honokiol	13-21	caspase 3	Homo sapiens	237-246
16181613-0	2005	Honokiol inhibits TNF-alpha-stimulated NF-kappaB activation and NF-kappaB-regulated gene expression through suppression of IKK activation.	honokiol	0-8	nuclear factor kappa B subunit 1	Homo sapiens	39-48
16181613-0	2005	Honokiol inhibits TNF-alpha-stimulated NF-kappaB activation and NF-kappaB-regulated gene expression through suppression of IKK activation.	honokiol	0-8	nuclear factor kappa B subunit 1	Homo sapiens	64-73
16181613-2	2005	In this study, we investigated whether honokiol affects the transcription factor nuclear factor-kappa B (NF-kappaB) which controls a large number of genes involved in angiogenesis, metastasis and cell survival.	honokiol	39-47	nuclear factor kappa B subunit 1	Homo sapiens	81-103
16181613-2	2005	In this study, we investigated whether honokiol affects the transcription factor nuclear factor-kappa B (NF-kappaB) which controls a large number of genes involved in angiogenesis, metastasis and cell survival.	honokiol	39-47	nuclear factor kappa B subunit 1	Homo sapiens	105-114
16181613-3	2005	We observed that the tumor necrosis factor-alpha (TNF-alpha)-induced NF-kappaB activation was blocked by honokiol in four different cancer cell lines as evidenced by EMSA.	honokiol	105-113	tumor necrosis factor	Homo sapiens	21-48
16181613-3	2005	We observed that the tumor necrosis factor-alpha (TNF-alpha)-induced NF-kappaB activation was blocked by honokiol in four different cancer cell lines as evidenced by EMSA.	honokiol	105-113	tumor necrosis factor	Homo sapiens	50-59
16181613-3	2005	We observed that the tumor necrosis factor-alpha (TNF-alpha)-induced NF-kappaB activation was blocked by honokiol in four different cancer cell lines as evidenced by EMSA.	honokiol	105-113	nuclear factor kappa B subunit 1	Homo sapiens	69-78
16181613-5	2005	Immunoblot experiments demonstrated that honokiol inhibited the TNF-alpha-stimulated phosphorylation and degradation of the cytosolic NF-kappaB inhibitor IkappaBalpha.	honokiol	41-49	tumor necrosis factor	Homo sapiens	64-73
16181613-5	2005	Immunoblot experiments demonstrated that honokiol inhibited the TNF-alpha-stimulated phosphorylation and degradation of the cytosolic NF-kappaB inhibitor IkappaBalpha.	honokiol	41-49	nuclear factor kappa B subunit 1	Homo sapiens	134-143
16181613-5	2005	Immunoblot experiments demonstrated that honokiol inhibited the TNF-alpha-stimulated phosphorylation and degradation of the cytosolic NF-kappaB inhibitor IkappaBalpha.	honokiol	41-49	NFKB inhibitor alpha	Homo sapiens	154-166
16181613-6	2005	Furthermore, honokiol suppressed the intrinsic and TNF-alpha-stimulated upstream IkappaB kinases (IKKs) activities measured by a non-radioactive kinase assay using immunoprecipitated IKKs, suggesting a critical role of honokiol in abrogating the phosphorylation and degradation of IkappaBalpha.	honokiol	13-21	tumor necrosis factor	Homo sapiens	51-60
16181613-6	2005	Furthermore, honokiol suppressed the intrinsic and TNF-alpha-stimulated upstream IkappaB kinases (IKKs) activities measured by a non-radioactive kinase assay using immunoprecipitated IKKs, suggesting a critical role of honokiol in abrogating the phosphorylation and degradation of IkappaBalpha.	honokiol	13-21	NFKB inhibitor alpha	Homo sapiens	281-293
16181613-6	2005	Furthermore, honokiol suppressed the intrinsic and TNF-alpha-stimulated upstream IkappaB kinases (IKKs) activities measured by a non-radioactive kinase assay using immunoprecipitated IKKs, suggesting a critical role of honokiol in abrogating the phosphorylation and degradation of IkappaBalpha.	honokiol	219-227	tumor necrosis factor	Homo sapiens	51-60
16181613-7	2005	In a HeLa cell NF-kappaB-dependent luciferase reporter system, honokiol suppressed luciferase expression stimulated by TNF-alpha and by the transient transfection and expression of NIK (NF-kappaB-inducing kinase), wild type IKKbeta, constitutively active IKKalpha and IKKbeta, or the p65 subunit.	honokiol	63-71	nuclear factor kappa B subunit 1	Homo sapiens	15-24
16181613-7	2005	In a HeLa cell NF-kappaB-dependent luciferase reporter system, honokiol suppressed luciferase expression stimulated by TNF-alpha and by the transient transfection and expression of NIK (NF-kappaB-inducing kinase), wild type IKKbeta, constitutively active IKKalpha and IKKbeta, or the p65 subunit.	honokiol	63-71	tumor necrosis factor	Homo sapiens	119-128
16181613-7	2005	In a HeLa cell NF-kappaB-dependent luciferase reporter system, honokiol suppressed luciferase expression stimulated by TNF-alpha and by the transient transfection and expression of NIK (NF-kappaB-inducing kinase), wild type IKKbeta, constitutively active IKKalpha and IKKbeta, or the p65 subunit.	honokiol	63-71	mitogen-activated protein kinase kinase kinase 14	Homo sapiens	181-184
16181613-7	2005	In a HeLa cell NF-kappaB-dependent luciferase reporter system, honokiol suppressed luciferase expression stimulated by TNF-alpha and by the transient transfection and expression of NIK (NF-kappaB-inducing kinase), wild type IKKbeta, constitutively active IKKalpha and IKKbeta, or the p65 subunit.	honokiol	63-71	mitogen-activated protein kinase kinase kinase 14	Homo sapiens	186-211
16181613-7	2005	In a HeLa cell NF-kappaB-dependent luciferase reporter system, honokiol suppressed luciferase expression stimulated by TNF-alpha and by the transient transfection and expression of NIK (NF-kappaB-inducing kinase), wild type IKKbeta, constitutively active IKKalpha and IKKbeta, or the p65 subunit.	honokiol	63-71	inhibitor of nuclear factor kappa B kinase subunit beta	Homo sapiens	224-231
16181613-7	2005	In a HeLa cell NF-kappaB-dependent luciferase reporter system, honokiol suppressed luciferase expression stimulated by TNF-alpha and by the transient transfection and expression of NIK (NF-kappaB-inducing kinase), wild type IKKbeta, constitutively active IKKalpha and IKKbeta, or the p65 subunit.	honokiol	63-71	component of inhibitor of nuclear factor kappa B kinase complex	Homo sapiens	255-263
16181613-7	2005	In a HeLa cell NF-kappaB-dependent luciferase reporter system, honokiol suppressed luciferase expression stimulated by TNF-alpha and by the transient transfection and expression of NIK (NF-kappaB-inducing kinase), wild type IKKbeta, constitutively active IKKalpha and IKKbeta, or the p65 subunit.	honokiol	63-71	inhibitor of nuclear factor kappa B kinase subunit beta	Homo sapiens	268-275
16181613-7	2005	In a HeLa cell NF-kappaB-dependent luciferase reporter system, honokiol suppressed luciferase expression stimulated by TNF-alpha and by the transient transfection and expression of NIK (NF-kappaB-inducing kinase), wild type IKKbeta, constitutively active IKKalpha and IKKbeta, or the p65 subunit.	honokiol	63-71	RELA proto-oncogene, NF-kB subunit	Homo sapiens	284-287
16181613-8	2005	Honokiol was also found to inhibit the nuclear translocation and phosphorylation of p65 subunit of NF-kappaB.	honokiol	0-8	RELA proto-oncogene, NF-kB subunit	Homo sapiens	84-108
16181613-9	2005	RT-PCR results showed that honokiol suppressed NF-kappaB-regulated inflammatory and carcinogenic gene products including MMP-9, TNF-alpha, IL-8, ICAM-1 and MCP-1.	honokiol	27-35	nuclear factor kappa B subunit 1	Homo sapiens	47-56
16181613-9	2005	RT-PCR results showed that honokiol suppressed NF-kappaB-regulated inflammatory and carcinogenic gene products including MMP-9, TNF-alpha, IL-8, ICAM-1 and MCP-1.	honokiol	27-35	matrix metallopeptidase 9	Homo sapiens	121-126
16181613-9	2005	RT-PCR results showed that honokiol suppressed NF-kappaB-regulated inflammatory and carcinogenic gene products including MMP-9, TNF-alpha, IL-8, ICAM-1 and MCP-1.	honokiol	27-35	tumor necrosis factor	Homo sapiens	128-137
16181613-9	2005	RT-PCR results showed that honokiol suppressed NF-kappaB-regulated inflammatory and carcinogenic gene products including MMP-9, TNF-alpha, IL-8, ICAM-1 and MCP-1.	honokiol	27-35	C-X-C motif chemokine ligand 8	Homo sapiens	139-143
16181613-9	2005	RT-PCR results showed that honokiol suppressed NF-kappaB-regulated inflammatory and carcinogenic gene products including MMP-9, TNF-alpha, IL-8, ICAM-1 and MCP-1.	honokiol	27-35	intercellular adhesion molecule 1	Homo sapiens	145-151
16181613-9	2005	RT-PCR results showed that honokiol suppressed NF-kappaB-regulated inflammatory and carcinogenic gene products including MMP-9, TNF-alpha, IL-8, ICAM-1 and MCP-1.	honokiol	27-35	C-C motif chemokine ligand 2	Homo sapiens	156-161
16181613-10	2005	In line with the observation that NF-kappaB activation may up-regulate anti-apoptotic genes, it was shown that honokiol enhanced TNF-alpha-induced apoptotic cell death.	honokiol	111-119	nuclear factor kappa B subunit 1	Homo sapiens	34-43
16181613-10	2005	In line with the observation that NF-kappaB activation may up-regulate anti-apoptotic genes, it was shown that honokiol enhanced TNF-alpha-induced apoptotic cell death.	honokiol	111-119	tumor necrosis factor	Homo sapiens	129-138
16181613-11	2005	In summary, our results demonstrate that honokiol suppresses NF-kappaB activation and NF-kappaB-regulated gene expression through the inhibition of IKKs, which provides a possible mechanism for its anti-tumor actions.	honokiol	41-49	nuclear factor kappa B subunit 1	Homo sapiens	61-70
16181613-11	2005	In summary, our results demonstrate that honokiol suppresses NF-kappaB activation and NF-kappaB-regulated gene expression through the inhibition of IKKs, which provides a possible mechanism for its anti-tumor actions.	honokiol	41-49	nuclear factor kappa B subunit 1	Homo sapiens	86-95
15922325-0	2005	Honokiol-induced neurite outgrowth promotion depends on activation of extracellular signal-regulated kinases (ERK1/2).	honokiol	0-8	mitogen activated protein kinase 3	Rattus norvegicus	110-116
15802533-5	2005	Honokiol-induced apoptosis was characterized by the activation of caspase-3, -8, and -9 and cleavage of poly(adenosine diphosphate-ribose) polymerase (PARP).	honokiol	0-8	caspase 3	Homo sapiens	66-87
15802533-5	2005	Honokiol-induced apoptosis was characterized by the activation of caspase-3, -8, and -9 and cleavage of poly(adenosine diphosphate-ribose) polymerase (PARP).	honokiol	0-8	poly(ADP-ribose) polymerase 1	Homo sapiens	104-149
15802533-5	2005	Honokiol-induced apoptosis was characterized by the activation of caspase-3, -8, and -9 and cleavage of poly(adenosine diphosphate-ribose) polymerase (PARP).	honokiol	0-8	poly(ADP-ribose) polymerase 1	Homo sapiens	151-155
15802533-6	2005	Exposure of B-CLL cells to honokiol resulted in up-regulation of Bcl2-associated protein (Bax) and down-regulation of the expression of the key survival protein myeloid-cell leukemia sequence 1 (Mcl-1), which is associated with response to treatment in B-CLL patients.	honokiol	27-35	BCL2 associated X, apoptosis regulator	Homo sapiens	90-93
15802533-6	2005	Exposure of B-CLL cells to honokiol resulted in up-regulation of Bcl2-associated protein (Bax) and down-regulation of the expression of the key survival protein myeloid-cell leukemia sequence 1 (Mcl-1), which is associated with response to treatment in B-CLL patients.	honokiol	27-35	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	161-193
15802533-6	2005	Exposure of B-CLL cells to honokiol resulted in up-regulation of Bcl2-associated protein (Bax) and down-regulation of the expression of the key survival protein myeloid-cell leukemia sequence 1 (Mcl-1), which is associated with response to treatment in B-CLL patients.	honokiol	27-35	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	195-200
15802533-7	2005	In addition, B-CLL cells pretreated with interleukin-4 (IL-4), a cytokine known to support B-CLL survival, underwent apoptosis when subsequently incubated with honokiol, indicating that honokiol could also overcome the prosurvival effects of IL-4.	honokiol	160-168	interleukin 4	Homo sapiens	41-54
15802533-7	2005	In addition, B-CLL cells pretreated with interleukin-4 (IL-4), a cytokine known to support B-CLL survival, underwent apoptosis when subsequently incubated with honokiol, indicating that honokiol could also overcome the prosurvival effects of IL-4.	honokiol	160-168	interleukin 4	Homo sapiens	56-60
15802533-7	2005	In addition, B-CLL cells pretreated with interleukin-4 (IL-4), a cytokine known to support B-CLL survival, underwent apoptosis when subsequently incubated with honokiol, indicating that honokiol could also overcome the prosurvival effects of IL-4.	honokiol	186-194	interleukin 4	Homo sapiens	41-54
15802533-7	2005	In addition, B-CLL cells pretreated with interleukin-4 (IL-4), a cytokine known to support B-CLL survival, underwent apoptosis when subsequently incubated with honokiol, indicating that honokiol could also overcome the prosurvival effects of IL-4.	honokiol	186-194	interleukin 4	Homo sapiens	56-60
15922325-3	2005	Honokiol-induced neurite outgrowth in the cultured rat cortical neurons was significantly reduced by PD98059, a mitogen-activated protein kinase kinase (MAPKK, MAPK/ERK kinase MEK, direct upstream of ERK1/2) inhibitor, but not by LY294002, a phosphoinositide 3-kinase (PI3K, upstream of Akt) inhibitor.	honokiol	0-8	mitogen activated protein kinase 3	Rattus norvegicus	165-168
15922325-3	2005	Honokiol-induced neurite outgrowth in the cultured rat cortical neurons was significantly reduced by PD98059, a mitogen-activated protein kinase kinase (MAPKK, MAPK/ERK kinase MEK, direct upstream of ERK1/2) inhibitor, but not by LY294002, a phosphoinositide 3-kinase (PI3K, upstream of Akt) inhibitor.	honokiol	0-8	mitogen activated protein kinase 3	Rattus norvegicus	200-206
15922325-3	2005	Honokiol-induced neurite outgrowth in the cultured rat cortical neurons was significantly reduced by PD98059, a mitogen-activated protein kinase kinase (MAPKK, MAPK/ERK kinase MEK, direct upstream of ERK1/2) inhibitor, but not by LY294002, a phosphoinositide 3-kinase (PI3K, upstream of Akt) inhibitor.	honokiol	0-8	AKT serine/threonine kinase 1	Rattus norvegicus	287-290
15922325-4	2005	Honokiol also significantly enhanced the phosphorylation of ERK1/2 in a concentration-dependent manner, whereas the effect of honokiol on Akt phosphorylation was characterized by transient enhancement in 10 min and lasting inhibition after 30 min.	honokiol	0-8	mitogen activated protein kinase 3	Rattus norvegicus	60-66
15922325-4	2005	Honokiol also significantly enhanced the phosphorylation of ERK1/2 in a concentration-dependent manner, whereas the effect of honokiol on Akt phosphorylation was characterized by transient enhancement in 10 min and lasting inhibition after 30 min.	honokiol	126-134	AKT serine/threonine kinase 1	Rattus norvegicus	138-141
15922325-5	2005	The phosphorylation of ERK1/2 enhanced by honokiol was inhibited by PD98059 as well as by KN93, a Ca2+/calmodulin-dependent kinase II (CaMK II) inhibitor.	honokiol	42-50	mitogen activated protein kinase 3	Rattus norvegicus	23-29
15922325-7	2005	Together with our previous findings, these results suggest that the signal transduction from PLC, IP3, Ca2+, and CaMK II to ERK1/2 is involved in honokiol-induced neurite outgrowth.	honokiol	146-154	mitogen activated protein kinase 3	Rattus norvegicus	124-130
15922325-2	2005	In this study, we examined the effects of honokiol on extracellular signal-regulated kinases (ERK1/2) and Akt, and their possible relationship to neurite outgrowth and Ca2+ mobilization.	honokiol	42-50	mitogen activated protein kinase 3	Rattus norvegicus	94-100
15922325-2	2005	In this study, we examined the effects of honokiol on extracellular signal-regulated kinases (ERK1/2) and Akt, and their possible relationship to neurite outgrowth and Ca2+ mobilization.	honokiol	42-50	AKT serine/threonine kinase 1	Rattus norvegicus	106-109
15856410-6	2005	Using a nuclear factor-kappaB (NF-kappaB) luciferase reporter assay system and Western analysis, we identified that magnolol and honokiol exert their anti-inflammatory effects by inhibiting the NF-kappaB element, which exists in Cox-2, IL-8, and TNF-alpha promoters [(15 microM magnolol: 44.8% inhibition), (15 microM honokiol: 42.3% inhibition)].	honokiol	129-137	C-X-C motif chemokine ligand 8	Homo sapiens	236-240
15856410-6	2005	Using a nuclear factor-kappaB (NF-kappaB) luciferase reporter assay system and Western analysis, we identified that magnolol and honokiol exert their anti-inflammatory effects by inhibiting the NF-kappaB element, which exists in Cox-2, IL-8, and TNF-alpha promoters [(15 microM magnolol: 44.8% inhibition), (15 microM honokiol: 42.3% inhibition)].	honokiol	129-137	tumor necrosis factor	Homo sapiens	246-255
15259066-0	2004	Honokiol induces apoptosis through p53-independent pathway in human colorectal cell line RKO.	honokiol	0-8	tumor protein p53	Homo sapiens	35-38
15259066-1	2004	AIM: To investigate the signal pathway of honokiol-induced apoptosis on human colorectal carcinoma RKO cells and to evaluate whether p53 and p53-related genes were involved in honokiol-treated RKO cells.	honokiol	176-184	tumor protein p53	Homo sapiens	133-136
15259066-1	2004	AIM: To investigate the signal pathway of honokiol-induced apoptosis on human colorectal carcinoma RKO cells and to evaluate whether p53 and p53-related genes were involved in honokiol-treated RKO cells.	honokiol	176-184	tumor protein p53	Homo sapiens	141-144
15259066-10	2004	CONCLUSION: Honokiol can induce RKO cells apoptosis through activating caspase cascade by p53-indepenent pathway.	honokiol	12-20	tumor protein p53	Homo sapiens	90-93
11731909-7	2001	Magnolol and honokiol inhibited the activity of MMP-9, which may have been responsible, in part, for the inhibition of tumor cell invasiveness.	honokiol	13-21	matrix metallopeptidase 9	Homo sapiens	48-53
12954355-5	2003	These data suggested that honokiol, acting as a potent reactive oxygen species inhibitor/scavenger, could achieve its focal cerebral ischemia/reperfusion injury protective effect by modulating enzyme systems related to reactive oxygen species production or metabolism, including NADPH oxidase, myeloperoxidase, cyclooxygenase, and GSH peroxidase in neutrophils.	honokiol	26-34	myeloperoxidase	Rattus norvegicus	294-309
12007567-0	2002	Down-modulation of Bcl-XL, release of cytochrome c and sequential activation of caspases during honokiol-induced apoptosis in human squamous lung cancer CH27 cells.	honokiol	96-104	BCL2 like 1	Homo sapiens	19-25
12007567-3	2002	Here, we found that honokiol-induced apoptotic cell death was accompanied by upregulation of Bad and downregulation of Bcl-XL, while honokiol had no effect on the levels of Bcl-2, Bcl-XS, Bag-1, Bax and Bak proteins.	honokiol	20-28	BCL2 like 1	Homo sapiens	119-125
12007567-3	2002	Here, we found that honokiol-induced apoptotic cell death was accompanied by upregulation of Bad and downregulation of Bcl-XL, while honokiol had no effect on the levels of Bcl-2, Bcl-XS, Bag-1, Bax and Bak proteins.	honokiol	20-28	BAG cochaperone 1	Homo sapiens	188-193
12007567-3	2002	Here, we found that honokiol-induced apoptotic cell death was accompanied by upregulation of Bad and downregulation of Bcl-XL, while honokiol had no effect on the levels of Bcl-2, Bcl-XS, Bag-1, Bax and Bak proteins.	honokiol	20-28	BCL2 associated X, apoptosis regulator	Homo sapiens	195-198
12007567-3	2002	Here, we found that honokiol-induced apoptotic cell death was accompanied by upregulation of Bad and downregulation of Bcl-XL, while honokiol had no effect on the levels of Bcl-2, Bcl-XS, Bag-1, Bax and Bak proteins.	honokiol	20-28	BCL2 antagonist/killer 1	Homo sapiens	203-206
12007567-4	2002	Moreover, honokiol treatment caused the release of mitochondrial cytochrome c to cytosol and sequential activation of caspases.	honokiol	10-18	cytochrome c, somatic	Homo sapiens	65-77
12007567-5	2002	Proteolytic activation of caspase-3 and cleavage of PARP, an in vivo substrate for caspase-3, were observed in honokiol-treated CH27 cells.	honokiol	111-119	caspase 3	Homo sapiens	26-35
12007567-5	2002	Proteolytic activation of caspase-3 and cleavage of PARP, an in vivo substrate for caspase-3, were observed in honokiol-treated CH27 cells.	honokiol	111-119	collagen type XI alpha 2 chain	Homo sapiens	52-56
12007567-5	2002	Proteolytic activation of caspase-3 and cleavage of PARP, an in vivo substrate for caspase-3, were observed in honokiol-treated CH27 cells.	honokiol	111-119	caspase 3	Homo sapiens	83-92
12007567-7	2002	These results demonstrated that modulation of Bcl-XL and Bad proteins, release of mitochondrial cytochrome c and activation of caspase-3, participated in honokiol-triggered apoptotic process in human squamous lung cancer CH27 cells.	honokiol	154-162	BCL2 like 1	Homo sapiens	46-52
12007567-7	2002	These results demonstrated that modulation of Bcl-XL and Bad proteins, release of mitochondrial cytochrome c and activation of caspase-3, participated in honokiol-triggered apoptotic process in human squamous lung cancer CH27 cells.	honokiol	154-162	cytochrome c, somatic	Homo sapiens	96-108
12007567-7	2002	These results demonstrated that modulation of Bcl-XL and Bad proteins, release of mitochondrial cytochrome c and activation of caspase-3, participated in honokiol-triggered apoptotic process in human squamous lung cancer CH27 cells.	honokiol	154-162	caspase 3	Homo sapiens	127-136
26629239-0	2015	KRT6B, a key mediator of notch signaling in honokiol-induced human hepatoma cell apoptosis.	honokiol	44-52	keratin 6B	Homo sapiens	0-5
11164091-8	2000	Taken together, these results suggest that this analog of honokiol acts at the benzodiazepine recognition site of the GABA(A)-benzodiazepine receptor complex.	honokiol	58-66	gamma-aminobutyric acid (GABA) A receptor, subunit gamma 1	Mus musculus	118-125
32890957-16	2020	The use of Honokiol increased the levels of p-ERK and p-Raf1, rescuing the function of BRAP downregulation in the MAPK pathway.	honokiol	11-19	mitogen-activated protein kinase 1	Homo sapiens	46-49
32890957-16	2020	The use of Honokiol increased the levels of p-ERK and p-Raf1, rescuing the function of BRAP downregulation in the MAPK pathway.	honokiol	11-19	Raf-1 proto-oncogene, serine/threonine kinase	Homo sapiens	56-60
32890957-16	2020	The use of Honokiol increased the levels of p-ERK and p-Raf1, rescuing the function of BRAP downregulation in the MAPK pathway.	honokiol	11-19	BRCA1 associated protein	Homo sapiens	87-91
8688675-6	1996	These results indicate that honokiol blocks LT synthesis by inhibiting 5-lipoxygenase activity.	honokiol	28-36	arachidonate 5-lipoxygenase	Rattus norvegicus	71-85
26629239-0	2015	KRT6B, a key mediator of notch signaling in honokiol-induced human hepatoma cell apoptosis.	honokiol	44-52	notch receptor 1	Homo sapiens	25-30
26629239-7	2015	The mRNA and protein expression of Notch1 was significantly lower in human hepatoma cells with honokiol treatment than that in the untreatment group.	honokiol	95-103	notch receptor 1	Homo sapiens	35-41
26629239-9	2015	Furthermore, cells were transfected with the wild type pLenti-KRT6B vector, the protein expression of KRT6B and NOTCH1 was significantly upregulated in human hepatoma cells with honokiol treatment.	honokiol	178-186	keratin 6B	Homo sapiens	62-67
26629239-9	2015	Furthermore, cells were transfected with the wild type pLenti-KRT6B vector, the protein expression of KRT6B and NOTCH1 was significantly upregulated in human hepatoma cells with honokiol treatment.	honokiol	178-186	keratin 6B	Homo sapiens	102-107
26629239-9	2015	Furthermore, cells were transfected with the wild type pLenti-KRT6B vector, the protein expression of KRT6B and NOTCH1 was significantly upregulated in human hepatoma cells with honokiol treatment.	honokiol	178-186	notch receptor 1	Homo sapiens	112-118
26629239-12	2015	KRT6B, a key mediator of Notch signaling, was downregulated in honokiol-induced hepatocellular carcinoma apoptosis, suggesting that KRT6B might be a novel therapeutic target for the treatment of hepatocellular carcinoma.	honokiol	63-71	keratin 6B	Homo sapiens	0-5
26629239-12	2015	KRT6B, a key mediator of Notch signaling, was downregulated in honokiol-induced hepatocellular carcinoma apoptosis, suggesting that KRT6B might be a novel therapeutic target for the treatment of hepatocellular carcinoma.	honokiol	63-71	notch receptor 1	Homo sapiens	25-30
26629239-12	2015	KRT6B, a key mediator of Notch signaling, was downregulated in honokiol-induced hepatocellular carcinoma apoptosis, suggesting that KRT6B might be a novel therapeutic target for the treatment of hepatocellular carcinoma.	honokiol	63-71	keratin 6B	Homo sapiens	132-137
34752757-0	2022	Honokiol improves cognitive impairment in APP/PS1 mice through activating mitophagy and mitochondrial unfolded protein response.	honokiol	0-8	presenilin 1	Mus musculus	46-49
33806040-0	2021	Honokiol Prevents Non-Alcoholic Steatohepatitis-Induced Liver Cancer via EGFR Degradation through the Glucocorticoid Receptor-MIG6 Axis.	honokiol	0-8	epidermal growth factor receptor	Homo sapiens	73-77
33806040-0	2021	Honokiol Prevents Non-Alcoholic Steatohepatitis-Induced Liver Cancer via EGFR Degradation through the Glucocorticoid Receptor-MIG6 Axis.	honokiol	0-8	nuclear receptor subfamily 3 group C member 1	Homo sapiens	102-125
33806040-0	2021	Honokiol Prevents Non-Alcoholic Steatohepatitis-Induced Liver Cancer via EGFR Degradation through the Glucocorticoid Receptor-MIG6 Axis.	honokiol	0-8	ERBB receptor feedback inhibitor 1	Homo sapiens	126-130
34752757-6	2022	Meanwhile, HKL-treated mice displayed much higher hippocampal expression and activity of mitochondrial sirtuin 3 (SIRT3).	honokiol	11-14	sirtuin 3	Mus musculus	103-112
34752757-6	2022	Meanwhile, HKL-treated mice displayed much higher hippocampal expression and activity of mitochondrial sirtuin 3 (SIRT3).	honokiol	11-14	sirtuin 3	Mus musculus	114-119
34965300-0	2022	A combination therapy using mTOR inhibitor and Honokiol effectively induces autophagy through the modulation of AXL and Rubicon in renal cancer cells, and restricts renal tumor growth following an organ transplantation.	honokiol	47-55	AXL receptor tyrosine kinase	Homo sapiens	112-115
34965300-0	2022	A combination therapy using mTOR inhibitor and Honokiol effectively induces autophagy through the modulation of AXL and Rubicon in renal cancer cells, and restricts renal tumor growth following an organ transplantation.	honokiol	47-55	rubicon autophagy regulator	Homo sapiens	120-127
34547831-0	2021	Engineered s-Triazine-based dendrimer-honokiol conjugates as targeted MMP-2/9 inhibitors for halting hepatocellular carcinoma.	honokiol	38-46	matrix metallopeptidase 2	Homo sapiens	70-77
34624416-8	2021	Honokiol restored GDNF levels following MEHP exposure by activating the ERK/c-fos signaling pathway, while the inhibitor U0126 further reduced the GDNF levels.	honokiol	0-8	glial cell derived neurotrophic factor	Rattus norvegicus	18-22
34948151-0	2021	Honokiol Acts as a Potent Anti-Fibrotic Agent in the Liver through Inhibition of TGF-beta1/SMAD Signaling and Autophagy in Hepatic Stellate Cells.	honokiol	0-8	transforming growth factor beta 1	Homo sapiens	81-90
34624416-8	2021	Honokiol restored GDNF levels following MEHP exposure by activating the ERK/c-fos signaling pathway, while the inhibitor U0126 further reduced the GDNF levels.	honokiol	0-8	Eph receptor B1	Rattus norvegicus	72-75
34624416-8	2021	Honokiol restored GDNF levels following MEHP exposure by activating the ERK/c-fos signaling pathway, while the inhibitor U0126 further reduced the GDNF levels.	honokiol	0-8	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	76-81
34426156-0	2021	Novel 1,3,4-thiadiazole/oxadiazole-linked honokiol derivatives suppress cancer via inducing PI3K/Akt/mTOR-dependent autophagy.	honokiol	42-50	AKT serine/threonine kinase 1	Homo sapiens	97-100
34844623-0	2021	Honokiol alleviates LPS-induced acute lung injury by inhibiting NLRP3 inflammasome-mediated pyroptosis via Nrf2 activation in vitro and in vivo.	honokiol	0-8	NLR family pyrin domain containing 3	Homo sapiens	64-69
34844623-0	2021	Honokiol alleviates LPS-induced acute lung injury by inhibiting NLRP3 inflammasome-mediated pyroptosis via Nrf2 activation in vitro and in vivo.	honokiol	0-8	NFE2 like bZIP transcription factor 2	Homo sapiens	107-111
34834886-13	2021	In addition, magnolol displayed inhibitory effects towards IL-1beta, IL-8 and TNF-alpha released from lipopolysaccharide (LPS)-stimulated human neutrophils, while honokiol only decreased IL-1beta secretion, compared to the untreated control.	honokiol	163-171	interleukin 1 alpha	Homo sapiens	187-195
34758848-0	2021	Honokiol attenuates lipotoxicity in hepatocytes via activating SIRT3-AMPK mediated lipophagy.	honokiol	0-8	sirtuin 3	Mus musculus	63-68
34671554-0	2021	Honokiol Suppresses Perineural Invasion of Pancreatic Cancer by Inhibiting SMAD2/3 Signaling.	honokiol	0-8	SMAD family member 2	Homo sapiens	75-82
34426156-0	2021	Novel 1,3,4-thiadiazole/oxadiazole-linked honokiol derivatives suppress cancer via inducing PI3K/Akt/mTOR-dependent autophagy.	honokiol	42-50	mechanistic target of rapamycin kinase	Homo sapiens	101-105
34287090-8	2021	Pharmacological activation of Sirt3, both invitro and in vivo, by Honokiol (HK), a known activator of Sirt3, abrogated the inhibitory effect of iron overload on active beta-catenin expression and prevented the iron induced upregulation of alphaSMA and TGFbeta expression.	honokiol	66-74	sirtuin 3	Mus musculus	30-35
34545325-0	2022	Inhibitory effect of honokiol on furin-like activity and SARS-CoV-2 infection.	honokiol	21-29	furin, paired basic amino acid cleaving enzyme	Homo sapiens	33-38
34545325-5	2022	In this study, we examined the inhibitory effects of two lignans (honokiol and magnolol) on furin-like enzymatic activity using a fluorogenic substrate with whole-cell lysates.	honokiol	66-74	furin, paired basic amino acid cleaving enzyme	Homo sapiens	92-97
34545325-6	2022	Of two compounds tested, honokiol partially inhibited furin-like enzymatic activity.	honokiol	25-33	furin, paired basic amino acid cleaving enzyme	Homo sapiens	54-59
34545325-7	2022	We further examined the anti-SARS-CoV-2 activity of honokiol using VeroE6 cell line, which is stably expressing a transmembrane protease serine 2 (TMPRSS2).	honokiol	52-60	transmembrane protease serine 2	Chlorocebus sabaeus	114-145
34545325-7	2022	We further examined the anti-SARS-CoV-2 activity of honokiol using VeroE6 cell line, which is stably expressing a transmembrane protease serine 2 (TMPRSS2).	honokiol	52-60	transmembrane protease serine 2	Chlorocebus sabaeus	147-154
34518519-8	2021	The activation of SIRT3 by honokiol ameliorated acetylation and prevented renal fibrosis.	honokiol	27-35	sirtuin 3	Mus musculus	18-23
34287090-8	2021	Pharmacological activation of Sirt3, both invitro and in vivo, by Honokiol (HK), a known activator of Sirt3, abrogated the inhibitory effect of iron overload on active beta-catenin expression and prevented the iron induced upregulation of alphaSMA and TGFbeta expression.	honokiol	66-74	sirtuin 3	Mus musculus	102-107
34287090-8	2021	Pharmacological activation of Sirt3, both invitro and in vivo, by Honokiol (HK), a known activator of Sirt3, abrogated the inhibitory effect of iron overload on active beta-catenin expression and prevented the iron induced upregulation of alphaSMA and TGFbeta expression.	honokiol	66-74	catenin (cadherin associated protein), beta 1	Mus musculus	168-180
34287090-8	2021	Pharmacological activation of Sirt3, both invitro and in vivo, by Honokiol (HK), a known activator of Sirt3, abrogated the inhibitory effect of iron overload on active beta-catenin expression and prevented the iron induced upregulation of alphaSMA and TGFbeta expression.	honokiol	66-74	actin alpha 2, smooth muscle, aorta	Mus musculus	239-247
34098216-0	2021	Liposomal honokiol promotes hair growth via activating Wnt3a/beta-catenin signaling pathway and down regulating TGF-beta1 in C57BL/6N mice.	honokiol	10-18	wingless-type MMTV integration site family, member 3A	Mus musculus	55-60
34098216-0	2021	Liposomal honokiol promotes hair growth via activating Wnt3a/beta-catenin signaling pathway and down regulating TGF-beta1 in C57BL/6N mice.	honokiol	10-18	catenin (cadherin associated protein), beta 1	Mus musculus	61-73
34287090-8	2021	Pharmacological activation of Sirt3, both invitro and in vivo, by Honokiol (HK), a known activator of Sirt3, abrogated the inhibitory effect of iron overload on active beta-catenin expression and prevented the iron induced upregulation of alphaSMA and TGFbeta expression.	honokiol	66-74	transforming growth factor alpha	Mus musculus	252-259
34098216-0	2021	Liposomal honokiol promotes hair growth via activating Wnt3a/beta-catenin signaling pathway and down regulating TGF-beta1 in C57BL/6N mice.	honokiol	10-18	transforming growth factor, beta 1	Mus musculus	112-121
34389732-9	2021	In addition, honokiol or adiponectin treatment effectively inhibits leptin-induced Med1 expression and improves tamoxifen efficacy in hyperleptinemic state.	honokiol	13-21	leptin	Mus musculus	68-74
34577585-8	2021	A biolayer interfero-metry (BLI) binding assay and molecular docking study revealed that 6p binds to human ACE2 protein with higher binding affinity and lower binding energy than the parental honokiol.	honokiol	192-200	angiotensin converting enzyme 2	Homo sapiens	107-111
34389732-9	2021	In addition, honokiol or adiponectin treatment effectively inhibits leptin-induced Med1 expression and improves tamoxifen efficacy in hyperleptinemic state.	honokiol	13-21	mediator complex subunit 1	Mus musculus	83-87
34389732-10	2021	These studies uncover the mechanistic insights how obese/hyperleptinemic state may contribute to poor response to tamoxifen implicating leptin-miR205-Med1 and leptin-Her2-EGFR-Med1 axes, and present bioactive compound honokiol and adipocytokine adiponectin as agents that can block leptin"s negative effect on tamoxifen.	honokiol	218-226	leptin	Mus musculus	282-288
34227879-0	2021	Honokiol-Loaded Methoxy Poly (Ethylene Glycol) Polycaprolactone Micelles for the Treatment of Age-Related Macular Degeneration.	honokiol	0-8	renin binding protein	Homo sapiens	94-97
34206989-0	2021	Honokiol Affects Stem Cell Viability by Suppressing Oncogenic YAP1 Function to Inhibit Colon Tumorigenesis.	honokiol	0-8	Yes1 associated transcriptional regulator	Homo sapiens	62-66
34202229-6	2021	Further, pharmacologic SIRT3 inducers (i.e., resveratrol, viniferin, and honokiol) each diminish oxidant-induced AEC mtDNA damage in vitro and, in the case of honokiol, protection occurs in a SIRT3-dependent manner.	honokiol	73-81	sirtuin 3	Mus musculus	23-28
34202229-6	2021	Further, pharmacologic SIRT3 inducers (i.e., resveratrol, viniferin, and honokiol) each diminish oxidant-induced AEC mtDNA damage in vitro and, in the case of honokiol, protection occurs in a SIRT3-dependent manner.	honokiol	73-81	sirtuin 3	Mus musculus	192-197
34202229-6	2021	Further, pharmacologic SIRT3 inducers (i.e., resveratrol, viniferin, and honokiol) each diminish oxidant-induced AEC mtDNA damage in vitro and, in the case of honokiol, protection occurs in a SIRT3-dependent manner.	honokiol	159-167	sirtuin 3	Mus musculus	192-197
34249443-0	2021	Honokiol induces ferroptosis in colon cancer cells by regulating GPX4 activity.	honokiol	0-8	glutathione peroxidase 4	Homo sapiens	65-69